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Abstract 
 
 
Introduction:  
Stereotactic Body Radiotherapy (SBRT) is a form of highly focal radiation therapy.  Treatment delivery 
is largely guided (“tracked”) by gold-marker fiducials for non-spinal body sites.  CyberKnife (CK) is 
purpose-built todeliver SBRT. 
Methods: 
An experimental system, using a radiotherapy “phantom”, was designed to assess the accuracy of the 
CK system in imaging static and migrating fiducials (Chapter 2).  An assumption in fiducial-tracked 
treatments is that the exact arrangement of fiducials at planning CT is maintained at treatment.  It is 
also crucial that relative Organ At Risk (OAR) and tumour position, is consistent between planning CT 
scan and treatment.  The validity of this assumption was assessed by comparing fiducial locations on 
Planning and Treatment CTs (Chapter 3).  The feasibility of achieving consistent bladder filling, and 
the impact of consistent filling on the ability to track translations/rotations in prostate cancer 
therapy was explored (Chapter 4).  Uncertainties in treatment planning/delivery for CK prostate 
patients was explored, and ideal planning margins were calculated (Chapter 5).  Optimum SBRT dose 
for localised pancreatic cancer, lymph node oligometastasis and oligometastatic breast cancer was 
explored (Chapter 6). 
Results: 
Imaging of fiducial position was accurate and reproducible across a clinically appropriate tracking 
range.  However, findings highlighted the need for vigilance at treatment delivery.  The reliability and 
“trackability” of implanted fiducials, as well as consistency of OAR position, varied according to 
tumour and implantation site.  Guidelines were generated accordingly.  Bladder filling/Margins 
guidelines have been generated.  Radiobiological analysis has indicated that there is scope for 
cautious dose escalation in the SBRT treatment of pancreatic cancer.  Analysis of SBRT-treated lymph 
node oligometastases has demonstrated that Local Control is 100% when SBRT is prescribed to a 
threshold 72Gy10. 
Conclusion: 
Refinements in patient preparation, fiducial placement, and dose/fractionation selection can 
optimise tracking accuracy and dose delivery in SBRT.   
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CHAPTER 1 
Background and Introduction 
 
1.1 Conventionally fractionated Conformal Radiotherapy 
Radiotherapy is the medical use of ionising radiation to kill malignant cells in order to control cancer.  
Ionising radiation is able to kill cancer cells (but also normal body cells), by damaging cellular DNA, via 
a number of different mechanisms.  Radiotherapy is a local form of treatment, and as normal tissue is 
radiosensitive, it is important that the deposition of radiation dose is accurately deposited on the 
tumour and spares collateral damage to adjacent normal healthy tissues. 
Once a patient is seen in clinic and consented for Radiotherapy, there a number of important steps in 
the Radiotherapy Planning Process which must occur before a patient can receive their treatment. 
 
1.1.1 Treatment Planning Process: 
Simulation 
The Radiotherapy planning process starts with the process of “simulation”.  The process of 
“simulation”, for many years, involved a patient being immobilised in their treatment position on a 
couch.  A “conventional” radiotherapy simulator would then capture two-dimensional (2D) 
information.  A conventional simulator comprised a diagnostic X-ray tube mounted to reproduce the 
geometric movements of a radiotherapy treatment machine, which was capable of imaging with 
fluoroscopy and diagnostic film.  Three-Dimensional (3D) information was inferred by taking 
orthogonal X-Ray films.  As conventional planning can only infer 3D information, this is a limitation of 
the technique, as accurate dosimetry requires full 3D information in order to fully evaluate 
attenuation of the photon beam within tissue. 
In order to overcome this limitation, conventional simulators have now largely been replaced by 
Computed Tomography (CT), or “virtual” CT simulators. These simulators comprise a CT scanner, 
laser marking system, and 3D work-station to allow the visualisation and manipulation of the CT data 
for treatment localisation.  The information derived through CT is inherently 3D, and contains both 
contour and tissue density information which is required for the planning process (1).  A 3D based 
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environment for imaging, planning and radiotherapy delivery is the current baseline standard 
according to the most recent National Radiotherapy Advisory Group (NRAG) report (2). 
 
Scanned images taken at virtual simulation are linked into treatment planning software that allows 
Clinical Oncologists to visualise and localise the tumour target in 3D.   
 
 
The International Commission on Radiation Units and Measurements Guidelines (ICRU):  
Target Concepts  
 
The ICRU 50 report (1993) defines standards for describing Radiotherapy prescription volumes. 
Gross Tumour Volume (GTV) represents the gross palpable or visible extent of disease. 
Clinical Target Volume (CTV) incorporates a margin of normal tissue for unknown subclinical or 
microscopic disease. 
Planning Target Volume (PTV) includes all other errors and uncertainties e.g. tumour motion and set-
up errors (3). 
 
The ICRU 62 report (1999) acknowledges the effect of organ/tumour movement, the resulting 
uncertainties are accommodated by expanding the CTV to an Internal Target Volume (ITV) by an 
Internal Margin (IM).  The report also accounts for uncertainties in treatment delivery due to errors 
in beam-patient positioning, called the Set Up margin (SM), to develop a Planning Target Volume 
(PTV) (4).  See Figure 1. 
 
Figure 1:  Diagram to illustrate the concepts of GTV, CTV, ITV, and PTV 
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Tumour localisation 
 
There have been a number of advances in recent years that have made it possible to more accurately 
delineate a target.   
 
It is now possible to fuse the 3D CT data set with Magnetic Resonance Imaging (MRI) scans.   This aids 
the outlining process, as some tumours, e.g. brain and prostate are more easily seen on MRI than CT 
(5).  In a study by Sannazzari et al, the CTV for localised prostate cancer (prostate plus seminal 
vesicles) was delineated on both CT and MRI studies.  Image fusion was achieved by fusing to 
anatomical fiducial markers.  There was a mean over-estimation of CTV of 34% with CT compared 
with MRI (6). 
 
The outlining of other tumours that are glucose-avid, e.g. Non-Small Cell Lung Cancer (NSCLC), 
Squamous cell cancers of the Head and Neck is helped by the ability to fuse Positron Emission 
Tomography (PET) scans to the Primary CT scan (7, 8). 
 
PET scans are performed following the administration of 18F-Fluoro-DeoxyGlucose (FDG), a glucose 
analogue.  As the FDG is labeled with 18F at the 2-prime hydroxyl position, the normal degradation 
that occurs during glycolysis is prevented, and the radio-labelled FDG accumulates within the tissue 
(9).  In this way, PET scans provide functional information (metabolic rate), and are good for 
identifying nodal disease Head &Neck cancers (see Figure 2, page 8), as well as areas of atelectasis in 
Thoracic cancer. 
 
Studies have demonstrated a change in the PTV in approximately 30% of cases of NSCLC, which may 
have important consequences for both toxicity and tumour control.  PET-fusion may allow smaller 
volumes to be outlined (especially likely in cases of atelectasis), this would allow smaller volumes of 
normal lung to be irradiated, which should improve the toxicity profile of the treatment (10).  
Alternatively, PET may increase the outlined tumour volumes (due to positive lymph nodes), which is 
likely to have a positive impact on tumour control (11). 
 
A disadvantage to PET (compared to CT), however, is that PET has poorer spatial resolution (12). 
 
 
8 
 
Figure 2: Image A shows a CT image taken at the level of the thoracic inlet.  The arrow shows a 
pathological lymph node which is relatively difficult to identify.  Image B shows a co-registered PET-
CT image.  The arrowed node avidly takes up radio-labelled FDG and is now easy to identify. 
 
  
 
The localisation of tumours can also be improved by the use of intravenous (or oral) contrast agents.  
If CT is being used as the imaging modality, contrast agents are iodinated.  These agents improve the 
delineation of anatomic structures, especially vascular structures, and improve the accuracy of lesion 
characterisation (13). 
 
Planning 
 
Once a tumour has been outlined on the primary CT (possibly with reference to other imaging e.g. 
MRI, PET), the planning process can begin.  As well as localising the target, it is important to also 
localise “Organs at Risk” (OAR), these are the adjacent critical normal body structures that limit the 
dose that can be safely delivered to target.  If safe doses to OARs are not respected the consequence 
will be increased toxicity of treatment (14).  Conformal planning techniques modify the shape of the 
beam, to match the shape of the tumour, hence decreasing the volume of normal tissue that is 
irradiated.  The beam shape is modified by the use of computer-controlled Multi-Leaf Collimators 
(MLCs) which are 0.5cm thick and are mounted in the treatment head of the Linear Accelerators (the 
machines used to deliver MegaVoltage (MV) Radiotherapy).  The movement of the MLCs at the time 
of treatment is pre-specified in the generated radiotherapy plan.  The use of MLCs for Conformal 
radiotherapy delivery represents an advance over previous shaping techniques both in terms of 
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conformality of treatment, and resources.  Previous techniques either employed the straight edges of 
the jaws in the treatment head (e.g. for a “4-field brick” prostate plan following 2D conventional 
simulation).  Alternatively, custom-made lead alloy blocks were used for beam shaping.  This 
technique had many resource implications as the blocks were time-consuming to make, and there 
were manual-handling issues as the blocks were heavy (15).  In Conformal radiotherapy, the fluence 
is uniform across the radiation field. 
 
 
Limitations of conformal radiotherapy 
 
Despite the improvements described above with respect to conformality of treatment with 
conformal over conventional radiotherapy technique, there are limitations.  It is not possible for 
conformal radiotherapy to cover concave clinical targets such as prostate and seminal vesicles, or 
thyroid, without irradiating normal tissue contained within the concavity as shown in Figure 3 (page 
10). 
 
 
Conformal radiotherapy has limitations also, in that it does not include any inherent motion 
management strategies.  This means that for tumours such as lung cancer, which are subject to a 
considerable degree of movement during a treatment fraction, generous CTV to PTV margins are 
required in order to ensure no geographic miss of target at any stage of the respiratory cycle.  The 
unfortunate consequence of this, however, is that a large volume of normal lung is irradiated. 
 
These limitations have been addressed in more recent advances in radiotherapy, which are discussed 
subsequently in this chapter. 
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Figure 3: 
Three-dimensional conformal radiotherapy (3D-CRT) plan-showing the isodose distribution for the 
prostate gland (royal blue outline) and surrounding structures (bladder=pink outline, rectum=yellow 
outline, femoral heads = red and sky blue outline).  The 3D analysis shows the extent of the high-dose 
area (red shaded area) with regards to covering the prostate and allows an appreciation for the 
volume of the rectum and bowel within the high-dose area. 
 
Image taken from “Technological advances in radiotherapy for the treatment of localised prostate 
cancer”, Mangar SA et al, European Journal of Cancer 41 (2005) 908–921. 
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1.1.2 Dose-fractionation issues 
 
Conventionally fractionated radiotherapy involves the delivery of 2Gy in a single fraction each day to 
tumour.  By convention, radiotherapy tends to be delivered on working days, therefore delivery of 5 
x 2Gy fractions of radiotherapy per week is standard.  The total dose to be delivered to tumour will 
depend partly on the aim of treatment (radical vs palliative).  Other considerations include the 
radiation sensitivity of the tumour: lymphoma is radio-sensitive and doses of 30-40Gy delivered at 
2Gy per fraction can be curative.  In contrast, NSCLC would require around 64Gy delivered at 2Gy per 
fraction to give a possibility of cure.  Total dose to the tumour also needs to take account of the 
nearby Organs At Risk (OARs).  Organs At Risk are the normal organs located near the tumour target 
which may be damaged during exposure to radiotherapy.  In practice, it is primarily dose to 
surrounding OARs that limits the dose that can be safely delivered to tumour targets.  Most radical 
treatments (where the aim of treatment is cure) deliver total doses of radiotherapy on the steep part 
of the Dose-Response curve as shown in Figure 4 (page 12).  This means that if it were possible to 
refine our radiotherapy technique in order that we could safely minimise irradiation of OARs 
(without compromising tumour coverage), dose escalation to tumour would be possible, and this 
would improve tumour control (for an equivalent level of toxicity). 
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Figure 4: 
Typical paired sigmoid dose-response curves for Tumour Control (A) and Normal Tissue 
Complications (B) 
 
Image taken from “Impact of PET on Radiation Therapy planning in lung cancer”, MacManus M et al, 
Radiologic Clinics of North America, 45 (4) 627-638, 2007. 
 
 
 
  
 
 
The aim of fractionation (splitting the total radiotherapy dose into multiple 2Gy daily fractions) is to 
spare late effects of radiotherapy on irradiated normal tissues, more than the tumour.  Normal body 
cells have an ability to repair the DNA damage inflicted by radiotherapy, which is superior to that of 
tumour cells.  Protracting the dose (i.e. giving multiple 2Gy daily doses, rather than a large single 
fraction of radiotherapy), allows DNA repair to occur, more so in normal body cells than tumour cells. 
 
Fractionation also aims to beat the phenomenon of hypoxia.  Hypoxic cells are resistant to radiation.  
When oxygenated cells are killed by irradiation, the perfusion of previously hypoxic cells is improved, 
making them more susceptible to radiation-induced cell death on the delivery of the next fraction.  
See Figure 5 (page 13). 
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Figure 5: 
The mechanism by which Fractionation overcomes Hypoxic Radioresistance. 
 
 
 
 
The delivery of radiotherapy at a rate of 2Gy daily fractions, tends to prolong overall treatment time, 
which is advantageous to limit early (acute) side effects of radiotherapy.  The disadvantage of a 
prolonged overall treatment time, however, is the phenomenon of accelerated repopulation.  This is 
especially relevant for courses of radiotherapy of over 3 weeks.  Accelerated repopulation describes 
the phenomenon whereby as a tumour shrinks with radiotherapy, surviving clonogens proliferate at 
an accelerated rate (this may have a negative impact on tumour control).  A further disadvantage to 
a prolonged course of radiotherapy, is patient convenience.  In fact, some cancer patients do not 
have the physical stamina required to undergo a course of radical radiotherapy lasting 6 weeks. 
 
Alternative dose/fractionation regimes are discussed later in this Chapter. 
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1.2 Intensity Modulated RadioTherapy (IMRT) 
 
1.2.1  Treatment planning for IMRT 
 
As described in the previous section, certain tumour targets e.g. thyroid, and prostate and seminal 
vesicles, cannot be covered with a high degree of conformality due to their complex shape.  If a 
number of beams are brought together around an isocentre, and each beam is of uniform fluence, 
the volume of intersection of such beams will be convex, and will contain no concavities. 
 
IMRT is an advance compared to 3D conformal radiotherapy.  The radiation fluence within any given 
radiation field can be varied, this enables the 3D high-dose volume  to have concavities within it to 
conform nearly perfectly with the 3D shape of the tumour.  The fluence may be varied by using 
multiple static fields where each segment, shaped by MLCs, contributes to the total treatment (Step 
and Shoot IMRT).  See Figure 6. 
 
Figure 6: 
Multiple Static Fields shaped by MLCs (green) to create the desired fluence profile (grey). 
 
 
 
 
Alternatively, the MLCs can be moved during beam delivery to create the desired fluence profile 
(Dynamic MLC delivery). 
 
Using either technique IMRT can achieve dose plans where the Target Volume has concavities within 
it, see Figure 7 (page 15). 
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Figure 8: 
IMRT Dose distribution for pelvic lymph nodes.  The high-dose volume (shaded red) has a concavity 
within it which allows dose to the Bladder to be minimised. 
 
 
    
 
 
In addition, the ability to vary the fluence within each radiation field enables the production of plans 
that have optimum dose homogeneity.   
 
Equally, planned dose inhomogeneities can be introduced into a radiotherapy plan in order to match 
the dose delivered with risk for tumour recurrence (16).  This approach is being trialled in the 
IMPORT-High trial for breast cancer (17). 
 
The desired 3D dose distribution can be reached via either “forward planned” or “inverse planned” 
techniques.  “Forward planning” involves the planner trying a variety of configurations of beams, 
wedges and beam weightings until a suitable match is found to the dose prescription.  Forward 
planning is possible for some forms of IMRT in which only a few beams will be employed, each with 
just a few “segments” (which will vary the fluence of each beam) e.g. Breast.   
 
“Inverse planning” requires the planner/oncologist to specify dose-volume constraints and/or dose 
limits to target and OARs.  These specifications drive the planning computer to satisfy the constraints 
as much as possible.  Inverse planning tends to be the preferred planning technique with more 
complex targets, and where more beams are likely to be needed to create an optimal 3D dose 
distribution e.g. head and neck target, and prostate/seminal vesicles (18). 
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IMRT delivery techniques vary.  They include (but are not limited to) multiple-static-field MLC 
technique, dynamic MLC technique (where MLCs will be moving while the beam is turned on) and 
robotic IMRT. 
 
As the complexity of radiotherapy planning and delivery techniques increases, there is increased 
potential for a plan to not be delivered as intended.  Quality assurance (QA) is therefore especially 
important for IMRT techniques.  An ESTRO report from 2008 gives practical guidance on 
recommended QA procedures (including phantom measurements and in vivo dosimetry) for 
departments which deliver IMRT (19). 
 
In summary, the perceived advantage of IMRT is sparing collateral damage to adjacent normal tissues 
by shaping the high-dose target volume more accurately to the borders of the irregular shaped 
tumour.  Alternatively, for any given dose to the adjacent normal structures, the dose to the tumour 
may be higher. 
 
1.2.2 Clinical evidence for gain over Conformal radiotherapy. 
 
A number of “planning studies” have shown potential advantages for IMRT planning and delivery, 
over 3D Conformal radiotherapy.  Arbea et al compared these techniques for the treatment of locally 
advanced rectal cancer (20).  Target coverage and normal tissue avoidance were compared using 
standard planning parameters.  Target dose distribution showed greater dose inhomogeneity after 
IMRT planning.  3D Conformal radiotherapy plans had significantly poorer conformality, as measured 
by the Conformity Index (CI).  The CI is the ratio between the target volume (PTV) and the irradiated 
volume at specified prescription dose (Vol PTV/Vol IR95%) (21).  The V40 (i.e. the volume receiving 
40Gy or more) and the D5 (the doses to 5% of the volume) for OARs were significantly lower in the 
IMRT plans. 
 
However, for a new radiotherapy technique to represent a true clinical gain over its predecessor, the 
potential dosimetric advantages outlined above should translate into improved toxicity profiles.  A 
new technique should either show equivalent tumour control, with reduced normal tissue toxicity; or 
improved tumour control with equivalent normal tissue toxicity. 
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An observational cohort study using data from the SEER-Medicare database compared men over 65 
years of age who had received radiotherapy for non-metastatic prostate cancer.  A cohort of over 
5000 men had received IMRT, whilst a further cohort of over 6000 men had received conformal 
radiotherapy.  The primary outcome measure was bowel complications.  IMRT was associated with 
reductions in composite bowel complications (24-month cumulative incidence, 18.8% vs 22.5% , 
HR=0.86, 95%CI=0.79-0.83)(22). 
 
Similar clinical gains for IMRT have been demonstrated for Breast (16) and Head and Neck (23) 
tumour sites. 
 
Overall, having given consideration to the improved dosimetry and clinical gains of IMRT over 3DCRT, 
the importance of IMRT nationally has been reviewed by the National Radiotherapy Advisory Group 
(NRAG).  NRAG produced a report in 2007 recommending that IMRT should become the standard of 
care between 2012 and 2017 (2). 
 
 
1.3 Stereotactic Body Radiotherapy (SBRT) 
1.3.1 Definition 
This is a form of high-precision radiotherapy delivered to extra-cranial sites characterised by: 
reproducible immobilisation to avoid patient movement during radiation delivery; measures to 
account for tumour motion during treatment planning and delivery; dose distributions tightly 
covering the tumour, with rapid dose fall-off in surrounding normal tissues in order to minimise 
toxicity; and most importantly, the use of extremely high doses of radiation, usually delivered in 3-5 
treatment fractions over a week (24). 
CyberKnife (Accuray, Sunnyvale, USA) is an image-guided robotic radiosurgery system purpose-built 
for delivery of SBRT.  A compact 6MV X-band linac is mounted onto a six-joint robotic arm.  This 
provides flexibility in beam pattern generation, allowing the system to produce very conformal non-
isocentric treatment plans.  A typical CyberKnife plan will utilise 100-250 beams to give optimum 
conformality.  Whilst conformality is clearly important, a CyberKnife planner and their Clinical 
Oncologist must always weigh up the clinical gains of conformality against the inconvenience to the 
patient of longer treatment times (which can be over an hour for CyberKnife vs <10mins for 3DCRT).  
The CyberKnife system also features a robotic couch with six degrees of freedom and near real-time 
kV image guidance (25) . 
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The technique represents a step forward as “body” (extra-cranial) tumour sites can now be treated 
with hypofractionated radiotherapy to a radical dose, over a short overall treatment time, with an 
acceptable toxicity profile, and excellent rates of tumour control. 
 
1.3.2 Key Components 
Immobilisation 
The immobilisation which is most appropriate depends on the target site and the SBRT delivery 
system which is being used. 
Certain target sites (e.g. lungs) are more difficult to immobilise than others (e.g. spine).   
A further consideration as to the degree of immobilisation that is required, is the image guidance 
system that is available (i.e. Real-time tracking vs. Cone-beam CT pre-treatment fraction). 
Immobilisation for SBRT treatments is often achieved with the use of a vacuum-formed personalised 
immobilisation device (Vacbag).  A treatment position must be chosen that the patient can 
comfortably maintain for the duration of treatment.  Consideration should also be given to arm 
position, as well as supine vs. prone, to allow the optimum range of beam angles to treat tumour, 
without passing through unnecessary non-target tissue e.g. arms, and without being constrained by 
the treatment couch.  (The CyberKnife system does not allow beams to enter through the treatment 
couch). 
 
Tumour motion 
Irrespective of the SBRT system being used, it is imperative that tumour motion can be accurately 
evaluated and accounted for, in order to avoid geographical miss. This is especially critical for 
tumours which are subject to respiratory motion e.g. thoracic, pancreatic, and hepatic tumours.  
Some SBRT systems can track such targets (e.g. Cyberknife, using the Synchrony system, see Section 
1.3.6).  Others are capable of gated delivery, i.e. the delivery of radiation only at certain pre-defined 
phases of the respiratory cycle (e.g. Gated RapidArc).  All systems require appropriate CTV to PTV 
expansions. 
The functions of the different commercially available SBRT system are discussed in Section 1.3.3. 
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1.3.3 SBRT Treatment Delivery Systems 
A number of modern Linear Accelerators (linacs) with on-board imaging capabilities meet the basic 
image guidance requirements for delivering SBRT, e.g. Varian Trilogy: RapidArc (Varian Medical 
Systems, Palo Alto, CA, USA) and Elekta Synergy (Elekta, Stockholm, Sweden).  A micro MLC can be 
added to produce the required degree of conformality for stereotactic plans. 
Newer developments include fully-integrated SBRT delivery systems.  Novalis TX has a Varian Trilogy 
linac base with micro (2.5mm) MLC.  This system incorporates the BrainLAB “ExacTrac X-ray 6D” 
system, which provides near real-time image guidance with six degrees of freedom, and a 
corresponding robotic treatment couch with associated software (BrainLAB, Munich, Germany).  The 
TrueBeam (Varian) and Elekta Axesse are similar integrated systems. 
The TomoTherapy Hi-Art System (TomoTherapy, Madison, WI, USA) has a ring gantry as used in 
diagnostic CT scanners and delivers helical IMRT via thousands of small beamlets.  The system has 
on-board image guidance with megavoltage CT. 
CyberKnife (Accuray, Sunnyvale, CA, USA) is an image-guided robotic radiosurgery system.  The 
system was outlined in Section 1.3.1 (page 17).  Treatment delivery is guided by 2 orthogonal X-ray 
sources mounted in the ceiling of the CyberKnife room, these cameras are orientated to point at the 
imaging centre of the room and X-Rays are received by plates in the floor of the room.  See Figure 9 
(page 20).  Extra-cranial, non-spine treatments are largely guided by fiducial tracking, because soft 
tissue tumours tend to be poorly visualised on the X-ray based image guidance system.  Fiducials are 
gold markers implanted in or around tumour, which act as a surrogate for tumour position. 
A key advantage of the CyberKnife system is the Respiratory Tracking System: Synchrony™.  This is a 
hybrid tracking system for lung tumour targets, and tumours that will move with respiratory motion.  
The system tracks tumour movements with 2 methods: a) Light Emitting Diodes (LEDs) that are 
placed on the patient’s upper abdomen.  3 cameras (see Figure 9, page 20) continually track the 
LEDs, b) Live X-rays taken of the tumour with implanted fiducial surrogates.  This information is fed 
into the Synchrony system and a breathing “model” of the patient’s breathing is created, which is 
used to allow the CyberKnife to accurately target treatment beams to a moving tumour (26). 
 
 
 
20 
 
 
 
 
Figure 9:  An image to demonstrate the CyberKnife Treatment Delivery System. 
 
 
 
 
  
 
1.3.4 Conformality 
As SBRT delivers an ablative dose to the target, it is essential that the target is covered with a high 
degree of conformality, with a sharp dose fall-off in the surrounding normal tissues.  This can be 
achieved due to complex inverse-planning computer systems, as always, guided by physicists and 
planning radiographers to achieve the desired dose-distribution.  Depending on the SBRT system 
being used, the IMRT delivery techniques described in section 1.2 can help to achieve the required 
X-Ray source 
 
Linear accelerator treatment head with 
collimator 
Robotic Delivery System 
Image detectors Treatment couch 
Cameras x3 for 
Synchrony™ system  
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degree of conformality.  In addition, the ability to deliver non-coplanar, non-isocentric beams can 
also help to achieve optimum conformality. See Figure 10 (page 21). 
Whilst optimum conformality is critical in SBRT, there are a number of caveats to this approach.  
Given the tight GTV to PTV margins that are applied with this technique, it is absolutely critical that 
target delineation is accurate.  This technique is potentially vulnerable to geographical target miss 
(with possible consequences of reduced tumour control and/or increased normal tissue toxicity) if 
there are errors in target localisation, or in treatment delivery. 
 
Figure 10: 
A CyberKnife treatment plan, (CT scan: axial slice), for treatment of a primary lung tumour.  A fiducial 
can be seen (arrowed) in the tumour.  The thick green line is the isodose prescription line.  The key in 
the top right hand corner of the image gives a scale for the isodoses (in cGy).  The plan shows a sharp 
fall-off in dose with distance from the tumour. 
 
 
Fiducial 
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1.3.5 Dose-fractionation issues 
As described in section 1.1.2, conventionally fractionated conformal radiotherapy delivers 2Gy per 
fraction to the tumour volume, together with a margin to account for inaccuracies of planning, set-up 
and delivery.  Total dose will vary according to the intrinsic radiation sensitivity of the tumour, as well 
as the radiation tolerance of the adjacent organs at risk.  The therapeutic benefit achieved with this 
dose fractionation has been appreciated for over 100 years, and clinical experience of the effects of 
this fractionation on both tumour, and normal tissues, has been accumulating over this time period.  
The development of radiobiological concepts such as the linear quadratic model (27) and the “4 R’s” 
of radiotherapy (Repair, Reassortment, Repopulation, and Reoxygenation)(28), as well as key clinical 
observations, have led to further understanding of the tissue effects of fractionation.  The 
radiotherapy community has accumulated a considerable body of evidence of “safe” dose limits to 
organs at risk when conventional fractionation is employed (14, 29). 
Conformality was known to be an important goal even in 1938 (30), although the necessary technical 
advances to achieve the desired conformality followed many years later.  Dose homogeneity 
delivered to the target was also considered an important principle. The ICRU 50 report 
recommended that the target is covered with a homogenous dose, i.e. -5% to +7% of the prescription 
dose (3).  The aim of radiotherapy has always been to damage every single potentially malignant cell 
to such an extent that it cannot continue to proliferate, and it is known that increasing total dose 
makes this more likely (31). However, this has to be weighed up against expected normal tissue 
toxicity.   
In practice, conventionally fractionated radiotherapy delivers a total dose to tumour which aims to 
prevent proliferation, whilst staying within “safe” dose constraints to nearby organs at risk. 
In contrast, the dose fractionation regimes employed in SBRT represent a departure from 
conventional dose fractionation.  Large doses per fraction (e.g. >8 Gy/#) are delivered with the aim of 
ablating all tissue within the PTV.  A moderate internal dose gradient is achieved, as SBRT is typically 
prescribed to a prescription isodose of 60-80%.  This creates considerable dose inhomogeneity within 
the target volume, certainly beyond that which is recommended in the ICRU 50 report.   However, 
there is some evidence to suggest that carefully planned target dose inhomogeneity may enhance 
the tumoricidal effect (32). 
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Whilst the potential benefits of ablative radiotherapy can be appreciated in terms of improved 
tumour control, there are also potential risks. 
Extra-cranial sites can be prone to significant inter- and intra-fraction movement of both tumour, and 
organs at risk.  As previously explained, this increases the risk of tumour miss, and increases the risk 
of irradiating normal tissue to ablative doses.   
Another note of caution is that the overwhelming experience with treating extra-cranial sites is with 
conventional dose fractionation.  There is concern, also, that the linear quadratic (LQ) model (which 
is used by Clinical Oncologists to predict tissue response to altered fractionation regimes), may not 
accurately predict cell response at the higher doses per fraction used in SBRT regimes (33). 
As a consequence of these uncertainties, there is wide variation in the SBRT dose fractionation 
regimes employed.  Current SBRT regimens have largely been based on cautious dose escalation in 
Phase I clinical trials (34), (35),(36). 
The radiation schedules used in SBRT cannot be directly compared with those used in conventional 
radiotherapy, as explained, because the dose per fraction is different.  To compare the regimes, 
therefore, Biologically Effective Dose (BED) must be calculated (37). To take primary lung cancer as 
an example, conventionally fractionated schedules delivered with curative intent e.g. 64Gy/32#, or 
70Gy/35#, typically have a BED of 70-80Gy.  These schedules are associated with a disappointing 
Overall Survival rate of 34% at 3 years (38).  In contrast, modern SBRT schedules use doses equivalent 
to a BED>100Gy, and a frequently used schedule for peripheral lung tumours is 20Gy x 3 which 
delivers a BED as high as 180Gy (34). These high-BED regimes result in superior tumour cell kill, and 
superior tumour control to conventional fractionation.  The RTOG 0236 was a Phase II multi-centre 
trial of SBRT for early stage NSCLC treating to 18Gy x 3 over 1.5 - 2 weeks.  Estimated 3-year primary 
tumour control rate was impressive at 97.6%.  Treatment was reasonably well tolerated (39).   
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1.4 Summary 
There has been a paradigm shift in recent years in the radical radiotherapy treatment of cancer (i.e. 
treatment with curative intent). 
For over 60 years, the radiotherapy community has been delivering 2Gy/#, treating 5 days a week, to 
a “radical” total dose.  In practice, the total dose prescribed would be a dose considered to have a 
reasonable prospect of cure (or long-term local control), whilst also having an acceptable toxicity 
profile. 
There were concerns that increasing the dose per fraction over 2Gy/# could increase especially the 
late effects of radiotherapy. 
A number of recent advances in radiotherapy, however, have enabled the safe delivery of SBRT 
regimes, which deliver a high dose per fraction, and a high BED.  These high-BED regimes achieve 
excellent rates of tumour control. 
SBRT marks a step change in radiotherapy delivery.  Whilst the benefits of this new approach can be 
appreciated, further developments are required to optimise effective dose delivery to tumour, and 
protect normal tissue.  
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1.5 Aims of this Research:  
 
1. To assess if the imaging and interpretation of fiducial position by the CyberKnife in-room imaging 
system is accurate and appropriate. 
I will create an experimental system that will utilise a solid water phantom with 3 fixed, and 1 
migrating, fiducials.  I will rigorously assess the ability of the CyberKnife imaging system to 
accurately identify and analyse fiducial position and migration. 
(Chapter 2) 
 
2. To evaluate whether the “Rigid Body Geometry” of fiducial arrangement, which is established at 
the time of planning CT, is maintained at the time of treatment? 
The accuracy of fixed fiducial tracked treatments is critically dependent on the assumption that 
there is “Rigid Body Geometry” i.e. that fiducial position will be identical at time of planning CT 
and at the time of Treatment CT. 
I will assess the magnitude of any fiducial movement between Planning and Treatment CT scans, 
in a range of body sites, evaluating the clinical scenarios and fiducial positions associated with the 
highest probability of fiducial migration.  My analysis will inform advice to be given on optimal 
fiducial placement to minimise risks of migration. 
(Chapter 3) 
 
3. To develop bladder filling guidelines for Radiotherapy and CyberKnife patients, based on optimal                 
dosimetry and reproducibility. 
To determine the relationship between the consistency of bladder filling (between planning and 
treatment), and the ability to track rotations of the tumour target for the CK treatment of 
prostate cancer. 
(Chapter 4) 
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4. To explore uncertainties in treatment planning/delivery for CK prostate patients, and to calculate 
ideal planning margins for the CK treatment of localised prostate cancer. 
 (Chapter 5) 
 
5. To perform a radiobiological comparison between a conventional radiotherapy schedule and 
SBRT schedule for the treatment of localised pancreatic cancer. 
To analyse the outcome of SBRT to lymph node oligometastases according to delivered 
Biologically Effective Dose (BED). 
To evaluate the outcome of SBRT to oligometastatic breast cancer according to delivered BED. 
(Chapter 6) 
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Chapter 2 
 
Fixed fiducial tracking in a phantom: an experimental model 
 
2.1. INTRODUCTION 
Stereotactic Body Radiotherapy (SBRT) requires a robust system for tracking accuracy. 
Non-spine/Brain SBRT treatments delivered by the CyberKnife system are tracked by the use of fiducials.   
Fiducials are radio-opaque markers e.g. gold seeds, which are inserted in, or close to, tumour.  They act 
as surrogates for tumour position and can be imaged by the integral in-room KV imaging system.   There 
are a number of fiducial placement criteria which must be fulfilled in order to achieve optimum fiducial 
tracking accuracy.  Ideally 3 - 6 fiducials are placed in or around the tumour, with a minimum of 2 cm 
spacing between fiducials to minimise uncertainty in measuring rotation. A minimum of 3 fiducials, 
ideally located in more than one axial plane, is required to track rotations.  The fiducials should be 
placed no more than 5 -6 cm from the target lesion.  This is firstly in order that the fiducials can all be 
captured on the Field of View (FOV) for live images of the CyberKnife treatment consoles, which 
measure 20cm x 20cm.  In addition, the greater the distance between a fiducial and tumour, the greater 
the risk of disparity between fiducial position and true tumour position.  There must also be at least a 
15° angle between any grouping of 3 fiducials i.e. they must not be collinear (1).   
Fiducial tracking is the primary tracking option for treating any soft tissue tumours where it is not 
possible to use bony structures for reference.  The technique was explored in detail by Kitamura et al (2).  
The aim of fiducial tracking is to find the relative translation and rotation (6D transformation including 
roll, pitch and yaw) between the patient position on the treatment couch, and that of the Computed 
Tomography (CT)-planning scan.  The fiducial tracking procedure implicitly assumes that the geometry in 
the planning CT scan (which establishes the relative position of the fiducials to the tumour), is 
reproduced on the day of treatment i.e. there is an assumption that there is Rigid Body Geometry (3). 
30 
 
The fiducial tracking method is often considered the “gold standard” in performance evaluation of other 
registration algorithms (4).  The CyberKnife system uses the Concurrent Viterbi with Association (CVA) 
algorithm to track fiducials.  The algorithm relies partially on analysis from DRRs (from the Planning CT).  
The algorithm then locates the fiducials at the time of treatment in additional steps. 
The fiducial tracking flowchart is shown below (Figure 1): 
 
Figure 1: Fiducial tracking flowchart 
 
 
    
    
   
 
 
  
  
 
 
The fiducial tracking algorithm works on prior knowledge (DRRs from the Planning CT) of 4 key criteria: 
1. Number of fiducials. 
2. Size of the fiducials. 
3. Location of the fiducials. 
4. “X” axis point will be the same in both cameras. 
Fiducial Kernel extraction 
LIVE IMAGES ACQUIRED 
X-Ray Image 
Enhancement 
Fiducial Candidate Extraction by CVA 
Estimation of target translations and 
global rigid rotations 
DRR Input Images 
DRR Image Enhancement 
Post Imaging  
Processing 
Analysis prior to 
acquisition of Live 
images 
31 
 
The DRR’s are reviewed first in a process called “Bandpass filtering” (BPF).  The images are filtered once 
to remove “features” smaller than a threshold size (which is just below the size of one fiducial).  The 
images are then filtered to remove “features” smaller than another threshold (which is just above the 
size of one fiducial).  By subtracting these two the system gets an image containing “features” with a size 
comparable to one fiducial (5).  See Figure 2A and 2B.  Figures 2A-4 are taken from Hatipoglu et al (5). 
 
Figure 2A: DRR image showing 5 implanted fiducials before BPF (Images from Hatipoglu et al) 
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Figure 2B: DRR image after BPF: Implanted fiducials can now be seen more clearly. 
 
The next step is Fiducial kernel extraction.  Fiducial “kernels” are extracted from the DRR’s.  The location 
of each fiducial in the Planning CT is known so the system knows which part of the image to use as a 
kernel.  The DRR’s are then enhanced to capture the kernel as a miniature image with the kernel 
displayed as white, with a small surrounding area of black.  The purpose of this step is to isolate the 
fiducial(s) and to eliminate “noise”.  See Figure 3 below. 
Figure 3:  
Fiducial kernel extraction has identified fiducial kernels for finding candidates in the Live images 
 
 
 
Fiducial 
kernel 
33 
 
“Live” images are then acquired at the time of treatment.  The two in-room X-Ray imagers capture 
orthogonal patient projections in the region of interest.  This step needs to be sensitive and avoid 
missing any potential fiducials, many hundreds of “candidate” fiducials are detected in this step.  
Candidate maps are generated (one map for each fiducial) by comparing each kernel from the enhanced 
DRR with the enhanced live images.  See Figure 4 below. 
 
Figure 4:  
Candidate maps for each fiducial 
 
 
The next step is image correlation.  The imaging system looks for focal areas of radio-intensity. The 
likelihoods of “candidates” for each fiducial on the orthogonal patient projections are then updated.  
The next step involves calculating the association likelihoods of candidates for the same fiducial in the 
two images (as a fiducial’s x-axis position is identical, or almost identical, in the paired images this helps 
the system to accurately identify a fiducial).  The probability of a fiducial candidate being an actual 
fiducial also depends partly on it being an “expected” (expected from DRR) distance away from other 
fiducials.   
Finally, the likelihoods of candidates in each image are updated again with the association likelihoods.  In 
this way, the algorithm converges on the “candidate of maximum likelihood” for each fiducial in the 
paired images.  The “candidates of maximum likelihood” generated, should represent the true fiducials.  
The “success rate” of this algorithm is reported by Accuray Inc to be >99%.  The accuracy was tested by 
reviewing a collection of images from more than 35 patient treatments with 3 fiducials in situ, and more 
than 10,000 image pairs (5). 
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As described, SBRT delivers hypofractionated, high BED, ablative doses of radiotherapy to the tumour 
target, with acceptable levels of toxicity.  The fiducial tracking process is complex as described above.  At 
the time of treatment delivery issues related to fiducial tracking can cause treatment delivery to be 
interrupted until specific interventions are made.  It is important that radiographers are given adequate 
guidance so that the interventions applied are appropriate to the specific clinical situation. 
It is critical that fiducial tracking is accurate, if not there are significant potential consequences: 
decreased tumour control and/or increased toxicity. 
I will investigate the accuracy of the fiducial tracking process in phantom and clinical models. 
 
2.2 AIM 
Is the imaging and interpretation of fiducial position by the CK in-room imaging system accurate and 
appropriate in a Phantom model? 
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2.3 METHODS AND MATERIALS 
Assessment was made of fiducial tracking in a phantom model, this was felt to be more comparable to a 
clinical situation than analysis of fiducial tracking by computer modelling (as reported by Murphy in the 
literature (6)).   
It was thought to be important to analyse the interpretation of both static and migrating fiducials as this 
would more closely represent “real-life” clinical scenarios.  An experimental system was therefore 
designed with 3 fixed (static) fiducials and 1 migrating fiducial. 
Importantly, Accuray, the manufacturers of CyberKnife, believe that this is the first work analysing the 
interpretation of migrating fiducial position in a phantom model. 
2.3.1  Phantom set-up 
A solid water phantom (WT1) measuring 30cm x 30 cm, and 3cm thick was used.  The phantom had 3 
gold fiducials drilled into it at fixed positions.  Each fiducial had dimensions 5 mm by 1 mm (Oncology 
Services Limited). 
The solid water phantom had a 2cm diameter channel within it.  A 2cm solid water tube fitted perfectly 
into this channel, and when the tube was fully inserted into the channel, the tube protruded from the 
phantom by 10.37mm.  A gold fiducial of identical dimensions (5 mm by 1 mm) was drilled into the end 
of the tube and fixed in place with araldite epoxy resin glue. 
A CT scan was taken of the phantom, with the phantom “sandwiched” between 2 solid water phantoms, 
each measuring 30cm x 30cm x 5cm thick.  The purpose of these 2 additional phantoms was to anchor 
the fiducial-bearing phantom in place on the treatment couch, in order to eliminate the risk of the 
phantom being inadvertently moved during the experiment.  The orientation of the fiducial-bearing 
phantom was such that the tube was protruding inferiorly.  See Figure 5. 
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Figure 5:  
A photograph of solid water phantom, with movable tube protruding from the inferior aspect of the 
phantom.  Green laser lights (seen) were used to position the phantom.  This photograph is taken with 
the phantom on the CyberKnife treatment couch, but orientation and set-up is identical to that at CT. 
 
 
 
 
 
 
The 00 and 2700 point was marked on both tube and phantom to ensure that there had been no rotation 
of the tube during the experiment.  See Figure 6. 
Movable tube 
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Figure 6:   
Close-up photograph of the movable tube to illustrate marks on the tube and the main phantom that 
ensured consistency of set-up. 
 
 
2.3.2 Treatment plan generation 
A treatment plan for the phantom arrangement described above was generated on the CyberKnife 
planning system version 4.5 (Accuray Inc, California). 
The planning system is able to automatically identify each of the 4 fiducials as “seed points”, but manual 
adjustments were made in order that the centre of each fiducial was accurately recorded.  The fiducials 
were numbered 1-4, fiducials 1-3 were fixed fiducials within the main body of the phantom.  The fiducial 
sited at the inserted end of the tube (which later represented the “migrating” fiducial), was labelled 
number 4.  See Figure 7. 
Tube Alignment mark 
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Figure 7: Image taken from MultiPlan system showing:  
1. Top left pane: Rendered view of phantom taken from above 
2. Top right pane: Axial view of phantom taken through a fiducial, artefact can be seen, the pink circle with 
crosshairs denotes the centre of this fiducial in the axial plane 
3. Bottom right pane: Coronal view of phantom, the movable tube can be seen with an air-channel within it 
(shown as a black stripe), as before pink crosshairs denote the centre of the “migrating” fiducial in this plane, the 
3 fixed fiducials can be seen in this view. 
4. Bottom left pane: Sagittal view of phantom, the movable tube and migrating fiducial are again shown, as well as 
an additional fixed fiducial. 
 
The image also shows a panel (far left) displaying the x/y/z co-ordinates of the centre of each fiducial. 
 
 
 
 
The inserted end of the tube was outlined as target, and an isocentric plan was generated to cover the 
target.  The purpose of creating this plan was so that at treatment delivery the in-room Cyber Knife 
imaging system would generate paired live images to assess fiducial position. 
“Migrating” fiducial in tip 
of movable tube 
3 x fixed fiducials 
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2.3.3 Fixed Fiducial Tracking: 1 migrating fiducial, 1 fixed fiducial 
The solid water phantom was arranged on the CyberKnife treatment couch exactly as it was at the time 
of the CT planning scan (see Figure 5).  The treatment couch was moved such that the in-room lasers 
intersected over the phantom, at the imaging centre of the room.  The starting position of the phantom 
was with the tube fully inserted.  The orientation of the tube was checked by reviewing the position of 
the 0° and 270° marks on both the tube and phantom (see Figure 6).  The starting position of the 
movable tube was with the tube protruding by 10.37mm, as measured with the depth gauge of digital 
callipers (see Figure 8).  Callipers were supplied by Mitutoyo Corporation with a calibration certificate 
confirming their accuracy to within 0.01mm. 
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Figure 8:  
Photograph showing the digital callipers.  This was the starting position of the experiment, with tube 
protruding by 10.37mm. A depth gauge (seen resting on the index finger of left hand) was used to 
accurately measure tube protrusion.  
 
 
A pair of live X-Ray images were taken (120kV, 100mA) to assess the position of the phantom.  The 
suggested couch corrections were applied, such that suggested couch corrections ultimately 
approximated 0, i.e. Suggested translational corrections ≤0.2mm, and rotational corrections ≤0.1°.  As 
the migrating fiducial was to be moving in the superior-inferior direction, it was prioritised that the 
suggested translation correction in this direction was 0mm at Start. 
A screen shot of the console data was taken at Start.  See Figure 9. 
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Figure 9:  
A photograph of the CyberKnife Treatment Console at the Start of the Experiment.   
2 rows of X-Ray images can be seen.  The top row labelled “A” refers to X-Ray images from Camera A. The bottom 
row shows images from Camera B.  The 1st column of images are “DRRs” (Digitally Reconstructed Radiographs) 
generated from the Planning CT. The air in the movable tube (shown as black) is easily seen. Each fiducial 1-4 is 
highlighted by a green square.  The 2nd column represents the “Live” X-Ray images that have been acquired.  The 
fiducial tracking algorithm has correctly identified each fiducial (highlighted by green circles). The 3rd column 
shows an Overlay of DRR and Live images.  The images overlay perfectly.  To the right of the Overlay images is a 
column for “corrections”.  The Corrections approximate 0mm (0-0.1mm), the rotational corrections approximate 
00 (0.20).  Despite excellent alignment of the phantom, there is still a “Rigid Body Error” generated of 0.48mm.  
The significance of this is discussed later in this thesis. 
 
 
Correction
s 
Rigid Body Error 
reading 
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The tube was moved by hand to protrude by an additional 2mm, i.e. by 12.37mm. Therefore, fiducial 4 
was positioned 2mm more inferiorly than the system was expecting.  The accuracy of positioning was 
confirmed to be correct by using the depth gauge of the digital callipers. 
A further pair of live images was acquired. 
As verification that the tube had been moved accurately by the specified distance, the system was 
initially interrogated to generate offsets and Rigid Body Errors for Fiducial 4 only, then subsequently to 
also generate offsets and RBEs for Fiducials 4 and 1 together (Fiducial 1 was chosen as this was the 
closest fiducial to Fiducial 4). 
Screen shots of the console data were taken after every shift of tube position, the tube was moved by 
2mm increments. 
The final position was 36.37mm protrusion of tube for the first experiment.  At subsequent repeats of 
this first experiment, the final position of the tube was 26.37 mm, this provided data for at least 9 
tube/fiducial positions for each experiment. 
The experiment was repeated twice in order to generate standard deviations for the results achieved. 
2.3.4 Fixed fiducial tracking, 1 migrating fiducial, 2-3 fixed fiducials 
The solid water phantom was set up on the CyberKnife treatment couch exactly as described in Section 
2.3.1.  As before, in order to verify that the tube had been moved accurately by the specified distance, 
the system was initially interrogated to generate offsets and Rigid Body Errors for Fiducial 4 only. 
In this Experiment, the system was then asked to “correlate”, i.e. analyse fiducial position relative to 
each other for the following combinations of fiducials after each 2mm move: 
Fid 4 only 
Fids 1, 2, 4 
Fids 1, 3, 4 
Fids 2, 3, 4 
All 4 Fiducials. 
 
Screen shots of the console data were taken as before.  The experiment was repeated twice in order to 
generate standard deviations for the results achieved. 
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2.4 RESULTS 
2.4.1 Fixed Fiducial Tracking Accuracy: Interpretation of Fiducial position 
In order to minimise the complexity of the analysis, although there were 3 fixed fiducials in the 
phantom, only the detection and correlation of fiducials 1 and 4 were analysed in this section.   
The results of the 1st Run of the experiment are shown in Appendix 2.1.  The experiment was repeated 3 
times. 
On the 1st Run of this experiment the tube was moved (in increments of 2mm) to a position 26mm away 
from the Start position.  The Results for positions up to 16mm from Start position only are shown for 
ease of displaying the data.  
The 1st column describes the move applied (in mm) to the tube (and therefore fiducial 4, the “migrating” 
fiducial).  The tube was moved in an Inferior direction only, so in order to “adapt” to this, when the 
system is being asked to look at Fiducial 4 only (Fiducial 4 only ticked in the “Fiducial tracking” panel on 
the console, see Figure 9 page e), the system should generate a “superior” move as a correction.  The 2nd 
column shows these corrections.  Appendix 2.1 shows good agreement between move applied to the 
tube, and “superior correction”.  Between 0 and 16mm from starting position of fiducial 4, the mean 
difference between the callipers measurement and that of the CyberKnife system was 0.04mm (Range 0-
0.1mm).  This good agreement continued until the tube was 26mm from Start position.  At this point, 
the superior correction was 0.2mm different to the move applied to the tube. The experiment was 
terminated at this point as a fiducial move of 26mm in a clinical situation would be certain to represent 
true migration (rather than deformation) and as such the fiducial would be unreliable for tracking 
purposes. 
The figures in brackets in red type in the 2nd column are the Standard Deviations for the Superior move 
(mm) for fiducial 4 across the 3 runs of the experiment.  For Run 2 the tube was moved to 20mm from 
Start position only, and for Run 3 to16mm.  The experiments were consistent, Standard Deviations 
approximated 0 (Range 0-0.09).   
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Standard deviation =  √
∑ (𝑥−?̅?)2𝑁𝑖=1
𝑁−1
 
Appendix 2.1 shows Reference positions (in x, y and z axis) for Fiducials 1 and 4.  These Reference 
positions are generated from the Planning CT and therefore are fixed.  Indeed, the “Reference” positions 
for both Fiducials are consistent as expected, despite the moves being applied to the tube. 
Fiducial 1  
Fiducial 1 is a fixed fiducial therefore its “Live” (imaged) position should be consistent.  The position of 
Fiducial 1 is accurately and consistently recorded between 0 and 14mm of the tube from its starting 
position.  There are slight differences between the Reference and Live positions of Fiducial 1 (0.17mm in 
x axis, 0.29mm in y axis, and 0.06mm in z axis). These differences are consistent.  The differences arise 
due to the process of the fiducial tracking algorithm.  Each “kernel” represents a certain number of 
pixels, and the kernel can only be moved to its candidate location by a whole number of pixels. 
At 16mm (Runs 1 and 3), and 18mm (Run 1) offset of the migrating fiducial from its expected position, 
the CyberKnife imaging system inappropriately identified Fiducial 1 and instead identified a point in 
space that was approximately the expected distance from Fiducial 4 (highlighted in yellow on the table).  
This was the case despite trying to “help” the system e.g. by decreasing the “tracking range” (the section 
of image in which the system will look for candidate fiducials).  From the console data at “Start” the 
inter-fiducial marker distance between Fiducials 1 and 4 = 19.81mm.  The inter-fiducial marker distance 
(where Fiducial 1 was mis-identified), and with tube at 16mm from the Start position = 22.53mm (on the 
1st Run) and 22.45mm (on the 3rd Run).  The system is therefore likely to be inappropriately identifying 
the same candidate fiducial or “feature”.  On the 2nd Run it was possible to help the system to correctly 
identify Fiducials 1 and 4 at 16mm offset of the tube from the Start position. 
From 20mm to 26 mm inclusive, the system was then able to appropriately identify Fiducial 1. 
Fiducial 4 (migrating fiducial) 
Appendix 2.1 displays the Fid 4 (x) Live positions for the migrating fiducial.  The tube was being moved in 
the x axis, therefore it was expected that the positions would change by 2mm each time (within the 
limitations of pixel size).  The x locations displayed showed this happened consistently for the first Run 
(Mean shift= 2.04mm, range 1.9-2.2mm).  On the second Run, the x axis displacement of migrating 
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fiducial 4 changed by a mean of 2.01 mm on each move (Range 1.9–2.1 mm).  On the third Run, the x 
axis displacement of migrating fiducial 4 was accurately tracked for all positions 0-16mm with a mean 
shift of 2.01mm (Range 1.9-2.2 mm).  Standard deviations for the observed shifts were 0.14mm, 0.1mm 
and 0.16mm on the 1st, 2nd and 3rd Runs respectively so the tracking is consistent. 
Fiducial 4 (y) and (z) Live positions are shown in Table 1.  The y location was accurately identified as -0.89 
and the z location as 8.48 (within the limits of pixel size), up until the 14mm position.  Thereafter the 
system had difficulty in capturing the fiducial accurately, and the reported position of Fid 4 was 
inaccurate, by 0.23mm. 
On the second execution of the experiment, the system accurately tracked the x axis position of Fiducial 
4 until 14mm.  The 16mm position was inaccurately captured, but the system was able to accurately 
track the migrating fiducial in the 18 and 20mm positions.  The Fid 4 (y) locations varied between -0.22 
position and -0.67 across the tracking range (ref position = -0.88).  The Fid 4 (z) locations varied between 
8.26 and 8.48 (ref position= 8.62) other than at 16mm, where it was inaccurately identified at 6.48. 
On the third execution of the experiment, the system accurately tracked the x axis position of Fiducial 4 
up to and including the 16 mm position.  The Fid 4 (y) locations varied between -0.45 and -0.67 (ref 
position = -0.88).  The Fid 4 (z) location varied between 8.26 and 8.48 (ref position = 8.62). 
Results overview: Fiducial 1 (Fixed fiducial) 
Overall, the mean difference between Reference and Live positions of Fid 1 in x axis across all 3 
executions was 0.17mm, as long as the fiducial was correctly identified.  This was very stable i.e. as long 
as the fiducial was correctly identified, Reference position was always -41.69, and Live x position was 
always -41.86. 
Overall, the mean difference between the Fiducial 1 Reference and Live positions in the y axis were small 
as long as the fiducial was correctly identified.  Across all 3 executions the mean difference between 
Reference and Live positions was 0.24 mm. 
The mean difference between the Fiducial 1 (z) Reference and Live positions was 0.06mm, (as long as 
the fiducial was correctly identified) averaged out over all 3 executions.   This was therefore highly 
accurate. 
In summary, the accuracy of fixed fiducial tracking for this experimental system is ≤ 0.24mm. 
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Results overview: Fiducial 4 (Migrating fiducial) 
The mean difference between Fid 4 (x) Reference and Live positions at Start was 0.01mm, therefore 
excellent correlation.  The tube was being moved in the direction of the x axis by 2mm increments, 
therefore the Fid 4 (x) Live position was expected to change by 2mm increments. In the 2nd and 3rd Runs, 
the position changed by on average 2.01mm.  In the 1st Run, the position changed by on average 
2.04mm.  The migrating fiducial was therefore accurately tracked in the x axis, to within 0.1mm. 
On the 1st Run the Fid 4 (y) axis Live position (which should not have changed as the tube was moved) 
was on average 0.01 mm different to the Reference position, so long as the fiducial was correctly 
identified.  On the 2nd Run the difference was 0.39mm, and for the 3rd execution this was 0.31.  Overall, 
the mean difference was 0.24mm. 
The mean difference between Fid 4 (z) Reference and Live positions was 0.19mm for the 1st Run.  For the 
2nd and 3rd executions this difference was 0.19mm, and 0.26mm respectively.  Overall, the mean 
difference was 0.23mm. 
 
2.4.2 Fixed Fiducial Tracking Accuracy: Robot corrections  
The experiment was conducted as described in section 2.3.1. 
In this Experiment, the system was asked to “correlate”, i.e. analyse fiducial position relative to each 
other, for the following combinations of fiducials after each 2mm move of the migrating fiducial: 
Fid 4 only 
Fids 1, 2, 4 
Fids 1, 3, 4 
Fids 2, 3, 4 
All 4 Fiducials 
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When the Fiducials are imaged in a different arrangement to what was expected (i.e. with reference to 
the DRR generated by the Planning CT scan), the CyberKnife system will generate a Correction (see 
Figure 9 image of Console data) and a Centre Of Mass (COM) Translation (see Figure 10, “Translation 
(x,y,z)” is recorded in “Algorithm data” section).  The COM refers to the COM of the fiducials.  The 
“Correction” is reported as a Couch correction, i.e. the move that the Treatment couch would need to 
make in order that the target was correctly aligned for treatment (incorporating a rotation if necessary), 
but in practice it is the Robot that moves by the required amount to ensure that the treatment is 
delivered accurately.  The COM Translation (by definition) does not incorporate any rotational 
corrections. 
 
As can be seen from the Algorithm data section of Figure 11, the COM Translation is reported as an x, y, 
z shift.  It is important to appreciate the x,y,z orientation of the CK room in order to understand the 
direction of shifts.  The room is set up as follows: 
 
X Sup (-)         Inf (+) 
Y Right (-)      Left (+) 
Z Post (-)       Ant (+) 
 
This data was used, as well as the “Start” Translational corrections, in order to calculate the COM 
translational correction using the root of the sum of the squares formula.  A shift was calculated (rather 
than simply using the x,y,z co-ordinates) in order that the relationship between migrating fiducial move 
and COM Translational correction (analogous to Robot corrections) could be explored. 
An example calculation of COM Translation is shown on the next page. 
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At “Start” (i.e. 0mm move of Migrating fiducial): 
 Translation (x, y, z): 0.03, 0.22, 0.02 (See Figure 10).  It can be seen that these Translations are 
analogous to the “Corrections” , the ant/post and the sup/inf translations approximate 0, whilst the 
left/right Correction approximates Left 0.2mm.  A small rotation (0.1 deg to right) is noted which 
accounts for the very slight discrepancy between Translations and Corrections. 
Figure 10:  
A photograph of the CyberKnife Treatment Console at the Start of the Experiment.  “Corrections” (in 
mm) are listed in the left of the image. The x,y,z Translations (in mm) are listed in the data panel 
 
 
 
 
Translational corrections 
49 
 
At 6mm move of Migrating fiducial (when considering Fids 1 and 4): 
COM Translation shift = -2.91, 0.08, 0.04 (see Figure 11 below). 
Figure 11: 
Photograph of CK console data to illustrate robot corrections for a migrated fiducial 
 
i.e. the suggested correction is in the superior direction by almost 3mm: 
√(0.03 + 2.91)2  +  (0.22 − 0.08)2 + (0.02 − 0.04)2 
 
= 2.94 (see Table 1, page 51). 
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This calculation was repeated for each 2mm move of the migrating fiducial, and according to the 
combination of fiducials being correlated.  
Results are recorded in Table 1 (see next page) and are displayed in Graph 1 (page 53).  Results are not 
displayed for “Fiducial 4 only”, as for a treatment tracked by a single fiducial, the Centre of the Fiducial is 
the Centre of Mass.  The “Corrections” for Fiducial 4 only are listed in the 2nd column of Appendix 2.1. 
The COM Translational corrections show good reproducibility of results, as can be seen from the 3 Runs 
of the experiment correlating Fiducials 1 and 4, the curves on Graph 1 overlie each other.  Standard 
deviation ranges between 0 mm and 0.15mm. 
When correlating combinations of 3 fiducials, standard deviation ranged between 0mm and 0.07mm. 
When correlating all 4 fiducials, standard deviation ranged between 0mm and 0.4mm. 
Therefore for a given Move of the migrating fiducial, the suggested COM Translational corrections are 
consistent to within 0.4mm. 
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Table 1:  
COM Translational correction (mm) vs. Migrating fiducial move (mm) according to combination of 
fiducials being assessed.  
Figures in red font indicate where a Fiducial was misidentified. 
   
Fiducial 4 
distance 
moved 
(mm) 
COM Translational Correction (mm) 
Fids: 
1 and 4 
Fids: 
1,2,4 
Fids: 
1,3,4 
Fids: 
2,3,4 
Fids: 
All 4 
0 0 0 0 0 0 
2 0.89 0.56 0.76 0.73 0.52 
4 2 1.25 1.44 1.41 1.02 
6 2.94 1.93 2.13 2.09 0.79 
8 3.88 2.61 2.81 2.78  
10 4.99 3.25 3.44 3.41  
12 5.93 2.25 2.07 2.08  
14 6.88     
16 13.7     
 
Graph 1 (page 53) and Table 1 above displays “move” applied to Fiducial 4 (in mm) compared to Centre 
of Mass translational correction (as reported by the CK system) according to the number and 
combination of fiducials being used (or “correlated”), for tracking purposes.  It is important that the CK 
system suggests the appropriate translational correction, as the CK system will generate “Robot 
corrections” analogous to these corrections (as has been shown).  The COM translational corrections 
have been plotted, rather than “Robot corrections”, because as a safety feature, once the Rigid Body 
Error>5, the system will not generate Robot corrections (and treatment is rendered “Undeliverable”), as 
it is considered that at this point (appropriately, given the tiny margins applied in SBRT) that the fiducials 
are no longer a good surrogate for tumour (see Figure 12).  Plotting COM translations therefore (rather 
than Robot corrections) allows more data points to be plotted. 
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Graph 1 and Table 1 show that the COM translational correction is greatest when only 2 fiducials 
(fiducials 1 and 4) are being correlated, as the COM will be equally dependent on each fiducial. On 
reviewing the relationship between COM translational correction and move applied to Fiducial 4, the 
COM translational correction approximates Fid 4 move (mm) divided by 2 when measured to the nearest 
mm (when correlating 2 fiducials).  At 16mm (from Start position), the CK in-room imaging system failed 
to accurately identify Fids 1 and 4, hence the erroneous reading of COM translational correction at 
16mm (Table 1 red font). 
Graph 1 and Table 1 show that COM translational correction, when correlating 3 fiducials (2 fixed 
fiducials and 1 migrating fiducial), approximates Fiducial 4 move (mm) divided by 3.  At and beyond 
12mm move of Fiducial 4, the CK system could not accurately identify both Fiducials 1 and 4. 
Graph 1 and Table 1 show COM translational correction when correlating all 4 fiducials, approximates 
Fiducial 4 move (mm) divided by 4 for the first 2 data points (i.e. where Fiducial 4 is 2mm and 4mm away 
from Start position).  Thereafter, the data points are erroneous because Fid 1 and 4 could not be 
accurately identified.   
Where fiducials are accurately identified, in a Phantom experiment with fixed fiducials and only one 
“migrating” fiducial: 
COM translational correction (mm)~ Move of migrating fiducial (mm) ÷ n 
Where n = number of fiducials.  
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Graph 1: Migrating fiducial distance moved vs COM Translational Correction 
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2.4.3 Rigid Body Error (RBE) 
RBE refers to the discrepancy (in mm) in Fiducial positions (relative to each other) between the CT 
Planning scan and the time of treatment.  The larger the RBE, the greater the change in Fiducial position 
from planning scan to treatment.  Table 2 shows the Fiducial 1-4 inter-marker distance, and RBE for the 
3 Runs of the experiment up to 14mm displacement of the tube.  Figures in red represent RBE values 
greater than the “deliverable” threshold.  The figures in blue font represent figures generated when at 
least 1 fiducial was misidentified.  Full raw data is shown in Appendix 2.1 as before.   
Table 2: Results from 1st Phantom experiment: focus on inter-fiducial distance and RBE 
Move (mm) 
tube from 
Start 
Fid 1-4 
Distance (mm) 
Run 1 
Fid 1-4 
Distance (mm) 
Run 2 
Fid 1-4 Distance 
(mm) 
Run 3 
RBE: Run 1 
(mm) 
RBE: Run 2 
(mm) 
RBE: Run 3 
(mm) 
0 19.81 19.78 19.81 0.04 0 0 
2 21.54 21.27 21.27 1.77 1.5 1.5 
4 23.18 23.18 23.32 3.41 3.41 3.55 
6 25 25 25 5.23 5.23 5.23 
8 26.71 26.71 26.71 6.94 6.94 6.94 
10 28.74 28.59 28.64 8.96 8.81 8.86 
12 30.49 30.4 30.4 10.71 10.62 10.62 
14 32.41 32.41 32.17 12.63 12.63 12.4 
16 22.45 13.41 22.53 2.67 6.36 2.75 
 
At the Start position, the Fiducial 1-4 distance was on average 19.8mm (range 19.78-19.81mm).  At the 
Start position we know that there should be no Rigid Body Error (RBE), as the arrangement of fiducials 
should be identical to that at the time of the CT planning scan, i.e. there is “Rigid Body” geometry 
between planning CT scan and the time of the live paired imaging of the phantom by the CyberKnife 
system.  The reported RBE at Start was on average 0.01mm (range 0-0.04mm). 
The CyberKnife system was able to accurately identify both Fiducials 1 and 4 in this experiment up to 
and including the 14mm position.  Considering only the 0-14mm positions the Fid 1-4 distances, and 
RBE’s will be analysed. 
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The mean increase in Fid 1-4 distance across all 3 Runs was 1.8mm (Range 1.5-2.05, SD = 0.16) each time 
the tube was moved by 2mm.  It was not expected that the Fid 1-4 distance would increase in 2mm 
increments as Fiducials 1 and 4 were not in the same x axis plane.  
The mean increase in RBE Fid 1-4 was 1.8mm (Range 1.5-2.05, SD = 0.16).  
On reviewing the RBE Fid 1-4, for each move, Fid 1-4 distance increase = RBE Fid 1-4 increase. 
Therefore, as only one Fiducial is moving (Fid 4), and system is being asked to correlate only 2 Fiducials 
(Fids 1 and 4, Fids2&3 switched off), Fid 1-4 distance change = RBE Fid 1-4.   
RBE is calculated by the CK system according to the following formula: 
√(∆x2  +  ∆y2  +  ∆z2) to get the shift in fiducial positions between “Reference” locations and  “Live” 
locations, where Δ = change in co-ordinates (Reference to Live) 
To verify RBE reporting for RBE at 2mm shift of Fiducial 4 (see Appendix 2.1): 
Calculate Reference (i.e. Planning scan) Fid 1-4 intermarker distance:  
∆x = (-41.69+25.45) = -16.24 
∆y = (-2.75+0.88) = -1.87 
∆z = (-2.52-8.62) = -11.14 
 
= √(−16.24)2  +  (−1.87)2 +  (−11.14)2 
 
= 19.78 
 
Calculate Live Fid 1-4 inter-marker distance at 2mm shift: 
∆x = (-41.86+23.6) = -18.26 
∆y = (-2.46+0.67) = -1.79 
∆z = (-2.46-8.26) = -10.72  
 
= √(18.26)2  +  (1.79)2 +  (10.72)2 
  
= 21.25 
21.25 (Live) – 19.78 (Ref) = 1.47 (i.e.1.5) (see Column 2, Appendix 2.1) 
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Therefore calculated and reported RBEs agree. 
These calculations were repeated for the data in Table 1 and for all data, calculated and reported RBE’s 
were in agreement. 
Tables 3 and 4 show further RBE results, when correlating combinations of 2 and 3 fixed fiducials and the 
single migrating fiducial.  Figures in red represent RBE values greater than the clinically “deliverable” 
threshold for a treatment plan.  The figures in blue font represent figures generated when at least 1 
fiducial was misidentified.  Figures in purple font in brackets represent Standard deviation (SD). 
Table 3:  
Move of Migrating fiducial (mm) vs RBE (mm) when correlating combinations of 2 fixed fiducials and 1 
migrating fiducial.  
Fid 4 
move 
(mm) 
Fids 
1,2,4 
1-2 RBE 
Fids 
1,2,4 
1-4 RBE 
Fids 
1,2,4 
2-4 RBE 
Fids 
1,3,4 
1-3 RBE 
Fids 
1,3,4 
1-4 RBE 
Fids 
1,3,4 
3-4 RBE 
Fids 
2,3,4 
2-3 RBE 
Fids 
2,3,4 
2-4 RBE 
Fids 
2,3,4 
3-4 RBE 
0          
2 
0.22 
(0.05) 
1.5 
(0.12) 
1.94 
(0.18) 
0.7 
(0.18) 
1.5 
(0.12) 
0.85 
(0.08) 
0.19 
(0.04) 
1.94 
(0.18) 
0.85 
(0.08) 
4 
0.22 
(0.03) 
3.51 
(0.08) 
3.59 
(0.1) 
0.7 
(0.09) 
3.51 
(0.08) 
2.48 
(0) 
0.19 
(0.03) 
3.59 
(0.1) 
2.48 
(0) 
6 
0.22 
(0.05) 
5.19 
(0.13) 
5.13 
(0.18) 
0.7 
(0.18) 
5.19 
(0.13) 
3.73 
(0.08) 
0.19 
(0.04) 
5.13 
(0.18) 
3.73 
(0.08) 
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Table 4:  
Move of Migrating fiducial (mm) and RBE (mm) when correlating all 3 fixed fiducials and 1 migrating 
fiducial.  
Fid 4 
move 
(mm) 
Fids 
1,2,3,4 
1-2 RBE 
Fids 
1,2,3,4 
2-4 RBE 
Fids 
1,2,3,4 
1-3 RBE 
Fids 
1,2,3,4 
1-4 RBE 
Fids 
1,2,3,4 
3-4 RBE 
Fids 
1,2,3,4 
2-3 RBE 
Fids 
1,2,3,4 
All 4 RBE 
0 
0.22 
(0.03) 
0.37 
(0.01) 
0.7 
(0.09) 
0.11 
(0.02) 
0.47 
(0.08) 
0.19 
(0.04) 
0.7 
(0.09) 
2 
0.22 
(0.03) 
1.94 
(0.18) 
0.7 
(0.09) 
1.5 
(0.19) 
0.85 
(0.08) 
0.19 
(0.04) 
1.94 
(0.18) 
4 
0.22 
(0.03) 
3.59 
(0.1) 
0.7 
(0.09) 
3.51 
(0.08) 
2.48 
(0) 
0.19 
(0.04) 
3.59 
(0.1) 
6 
0.22 
(0.03) 
0.81 
(0.03) 
0.7 
(0.09) 
0.1 
(0) 
1.79 
(0.13) 
0.19 
(0.04) 
1.79 
(0.13) 
 
As can be seen from Tables 3 and 4, when the system is asked to correlate only fixed fiducials (e.g. 1-
2RBE, 1-3 RBE and 2-3RBE) the RBE is small (Range 0.19-0.7mm), and the RBE is consistent and 
reproducible (SD = 0.03-0.18mm).  These RBEs reported for fixed fiducial correlation are small enough to 
allow a treatment to be deliverable. 
In contrast, when correlating a fixed fiducial (Fids 1-3) with a migrating fiducial (Fid 4), the RBE is larger.  
The reported RBEs remain consistent and reproducible (SD=0.01-0.19mm).   As expected, the RBE 
increases as Fiducial 4 move increases.   
When correlating 2 fixed fiducials and the migrating fiducial (Table 3) at a 2mm move of the migrating 
fiducial, the treatment would be considered “deliverable”.  Even though the only migrating fiducial is 
fiducial 4, and all other fiducials (1-3) are fixed, the reported RBE varies from a minimum of 0.85mm (3-
4RBE) to a maximum of 1.94mm (2-4RBE) when the migrating fiducial moves by 2mm. 
Of note, when correlating 3 fixed fiducials with a migrating fiducial, at 6mm move of the migrating 
fiducial, the CK in-room imaging system starts to misidentify a fiducial (see Table 4).  The RBE generated 
at a move of 6mm of the migrating fiducial is “deliverable” in all cases (RBE 0.1-1.79mm) despite this 
large fiducial migration (blue font for erroneous RBE due to misidentified fiducial but “deliverable” RBE.  
The implications of this will be discussed.  
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2.5 DISCUSSION 
An important component of SBRT is that the margin between GTV (Gross Tumour Volume) and PTV 
(Planning Target Volume) is small, typically only 2-5mm. 
This means that, as long as targetting by the SBRT system is accurate, there will be minimal normal 
tissue in the PTV, and High BED (Biologically Effective Dose) ablative doses of radiotherapy may be safely 
delivered (as long as appropriate dose constraints are respected)(7).  
A caveat to the above is that it is vitally important that target outlining is accurate, and that SBRT 
treatment is delivered exactly as intended.  If there are errors in either target outlining, or treatment 
delivery, there could be target miss (which would negatively impact on tumour control).  There could 
also be overdose of nearby OARs (organs at risk), which could have a serious impact on acute and late 
toxicity. 
 
2.5.1   Fixed fiducial tracking accuracy: Interpretation of fiducial position 
Single fiducial: 
When reviewing the results of the 1st experiment, the CyberKnife imaging system could accurately 
identify Fiducial 4 (the migrating Fiducial), when this was the only Fiducial the system was being asked to 
locate, out to at least 26mm (away from “Expected“position).  The callipers used to measure the 
distance moved by Fiducial 4 were accurate to within 0.01mm, so this was considered the “gold 
standard” measure of distance moved.  Against this standard, the system accurately calculated the 
“Superior correction” i.e. the move that the robot would need to make to line it up with Fiducial 4 to 
within 0.05mm (range 0-0.2mm).  There was only a single discrepancy of 0.2 mm, this was at the most 
extreme position of Fiducial 4, 26mm away from where the system was expecting it to be.  At this 
position, although the tube still fitted snugly into its channel, it is certainly plausible that it was more 
difficult to accurately move the fiducial-bearing tube.  In routine clinical practice a fiducial detection 
accuracy of 0.05mm (as achieved out to 26mm) would be considered clinically acceptable, as given the 
GTV to PTV margins applied of a minimum of 2mm this should not lead to target miss or overdose of 
nearby OARs. 
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It should be borne in mind, however, that in this phantom experiment the system is being asked to 
locate a radio-opaque fiducial, in a homogenous solid-water phantom, and the y/z axis positions were 
exactly as expected from the CT-planning scan.  This is likely to be an easier case to interpret than a 
clinical case where there is less contrast between fiducial and soft tissue, and y/z positions may have 
changed. 
Multiple fiducials 
The experiment next looked at whether the system could accurately detect both a migrating fiducial 
(Fiducial 4) and a fixed fiducial (Fiducial 1).  The system could accurately detect both fiducials from 0mm 
to 14mm displacement of the migrating fiducial from its expected position, beyond this distance the 
migrating fiducial is misidentified.   In clinical terms, a 14mm shift of a fiducial from its expected position 
is a relatively large distance.  If this shift is due to a fiducial migration, a shift of this magnitude would 
lead a Radiographer/Clinician to question whether the fiducial was a good surrogate for tumour.  When 
multiple fiducials are being tracked a RBE will be generated, and at a shift of 14mm the RBE will certainly 
be beyond the “deliverable” threshold (see Section 2.4.3) which is an important “safety mechanism”, to 
limit the possibility of a treatment being delivered when the fiducials are no longer a good surrogate for 
tumour.   
This phantom experiment has shown that when tracking 2 “fixed” fiducials, the CyberKnife system is 
able to accurately interpret fiducial position, even when one fiducial migrates to a clinically large 
distance of 14mm from its expected position (expected according to CT planning scan). 
Graph 1 (page 53) shows that when the system is asked to track 3 fiducials, a migrating fiducial can be 
accurately detected to 10mm away from its expected position.  Graph 1 also shows that when 
correlating all 3 fixed fiducials, a migrating fiducial can be accurately detected up to only 4mm away 
from its expected position.   
Overall, this experiment has shown that the accurate interpretation of fiducial position is not only 
dependent on the distance that a migrating fiducial has moved relative to its reference position.  It is 
also dependent on the number of other fixed fiducials available for correlation.  The greater the number 
of fixed (accurately located) fiducials that the system has available to correlate, the shorter the distance 
over which the system can accurately locate a migrating fiducial.  The reason for this is not entirely clear, 
but is likely to be related to the fiducial tracking algorithm.   
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As explained in the Introduction, the system assumes that the probability of a candidate fiducial being 
an actual fiducial is partly dependent on the discrepancy between its actual distance from other fiducials 
and the expected distance.  The results from this experiment suggest that the probability calculations 
are dependent also on the number of accurately located fixed fiducials available for correlation.  The 
calculated probability of a candidate fiducial being an actual fiducial is lower in the presence of a greater 
number of accurately located fiducials. 
 
2.5.2: Fixed Fiducial Tracking: Robot Corrections 
The results of the experiment correlating Migrating Fiducial distance moved vs COM Translational 
Correction show that as long as the migrating fiducial is correctly identified, the COM Translational 
Correction is appropriately reported.  This was validated manually in the root of the sum of the squares 
calculations (See Section 2.4.2).  This result gives confidence in the Corrections generated at the time of 
CyberKnife treatment. 
The Corrections generated (based on COM Translational Corrections) show good reproducibility of 
results which further gives confidence that for a given fiducial arrangement in a patient, their treatment 
could be executed consistently and appropriately on consecutive treatment days.  It is important to note 
though, that there would be a number of caveats to assuming that the clinical scenario would be 
analogous to this phantom scenario.  Firstly, interpretation of fiducial position is more difficult in a 
clinical situation with multiple tissue densities in the “region of interest”.  Additionally, fiducials which 
are implanted into a tumour volume, or an adjacent structure, can rotate, and the tissue can deform, 
such that the orientation of the fiducial(s) compared to that at the time of Planning CT can change, 
making it harder for the in-room imaging system, and indeed the Treatment Radiographers to accurately 
identify the fiducial(s). 
Robot corrections were analogous to COM Translational Corrections (see Figure 10) except where 
Rotational corrections were required. 
Robot corrections were appropriately generated on all occasions that the RBE was “within threshold”, 
but were not generated on any occasion that the RBE was out of threshold, see Figure 12. 
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Figure 12:  
Screenshot showing RBE>5.  The CK system has not generated Robot Corrections and the “Start” button 
is greyed out because delivering a treatment with such a high RBE would not be clinically appropriate. 
 
 
 
It should be noted, however, that if a fiducial is misidentified, a RBE may be reported that allows a 
Correction to be generated (See Table 4, page 57, at Fiducial 4 move of 6mm), but in this scenario the 
Correction would be inappropriate because it would be based on an erroneous fiducial location and 
treatment could proceed inappropriately.  The treatment radiographers are vigilant though and they 
would take appropriate measures, such as “switching off” a fiducial if they believed it had migrated.  
Other options are reducing the “tracking range” in order to prompt the system to look only in a limited 
window (where the radiographers can see the fiducial). 
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2.5.3. Rigid Body Error (RBE) 
RBE: 1 fixed fiducial and 1 migrating fiducial  
The RBE when assessing the above combination of fiducials is greater than a “deliverable” threshold 
(Threshold = 1.8-2) at and beyond a 4mm move of the migrating fiducial (see Table 3, page 56).  These 
results were consistent and could be validated by calculating the RBE as explained in Section 2.4.3, which 
is reassuring when considering being able to deliver clinical treatments accurately and consistently on 
consecutive days.  At a 2mm move of the migrating fiducial, the RBE is within threshold (RBE=1.5), and it 
could be argued that this might not be clinically appropriate.  In a scenario where one fiducial is in the 
GTV (therefore the optimally placed fiducial), and the other fiducial is lying outside the PTV, a clinical 
event associated with a 2mm shift of the optimally placed fiducial relative to the other could be 
concerning with regards to the accuracy of fiducial tracking.  If the optimal fiducial remains within GTV, 
and there is adequate expansion to PTV, a treatment is likely to proceed accurately.  However, if the 
optimal fiducial has migrated out of the GTV by 2mm, this could compromise the accuracy of treatment 
delivery.  Such a small shift is difficult to appreciate for the Radiographers.  In delivering a treatment 
tracked with 2 fiducials, the RBE can be dependent on a shift of either fiducial, or both, and it is difficult 
to appreciate which fiducial may have moved (or both) by this distance with reference to bony anatomy.  
A new feature of the CyberKnife Treatment Delivery System Version 9.6 is that a “red square” is placed 
next to the fiducial that is contributing the most do the RBE generated.  The aim of this would be to 
guide the Radiographers, to either adjust patient positioning if possible, such that the arrangement of 
fiducials at planning is more closely recreated, or if it is believed that a fiducial has migrated such that it 
is no longer a surrogate for tumour, the migrated fiducial can be “switched off”.   
In this experiment fiducial 4 was always the migrating fiducial.  However, when assessing the tracking of 
Fiducials 1 and 4 only, from 6mm displacement of the migrating fiducial (Fid 4), the system erroneously 
showed a “red square” adjacent to fiducial 1 (the fixed fiducial), see Figure 13 (page 64). In a clinical 
scenario where only 2 fiducials are being tracked, it would be difficult for the delivery system to assess 
which fiducial may have moved (or both may have moved by the same amount).  None-the-less it was 
surprising that the error was attributed to fiducial 1 as the “Live” location of this fiducial was very close 
(<0.29mm) to its Expected (“Reference”) position.  In contrast, fiducial 4 “Live” location was different (by 
6mm in the x axis) to the expected “Reference” position.  It is important for Radiographers to be 
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sceptical of the “red square” guidance at the time of treatment, and to review the position of the 
fiducials on the Live images adjacent to bony anatomy in order to ensure that the decisions taken to 
optimise fiducial tracking are appropriate. 
Of note, it would be possible for a treatment to be rendered “Undeliverable” due to a RBE>Threshold 
owing to a “potentially migrated” fiducial.   The position of this fiducial relative to other implanted 
fiducials may appear different to that at the time of Planning CT, but the fiducial may not have migrated 
(and may still therefore be a good surrogate for tumour), it may be correctly located at the site of 
implantation, but there may be deformation of the target due to e.g. filling of an adjacent 
bowel/duodenum loop.  This issue will be further discussed in Chapter 3. 
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Figure 13:  
Screenshot showing that the CK system has interpreted (erroneously) that Fiducial 1 is contributing most 
to the Rigid Body Error (RBE), as shown by the red square next to Fiducial 1.  The system is being asked 
to correlate only Fiducials 1 and 4 (see “live” images).  Fiducial 4 is the “migrating” fiducial. 
  
 
RBE: 1 migrating fiducial and 2/3 fixed fiducials 
When correlating combinations of 2 fixed fiducials and the single migrating fiducial, RBE is within 
“deliverable” threshold for up to a 2mm move of the migrating fiducial (RBE<2mm), see Table 3.  At 
4mm move of the migrating fiducial and beyond the RBE is beyond “deliverable” threshold as before, 
which is clinically appropriate. 
It is notable that whilst the RBE is small (0.19-0.7mm) when the system is asked to correlate only fixed 
fiducials (which we know cannot have moved), the RBE is not 0.  The reported RBE represents the 
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inherent error in defining the centre of each fiducial at the time of planning, and in interpreting the 
centre of each fiducial (which is limited by pixel size) in the Live X-rays at the time of treatment. 
As expected, the RBE is larger (0.85-1.94mm) when correlating one of the two fixed fiducials with the 
migrating fiducial (at a 2mm move). The range for RBE encountered is likely to be related to how 
accurately the centre of each fiducial was defined at the time of planning (again there are limitations to 
this according to pixel size), and also whether the centre of each fiducial falls into the centre of a pixel or 
not on the Live images. 
Of note, when correlating 3 fixed fiducials with a migrating fiducial, at 6mm move of the migrating 
fiducial, the CK in-room imaging system starts to misidentify a fiducial (see Table 4 and Graph 1).  The 
RBE generated at a move of 6mm of the migrating fiducial (with 3 fixed fiducials) is “deliverable” in all 
cases (RBE 0.1-1.79mm) despite this large fiducial migration.  This is important to note as in these 
scenarios, when a fiducial is misidentified, it is erroneously located relatively close to its expected 
position, resulting in a RBE which is “deliverable” which will not be appropriate in a fiducial-tracked 
treatment with typical (small) radiosurgical margins. 
When correlating other fiducial combinations (e.g.fiducial 1 and 4, see Appendix 2.1), once a fiducial is 
misidentified (at 16mm move of fiducial 4), the RBE>2.75mm which is greater than the deliverable 
threshold. 
The treatment radiographers therefore need to be even more vigilant when multiple fiducials (e.g. 4) are 
sited than when 2 fiducials are sited. 
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2.6 CONCLUSIONS 
In this novel experimental phantom model with 1-3 fixed fiducials and 1 migrating fiducial: 
1. The imaging of fiducial position by the CK in-room imaging system is accurate (to within 0.24mm) 
and reproducible (SD=0-0.09mm) as long as fiducials are correctly identified. 
 
2. Fiducials are correctly identified across a clinically appropriate tracking range for fixed fiducial 
tracking (within 4mm of expected position). 
 
3. Accurate interpretation of fiducial position depends not only on the distance that a migrating fiducial 
has moved relative to its reference position; it is also dependent on the number of fixed fiducials 
available for correlation.  The greater the number of accurately located fiducials, the less likely the 
CK in-room system is to accurately locate a migrating fiducial. 
 
4. Robot corrections (to adapt to discrepancies in fiducial position between Planning CT and time of 
treatment) are consistent (SD=0-0.4mm) for a given move of a migrating fiducial. 
 
5. Robot corrections are mathematically appropriate based on the observed shift in fiducial centre of 
mass (as shown by manual verifications based on the root of the sum of the squares formula). 
 
6. Where all fiducials are accurately identified in this phantom experiment with fixed fiducials and one 
migrating fiducial, 
Robot correction ~ Move of migrating fiducial (mm) ÷ n 
Where n = number of fiducials. 
 
7. Reported Rigid Body Error (RBE) results have been manually verified (based on the root of the sum of 
the squares formula). 
 
8. RBE > “Deliverable” threshold (therefore Robot corrections not generated) occurred when migrating 
fiducial had moved ≥4mm from its position at Planning CT.  This would be considered clinically 
appropriate for fixed fiducial tracking given the small treatment margins applied in stereotactic 
treatments.  See Discussion for caveats to this statement. 
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9. RBE within “Deliverable” threshold (i.e. Robot corrections generated and treatment can proceed) 
was achieved when migrating fiducial was ≤ 2mm from its position at Planning CT. This would be 
considered clinically appropriate (as 2mm will be less than CTV-PTV margin for fixed fiducial-tracked 
treatment). See Discussion for caveat to this statement. 
 
10. When correlating all 4 fiducials with a move of 6mm (from Planning CT position) of the migrating 
fiducial, a fiducial was consistently misidentified close to its Expected location such that the RBE was 
within “Deliverable” threshold.  This scenario is potentially concerning and confirms the need for 
close vigilance by the treatment radiographers at time of CK treatment. 
 
These pre-clinical experiments have provided a foundation for understanding the accuracy and 
interpretation of fiducial location by the CyberKnife fiducial tracking system.  Chapter 3 explores fiducial 
tracking in a clinical model. 
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Appendix: 
Appendix 2.1: Results from first Phantom Experiment: 1 fixed fiducial and 1 migrating fiducial 
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 CHAPTER 3 
Stability and reproducibility of fiducial placement and Organ at Risk position 
in CyberKnife patients 
 
3.1 INTRODUCTION 
Non-spine Body treatments are usually tracked by fiducials (gold markers implanted in or around 
tumour). They act as surrogates for tumour position and their position can be determined by an in-room 
KV imaging system.  The accuracy of fiducial-based tracking depends on the assumption that the inter-
relationship between fiducials/tumour and Organs At Risk (OAR) is the same at the time of planning CT 
as at the time of treatment (1).  However, it is known that a number of factors could invalidate this 
assumption.  
3.1.1 Fiducial migration: Principles 
Fiducial migration describes the movement of the inserted fiducials from their original position (at the 
time of fiducial placement) to a remote position, where they are no longer an adequate surrogate for 
tumour position/movement.  It is recommended that the Planning CT scan is performed at least a week 
after insertion of fiducials to allow time for fiducial migration to occur (2).  In theory, fiducial position 
captured on a Planning CT scan a week after fiducial insertion should be stable.  There have been 
instances at my Centre, however, where this has not been the case.  
Clinical example one: One CyberKnife patient with renal cell carcinoma of the superior pole of the right 
kidney had 4 fiducials inserted around the tumour.  Post-insertion CT imaging (one-week later) showed 
that 3 fiducials were not well sited, the most optimally placed fiducial lay at the superior edge of the 
kidney. The physicists advised that treatment should be tracked with reference to this single optimally-
placed fiducial, the other 3 fiducials were too far from the target to be reasonable surrogates.  At the 
time of treatment on Day 1 the radiographers noted the relative arrangement of the fiducials appeared 
different to the DRR arrangement.  Given that a single fiducial was to be tracked (therefore RBE would 
not be generated), and fiducial arrangement suggested possible fiducial migration, a CT was performed 
to assess fiducial position in more detail.  This CT scan showed fiducial migration of the “optimally-
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placed” fiducial (which had been inserted into peri-nephric fat), and treatment was postponed until 
further (well-placed) fiducials had been sited. 
A further 4 fiducials were sited, all within the PTV, and treatment proceeded without event.  The patient 
has had a Complete Response to treatment and remains well.   
Clinical example two: A further patient with recurrent colorectal cancer with a solitary mesenteric node 
had three fiducials sited into adjacent mesenteric fat.  Post fiducial insertion images showed the fiducials 
were well sited, but on the Planning CT two of the three fiducials had significantly migrated.  The patient 
underwent treatment planning as it was felt that the single well-placed fiducial would be appropriate for 
tracking.  However, at Day 1 CT, the fiducial had moved by 3cm from its position at Planning CT, and the 
patient did not proceed to treatment.  A further CT another week later showed the fiducial had moved 
again, this time by 2cm.  Radiology input concluded that the fiducial was lying in mesenteric fat, which 
was moving with bowel motion, and moving differently to the tumour target. 
Following these examples, the Centre changed its protocol and a Day 1 CT scan is now performed on all 
patients that are to be tracked with fiducial tracking where the tumour is subject to respiratory motion 
i.e. Synchrony™ cases.  Equally, if the CyberKnife team feel that a Day 1 CT is warranted due to specific 
concerns, then this is arranged.   
It is our firm recommendation that the Day 1 CT be incorporated into routine clinical practice in such 
clinical scenarios, and therefore the archive of Day 1 CT scans is an important data set for analysis. 
Various factors may contribute to the likelihood of fiducial migration.  Intuitively, the most likely factor 
contributing to fiducial migration is “stability” of the tissue the fiducial is inserted into.  The stability of a 
tissue is hard to quantify.  Stability may partially depend on the density of the tissue (which would be 
relatively easy to quantify from CT data by Hounsfield Units), but also crucially on the micro-structure of 
the tissue, including the arrangement and contribution of connective tissue such as cartilage and fibrin 
strands.  The stability of the tissue that the fiducial is inserted into will be assessed, this will be a 
qualitative judgement.  It is hoped that the results may allow feedback to Radiologists/Endoscopists that 
perform fiducial placement, in order to maximise the chances of a successful fiducial implantation. 
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3.1.2 Fiducial migration: Histopathology of tumour 
Tumour targets for treatment by CyberKnife vary in size, shape, and tissue of origin.  The strategy for 
fiducial placement varies according to size/shape of the tumour target, and the relationship of the target 
with adjacent critical structures.  Factors linked directly to the histopathology of the tumour are also 
considered, such as the risk of “seeding”.  This is more common in Gastro-intestinal malignancy, it refers 
to a tumour “seeding” in a biopsy or fiducial insertion tract (3). 
An important principle of fiducial guidance is that the inserted fiducials act as true surrogates for tumour 
position.  Therefore, whether the tumour target is potentially static (e.g. inguinal lymph node), or mobile 
(e.g. early stage lung tumour), it is important that implanted fiducials move exactly as tumour moves (4). 
Fiducials may be either inserted directly into the tumour target, or surrounding the tumour target. 
As an example, if the tumour target is a small, early stage (Stage 1) lung tumour (Non-Small Cell Lung 
Cancer, NSCLC), a single fiducial can reasonably be inserted into the tumour.  This is particularly true 
when the tumour target is uniformly round, as rotations cannot be tracked with a single fiducial in situ.  
Translations only (not rotations) can be tracked with the Synchrony respiratory tracking system for lung 
tumours with a single fiducial target (5). The risk of seeding with a NSCLC tumour is negligible (<0.06%) 
(3).  
An alternative strategy for an early stage lung tumour is to site 3-4 fiducials around the lung tumour. A 
potential disadvantage is that the further a fiducial is sited from the edge of a tumour target, the greater 
the potential that the fiducial could move differently to the tumour target.  The potential for 
pneumothorax also increases according to the number of passes of the fiducial-placement needles, and 
the needle gauge.  Pneumothorax risk reported is highly variable (8-38%) (6, 7).  A potential advantage 
of inserting multiple fiducials surrounding tumour target, is that the accuracy of outlining of the tumour 
target may be improved by avoidance of CT artefact from a fiducial sited in the centre of the target, 
although this is more relevant for smaller tumours (8).  A further advantage is that treatment (with 
rotational data captured) can still proceed if 1 of the 4 sited fiducials migrates (9).  The Synchrony 
system can track tumour target translations (to within 25mm movement) and rotations (to within 10 for 
pitch and roll, and 30 for yaw (10).   
A different example of a tumour target is a liver metastasis.  There is some evidence that gastro-
intestinal malignancies can seed along needle track sites (3).  Liver metastases are often irregular in 
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shape.  The fiducial placement strategy for liver metastases is therefore to site 3-4 fiducials surrounding 
the tumour.  Fiducials should be sited >2cm apart, and not in the same sagittal plane. They should be 
sited in normal tissue (to avoid the potential risk of seeding if this is a consideration bearing in mind the 
histopathology), but as close to the edge of tumour as possible to maximise the chances that the 
fiducials will move in the identical way to the tumour target (2, 9). 
Due to the different fiducial placement strategies according to tumour type described above, the 
Histopathology of the tumour type will be recorded when evaluating the stability of fiducial position 
between insertion and Planning CT/1st Day CT. 
3.1.3 Number of fiducials in/around target, and proximity of fiducials to tumour target 
When a tumour target is relatively large and accessible (to radiologist-guided fiducial placement), with 
no risk of tumour seeding, at least 3 fiducials may be sited within the tumour target e.g. prostate.  
However, a combination of size, accessibility, and seeding issues means that it is often not feasible or 
appropriate to site 3 fiducials in tumour lung, liver and pancreas sites.  
As explained, rotation of the target can be assessed using 3 or more fiducials. Murphy et al (9), showed 
that the number of fiducials sited is also relevant.  He stated that “if the orientation of a target site is 
important in the dosimetry, then at least 4 fiducials should be used”. 
Where fiducials are sited outside the tumour target, the distance of the fiducials to the edge of the 
tumour may also be an important consideration, when evaluating the likelihood of a given fiducial being 
a good surrogate for tumour. 
 I will examine the impact of these factors on the stability of fiducial placement.  
3.1.3 Tumour deformation 
If multiple fiducials remain fixed in position at the site of their insertion, but if fiducial position changes 
relative to their neighbouring fiducials (due to deformation), this can pose difficulties with the feasibility 
of fiducial tracking. Tumour deformation can occur due to changes in adjacent OARs (such as organ 
filling) between Planning CT and Day 1 CT.  Tumour deformation can also occur due to a direct tumour 
effect e.g. growth of NSCLC to occlude an airway with deformation of tumour target due to collapse of 
adjacent lung. 
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Prior to delivery of each treatment beam the CyberKnife treatment console will display the expected 
positions of each fiducial as a Digitally Reconstructed Radiograph (DRR) generated from the Planning CT.  
The in-room imaging system will capture X-Rays to check positioning of fiducials and these live images 
are correlated with the DRR.  If the entire tumour target has moved e.g. due to movement of a 
neighbouring structure such as bowel, but the relative positions of fiducials are identical to that of 
Planning CT, the CyberKnife system can generate the required corrections, the robot position can adjust 
accordingly and treatment can be delivered according to the treatment plan.  If, however, the positions 
of the fiducials change relative to each other due to tumour deformation, a “Rigid Body Error” (RBE) will 
be generated by the CyberKnife system.  If the RBE generated due to fiducial shift is greater than a 
certain threshold, a beam will not be able to be delivered, as there could be target miss.  This scenario 
presents difficulties for treatment radiographers at the time of treatment delivery. 
It may be that certain tumour targets are more at risk of tumour deformation than others. The CT data 
sets provide 3D information and are a unique data set to assess for tumour deformation.  In contrast, 
the 2D imaging that is available for review at the time of treatment (via the treatment console) is more 
difficult to analyse for deformation, because it is not possible to define the edge of target on the 2D 
plain XR imaging. 
Tumour deformation between Planning CT and Day 1 CT will be analysed in this Chapter. 
3.1.4 Tumour growth 
After a patient’s CT planning scan has been performed, other Planning scans e.g. PET and MRI may also 
be performed for fusing with the Primary (Planning CT) scan. 
The tumour target will then be outlined by the Oncologist, sometimes in collaboration with other 
Specialists, such as Surgeons and Radiologists.   
Once a tumour target has been defined, and dose prescription and dose constraints have been set, 
CyberKnife Physicists will undertake planning.  Given the ablative doses prescribed to target, and the 
proximity of radiosensitive OARs, the process of planning can take a number of days.  There is therefore 
the potential for tumour growth in the interval between a Planning scan and treatment.  This depends 
partly on the “Volume Doubling Time” of the tumour (this varies widely according to Histopathology; it 
also depends on the time interval between CT Planning and Treatment. 
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I will outline the tumour volume on the Planning CT and 1st Day CT to quantify the possible impact of 
tumour growth on fiducial spacing/arrangement. 
3.1.5 Dose-limiting Organ At Risk (OAR) shift towards PTV 
On the planned Treatment start day (Day 1), if there is an apparent change in fiducial 
location/arrangement compared to the planning scan, it is clinically important to understand the 
reason(s) for this, in order that appropriate action can be taken to accurately deliver a treatment to the 
tumour target.   
However, delivery of the intended dose to the tumour target is not the only consideration.  An equally 
important consideration is:  will the dose-limiting OAR receive a safe dose of radiotherapy? 
The stability of dose-limiting OAR relative to tumour target was recorded. The direction and magnitude 
of any shift in position was noted, and the effect of the shift on dosimetry was quantified. 
3.1.6 Planning margins 
As described in Section 1.1.1, the ICRU 50 report defined standards for describing radiotherapy 
prescription volumes (11).  The Gross Tumour Volume represents the gross palpable or visible extent of 
disease. The Clinical Target Volume (CTV) incorporates a margin of normal tissue for unknown 
microscopic spread or subclinical disease. The Planning Target Volume (PTV) includes all other errors and 
uncertainties e.g. tumour motion and set-up errors. 
The margin applied to transform a CTV to a PTV is termed a planning margin. Planning margins reported 
in the literature for Synchrony-tracked treatments vary between 2 and 8mm, margins of 3-5mm are 
commonly employed (12) 
Standard planning margins at my Centre for the tumour sites studied here are as follows: 
Lung:   CTV to PTV margin: 2mm 
Liver:  CTV to PTV margin: 2-3mm 
Pancreas: GTV/CTV to PTV margin: 2-3mm 
The appropriateness of the above planning margins will be evaluated in light of the outcomes of the 
assessments made. 
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3.2 MATERIALS AND METHODS 
3.2.1 Notes review  
The CyberKnife database was retrospectively interrogated to retrieve names and details for patients 
receiving fiducial-tracked treatment for the following tumour sites:  Lung, Liver and Pancreas.  For each 
tumour site, where possible, a sample of patients with multiple fiducials available for tracking was 
selected, as well as a sample of patients where only a single fiducial was available for tracking.  The 
patients were otherwise unselected and were therefore considered a representative sample of 
CyberKnife patients treated at this centre.   
Primary histopathology of tumour, and number of fiducials inserted was recorded for each patient.  Date 
of Planning CT and Day 1 Treatment CT was also recorded. 
3.2.2 Imaging Analysis: Tumour Volume  
The GTV volume (in cc’s) drawn by the patient’s Clinician was recorded from the MultiPlan system.  In 
order that the Planning CT volume and Day 1 Treatment CT volume could be most meaningfully 
compared, the Planning CT GTV was drawn by myself (with the Clinician’s contour “switched off”, so that 
it was not visible at contouring).  Where additional scans were fused to the Planning CT to aid the 
contouring process (e.g. PET, Contrast CT), these were always reviewed. 
This process was repeated for the Day 1 CT (“B scan”), although the Day 1 CT scans were always non-
Contrast scans.  
 The Window and Level selected for contouring was noted. The percentage difference in volume 
between the Clinician GTV contour and my own GTV contour from the Planning scan was calculated.  
The Clinician GTV contour was taken as the “reference” volume for calculation purposes.  Therefore a 
“negative” percentage difference represented a GTV which was larger from the Clinician contour, than 
the GTV volume contoured by myself.   
The percentage change in GTV volume between Planning CT and Day 1 treatment CT (both contoured by 
myself) was also calculated and recorded.  The Planning CT was taken as the “reference” volume for this 
calculation.  Therefore a “negative” percentage difference represented a GTV volume which had been 
contoured smaller on the Day 1 CT scan as compared to the Planning CT. 
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Tumour deformation is difficult to quantify.  A qualitative judgement on this was made. 
3.2.3 Imaging analysis: Fiducial location 
CT Planning and Day 1 Treatment CT scans for the above patients were uploaded onto the CyberKnife 
MultiPlan planning system version 4.5 (Accuray, California).   Both scans were captured in exhale breath-
hold, with identical imaging parameters.  CT slice spacing was 1.25mm. 
These scans had been previously fused on Day 1 of patient Treatment by the Physics team, in order to 
confirm that there had been no significant fiducial migration, or significant Organ At Risk shift, and to 
determine that the planned PTV appropriately covered the tumour as seen on the Day 1 scan. 
When viewing the scans on Multiplan, the Planning CT scan was always designated the “A” scan, the 
Primary scan.  The “Align” tab on the MultiPlan system was selected, and number of fractions, body site, 
and treatment path was selected in order that it was possible to proceed to the “Fiducial” tab.   
A judgement was made as to the stability of fiducial insertion site.  This qualitative judgement was 
recorded, and it was also noted whether or not the fiducial was implanted in the GTV.   
The centre of each fiducial had already been set (at the time of treatment planning), but each position 
was verified in this work.  This was done by viewing each fiducial on axial, coronal and sagittal viewing 
planes, and then selecting (by clicking the mouse) the centre of the fiducial.  Any discrepancy in x/y/z co-
ordinate of fiducial >1mm (between the recorded centre, and my own judgement), was recorded.  If any 
fiducial had migrated, this was recorded.  Where more than one fiducial was sited, fiducials were ranked 
according to their location: the most optimally placed fiducial was ranked 1. 
The Centre of Mass (COM) of the fiducials is referred to as the “Treatment Centre”, this was calculated 
and recorded.  Treatment Centre x, y, z position can be calculated according to the following formula: x= 
∑x/n, y= ∑y/n, z= ∑z/n, where n= number of fiducials.  It was noted whether the Treatment Centre lay 
within the PTV. 
The above process was repeated for the Day 1 CT scan (designated the “B” scan).  Of note, when 
assessing the centre of each fiducial on the B scan, it was important to disable the “Auto-Centre” 
function on Multiplan.  This is because “the system” is always looking primarily at the A scan, and if my 
judgement was that a fiducial on the B scan is lying in a slightly different position, I would not be able to 
designate the centre of the fiducial on the B scan (the Auto-Centre function would mean that the fiducial 
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centre would default to the centre of that fiducial on the A scan). The shifts between Planning CT and 
Day 1 CT were recorded for each fiducial, and for the fiducial COM. 
Where a fiducial lay outside the PTV, the distance of the fiducial to the closest PTV edge was recorded.  
If the Physics team had decided to reject a fiducial for tracking prior to treatment the reasons for this 
were recorded.  Equally, if a fiducial was rejected by Radiographers at the time of treatment delivery, 
the reasons for this were also recorded. 
3.2.4 Imaging Analysis: Organ At Risk (OAR) position and Dosimetry 
The dose-limiting OAR was selected for analysis.  The OAR was contoured on the Day 1 CT, with the 
original OAR contour (as drawn by the Clinical team on the planning scan) “switched off” as before, so 
that it would not prejudice my contouring. 
As an initial assessment, the proximity of the “Day 1 OAR” to PTV was measured and compared to the 
proximity of Plan CT OAR to PTV.  If the Day 1 OAR contour had shifted closer to PTV than on the Plan CT, 
further analysis was undertaken as described below. 
Unfortunately it is not possible in MultiPlan to simply copy the original treatment plan on to a new 
dataset containing new contours.  It is possible however, to sum the dose from the original plan with a 
plan created on the new dataset.  Therefore, a workaround was developed which involved creating a 
dummy plan containing negligible dose at the location of the OAR, which could then be summed with 
the original plan on the new dataset.  To create the dummy plan a false target was created at the 
inferior/anterior extent of the CT dataset, far away from the original target/OAR structures.  A plan was 
then created containing multiple beams directed at this false target, and all but one of the beams were 
set to 0MU, with the remaining beam set to 1MU (MultiPlan requires all plans to contain at least 1MU 
before they can be summed).  A high resolution dose calculation was then performed over the whole CT, 
and the dose at the OAR from the dummy plan was confirmed to be negligible.  Therefore, once the 
original plan and the dummy plan were summed on the new dataset, the dose displayed at the OAR 
location consisted only of dose contributions from the original plan.   
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3.3 RESULTS 
3.3.1 Lung tumour site: Tumour volume 
Histopathology and Tumour volume data for 10 patients with implanted fiducials are shown in Table 3.1. 
Table 3.1: Lung tumour cases: Tumour volume 
Patient Histopathology 
Interval Plan 
CT to  
Day 1 CT 
(Days) 
Clinician 
GTV (cc) 
Planning CT 
GTV CG (cc) 
Day 1 
GTV CG 
(cc) 
Change 
Clinician GTV to 
CG Planning CT 
GTV (%) 
Change CG 
GTV Planning 
to Day 1 CT 
(%) 
1 NSCLC 7 1.7 1.8 1.3 +6 -28 
2 NSCLC 7 2.9 N/A N/A N/A N/A 
3 Colorectal 4 16.6 18.5 18.2 +11 -2 
4 NSCLC 7 35.6 41.3 44.4 +16 +7 
5 NSCLC 12 63.6 53.8 58.6 -15 +8 
6 Colorectal 8 2.1 2.5 2.6 +16 +4 
7 Colorectal 5 10.4 7.7 6.6 -26 -14 
8 Colorectal 8 21.2 21.1 19.4 -0.5 -8 
9 NSCLC 6 74 62.5 64.6 -16 +3 
10 NSCLC 4 1.7 0.9 0.9 -47 0 
Mean 7 23 23.3 24.1 -6 -3 
 
As can be seen from the above table, 6 of the patients were treated for Non-Small Cell Lung Cancer 
(primary disease), and 4 patients were treated for Colorectal Cancer metastasis. 
The interval (days) between Planning CT and the Day 1 of Treatment CT for each patient is displayed in 
the 3rd column.  The mean and median interval between scans for this group as a whole were 6.8 days 
and 7 days respectively. Standard deviation = 2.2 days. 
Clinician GTV volume (cc) and Planning CT GTV volume (cc) drawn by myself (“CG” as my initials) are 
displayed.  Both contours were drawn on the same Planning CT scan.  It was not possible to outline the 
“GTV” of Patient 2.  This patient underwent surgical resection of endobronchial disease, and fiducials 
were placed at the time, to define the area that would be at high risk for recurrence in the future.  The 
Surgeon defined the target volume in this case.  There was no visible disease at the time of Planning CT. 
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Despite the fact that the GTV was outlined on the same Planning CT scan by both the Clinician and 
myself, there is a wide variability in volumes. The Mean and Standard Deviation of the percentage 
difference between the volumes are -7.2%, and 21.1%, confirming the variability in contouring between 
Clinical Oncologists (inter-observer variability).   
There was also a wide variability between the GTV volumes drawn by myself on the Planning CT 
compared to the Day 1 CT volume.  The Mean and Standard Deviation of the percentage difference 
between the volumes are -4.1% and 11.2% respectively.  For this analysis, there was no risk of inter-
observer variability skewing the results, as the same observer contoured both volumes.   
None of the patients were receiving anti-cancer therapy between Planning CT, and Day 1 CT, so it may 
have been expected that the Day 1 CT volumes would be larger than the Planning CT volumes, but this 
was not always the case.  Of note, the Day 1 CT scans were always Non-Contrast, as described, which 
made it more difficult to define the target on several of the Day 1 CT volumes.  Patient 7’s GTV was 
particularly difficult to define, and this patient was notable for showing moderate variability between 
Planning CT and Day 1 CT volumes.  Patient 1 also had a difficult GTV to define, especially on the non-
contrast Day 1 CT due to surrounding vasculature. 
The limitations described above mean that it would not be reasonable to draw any conclusions about 
tumour growth between Planning and Day 1 CT scans. 
There was no tumour deformation noted in any of the above cases. 
 
3.3.2 Lung tumour site: Fiducial Reproducibility 
Fiducial reproducibility data for 9 patients with single-implanted fiducials is displayed in Table 3.2. 
COM = Centre Of Mass of fiducials 
Std Dev = Standard Deviation 
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Table 3.2 Lung tumour site: Single fiducial: Fiducial reproducibility 
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There was agreement between fiducial location as registered by the Physics team, and as registered by 
myself to within 1mm, except for patient 2.  For patient 2, there was agreement on x and z locations, but 
the y location that was registered varied by 3mm between the Physics team and myself.  The fiducial for 
patient 2 had a large artefact on CT. 
The “Means” displayed in Table 3.2 were calculated to be Mean shift of fiducials from the Plan CT 
position.  The direction of shift from the original position was not significant, only the magnitude of shift, 
therefore any minus signs were ignored when calculating the Means. 
For a single-fiducial tracked CyberKnife treatment, as there is only one fiducial, the fiducial location 
position (at Planning CT), and the Planning CT COM is the same.  Table 3.2 shows that Plan CT fiducial = 
Plan COM for each patient (columns highlighted in yellow) and similarly Day 1 CT fiducial = Day 1 CT 
COM (columns highlighted in blue).  Equally Fiducial shift = COM shift for each patient, as there is only a 
single fiducial located. 
Mean apparent shift in fiducial/COM position between initial Planning CT and Day 1 CT for the patient 
group as a whole is 0.55, 0.9 and 0.7mm in x, y and z directions respectively.  Standard deviations were 
0.41, 0.77 and 0.29mm for x, y and z directions respectively.  The possible limitations to the accuracy of 
the methodology to calculate these shifts will be discussed in the Discussion. 
 Fiducial location and reproducibility data for an example patient with multiple-implanted fiducials is 
displayed in Tables 3.3A.  Full data on the first 6 patients with multiple fiducials implanted for treatment 
of lung tumours is displayed in Appendix 1. 
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Table 3.3A: Lung tumour site: Multiple fiducials: Fiducial reproducibility: Patient 1 
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The Plan CT COM is reported in Multiplan, but it can also be calculated.  The x location of the Plan CT 
COM is the average of the x locations of fiducials 1-3 (see Table 3.3A, page 83).  The y and z locations of 
the Plan CT COM are calculated in a similar way. 
The Day 1 CT COM for each patient was also calculated. 
Fiducial reproducibility data for 9 patients with lung tumours and multiple implanted fiducials is 
displayed in Figure 3.3B. 
 
Table 3.3B: Lung tumour site: Multiple fiducials: Fiducial reproducibility 
Patient Number of fiducials 
COM Shift (mm) 
x y z 
1 3 -1.96 -2.97 0.78 
2 2 0.1 0.08 0.98 
3 3 -0.32 0.02 -0.08 
4 3 0.42 0.21 -0.42 
5 3 2.44 0.33 -1.11 
6 4 0.23 -0.43 0.86 
7 3 -0.05 -0.37 -0.14 
8 3 -0.14 -0.15 0.83 
9 3 -0.01 -1 0.04 
Mean 3 0.63 0.62 0.58 
Standard Deviation 0.47 0.86 0.87 0.39 
 
The “Means” displayed in Table 3.3B were calculated to be Mean shift of fiducial COM from the Plan CT 
position to the Day 1 CT position.  As before, the direction of shift from the original position was not 
significant, only the magnitude of shift, therefore any minus signs were ignored when calculating the 
Means. 
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The mean shift (in mm) for fiducial COM for the group of patients with lung tumours and multiple 
fiducials is 0.63, 0.62 and 0.58 in x, y, and z directions respectively.  The Standard Deviations were 0.86, 
0.87 and 0.39. 
The magnitude of mean shifts in COM for the multiple-fiducial cases described, are similar to the single-
fiducial cases (COM shift 0.55, 0.9 and 0.7mm in x, y and z directions). 
For the lung tumour patients as a whole the shift in fiducial COM between planning CT and Day 1 CT is 
sub-millimetre, overall mean shift was 0.59, 0.76 and 0.64mm in x, y and z directions respectively. 
 
3.3.3 Lung tumour site: Fiducial Location 
Assessment of Planning CT and Day 1 CT fusion allows a check that there has been no fiducial migration, 
and that the arrangement of fiducials is similar on the Day 1 CT to the Planning CT.  There are other 
benefits to this assessment but these will be discussed later.   
Stability/reproducibility of fiducial position is not the only consideration, an optimally located fiducial is 
also important.  A sub-optimum placement can lead to difficulties in tracking at the time of treatment 
delivery.  As there are risks to fiducial placement (bleeding, pneumothorax), it is advisable that every 
fiducial placed contributes to tracking.  These aspects are displayed in Table 3.4. 
NSCLC = Non-Small Cell Lung Cancer, CRC = Colorectal Cancer 
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Table 3.4: Lung tumour site: Single implanted fiducial: Fiducial location 
Patient Pathology 
Fiducial in 
GTV/PTV 
Implant 
tissue 
Distance 
fiducial to PTV 
(mm) 
Fiducials rejected? 
1 NSCLC Yes Tumour N/A No  
2 NSCLC Yes Tumour N/A No 
3 Melanoma No Lung 4.4 No 
4 NSCLC Yes Tumour N/A 
Yes: a 2
nd
 fiducial 
migrated 
5 NSCLC Yes Tumour N/A No 
6 NSCLC Yes Tumour N/A No 
7 NSCLC Yes Tumour N/A No 
8 CRC Yes Tumour N/A No 
9 NSCLC Yes Tumour N/A No 
 
For a single-fiducial tracked treatment it is ideal that the fiducial lies in the tumour, so that it can be a 
true surrogate for tumour.  This was the case for 8 out of 9 cases (89%).  Patient 3 had a fiducial placed 
4.4mm from PTV.  It was judged that the fiducial was close enough to the tumour to be a good 
surrogate, and the patient proceeded to treatment without event. 
There were no instances of a fiducial migrating out of the lung tumour once placed.  Patient 4 had 2 
fiducials placed, 1 in tumour (which was used for tracking), and the other in lung.  The fiducial placed in 
lung migrated however, it was deposited close to the pleural edge, and review of the Planning CT 
showed that it had slipped in between the pleural layers, and was lying in the pleural recess.  
Fiducial location data for 9 patients with multiple fiducials available for tracking are shown in Table 3.5.  
NSCLC = Non-Small Cell Lung Cancer, CRC = Colorectal Cancer, Path=Pathology 
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Table 3.5: Lung tumour site: Multiple implanted fiducials: Fiducial location 
Patient 
 
Path Fiducial 
Fiducial 
in 
GTV/PTV 
Implant 
tissue 
Plan CT 
Fid COM 
in PTV 
Distance fiducial 
to GTV/PTV(mm) 
Fiducials  
rejected? 
1 
 
NSCLC 
1 
No Bronchus No 
29/22.9 
Yes: 
Fids 1,2 
2 18.7/13.9 
3 13.5/8.8 
2 
 
NSCLC 
1 No Lung 
No 
16.7/13 Yes:  
Fid 1 2 Yes Tumour N/A 
3 
 
CRC 
1 Yes Tumour 
Yes 
N/A 
No 2 Yes Tumour N/A 
3 No Lung 9/1.6 
4 
 
NSCLC 
1 
Yes Tumour Yes N/A No 2 
3 
5 
 
NSCLC 
1 
Yes Tumour Yes N/A No 2 
3 
6 
 
CRC 
1 No Lung 
No 
13.5/7.9 
Yes: 
Fids 1,2,4 
 
2 No Lung 22/17 
3 Yes Tumour N/A 
4 No Lung 11.1/4.3 
7 
 
CRC 
1 Yes Tumour 
Yes 
N/A 
No 2 No Lung 6.7/4.1 
3 Yes Tumour N/A 
8 
 
CRC 
1 No Lung 
No 
21.4/16.5 
Yes:  
Fid 1  
2 No/Yes Lung 4.1/In PTV 
3 No/Yes Lung 11.2/In PTV 
9 
 
NSCLC 
1 
Yes Tumour Yes N/A No 2 
3 
 
There was no apparent fiducial migration (between Planning CT and Day 1 CT) for the cases displayed 
above. 
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7 out of 9 patients (78%) had fiducials implanted into tumour.  Patient 1 had no tumour visible, 
therefore fiducials could not be inserted into tumour.  Patient 8 (CRC) had no fiducials implanted in 
tumour, but tumour seeding is thought to be a risk of directly implanting the tumour. 
27 fiducials were sited in total.  15/27 (56%) fiducials were sited in tumour.  
Of the 12 fiducials that were not sited in tumour, 8 may have been deliberately placed in lung (rather 
than tumour) to avoid the risk of seeding. 4/8 (50%) of the fiducials placed in lung (not tumour) in 
Colorectal cancer cases were rejected prior to treatment delivery.  The cases with rejected fiducials are 
described in more detail below. 
Fiducials 1 and 2 of case 1 (NSCLC) were both rejected, only the closest fiducial was used to track 
treatment.  The rejected fiducials were located 29 and 18.7mm away from GTV respectively. 
Fiducial 1 of case 2 was rejected, it was located 16.7mm from the GTV, the other fiducial available was 
located inside the tumour. 
Fiducials 1, 2 and 4 of case 6 were rejected prior to treatment delivery.  The fiducials were situated 13.5, 
22 and 11.1mm respectively from the closest edge of the GTV.  Treatment was tracked instead using 
Fiducial 3 alone, which was located inside the GTV. 
Fiducial 1 in case 8 was rejected, it was sited 21.4mm from the tumour (GTV), in the lung apex.  At 
attempted treatment delivery, if this fiducial was included in fiducial tracking, the Rigid Body Error (RBE) 
increased to 2.5, suggesting that the fiducial may be moving differently to tumour.  It was felt safer to 
reject this fiducial and track from the remaining 2 fiducials, which were inside the PTV. 
Mean distance between a rejected fiducial and GTV was 18.9mm.  In contrast, the mean distance 
between an acceptable fiducial and GTV was 4.2mm. 
Even if individual fiducials are not located inside a tumour target, it is optimum for the fiducial COM to 
lie within PTV, to increase the chance that the fiducials will be a good surrogate for tumour.  5/9 cases 
(56%) had the Plan CT fiducial COM lying in the PTV.  The “rejection strategy” for fiducials in Cases 2, 6 
and 8, meant that the fiducial COM at the time of treatment delivery was located inside the PTV in 8/9 
cases (89%).  It was not possible to employ a fiducial rejection strategy for Case 1 that would shift the 
fiducial COM to inside the PTV, because all fiducials were placed superiorly to the target. 
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For the lung tumour group as a whole, fiducial migration occurred in just 1/18 patients (6%), and in 1/37 
fiducials placed (3%). Fiducial COM (at the time of treatment delivery) was located inside the PTV for 
16/18 patients (89%). 8/37 fiducials placed (22%) were rejected. 1 fiducial was rejected at planning due 
to migration into the pleural space, and the further 7 fiducials were rejected prior to/at the time of 
treatment delivery as described. 
 
3.3.4 Lung tumour site: Organ At Risk Reproducibility 
Assessment of Planning CT and Day 1 CT fusion allows a check on fiducial stability and reproducibility.  As 
described the assessment allows a final time for reflection on the optimum combination of fiducials to 
be tracked to maximise the chances of accurate tracking of tumour at the time of treatment delivery. 
The PTV contour can be overlaid on the Day 1 CT to check that by eye there is adequate coverage of the 
tumour. 
The further important check of the fusion assessment, is to check that the Organs At Risk (OAR) will be 
receiving a safe dose.  If there is shift of OAR into the high-dose region on the Day 1 CT, a CyberKnife 
treatment plan that was “safe” (based on Planning CT positions of tumour/OARs), may become unsafe. 
Table 3.6 displays data on OAR reproducibility for 10 patients for the lung tumour site (the same patients 
as in Table 3.1).  In each case the OAR specified in the table was the dose-limiting OAR. 
NSCLC = Non-Small Cell Lung Cancer, CRC = Colorectal Cancer 
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Table 3.6: Lung tumour site: Organ At Risk (OAR) Reproducibility 
Patient Pathology OAR 
Dose-limiting OAR 
shift to PTV 
Min Distance OAR 
to PTV on Plan CT 
(mm) 
Min Distance OAR to 
PTV on Day 1 CT 
(mm) 
1 NSCLC Aorta No 19.1 19.1 
2 NSCLC N/A N/A - - 
3 CRC Bronchus N/A - - 
4 NSCLC Chest Wall No 0 0 
5 NSCLC Chest Wall Yes 
1mm overlap with 
PTV 
2.5mm overlap with 
PTV 
6 CRC Chest Wall No 15 17.5 
7 CRC N/A N/A - - 
8 CRC Bronchus Yes 1.5 2.5 
9 NSCLC 
Chest Wall No 
1.9mm overlap 
with PTV 
1.9mm overlap with 
PTV 
Bronchus Yes 5.3 1.9 
10 NSCLC Spinal cord No 8.1 8.1 
 
Of the 10 patients reviewed in Table 3.6, 7/10 (70%) had OARs which were either unsuitable for 
assessment, or had an identical/more favourable set-up with respect to OAR position on Day 1 CT as 
compared to Planning CT. 
Patients 2, 3 and 7 had OARs unsuitable for assessment.  Patients 2 and 7 had a small, peripheral lung 
tumour, the tumours were located remote from OARs such as chest wall, bronchi, mediastinum and 
cord.  Patient 3 had a central lung tumour encircling the bronchus (OAR), Day 1 CT appearances showed 
the tumour encircling the bronchus exactly as at the Planning CT.   
Patients 1, 4 and 10 had a perfectly reproducible OAR position between Planning CT and Day 1 CT.  The 
OARs were Aorta, Chest Wall, and Spinal cord respectively.  Patient 6 had a more favourable OAR 
position at Day 1 CT as compared to Planning CT. 
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Patient 9 had a less favourable position of bronchus at Day 1 CT as compared to Planning CT, (although 
chest wall position was stable).  However, bronchus was not drawn on the original Planning CT so the 
impact of the OAR shift on bronchus dosimetry cannot be explored further. 
Patients 5 and 8 had a less favourable position of their dose-limiting OARs (chest wall and bronchus 
respectively) on Day 1 CT as compared to the Planning CT scan.   
 
3.3.5 Lung tumour site: Organ At Risk (OAR) Dosimetry 
The impact of the OAR shift on OAR dosimetry for Patients 5 and 8 is explored further in Table 3.7. 
MPD = Maximum point dose (dose limit allowed to be delivered to 0.035cc of OAR) 
Table 3.7: Lung tumour site: Organ At Risk (OAR) Dosimetry 
Patient 
Number 
of 
fractions 
OAR  
MPD 
(Gy) 
1cc 
threshold 
(Gy) 
4cc 
threshold 
(Gy) 
30cc 
threshold 
(Gy) 
5 5 
Chest 
Wall 
Protocol 43 35 N/A 37.3 
Plan CT 58.1 53.9 N/A 44.3 
Day 1 CT 57.7 53.9 N/A 43.9 
8 4 Bronchus 
Protocol 35 N/A 16 N/A 
Plan CT 34.3 N/A 13.4 N/A 
Day 1 CT 35.8 N/A 15.7 N/A 
 
It can be seen that Patient 5’s planned doses to Chest Wall exceeded protocol dose, when considering 
both MPD, and the threshold limits.  This was due to a decision taken by the treating Consultant to 
prioritise dose delivery to PTV over OAR dose.   The coverage of PTV was 98.97%, meaning 98.97% of the 
PTV target was being treated to the prescription dose or greater.  “Good” coverage is >95% and 
“Excellent” coverage is >98%.  In order to maintain coverage of the PTV in this case, given the proximity 
of Chest Wall and tumour, the Chest Wall was treated to doses beyond those stated in the protocol.  It is 
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noted that the doses to Chest Wall based on the Day 1 CT position of Chest Wall are overall marginally 
safer than anticipated (0.7% reduction in MPD, 0.9% reduction in 10cc threshold dose, 30cc threshold 
dose stable), though still greater than protocol doses. 
Patient 8 had doses to Bronchus that were within protocol limits according to the Plan CT/treatment 
plan.  However, due to the shift of bronchus towards PTV on the Day 1 CT scan, the MPD to Bronchus 
now breaches the “safe” protocol limits.  The 4cc threshold dose has also increased due to the shift, but 
the calculated dose remains within protocol limits. 
Overall, 1/7 patients treated for lung tumours (14%) eligible for assessment had an OAR shift towards 
PTV on Day 1 CT which resulted in an increase in calculated dose to the dose-limiting OAR beyond “safe” 
protocol levels.  
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3.3.6 Liver tumour site: Tumour volume 
Histopathology and Tumour volume data for 6 patients with implanted fiducials are shown in Table 3.8. 
Table 3.8: Liver tumour cases: Tumour volume 
Patient Histopathology 
Interval Plan 
CT to  
Day 1 CT 
(Days) 
Clinician 
GTV (cc) 
Planning CT 
GTV CG (cc) 
Day 1 
GTV CG 
(cc) 
Change 
Clinician GTV to 
CG Planning CT 
GTV (%) 
Change CG 
GTV Planning 
to Day 1 CT 
(%) 
1 Colorectal 8 116.4 186.2 103.6 +60 -44 
2 Melanoma 5 5.5 4.4 7.5 -20 +71 
3 Colorectal 5 37.2 35.6 39 -4 +10 
4 Carcinoid 13 132.3 142.6 N/A +8 N/A 
5 Breast  4 1.7 2.8 3.8 +65 +36 
6 Breast 6 6.4 10.2 10.4 +59 +2 
Mean 7 49.9 63.6 32.9 +28 +15 
 
The patients studied were all treated for metastatic disease.  The histopathology of their primary disease 
is listed. 
The interval (days) between Planning CT and the Day 1 of Treatment CT for each patient is displayed in 
the 3rd column.  The mean and median interval between scans for this group as a whole were 7 days and 
6 days respectively. Standard deviation = 3 days. 
Clinician GTV volume (cc) and Planning CT GTV volume (cc) drawn by myself (“CG” as my initials) are 
displayed.  Both contours were drawn on the same Planning CT scan.  Despite the fact that the GTV was 
outlined on the same scan by both the Clinician and myself, there is a wide variability in volumes. The 
Mean and Standard Deviation of the percentage difference between the volumes are +28%, and 34%, 
confirming the variability in contouring between Clinical Oncologists (inter-observer variability).   
There was also a wide variability between the GTV volumes drawn by myself on the Planning CT 
compared to the Day 1 CT volume.  The Mean and Standard Deviation of the percentage difference 
94 
 
between the volumes are +15% and 38% respectively.  For this analysis, there was no risk of inter-
observer variability skewing the results, as the same observer contoured both volumes.   
Patient 4 had a target volume which I felt was impossible to contour without the aid of Contrast (which 
is never given for the Day 1 CT scans).  Liver metastases tend to enhance well with venous-phase 
contrast, and outlining is particularly difficult on non-contrast scans.  It is likely, therefore, that any 
observed difference in tumour volume between Planning CT scan and Day 1 CT scan is more likely to be 
due to contouring difficulties, than a true change in size. 
Tumour deformation was noted in patients 2 and 3. 
 
3.3.7 Liver tumour site: Fiducial Reproducibility 
Liver metastases tend to be irregular in shape (so it is important for tumour rotations to be tracked), and 
they are often reasonably large by the time of treatment with stereotactic body radiotherapy.  In 
addition colorectal cancer, which frequently metastasises to liver, is prone to seeding along the needle 
track.  For all these reasons, liver metastases tend to be marked with multiple gold fiducials surrounding 
the tumour for tracking purposes. 
There is, therefore, no single-fiducial group for comparison for liver tumour site. 
Fiducial reproducibility data for 9 patients with multiple-implanted fiducials is displayed in Table 3.9.   
COM = Centre Of Mass of fiducials 
 
95 
 
Table 3.9: Liver tumour site: Multiple fiducials: Fiducial reproducibility 
Patient Number of fiducials 
COM Shift (mm) 
x y z 
1 4 -2.05 0.45 -3.33 
2 3 0.22 0.19 0 
3 4 -0.15 -0.81 -2.88 
4 3 0.12 -1 -0.2 
5 4 1.36 -0.35 -2.19 
6 4 0.67 -0.04 0.47 
7 4 -0.26 0.12 0.16 
8 4 0.3 -0.46 -0.61 
9 4 -0.21 -0.04 0.57 
Mean 3.8 0.59 0.38 1.16 
Standard Deviation 0.4 0.63 0.32 1.21 
 
The “Means” displayed in Table 3.9 were calculated to be Mean shift of fiducial COM from the Plan CT 
position to the Day 1 CT position.  As before, the direction of shift from the original position was not 
significant, only the magnitude of shift, therefore any minus signs were ignored when calculating the 
Means. 
The mean shift (in mm) for fiducial COM for the group of patients with liver tumours and multiple 
fiducials is 0.59, 0.38 and 1.16 in x, y, and z directions respectively.  The Standard Deviations were 0.63, 
0.32 and 1.21.  The mean shift in the z axis COM for liver tumours is >1mm, whereas for lung tumours 
COM shift was <1mm in all axes.  The Standard Deviation for COM shift in the z axis for liver tumours is 
also >1.  The possible reasons for this, and the implications, will be discussed in the Discussion.  
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3.3.8 Liver tumour site: Fiducial Location 
As described, the general approach for siting fiducials to mark liver tumours is to site multiple fiducials 
surrounding the tumour.  The fiducials should be located close enough to tumour to be a good surrogate 
for tumour motion as the liver moves with respiration/bowel filling. 
Fiducial location data for 9 patients with liver tumours is shown in Table 3.10. 
CRC = Colorectal cancer, HCC = Hepatocellular cancer 
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Table 3.10: Liver tumour site: Fiducial location 
Patient Pathology Fiducial 
Fiducial in 
GTV/PTV 
Implant tissue 
Plan CT 
Fid COM 
in PTV 
Distance fiducial 
to GTV/PTV(mm) 
Fiducials  
rejected? 
1 
 
Melanoma 
1 No Liver 
No 
32/24 
Yes: 
Fids 1,2,4 
2 No Liver 34/25 
3 Yes Tumour N/A 
4 No Liver 22/14 
2 CRC 
1 Yes Tumour 
Yes 
N/A 
Yes: 
Fid 1 
2 Yes Tumour N/A 
3 No/Yes Liver 1/0 
3 Carcinoid 
1 Yes Tumour 
Yes 
N/A 
Yes: 
Fids 2,3 
2 No/Yes Liver 1/0 
3 No Liver 16/8 
4 No/Yes Liver 1/0 
4 Breast 
1 No Liver 
Yes 
25/16 
Yes: 
Fid 2  
2 No Liver 12/6 
3 Yes Tumour N/A 
5 Breast 
1 
No 
Liver 
No 
10/1 
Yes: 
Fid 2,3,4 
2 Liver 10/3 
3 Liver 12/5 
4 Liver 46/37 
6 CRC 
1 No Liver 
No 
11/8 
Yes: 
Fid 3 
2 No/Yes Liver 1/0 
3 No Liver 37/34 
4 No Liver 14/9 
7 HCC 
1 No/Yes Liver 
Yes 
1/0 
Yes: 
Fid 2 
2 No/Yes Liver 1/0 
3 No/Yes Liver 1/0 
4 No Liver 47/38 
8 CRC 
1 Yes Tumour 
Yes 
N/A 
No 
2 No/Yes Liver 1/0 
3 Yes Tumour N/A 
4 Yes Tumour N/A 
9 CRC 
1 No Liver 
No 
19/14 
Yes: 
Fids 1,3,4 
2 Yes Tumour N/A 
3 No Liver 35/28 
4 No Liver 33/27 
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There were no instances of a fiducial migrating from the site of implantation when fusing Plan CT and 
Day 1 CT.   
As explained, the general approach for the above patients is to site multiple fiducials surrounding 
tumour.  However, 6/9 patients (67%) and 8/9 patients (89%) had at least one fiducial sited in GTV and 
PTV respectively.  Of the 3 patients with no fiducials sited in tumour the pathology of their primary 
disease was breast, colorectal and hepatocellular cancer. 
34 fiducials were sited in total, 9/34 (26%) were sited in tumour.  Of the 25 fiducials that were sited in 
liver (rather than tumour), 9/25 (36%) were sited to mark colorectal cancer metastases, 6/25 (24%) to 
mark breast cancer metastases, 4/25 (16%) to mark a hepatocellular metastasis and 3/25 (12%) to mark 
a carcinoid and a melanoma metastasis. 
15/34 fiducials (44%) were rejected for tracking.  Mean distance of a rejected fiducial to the closest GTV 
edge was 21mm (range 0-46mm).  In contrast, the mean distance of an accepted fiducial to the GTV was 
6mm (range 0-47mm). 
The reasons for rejecting fiducials are explained in more detail below. 
Patients 1 and 9 both had 4 fiducials sited. In each case, 3/4 of the fiducials were sited moderately far 
from the tumour target, but the remaining fiducial was located in tumour target.  The 3 remote fiducials 
were rejected in each case, and treatment was performed tracking the solitary intra-tumour fiducial 
only. 
Patient 2 had 3 well-placed fiducials, however, an intra-tumour fiducial was rejected at treatment 
delivery because its position was inconsistent (as viewed on the live X-rays and by reference to RBE 
readings).  This metastasis appeared low-density and necrotic on CT.   A potential contributing factor for 
patient 2 was tumour deformation.  The metastasis was peripherally-located, and different duodenal 
filling between Plan CT and Day 1 CTs appeared to affect the position of fiducial 1. 
Patient 3 had 2 fiducials rejected.  One was 16mm from tumour, the other rejected fiducial was just 
1mm from the edge of tumour. This patient may also have experienced tumour deformation.  The 
metastasis was peripheral.  Differential filling of bowel was noted between Plan CT and Day 1 CT.  Of 
note, this patient had had prior hepatic resection therefore a number of loops of bowel were lying more 
superior than normal, adjacent to the tumour target. 
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Patient 4 had a single fiducial rejected.  The fiducial was 12mm away from tumour.  The fiducial was 
rejected for 2 out of the 3 treatment fractions (due to RBE increasing when it was included), but it was 
tracked without issues for the remaining fraction. 
Patient 5 had 3 well-placed fiducials, and a further fiducial which was further from tumour.  At treatment 
only the closest fiducial was tracked however.  Inclusion of all other fiducials increased the RBE. 
Patient 6 had 3 well-placed fiducials (within 15mm of tumour), and a fiducial lying 37mm from tumour 
which was rejected. 
Finally, patient 7 had a necrotic tumour with 3 fiducials placed at the edge of the tumour, and a fiducial 
lying 47mm from tumour.  At Plan CT/Day 1 CT fusion it was advised that tracking would be done by the 
3 fiducials at the tumour edge, and reject the remote fiducial.  In practice, however, one of the edge 
fiducials was rejected due to inconsistent position, and the fiducial that was 47mm away from tumour 
was tracked as it seemed to be a good surrogate for tumour, and to allow rotations to be tracked. 
In summary, fiducials were rejected for reasons of:  
1. Remote placement ≥ 10mm from tumour, 12/15 fiducials (80%) 
2. Tumour deformation, 2/15 fiducials (13%) 
3. Necrotic tumour, 1/15 fiducials (7%). 
Assessing the fiducial COM, this was located in the tumour in 5/9 cases (56%).  The rejection strategies 
employed which have been described, shifted the COM into the tumour in a further 2 cases (22%).  The 
remaining 2 cases had the COM shifted the edge of PTV by the rejection strategy employed. 
In summary, for liver tumour site, fiducial migration did not occur in the sample of patients studied.  
Fiducial COM was located in the tumour at the time of treatment delivery for 7/9 (78%) of patients.  
15/34 fiducials (44%) were rejected for tracking.  A majority of fiducials (80%) rejected were placed 
remote from tumour (≥10mm).  Other fiducials were rejected due to issues related to tumour 
deformation and necrotic tumour. 
 
 
 
100 
 
3.3.9 Liver tumour site: Organ At Risk reproducibility 
Table 3.11 displays data on OAR reproducibility for 6 patients for the liver tumour site.  In each case the 
OAR specified in the table was the dose-limiting OAR. 
CRC = Colorectal Cancer 
Table 3.11: Liver tumour site: Organ At Risk (OAR) Reproducibility 
Patient Pathology OAR 
Dose-limiting 
OAR 
shift to PTV 
Min Distance OAR 
to PTV on Plan CT 
(mm) 
Min Distance OAR to 
PTV on Day 1 CT 
(mm) 
1 CRC 
Oesophagus No 8 10 
Spinal cord No 49 57 
2 Melanoma Chest Wall No 1.5 2 
3 CRC 
Duodenum No 
1.6mm overlap 
with PTV 
0.5mm overlap 
 with PTV 
Bowel No 
13.5mm overlap 
with PTV 
2mm overlap  
with PTV 
4 Carcinoid 
Bowel Yes 
4.3mm overlap 
with PTV 
7mm overlap  
with PTV 
Liver N/A See text See text 
5 Breast Duodenum Yes 0.8 0.2 
6 Breast Chest Wall No 0 0 
 
Out of the 6 patients assessed, 2 patients (33%) had a shift in OAR position towards the PTV (on the Day 
1 CT as compared to the Plan CT). Patient 6 appeared to have a stable OAR position on Day 1 CT 
compared to Plan CT. The remaining patients had a shift of OAR away from PTV (on Day 1 CT as 
compared to Plan CT). 
Patient 4 had a large liver metastasis in a liver which had previously been resected.  In this patient 
therefore, dose to liver was potentially limiting, and accurate outlining of liver volume was crucial.  Liver 
volume as outlined on Plan CT for this case was 1343.6cc.  Liver volume as outlined on Day 1 CT by the 
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author = 1344.6cc.  These volumes are very similar, and the Day 1 CT liver volume was more generous, 
which is reassuring regarding liver doses received by this patient. 
 
3.3.10 Liver tumour site: Organ At Risk dosimetry 
The OAR dosimetry of the patients with a less favourable OAR position at Day 1 CT, in addition to the 
patient with a stable OAR position at Day 1 CT, is explored in Table 3.12. 
 
Table 3.12: Liver tumour site: Organ At Risk (OAR) Dosimetry 
MPD = Maximum point dose (dose limit allowed to be delivered to 0.035cc of OAR) 
Patient 
Number 
of 
fractions 
OAR  
MPD 
(Gy) 
5cc 
threshold 
(Gy) 
10cc 
threshold 
(Gy) 
30cc 
threshold 
(Gy) 
4 3 Bowel 
Protocol 25.2 17.7 N/A N/A 
Plan CT 26.2 18.4 N/A N/A 
Day 1 CT 29.8 18.6 N/A N/A 
5 3 Duodenum 
Protocol 24 16.5 11.4 N/A 
Plan CT 22.8 8.3 5.4 N/A 
Day 1 CT 27.7 8.9 6.1 N/A 
6 3 Chest Wall 
Protocol 36.9 N/A 
30  
(ideal) 
30 
(absolute) 
Plan CT 43.1 N/A 17.1 11.6 
Day 1 CT 42.2 N/A 16.5 11.4 
 
It can be seen that Patient 4’s planned doses to Bowel exceeded protocol dose, when considering both 
MPD, and the 5cc threshold limit.  This was due to a decision taken by the treating Consultant to 
maximise dose delivery to PTV, whilst also bearing in mind OAR dose.   The coverage of PTV in this case 
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was 93.9% (less than the ideal coverage of 95%).  In order to maintain coverage of the PTV in this case, 
given the proximity of Bowel and tumour, the Bowel was treated to doses beyond those stated in the 
protocol.  It is noted that the doses to Bowel based on the Day 1 CT position of Bowel were higher than 
anticipated (13.7% increase in MPD, 1.1% increase in 5cc threshold dose).  This could increase the risk of 
morbidity for the patient. 
Patient 4’s Liver doses were also calculated.  Protocol specifies that doses ≥21Gy should be received by 
≤30% of liver volume, and doses ≥15Gy should be received by ≤50% of liver volume.  Despite the large 
tumour/resected liver, planned doses were well within limits (14.3Gy to ≤30% liver, and 9.7Gy to ≤50% 
liver).  Day 1 CT calculated doses to liver were identical to the planned doses. 
Patient 5 had doses to Duodenum that were within protocol limits according to the Plan CT/treatment 
plan.  However, due to the Duodenum shift towards PTV on the Day 1 CT scan, the MPD to Duodenum 
now breaches the “safe” protocol limits (21.5% increase in MPD compared to Plan CT doses).  The 5cc 
and 10cc threshold doses also increased due to the shift, but the calculated doses remain within 
protocol limits. 
Patient 6 had planned MPD to the Chest wall exceeding protocol limits, although 10cc and 30cc 
threshold doses were well within limits.  Coverage of the PTV by the prescribed dose was 98.6% and the 
treating Consultant wished that the dose to PTV was not compromised in order to reduce chest wall 
doses.  It is noted that doses to Chest wall are marginally reduced according to the Day 1 CT position of 
Chest wall (2.1% decrease) although the MPD still exceeds protocol limits. 
Overall, 2/6 patients with liver tumours (33%) had an OAR shift towards PTV on Day 1 CT which resulted 
in an increase in calculated dose to the dose-limiting OAR beyond “safe” protocol levels.  This could 
potentially increase the risk of toxicity. 
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3.3.11 Pancreas tumour site: Tumour volume 
Histopathology and Tumour volume data for 4 patients with implanted fiducials is shown in Table 3.13.  
All pancreatic tumours studied were adenocarcinoma of pancreas. 
Table 3.13: Pancreatic tumour cases: Tumour volume 
Patient 
Interval Plan CT 
to  
Day 1 CT 
(Days) 
Clinician GTV 
(cc) 
Planning CT 
GTV CG (cc) 
Day 1 GTV CG 
(cc) 
Change 
Clinician GTV to 
CG Planning CT 
GTV (%) 
Change CG 
GTV Planning to 
Day 1 CT (%) 
1 5 39 31.6 32.7 -19 +4 
2 6 84.6 72.3 88 -15 +22 
3 5 54.4 38.6 52.5 -29 +36 
4 12 18.7 22.2 17.9 +19 -19 
Mean 7 49.2 41.2 47.8 -11 +11 
 
The mean and median interval (days) between Planning and Day 1 CT scans for patients with pancreatic 
tumours were 7 days and 5.5 days respectively. Standard deviation = 3 days. 
Clinician GTV volume (cc) and Planning CT GTV volume (cc) drawn by myself (“CG” as my initials) are 
displayed.  Both contours were drawn on the same Planning CT scan.  Despite the fact that the GTV was 
outlined on the same scan by both the Clinician and myself, there is again a wide variability in volumes. 
The Mean and Standard Deviation of the percentage difference between the volumes are -11%, and 
18%, confirming the variability in contouring between Clinical Oncologists (inter-observer variability).  Of 
note, for the first 2 patients listed, the volume drawn by the Clinician was labelled as “Clinical Target 
Volume (CTV)”.  The visible disease may therefore have been outlined generously to incorporate 
microscopic spread of disease, and this may be an explanation for the Clinician volume being greater 
than the volume drawn by myself. 
There was also a wide variability between the GTV volumes drawn by myself on the Planning CT 
compared to the Day 1 CT volume.  The Mean and Standard Deviation of the percentage difference 
between the volumes are +11% and 18% respectively.  For this analysis, there was no risk of inter-
observer variability skewing the results, as the same observer contoured both volumes.  However, as 
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before, the Day 1 CT scans were performed without intravenous contrast, and in all cases outlining on 
the non-contrast Day 1 CT scans was very difficult due to poor definition of structures. 
There was no tumour deformation noted in any of the above cases. 
 
3.3.12 Pancreas tumour site: Fiducial Reproducibility 
Pancreatic tumours tend to be irregular in shape, so ideally multiple fiducials would be placed 
surrounding tumour target such that rotations can be tracked.  However, optimum fiducial placement is 
often limited by the proximity of critical structures to the tumour (bowel, mesenteric blood vessels).  
Fiducials to mark pancreatic tumours can be placed percutaneously under CT guidance, endoscopically 
via stomach/duodenum, or laparoscopically. 
Fiducial reproducibility data for 9 patients with single-implanted fiducials is displayed in Table 3.14.   
COM = Centre Of Mass of fiducials 
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Table 3.14 Pancreas tumour site: Single fiducial: Fiducial reproducibility 
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There was agreement between fiducial location as registered by the Physics team and as registered by 
myself to within 1mm. 
The “Means” displayed in Table 3.14 were calculated to be Mean shift of fiducials from the Plan CT 
position.  The direction of shift from the original position was not significant, only the magnitude of shift, 
therefore any minus signs were ignored when calculating the Means. 
For a single-fiducial tracked CyberKnife treatment, as there is only one fiducial, the fiducial location 
position (at Planning CT), and the Planning CT COM is the same.  Table 3.14 confirms that Plan CT fiducial 
= Plan COM for each patient (columns highlighted in yellow) and similarly Day 1 CT fiducial = Day 1 CT 
COM (columns highlighted in blue).  Equally Fiducial shift = COM shift for each patient, as there is only a 
single fiducial located. 
Mean apparent shift in fiducial/COM position between initial Planning CT and Day 1 CT for this patient 
group with pancreatic tumours and single-implanted fiducials was 0.29, 1.01 and 0.58mm in x, y and z 
directions respectively.  Standard deviations were 0.29, 0.8 and 0.65mm for x, y and z directions 
respectively.  
Summary data for 9 patients with pancreatic tumours and multiple implanted fiducials is shown in Table 
3.15.   
COM = Centre Of Mass of fiducials. 
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Table 3.15: Pancreas tumour site: Multiple fiducials: Fiducial reproducibility 
Patient Number of fiducials 
COM Shift (mm) 
x y z 
1 3 0.68 1.87 0.2 
2 4 0.24 0 -0.25 
3 3 -0.25 0.49 0.09 
4 3 1.51 -1.31 -0.1 
5 3 0.2 -0.44 -0.06 
6 2 0.17 0.51 0.05 
7 2 2.93 -0.87 1.67 
8 2 -0.33 0.44 -0.24 
9 2 -2.72 -0.81 0.98 
Mean 2.7 1 0.75 0.4 
Standard Deviation 0.7 1.05 0.52 0.52 
 
The “Means” displayed in Table 3.15 were calculated to be Mean shift of fiducial COM from the Plan CT 
position to the Day 1 CT position.  As before, the direction of shift from the original position was not 
significant, only the magnitude of shift, therefore any minus signs were ignored when calculating the 
Means. 
The mean shift (in mm) for fiducial COM for patients with pancreatic tumours and multiple fiducials was 
1, 0.75 and 0.4mm in x, y, and z directions respectively.  The Standard Deviations were 1.05, 0.52 and 
0.52mm. 
The magnitude of mean shifts in COM for the multiple-fiducial cases described, are similar to the single-
fiducial cases (COM shift 0.29, 1.01 and 0.58mm in x, y and z directions). 
For the pancreas tumour patients as a whole, the shift in fiducial COM between planning CT and Day 1 
CT was sub-millimetre, overall mean shift was 0.65, 0.88 and 0.49mm in x, y and z directions 
respectively. 
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3.3.13 Pancreatic tumour site: Fiducial Location 
As described, the general approach for siting fiducials to mark pancreatic tumours is to site multiple 
fiducials surrounding the tumour.  This is most often performed percutaneously via CT guidance.  The 
fiducials should be located close enough to tumour to be a good surrogate for tumour motion as the 
pancreas moves with respiration/bowel and duodenal filling. 
The location of certain pancreatic tumours prevents a percutaneous approach due to access issues.  If 
this is the case, either an endoscopic, or more rarely, a laparoscopic approach is undertaken. 
Fiducial location data for 9 patients with pancreatic tumours and multiple implanted fiducials is shown in 
Table 3.16. 
Lap = Laparoscopic approach to implant fiducials 
CT = Percutaneous approach with CT guidance to place fiducials 
EUS = Endoscopic UltraSound approach to site fiducials 
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Table 3.16: Pancreas tumour site: Fiducial location: Multiple-implanted fiducials 
Patient Approach Fiducial 
Fiducial in 
GTV/PTV 
Implant tissue 
Plan CT 
Fid COM 
in PTV 
Distance 
fiducial to 
GTV/PTV(mm) 
Fiducials  
rejected? 
1 CT 
1 No Pancreas 
Yes 
44/42 
Yes: 
Fid1 
2 Yes Tumour N/A 
3 Yes Tumour N/A 
2 CT 
1 No Pancreas 
Yes 
11/5 
Yes: 
Fids 1,2 
2 No/Yes Pancreas 4/0 
3 Yes Tumour N/A 
4 Yes Tumour N/A 
3 CT 
1 
Yes Tumour Yes N/A 
Yes: 
Fid1 
2 
3 
4 Lap 
1 
Yes Tumour Yes N/A  No* 2 
3 
5 CT 
1 No Mesenteric fat 
No 
24/19 
Yes: 
Fids 1,2 
2 No Mesenteric fat 11/5 
3 Yes Tumour N/A 
6 EUS 
1 
Yes Tumour Yes N/A No 
2 
7 CT 
1 
Yes Tumour Yes N/A 
Yes: 
Fid 1 2 
8 EUS 
1 
Yes Tumour Yes N/A No 
2 
9 EUS 
1 Yes Tumour 
Yes 
N/A Yes: 
Fid 2 2 No Mesenteric fat 3/1 
 
5/9 patients (56%) had fiducials placed percutaneously, 3/9 patients (33%) by endoscopic ultrasound, 
and a single patient (11%) had fiducials sited at laparoscopy. 
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Patient 4 had to have a second fiducial placement procedure due to migration of fiducials following the 
first implantation.  There was no imaging taken immediately after the first laparoscopy, but at the first 
Planning CT all 3 fiducials had apparently migrated.  The fiducials were located 3.2cm, 7.3cm and 8cm 
from the tumour.  The fiducials may have migrated along fat planes as they came to rest in the 
perinephric fat.  At repeat laparoscopy all 3 fiducials were placed in the tumour and this was a stable 
position. 
There were no further instances of a fiducial migrating from the site of implantation when fusing Plan CT 
and Day 1 CT.   
All patients had at least one fiducial placed in tumour. 
24 fiducials were sited in total (excluding the 3 migrated fiducials from Patient 4). 
18/24 (75%) were sited in tumour, 3/24 (12.5%) in pancreas, and 3/24 (12.5%) in mesenteric fat.   
8/24 fiducials (33%) were rejected for tracking.  Mean distance of a rejected fiducial to the closest GTV 
edge was 16mm (range 0-44mm).  In contrast, all accepted fiducials were located inside the GTV (i.e. 
inside tumour).  However, not all intra-tumour fiducials were accepted, 14/16 intra-tumour fiducials 
were accepted (88%). 
6/9 patients (67%) had instances of fiducials being rejected. 
Patient 1 had a pancreatic head tumour, and one rejected fiducial, this was located in the tail of 
pancreas 4.4cm from tumour.  At treatment, it was noted to be moving differently to the 2 intra-tumour 
fiducials. 
Patient 2 had two rejected fiducials lying only 11mm (fiducial 1) and 4mm (fiducial 2) from tumour.  
Fiducial 1 was rejected for each of the 3 treatment fractions as it moved differently to the 2 intra-
tumour fiducials (fiducials 3 and 4). Fiducial 1 was located on the periphery of pancreas, adjacent to 
stomach.  The stomach was noted to be fuller at Planning CT.  Fiducial 2 was rejected for fraction 3 only, 
it was positioned at the interface between the tumour and the second part of the duodenum. 
Patient 3 had an intra-tumour fiducial rejected because it was lying too close (13 mm separation) to the 
other intra-tumour fiducial.  The orientation of fiducial 1 was also changed compared to the orientation 
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at Planning CT (long axis of fiducial orientated anterior/posterior at Planning CT compared to right/left at 
Day 1 CT), which contributed to tracking issues at the time of treatment delivery. 
Patient 5 had 2 fiducials rejected, both were located in fat, anterior to the tumour.  Fiducial 1 was 
located in peri-bowel fat.  Both of these rejected fiducials moved differently to the remaining intra-
tumour fiducial. 
Patient 7 had an intra-tumour fiducial rejected (fiducial 1).  This was located anteriorly in the tumour, 
and adjacent to the duodenum.  It was noted that the stomach/duodenum was more dilated at planning 
CT than at Day 1 CT.  Differential stomach/duodenum filling may have contributed to apparent fiducial 
shift between scans (shift for fiducial 1 was 1.31, 0.89 and 3.75mm in x, y, and z directions respectively). 
Patient 9 had a fiducial rejected which was located in mesenteric fat anterior to the tumour, and 
adjacent to the pylorus of stomach.  At Day 1 CT this fiducial appeared to have shifted position, although 
it was still lying in mesenteric fat. The fiducial had shifted by 4.81, 1.31, and 0.36mm in x, y and z axes 
respectively compared to the planning CT. 
In summary, fiducials were rejected for reasons of:  
1. Unstable fiducial placement in mesenteric fat, 3/8 fiducials (38%) 
2. Fiducial placement in pancreatic periphery, adjacent to stomach/duodenum, different filling of 
stomach/duodenum on Planning CT vs Day 1 CT, 3/8 fiducials (38%) 
3. Remote fiducial placement (>4cm from tumour) in pancreas, 1/8 fiducials (12.5%) 
4. Fiducial placement too close to indwelling fiducial, 1/8 fiducials (12.5%) 
Assessing the fiducial COM, this was located in the tumour in 8/9 cases (89%).  The rejection strategies 
employed which have been described, shifted the COM into the tumour in the remaining case.   
In summary, for pancreas tumour site and multiple-implanted fiducial cases, fiducial migration occurred 
solely following a laparoscopic approach to implant fiducials.  Fiducial COM was located in the tumour at 
the time of treatment delivery for all patients.  8/24 fiducials (33%) were rejected for tracking.  All 
fiducials sited in mesenteric fat were rejected as they were a poor surrogate for tumour motion.  
Fiducials placed at the periphery of pancreas, and adjacent to stomach/duodenum were rejected due to 
apparent shift from their position at Planning CT, which was likely to be explained by differential 
stomach/duodenal filling (at Day 1 CT compared to Planning CT).  Further fiducials were rejected for 
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being too remote from tumour, (and therefore an inappropriate surrogate for tumour), and for being 
too close (<2cm) to other implanted fiducials. 
A further 6 patients with pancreatic tumours and single-implanted fiducials were assessed. 4/6 patients 
(67%) had the fiducial placed by endoscopic ultrasound, and the remaining 2 patients (33%) had the 
fiducial placed laparoscopically.  One of the laparoscopic cases had initially had 3 fiducials implanted, but 
2 fiducials had migrated (to >10cm from the tumour) by the time of Planning CT leaving a solitary intra-
tumour fiducial.  The operation note described that the two migrated fiducials were both placed in fat 
adjacent to the tumour. 
5/6 patients (83%) had the solitary fiducials placed in the tumour.  The remaining patient had the fiducial 
sited via endoscopic ultrasound, the fiducial was lying in the duodenal wall, on the periphery of the PTV 
and just 3mm from tumour.  The position at Planning CT and Day 1 CT was stable. 
In summary, for the 15 patients with pancreatic tumours described above, the following has been 
observed: 
1.  All fiducials sited in fat (8 fiducials) were rejected for tracking (either due to fiducial migration, or 
due to being a poor surrogate for tumour motion). 
2. 14/15 patients (93%) had at least one intra-tumour fiducial placed. 
3. 14/15 patients (93%) had a fiducial COM located in tumour at the time of treatment delivery. 
4. The remaining patient had the fiducial sited at the edge of the PTV and only 3mm from tumour. 
5. Fiducial tracking issues were sometimes encountered when fiducials were located at the 
periphery of normal pancreas and adjacent to duodenum/stomach.  The difficulties appeared to 
be related to differential stomach/duodenal filling at treatment compared to planning. 
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3.3.14 Pancreas tumour site: Organ At Risk reproducibility 
Table 3.17 displays data on OAR reproducibility for 1 patient for the pancreas tumour site.   
Table 3.17: Pancreas tumour site: Organ At Risk (OAR) Reproducibility 
Patient OAR 
Dose-limiting 
OAR 
shift to PTV 
Min Distance OAR 
to PTV on Plan CT 
(mm) 
Min Distance OAR to 
PTV on Day 1 CT 
(mm) 
1 Duodenum Yes 6mm overlap 11mm overlap 
 
3.3.15 Pancreas tumour site: Organ At Risk dosimetry 
The OAR dosimetry of the above patient is displayed in Table 3.18. 
 
Table 3.18: Pancreas tumour site: Organ At Risk (OAR) Dosimetry 
MPD = Maximum point dose (dose limit allowed to be delivered to 0.035cc of OAR) 
Patient 
Number 
of 
fractions 
OAR  
MPD  
(Gy) 
5cc threshold  
(Gy) 
10cc threshold 
(Gy) 
1 3 Duodenum 
Protocol 24 16.5 11.4 
Plan CT 30.1 25.6 22.3 
Day 1 CT 31.2 28.6 23.6 
 
It can be seen that Patient 1’s planned doses to Duodenum exceeded protocol dose, when considering 
both MPD, and the 5cc/10cc threshold limits.   
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3.4 DISCUSSION 
A key requirement for the accurate delivery of SBRT is that there is stability between Planning CT and 
the time of treatment.  The tumour volume should be stable (in size and formation), and the positional 
inter-relationship of tumour, fiducials, and Organs at Risk (OAR) should also be stable.   
“Planning margins” are added to the imaging-defined tumour volume (GTV) to account for potential 
differences in tumour position between planning and treatment, with the aim of avoiding geographical 
miss (11).  However, selection of an “appropriate” planning margin is a challenge for clinicians.  The 
margin should be sufficient to encompass tumour position across the full range of inter-fraction and 
intra-fraction motion.  However, given the high BED doses of SBRT, the margin should be small enough 
to protect normal tissue.  This is a difficult balance to strike.  The consequence of a margin which is too 
tight is potential loss of tumour control, and the consequence of a margin which is too generous is 
potential toxicity (13). 
The selection of an “appropriate” planning margin should be informed by, among other factors, the 
stability of tumour volume and the positional stability of tumour/fiducials/OAR.   
 
3.4.1 Tumour growth 
Cancer cells stimulate their own growth, resist anti-growth signals, and have an ability to multiply 
indefinitely (14).  Tumours grow exponentially (15) and therefore there is the potential for there to be a 
noticeable increase in tumour volume between planning and treatment even if the time interval is 
relatively short. 
The methodology described in section 3.2.2 aimed to assess this potential growth by comparing the 
measured tumour volume at planning versus treatment.  However, it was not possible to accurately 
determine change in tumour volume, due to the limitations encountered in the accuracy of contouring 
which are described below. 
A number of studies reported in the literature describe moderate to large inter-observer variability in 
tumour volume contouring (16, 17).  This includes a wide variability for contouring of the tumour sites 
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studied here i.e. lung, liver, pancreas (18-21).   Accurate contouring of tumour volumes is a challenge for 
oncologists, and the observed variations in contouring across several studies demonstrate this. 
When considering the methodology for assessing tumour growth for the patients studied in section 
3.2.2, an option would have been to contour tumour on both Planning and Day 1 CT scans, with no 
comparison to the clinician’s contoured volume.  However, it was felt that comparison to the clinician’s 
contoured tumour volume was an important assessment to evaluate the validity of the tumour volumes 
observed.  Consistency in contoured volumes would have given some confidence to the accuracy of 
contoured volumes, although the observed variation in the literature would indicate that the accuracy of 
volumes should be viewed cautiously.  In practice, there was a wide variation in Planning CT tumour 
volume observed between the clinician and the author.  This suggests that all tumour volumes should be 
viewed with caution. The variation could be explained in a minority of cases by the clinician labelling the 
tumour volume as GTV (Gross Tumour Volume, as defined on imaging), but in practice drawing a CTV 
(Clinical Target Volume, to incorporate GTV plus a margin to account for microscopic spread).  In these 
instances, the clinician volume would be expected to be greater than the GTV drawn by myself. In the 
majority of cases, however, the likely scenario was that the differences in contoured volumes was due to 
inter-observer variability (consistent with the reported literature). 
Intra-observer variability has been reported in the literature, although the variability is less than for 
inter-observer variability (17, 22).  The studies report the variability for the same observer contouring 
the same scans.  The variability would therefore be expected to be much less in these studies from the 
literature, compared to the assessment of tumour volume (between planning and Day 1 CT scans) in this 
current work.  The assessment described in 3.3.1 compared volumes contoured on two different scans 
(captured approximately 1 week apart), so tumour growth is possible, indeed assessment of tumour 
growth was the aim of this section.  A complicating issue for the assessment, however, was that the Day 
1 CT scans were performed without the aid of intravenous contrast. It is known that intravenous 
contrast aids in the tumour definition of lung (23), liver (24) and pancreatic tumours (25).  It was 
certainly my experience that it was more difficult to be certain of the edge of the tumour on the Day 1 
CT scans due to the lack of contrast enhancement. 
The growth rate of tumours shows considerable variability between tumours of different histology, as 
well as between primary and metastatic lesions.  Growth rates are typically quantified as Volume 
Doubling Times (VDT).  The VDT is defined as the time taken for a tumour to double in volume (26).   
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The observed changes in tumour volume are reviewed with reference to tumour VDTs and interval 
between scans for each of the tumour sites studied below. 
3.4.1A: Lung tumour site 
Ten patients with lung tumours were studied.  
Six patients were treated for primary Non-Small Cell Lung Cancer (NSCLC).  Mean VDTs for primary 
NSCLC have been reported as 158 days by Kanashaki et al (27) and 181 days by Winer-Muram et al (28).  
The mean interval between planning and treatment scans for the six NSCLC patients studied was 7 days 
as shown in Table 3.1.  For the NSCLC group as a whole the mean percentage change in tumour volume 
between planning and treatment was -2%.  An average shrinkage in tumour volume is unexpected (given 
the exponential growth patterns of tumours) and is likely to be due to the limitations in contouring 
described.  The results are also skewed by patient 1, who had a recorded decrease in tumour volume by 
28% between scans, this tumour volume was notably difficult to contour on the non-contrast Day 1 CT.  
The remaining NSCLC patients had stable, or modest increase in tumour volumes (+3 to +8%) as might be 
expected given the VDT and the 7 day interval between scans. 
Four patients were treated for Colorectal cancer (CRC) metastasis.  Mean VDTs for CRC metastasis has 
been reported as 71 days (29) and 56 days (30).  The mean interval between planning and treatment 
scans for the four CRC patients studied was 6 days as shown in Table 3.1.  For the CRC group as a whole 
the mean percentage change in tumour volume between planning and treatment was -5%.  As before, 
an average tumour shrinkage would not be expected.  3/4 patients had a recorded shrinkage of tumour 
size.  Only patient 6 had an increase in tumour volume between scans of +4%, this increase in tumour 
size may be feasible given the quoted VDTs of metastatic CRC and the scan interval (in this patient) of 8 
days. 
 
3.4.1B: Liver tumour site 
Six patients with liver metastases were studied. 
Two patients were treated for CRC metastasis.  Mean VDTs for CRC metastasis to the liver has been 
reported as 155 days (Standard deviation = 34 days) (31).  The mean interval between planning and 
treatment scans for the two CRC patients studied was 7 days as shown in Table 3.8.  The average 
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percentage change for these patients was -17%, an observed shrinkage in tumour volume.  According to 
the results Patient 1’s tumour volume almost halved in size.  This is again thought to be a result which 
reflects the challenges (and therefore inaccuracies) of contouring on a non-contrast CT for the Day 1 
Treatment CT scan. 
Two patients were treated for breast cancer metastasis.  Mean VDTs for Breast cancer metastasis has 
been reported as 98 days (30). The mean interval between planning and treatment scans for the two 
breast cancer patients studied was 5 days as shown in Table 3.8. The average percentage increase in 
tumour volume between planning and treatment scans in these patients is 19%.  However, the results 
are being skewed by patient 5 who had an apparent large increase (+36%) in tumour volume as 
compared to a small increase in volume (+2%) in patient 6. 
A single patient with a melanoma metastasis was studied.  Mean VDTs for melanoma metastasis have 
been reported as 64 days (range 8-212) (32).  There was a 5 day interval between planning and 
treatment scans for this patient, with an apparent increase in tumour volume of +71%.  Whilst 
metastatic melanoma is known to be a fast-growing tumour (note VDT can be as little as 8 days), it was 
notably challenging to outline this tumour on the Day 1 treatment CT scan, and I would be sceptical that 
this is a true and accurate result. 
It was not possible to contour the metastasis the single patient with a carcinoid metastasis on the Day 1 
CT scan. 
 
3.4.1C: Pancreas tumour site 
Four patients with pancreatic tumours were studied, all had primary disease.  Mean VDTs for primary 
pancreatic cancer has been reported as 42 days (30) .  Mean interval between planning and treatment 
scans for these patients was 7 days as shown in Table 3.13.  For the group as a whole there was a mean 
increase in tumour volume at treatment of +11%.  However, there was a wide variation in the change of 
tumour volume (range -19% to +36%).  The apparent reduction in tumour volume of -19% for patient 4 
should certainly be viewed with suspicion. 
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3.4.1D Summary: Tumour growth  
Evaluating all patients studied (lung, liver, pancreas) for potential tumour growth between Planning and 
Day 1 treatment CT scans, the following observations are noted: 
1.  Mean interval between Planning and Day 1 Treatment CT scans is 7 days (for the group as a whole, 
and for each tumour site). 
2.  For all histopathologies studied, mean VDTs far exceeded the interval between scans, although it was 
noted that there was wide variation in VDTs reported in the literature. 
3.  In spite of careful contouring on Planning CT and Day 1 treatment CT scans, it was not possible to 
draw conclusions about tumour growth between scans due to: 
a) the challenging nature of contouring (as experienced here and evidenced by inter- and intra-observer 
variablity reported in the literature), and 
b) the limitation of having a non-contrast CT only available for contouring on the Day 1 Treatment CT. 
4.  The magnitude of inter- and intra-observer variability observed in these volume assessments suggests 
that contouring is likely to be a much larger source of potential error in SBRT delivery, as compared to 
the sub-millimetre accuracy of fiducial tracking demonstrated in Chapter 2. (Although it is noted that the 
studies in Chapter 2 were phantom studies, and fiducial tracking in clinical situations may be less 
accurate). 
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3.4.2 Tumour Deformation: 
SBRT is a highly conformal radiotherapy technique.  Treatment plans are produced where the 
prescription isodose line conforms tightly to the PTV contour (33).  As a consequence of this 
conformality it is critical to consider, estimate, and account for all geometrical uncertainties, such as 
tumour deformation. 
Assessment of tumour deformation has been performed in a variety of ways in the literature.  The most 
sophisticated assessments of deformation incorporate statistical modelling and deformable registration 
tools.  These assessments have demonstrated that tumour shape changes during radiotherapy 
treatment (compared to the formation at the time of planning images) for rectal and prostate tumours 
(34-36).  The shape changes were shown to be significant, such that adaptive margins were suggested. 
Harris et al assessed breast tumour cavity deformation with statistical modelling without deformable 
registration, using the cavity marker clips as fiducials (37).  The authors proposed an adaptive strategy to 
compensate for the volumetric and shape changes observed. 
Barker et al pursued a more subjective approach to assessment and confirmed visible changes in tumour 
formation during a radiotherapy course for Head and Neck cancer (38). 
It was beyond the scope of this study to assess tumour deformation with statistical modelling and image 
registration tools.  Further, it was not possible to pursue the approach of Harris et al as fiducials were 
not inserted into the edge of tumour volumes in the patients studied here. 
Initially, it was explored whether a suitable surrogate measure for tumour deformation could be the 
maximum contour deviation of the Day 1 CT, measured as a perpendicular to the reference planning CT 
contour.  A deviation of the Day 1 contour beyond the planning CT contour would be potentially 
significant because this would risk underdose of tumour.  Equally, deviation of the Day 1 CT contour 
inside the reference planning CT contour may be significant as this would be likely to occur due to 
changes in normal tissues, and these could therefore be overdosed (e.g pancreatic head tumour could 
be deformed due to increased duodenal filling on Day 1 vs Planning CT, with possible overdose of 
duodenum).     
In practice, however, it became clear that there were a number of issues with the approach proposed.  
Firstly, there was recognised intra-observer variability, as described in section 3.4.1, exacerbated by the 
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use of non-contrast CTs for the Day 1 CT scans, therefore I did not consider the contours valid for 
assessment.  A further issue was that it became clear that the maximum contour deviation was not a 
representative measure for the overall change in contours between planning CT and Day 1 CT.  This 
approach was ultimately abandoned for the above reasons. 
It would have been possible to contour the areas where the Day 1 CT contour was larger (or smaller) 
than the reference planning CT contour and calculate the volume of these structures in MultiPlan.  This 
assessment would have been more representative of potential tumour deformation than the 
perpendicular contour deviation approach initially proposed.  However, it was recognised that this 
approach was labour-intensive, and I felt that the issues regarding the reliability of the contours drawn 
meant that pursuing this approach was unwarranted. 
On subjective assessment of the tumour volumes for the cases studied (lung, liver, pancreas), within the 
limitations described regarding delineation uncertainties, tumour deformation between Planning and 
Day 1 CT scans was noted for two liver tumours only (patients 2 and 3).  In each case, the likely cause of 
tumour deformation was differential duodenal/bowel filling. 
 
3.4.3 Fiducial Migration: 
Fiducial migration describes the movement of implanted fiducials from their original position, (at the 
time of initial fiducial placement) to a remote position where they are no longer an appropriate 
surrogate for tumour position/movement.  Fiducial migration can occur early, where it is noted by the 
clinician at the time of fiducial deployment, or on the immediate post-placement imaging.  “Delayed” 
fiducial migration can also occur, where the migration is noted on Planning CT scans which are typically 
captured 1 week after fiducial placement (2).  Early migration is less problematic to the patient as an 
additional fiducial can be placed at the same session to replace the migrated fiducial.  Delayed 
migration, only noted at Planning CT, could mean that the patient requires a second fiducial placement 
session, and ultimately suffers a treatment delay, and the attendant risks of a second procedure. 
It is not possible to treat a patient using fiducials which are situated >5-6cm away from the tumour 
target.  This is partly to ensure that all fiducials can be captured on the Field of View (FOV) of the 
CyberKnife treatment consoles, which measure 20x20cm (2).  In addition, the greater the distance 
between a fiducial and tumour, the greater the risk of disparity between fiducial and tumour position. 
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This section will consider “fiducial migration” as those cases where fiducials migrate >5cm from the 
implanted position.  A more moderate degree of fiducial migration sometimes occurs, however, these 
cases will be considered in the next section on fiducial reproducibility (section 3.4.4). 
3.4.3A: Fiducial Migration: Lung tumour site 
Kothary et al (2) commented that fiducial migration is most often seen in the lung.  The group 
hypothesised that this could be due to the risk of pneumothorax, and fiducials dropping into the pleural 
space. 
Fiducial migration rates reported in the literature vary widely (1-53%) according to the fiducials used, 
site of insertion, and insertion technique (39-41). 
Schroeder et al (41) reported on migration rates following 234 fiducial placements sited at 
bronchoscopy.  The first 4 patients had linear fiducials placed, but 53% of these fiducials migrated 
(delayed migration).  This resulted in 2 patients requiring a second insertion procedure.  The centre 
therefore switched to inserting coil fiducials, which may have design features to reduce the risk of 
migration.  Subsequent to this switch in fiducial type, the migration rate was much improved at 1%. 
Patel et al reported an 8% migration rate of fiducial markers (delayed migration).  Fiducials were 
inserted percutaneously under CT guidance.  4 fiducial markers migrated into the pleural space, whilst a 
further marker migrated into the extra-pleural soft tissue. 
Bhagat et al reported a 19% migration rate.  Fiducials were inserted percutaneously under CT guidance.  
Out of 11 migrated fiducials, 10 had migrated into the pleural space, the remaining fiducial migrated into 
an airway, and was thought to have been subsequently coughed up.  The group noted an increased risk 
of migration when a fiducial was placed a shorter distance from pleura, and when a fiducial was placed 
outside of tumour. 
As described in Methods section 3.2.3, a qualitative judgement as to the stability of a fiducial 
implantation site was due to have been recorded for each fiducial placed.  However, in practice, I felt 
unable to make an informed judgement as to the likely stability of each site.  The making of this 
qualitative judgement at the time of first reviewing the cases was therefore abandoned.  However, full 
analysis of migration results has led me to be more informed on the likely stability of implantation sites, 
as will be discussed in this section. 
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A total of 18 patients with lung tumours were assessed for fiducial migration.  All fiducials were placed 
percutaneously under CT guidance.  Fiducial migration occurred in just 1/18 patients (6%) and 1/36 
fiducials placed (3%).  The solitary migrated fiducial was deposited close to the pleural edge (3 mm from 
pleural edge) and on planning CT was noted to be lying in the pleural recess.  The patient did not 
develop a pneumothorax post-insertion.  Fortunately, the patient did not require a second fiducial 
insertion procedure, because a second fiducial was optimally placed within tumour.   
The migration rates observed here compare favourably with those reported by Bhagat et al, and Patel et 
al, where fiducials were inserted with the same technique.  In keeping with the observations of Bhagat 
et al, there were no instances of fiducial migration where the fiducial was placed inside tumour.  In 
addition, the solitary case of fiducial migration occurred where a fiducial was placed close to the pleura. 
 
3.4.3B: Fiducial Migration: Liver tumour site 
Jarraya et al reported the results of a large study of 328 patients, and 1444 implanted fiducials (42).  All 
fiducials were placed into the liver percutaneously under CT-guidance.  The centre’s policy was to avoid 
placing fiducials in tumour due to concerns over tumour seeding, and also a concern over the potential 
for tumour necrosis during treatment causing fiducials to shift (43).  834 fiducials placed were single 
fiducials, 610 fiducials were linked by a strand.   
There were no instances of fiducial migration for linked fiducials.  In contrast, there was a 2.7% 
immediate migration rate for single fiducials.  Out of 9 immediately migrated fiducials, 4 migrated to the 
heart (requiring overnight observation but no intervention), 3 migrated to a subcapsular location, and 2 
fiducials migrated to the Inferior Vena Cava.  There were 3 patients (0.9%) who had delayed migration of 
fiducials noted at planning CT.  The initial site of implantation for the migrated fiducials was not 
described further. 
Kim et al (44) reported on fiducial migration rates for Ultrasound-guided fiducial placements for the 
treatment of malignancy in intra-abdominal lymph nodes, liver, pancreas and prostate.  Overall, 77 
patients and 270 fiducial placements were studied.  Considering the 96 fiducials placed to mark hepatic 
tumours, there was one case of delayed fiducial migration (1%).  The tumour was a hepatocellular 
malignancy, and the migrated fiducial was lying in the adjacent capsule. 
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Nine patients with liver tumours were studied here, with 34 implanted fiducials.  Results are reported in 
section 3.3.8.  All fiducials were placed percutaneously under CT guidance.  There were no instances of 
fiducial migration observed (either immediate or delayed).  Whilst this is a smaller sample of patients 
than those studied by Jarraya and Kim et al, the fiducial migration rate observed here compares 
favourably. 
 
3.4.3C: Fiducial Migration: Pancreas tumour site 
Fajardo et al (45) reported on 23 patients with 63 fiducials sited to mark pancreatic tumours.  All 
fiducials were sited under Endoscopic Ultrasound (EUS) guidance.  The group noted a fiducial migration 
rate of 9.5% (6/63 implanted fiducials).  The intended site of implantation for all fiducials was described 
only as “the tumour area”.   
Sanders et al (46) reported on 51 patients who had undergone EUS-guided placement of fiducials to 
mark pancreatic tumours.  A 7% delayed migration rate (occurring in 3/51 patients) was noted, and the 
patients had to undergo a second fiducial placement procedure.  The intended site of implantation for 
fiducials at the outset was “into or adjacent to tumour”.  Out of the 3 patients described above that 
suffered a fiducial migration, 1 patient had a fiducial placed successfully in the tumour mass at the 
second EUS procedure.  The remaining 2 patients had fiducials placed in the tumour mass, and also the 
left hepatic lobe at their 2nd EUS procedure.  Following these instances of fiducial migration, the group 
aimed to site 2 fiducials in the tumour mass, and a further fiducial in the left hepatic lobe per patient.  
The authors noted that it was “unclear” why there were cases of delayed migration. 
Kim et al (44) inserted fiducials via ultrasound guidance to mark pancreatic tumours in 39 patients.  
There were no instances of fiducial migration recorded in these patients. 
Data for 9 patients with pancreatic tumours marked by fiducials are shown in Table 3.14.  5/9 patients 
(56%) had fiducials placed percutaneously under CT guidance, 3/9 patients (33%) by endoscopic 
ultrasound, and a single patient (11%) had fiducials sited at laparoscopy. 
The patient who had 3 fiducials sited at laparoscopy (patient 4), had delayed migration of fiducials noted 
on Planning CT.  There was no immediate post-implantation image taken, but at Planning CT fiducials 
were located 3.2cm, 7.3cm and 8cm from the tumour.  Whilst the fiducial lying 3.2cm from tumour is 
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clearly <5cm from tumour, it is considered here because it had come to lie in a completely separate 
tissue, and was judged by the team to be likely to be a poor surrogate for tumour position.  The fiducials 
may have migrated along fat planes as they came to rest in perinephric fat.  At repeat laparoscopy a 
further 3 fiducials were successfully placed in tumour, with no subsequent migration.  
There were no instances of fiducial migration for the remaining 8 patients with fiducials sited by EUS or 
CT guidance.   
The site of fiducial implantation for the successful fiducials re-sited for patient 4, and the above 8 
patients were: tumour (75%), pancreas (12.5%), and mesenteric fat (12.5%). 
In summary, there were no cases of fiducial migration observed for fiducials placed under EUS guidance, 
or percutaneously under CT guidance.  This was a small sample of patients, but the results compare 
favourably with the fiducial migration rates reported in the literature (7-9.5%).   
Equally there were no cases of fiducial migration observed when fiducials were implanted into tumour 
or pancreas. 
A fiducial migration rate of 50% was observed in a single patient with laparoscopically-placed fiducials.  
No fiducial migration was observed by this technique when fiducials were implanted into tumour.   
The fiducial migration rate was noted to be 50% in fiducials implanted into mesenteric fat. 
The case described was early in the learning curve for the Surgeon doing the fiducial placement.  I feel 
that it is more likely that the significant predisposing factor for fiducial migration in this case, was the 
implantation in mesenteric fat, rather than the laparoscopic approach.  Indeed, a laparoscopic approach 
was pursued in this case because the position of nearby critical structures prohibited safe placement 
under EUS or CT guidance. 
Fiducial migration following implantation into fat or mesentery was also noted for the 2 clinical 
examples described in the Introduction (section 3.1.1).  A further clinical example of fiducial migration 
following insertion into peri-cardiac fat has also been noted.  3 fiducials were placed percutaneously, 
with laparoscopic guidance.  Immediately post-implantation, a Chest X-Ray suggested that all fiducials 
were well sited.  But at Planning CT it was clear that the fiducials had migrated (delayed migration). The 
patient (who had a cardiac metastasis of carcinoid tumour to the left ventricular wall) had a repeat 
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fiducial placement procedure, percutaneously under CT-guidance, with 2 fiducials placed directly into 
tumour. The tumour-implanted fiducials did not migrate, and treatment was delivered without event. 
Kim et al (44) noted 5 instances of fiducial migration when fiducials were inserted to mark intra-
abdominal lymph nodes.  The authors commented that migration may have occurred “possibly from 
movement of the mesentery”. 
3.4.3D: Fiducial migration: Summary 
It is already known from the literature that fiducial migration is a recognised complication following 
fiducial implantation.  Migration rates vary according to tumour site, fiducial type and implantation 
technique.  Observed fiducial migration rates are 1-53%, 1-3.5%, and 0-9.5% for lung, liver and pancreas 
tumour sites respectively. 
Fiducial migration rates noted in this study are 6%, 0%, and 11% for lung, liver and pancreas tumour sites 
respectively.  These migration rates are broadly in line with those reported in the literature, confirming 
earlier findings. 
The studies reported above have large focussed on immediate complications of fiducial placement e.g. 
pneumothorax/bleeding/pain (these complications are not considered in this study), as well as fiducial 
migration rates.  One study (39) reported that fiducial migration was unlikely to occur where fiducials 
were inserted in tumour, and  2 studies reported increased risk of fiducial migration where fiducials 
were implanted close to pleura, or close to liver capsule (39, 44).  The studies did not explore in any 
further detail, the risk of fiducial migration following implantation into different tissues. 
The analysis described here demonstrates a new and important finding: fat (mesenteric, peri-nephric, 
peri-cardiac) is an unsuitable tissue for fiducial implantation, due to an extremely high fiducial migration 
rate.  Fiducial migration following insertion into fat occurred for 4/4 fiducials in perinephric fat, 3/3 
fiducials in peri-cardiac fat, and 5/9 fiducials inserted into mesenteric fat (2 migrated fiducials from the 
case described in the Introduction, and 3 fiducials from pancreas Patient 4).  This represents an overall 
fiducial migration rate of 75% for fiducials implanted into fat, which is unacceptable given the risks of 
fiducial placement, and the treatment delay that occurs by requiring a second fiducial implantation 
procedure. It is likely that the density and tissue architecture of fat makes it an unsuitable tissue to 
anchor fiducials.  In addition, mesenteric and peri-cardiac sites are subject to significant motion, which 
may contribute to dislodging implanted fiducials. 
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3.4.4 Fiducial Reproducibility: 
As previously stated, it is important that the positional relationship of fiducials to each other, and to 
tumour and organs at risk (OAR), is stable at treatment with respect to their positions at planning CT. 
Section 3.4.3 reviewed cases where fiducials had migrated >5cm from their site of implantation, and 
could therefore not be used to guide treatment delivery.   
However, given the small planning margins applied in SBRT treatment, a fiducial shift/migration of only a 
few millimetres from the planning position to a different treatment position, could potentially cause a 
risk of geographical miss of tumour, and risk of overdose to OARs.  The likelihood of this issue arising, 
and its potential impact on treatment delivery, is reviewed here. 
3.4.4A Fiducial Reproducibility: Lung tumour site 
Van der Voort van Zyp et al (47) explored fiducial stability in 42 patients with lung tumours treated by 
CyberKnife.  Each patient had a planning CT scan followed by 2-3 repeat scans, taken at intervals during 
the treatment course. Slice spacing of the CT scans was 1.5-2mm.  This group co-registered the CT scans 
by tumour-to-tumour soft tissue matching.  The 3D marker co-ordinates where then determined on the 
planning CT scan and compared to the repeat CT scans. They found median marker displacement to be 
1.3mm, median COM displacement was 1mm.  As the CyberKnife real-time tumour-tracking system 
localises the tumour using the fiducial COM, the group explored whether a COM displacement of ≥2mm 
could be detected by changes in inter-marker distance.  They found inter-marker distance change of 
>1.5mm predicted a COM displacement of ≥2mm in 96% of treatment fractions. 
Hong et al (48) investigated fiducial stability in 32 patients with lung tumours who were to be treated 
with CyberKnife.  The patients had 147 implanted fiducials.  The patients had post-implantation CT scans 
co-registered with planning CT scans, this time co-registration was performed by fiducial-to-fiducial 
matching.  Median fiducial migration was found to be 1.28mm, remarkably similar to the Van der Voort 
van Zyp group, despite the difference in methodology.  They concluded that fiducial migration of this 
magnitude was unlikely to cause geographic miss. 
Table 3.2 shows the mean fiducial displacement between planning CT and Day 1 treatment CT for 9 
patients with lung tumours and single implanted fiducials.  Co-registering CT scans by fiducial matching 
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(similar to Hong et al (48)) showed a mean fiducial shift of 0.72mm.  Clearly, the most important step in 
assessing fiducial displacement is in deciding the centre of each fiducial.  The process could be prone to 
inter-observer variability, but the variability between the Physicists and myself was found to be sub-
millimetre apart from the y co-ordinate of a single fiducial.  Appendix Table 1A shows fiducial 
displacements for 6 patients with multiple implanted fiducials.  Mean fiducial shift observed in the group 
of 9 patients with multiple fiducials was 0.75mm.  Mean fiducial shift for the lung group overall was 
0.74mm. 
Mean COM shift was 0.72mm in the single-fiducial group (as centre of single fiducial = COM).  Mean 
COM shift for the multiple fiducial group was 0.61mm (Table 3.3B). Overall mean COM shift for the lung 
tumour group was 0.67mm. 
The observed fiducial and COM shift observed here compares favourably with the results reported in the 
literature above.  However, the studies cannot be directly compared due to a few key differences which 
will be discussed. 
The larger CT slice spacing (1.5-2mm) of the Van der Voort van Zyp group (47) may increase the risk of 
potential error in recording the true centre of each fiducial, compared to the standard 1.25mm slice 
spacing at our centre.  In addition, this group recorded fiducial and COM displacement at several time-
points during treatment.  It could therefore be expected that the effects of treatment could increase 
fiducial displacement, indeed the group found that an increased interval between planning CT and 
repeat CT was associated with a small but significant increase of 0.3mm/day in fiducial displacement.  
This group also co-registered CT scans by means of tumour-to-tumour matching, rather than fiducial 
matching, so it could be expected that fiducial displacements would be greater, although interestingly 
the fiducial displacements observed were very similar to the Hong et al group. 
The Hong group used similar methodology to assess fiducial stability to the patients assessed here.  The 
decision to measure fiducial displacement based on fiducial-to-fiducial matching was based on the fact 
that this is how the scans are co-registered on the first day of treatment at this centre.  Equally, the 
CyberKnife radiographers will set the patient up according to the positioning instructions from the CT-
simulator staff, but then will fine-tune patient position based on fiducial configuration.   
The median interval between CT scans for the Hong group was 8 days, which compares well to the 
interval in the patients studied here (7 days).  The Hong group assessed fiducial displacement between 
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immediate post-implantation CT scans, and planning CT scans, therefore the scans were both taken 
much sooner after fiducial placement.  It is plausible that the initial inflammation immediately post-
fiducial implantation could affect the spatial resolution of fiducials.  Indeed, this is one of the reasons 
why it is recommended that Planning CT scans are performed approximately 1 week after fiducial 
insertion (2).  This could have affected the results recorded by the group.  In addition, there are 
histopathological responses to fiducial placement that evolve over time.  Imura et al (49) investigated 7 
patients who had had 16 marking fiducials sited at bronchoscopy.  The patients underwent video-
assisted thoracoscopic surgical (VATS) resection within 7 days of fiducial placement and the histological 
changes surrounding fiducials were reviewed.  Fibrin exudation was noted at 1 or 2 days after insertion, 
and fibrotic changes (which might serve to anchor a fiducial in place) and hyperplasia of Type 2 
pneumocytes were seen at 5 or 7 days after insertion.  
In summary, the patients assessed here had a mean shift of fiducial position of 0.74mm which compares 
well with that reported in the literature (1.28-1.3mm).  Similarly, mean shift in fiducial COM of 0.67mm 
compares well with the literature (1mm), although differences in methodology between the patients 
treated here and those in the literature are noted.  As the CyberKnife real-time tumour-tracking system 
localises the tumour using the fiducial COM, COM shift analysis is more relevant to assessing the 
likelihood of a treatment being accurately delivered as intended.  The results of COM shift being sub-
millimetre (0.67mm) suggest that geographical miss would be unlikely. 
3.4.4B Fiducial Reproducibility: Liver tumour site 
Kitamura et al (50) investigated fiducial stability in a mixed group of patients with prostate cancer and 
liver tumours treated by conventionally-fractionated radiotherapy.  Only the 4 patients with liver 
tumours will be considered here.  The patients had a single fiducial inserted into tumour.  Planning CT 
was performed in exhale, the slice gap was 1mm at the level of the fiducial marker, and 5mm elsewhere.  
This scan was considered the reference scan for comparison.  CT scans were repeated weekly until the 
end of treatment.  Several clinicians were asked to contour the single marker, as well as the liver contour 
on each CT scan.  Inter-observer variability of the COM was within 0.4mm for the fiducial, and within 
2mm for the liver.  The mean fiducial shift noted was 0.2mm in Left/Right direction, 1.5mm in 
Cranio/Caudal direction, and 1.4mm in Anterior/Posterior direction.  Shift was calculated by comparison 
of 3D co-ordinates from the treatment planning system.  The group noted there was no influence of 
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time (since planning scan) on the magnitude of fiducial displacement (in contrast to the findings of Van 
der Voort van Zyp (47) for lung tumours). 
Summary data for fiducial COM shift for 9 patients with multiple implanted fiducials is displayed in Table 
3.9.  The mean shift in fiducials, and fiducial COM is 0.59mm in x (Left/Right), 0.38mm in y (Ant/Post) 
and 1.16mm in z (Sup/Inf) directions respectively.  Considering the shifts in individual fiducial positions 
from individual patient data it was noted that the mean displacements are skewed in some cases by one 
or two fiducials with a large shift (e.g. Patient 1, fiducials 1, 2 and 4).  If these fiducials are subsequently 
rejected due to concerns that they are a poor surrogate for tumour movement (this issue will be 
discussed in the next section), the COM shift for the fiducials that are ultimately used at treatment 
delivery will be decreased, and the accuracy of treatment delivery will be likely to increase (as long as 
the fiducial rejection strategy employed is not flawed).  There were no discrepancies in fiducial centre of 
>1mm between the Physics team and myself, confirming the sub-millimetre inter-observer variability in 
marking a fiducial accurately shown by Kitamura et al.  Both the Kitamura group and ourselves observed 
sub-millimetre displacement in the Left/Right direction, but >1mm displacement in the cranio-caudal 
direction.  The results for displacement in the Ant/Post direction are different however (1.4mm vs 
0.38mm).  The Kitamura group had a small sample size (4 patients), and it may be that the mean results 
were skewed by one or two patients whose fiducials had migrated.  When assessing a single-fiducial scan 
it is harder to assess for true migration, as there is no possibility of calculating inter-marker distance as 
done by Van der Voort van Zyp (47). 
3.4.4C Fiducial Reproducibility: Pancreas tumour site 
Van der Horst et al (51) explored fiducial stability in 13 patients with pancreatic tumours and 2-3 
implanted fiducials per patient.  The patients were treated by Linac-based conventionally fractionated 
radiotherapy.  Adjustments to patient position could be made following Cone beam CT analysis, but 
there was no intra-fractional tracking of tumour motion.  The planning CT was the reference CT, it was 
performed a mean of 4.5 days post-implantation (range 2-12 days).  The free-breathing on-treatment 
Cone beam CTs were compared with the Reference CT.   CT scans were co-registered by fiducial-to-
fiducial matching. 
Comparison of fiducial position was made by review of fiducial marker pairs.  Inter-observer variability 
was compatible with previous literature, mean = 0.4mm (SD 0.9mm).  The largest mean displacements 
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were noted in the Sup/Inf directions.  Fiducial COM varied by 1-25.6mm compared to the Reference CT, 
especially in the Sup/Inf direction.  This is not surprising as the Cone Beam CTs were free-breathing 
(therefore could have been captured at an entirely different respiratory phase to the reference CT) and 
the pancreas is known to move considerably with respiration.  Mean fiducials COM shift was 1.5mm. 
1.5mm and 0.3mm in the Left/Right, Sup/Inf and Ant/Post directions respectively. 
Fiducial stability data for 9 patients with pancreatic tumours and single-implanted fiducials is shown in 
Table 3.14.  Mean observed shift for the fiducials between Planning and Day 1 Treatment CT were 
0.29mm, 1.01mm and 0.58mm in Left/Right, Ant/Post and Sup/Inf directions respectively.  Summary 
data for 9 patients with multiple implanted fiducials is shown in Table 3.15.  The mean fiducial COM shift 
for these patients are 1mm, 0.75mm and 0.4mm in Left/Right, Ant/Post and Sup/Inf directions 
respectively.  Inter-observer variability was again noted to be sub-millimetre.  The different 
methodology does not offer direct comparison of the patient groups studied here with the Van der Horst 
group, most notably that the Cone beam CTs, and the Planning CT scans were captured in free breathing 
for the Van der Horst group, but in exhale breath-hold for the patients studied here.  The planning CT 
scans must be taken in breath-hold for CK purposes, otherwise there is a risk that fiducial will be 
captured as smeared across several cranio-caudal scan levels, and the actual true centre of its position 
with respect to tumour will not be known. 
3.4.4C Fiducial Reproducibility: Summary 
The analysis of fiducial stability presented here has assessed fiducial position at Planning CT scan in 
comparison with fiducial position on the Day 1 treatment CT scan taken a mean of 7 days later.  Scans 
were acquired with identical imaging parameters, in identical treatment position, and at the same 
respiratory phase (exhale breath-hold), so the scans were directly comparable. 
Each scan represents a “snapshot” of tumour and fiducial position/configuration.  The individual fiducial 
and fiducial COM displacements noted are examples of inter-fractional position variation.  These inter-
fractional position variations can introduce both random and systematic positioning errors, so it is 
important the variation is minimal to allow accurate tumour targeting. 
Co-registering of CT scans by means of a single implanted fiducial showed fiducial shift of 0.55, 0.9 and 
0.7mm in Left/Right, Ant/Post and Sup/Inf directions respectively for lung targets.  Single-fiducial 
matching showed fiducial shift of 0.29mm, 1.01mm and 0.58mm for pancreas targets. 
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Co-registering of CT scans by a seed-point transformation on a single-implanted fiducial should be the 
least challenging of fusion tasks.  The gold fiducials are dense, so they can be easily seen on CT scans, 
and fusing CT to CT (same modality) should be an easily-performed task.  The only caveat to the above is 
that gold fiducials can be associated with a moderate amount of artefact, due to their high electron 
density.  Despite the note on artefacts, I feel that the “fiducial shifts” for single-fiducial cases observed 
above (0.29-1.01mm) represent the margin of error in co-registering scans.  It is known to be more 
challenging to fuse scans of different modalities (e.g. Prostate CT with Prostate MRI), therefore the 
potential fusion errors described above are likely to represent a best-case scenario.  This observation is 
of particular interest when considering delineation uncertainty for prostate tumours in Chapter 5. 
Considering cases of multiple-implanted fiducials, mean fiducial COM shift was 0.61mm, 1mm, and 
0.72mm in lung, liver and pancreas sites respectively, which is broadly in keeping with the fiducial 
displacements described in the literature, within the limitations of different methodologies employed.  
Fiducials here were matched according to a “best-fit” scenario, respiratory phase was identical 
(assuming patient compliance).  It is interesting that the liver fiducials show the greatest displacement 
overall.  When attempting to fuse MRI liver and CT liver scans, it is notably challenging. The larger shift in 
fiducial COM for liver cases, together with the difficulties in fusing liver scans observed, suggest that the 
liver is especially prone to deformation. 
Overall mean fiducial COM shift for all tumour sites studied is ≤1mm.  
 
3.4.5 Fiducial Location: 
The relationship between fiducial marker and tumour target volume constitutes the largest uncertainty 
of Synchrony-based SBRT, and optimal fiducial placement is essential (50).  CyberKnife plans are 
chacterised by a sharp-dose gradient away from tumour, therefore any small geometric errors in fiducial 
tracking can lead to a large change in dose-delivery. 
As previously stated, fiducials must be placed greater than 2cm from each other, less than 6cm from the 
tumour, have greater than 150 angle between fiducials, and they should not be super-imposed on the 
450 oblique X-Ray views taken by the in-room imaging system (2, 52, 53).   
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It is also critical that fiducial markers are placed close enough to tumour to be an accurate surrogate for 
tumour position/motion.  It is known that deformations, rotations or non-synchronous movements may 
induce changes in fiducial marker groups which do not necessarily correspond with displacements in 
distant parts of an organ containing tumour (4).  In addition, if multiple fiducials are placed, they should 
ideally be placed with a configuration such that the COM of fiducials lies inside the tumour.  This will 
maximise the likelihood that fiducial tracking will lead to accurate tumour tracking (54).   
However, whilst the above guidance is well recognised, the literature does not report clear guidance on 
threshold distances for fiducial-to-tumour which are likely to ensure accurate treatment delivery.   
 
3.4.5A Fiducial location: Lung tumour site 
Van der Voort van Zyp et al (47) explored aspects of fiducial tracking in 42 patients with lung tumours as 
reported previously.  A total of 111 fiducials were sited.  The causes of fiducial displacement >5mm 
(from their position relative to tumour noted at Planning CT) were explored. Fiducial displacement 
>5mm occurred for 13/111 fiducials (12%).  The most frequent cause of fiducial displacement was non-
synchronous motion of fiducials and tumour (6/111 fiducials, 5%).  After CT co-registration, tumour-to-
tumour matching was noted to be good, but a different respiratory phase was noted as evidenced by 
rib/diaphragm position, therefore the authors considered non-synchronous motion (between 
tumour/fiducials) to be the issue.  They noted all 6 fiducials were placed further from tumour than other 
markers.  Mean distance of fiducial to tumour centre was 3.5cm (Range 2.7-8.4cm) for the fiducials 
displaying non-synchronous motion.  Tumour diameter for the above patients was 2.5cm vs 6.9cm.  The 
authors did not report further details of fiducials employed at treatment vs. fiducials that may have been 
rejected at treatment delivery. 
Results of an evaluation of optimum fiducial placement for lung tumour patients was reported in Section 
3.3.3.  Table 3.4 displays results for 9 lung tumour patients with a single-implanted fiducial.  89% of cases 
had the fiducial placed in tumour.  For the single patient with a fiducial placed outside the tumour, this 
fiducial was 4mm from PTV edge.  The team judged that this fiducial was close enough to tumour to be a 
good surrogate for tumour. 
Table 3.5 shows the results for 9 patients with lung tumours and multiple implanted fiducials (27 
fiducials).  12/27 fiducials (44%) were sited outside of tumour, therefore they could potentially move 
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non-synchronously to tumour.  7/12 (58%) of these outside-of-tumour fiducials were rejected.  The 
mean distance from rejected fiducial to closest tumour edge was 1.9cm (vs. 0.4cm for an accepted 
fiducial).  Observations made by CyberKnife radiographers suggested that non-synchronous motion of 
fiducial/tumour was the reason for rejection in 1/7 rejections (14%), this fiducial was 2.1cm from the 
closest tumour edge, and was the only fiducial rejected during treatment delivery.  The remaining 6/7 
(86%) fiducial rejections, affecting 3 patients, were guided by physicists due to combined concerns over 
the distance of a fiducial to tumour edge (and possibility of non-synchronous fiducial/tumour motion), 
and also concerns about fiducial configuration (and fiducial COM lying in a sub-optimum location).  
Fiducial configuration/fiducial COM may have been the dominant concern for the physicists, because the 
rejection of fiducials advised shifted the fiducial COM from outside tumour, to inside tumour for 2 
patients (4 rejected fiducials).  The remaining 2 fiducial rejections advised for Patient 1, moved the 
fiducial COM closer to tumour.  All fiducials for Patient 1 were sited superior to tumour target, and the 
closest fiducial was the only one used for tracking. 
Taking the results from Section 3.3.3 overall, if a small, uniformly round, tumour target is to be tracked 
with a single fiducial, the fiducial should ideally be placed in the centre of tumour. 
For larger, more irregularly-shaped lung tumours, multiple-fiducials are recommended for tracking.  Four 
fiducials are ideal as the challenging nature of fiducial placement means that often a fiducial needs to be 
rejected (22% rejection rate overall), and 3 remaining fiducials allows rotations to be tracked. The 
fiducial configuration should be such that the fiducial COM lies inside the tumour.  In practice, if an intra-
tumour fiducial was placed (5 patients), any fiducial placed >1cm from tumour edge was rejected.  All 
fiducials placed within 1cm of tumour edge were accepted in practice.  Radiologists should aim to place 
fiducials within 1cm of tumour edge, as well as fulfilling the other fiducial placement guidelines which 
are well known (2, 52, 53). 
3.4.5B Fiducial location: Liver tumour site 
Jarraya et al explored fiducial tracking in 328 patients with liver tumours as described in Section 3.4.4B 
(42).  Fiducials were placed in an “unintended” position in 27/328 patients (8%), where fiducial-to-
tumour distance was ≥6cm.  The radiologists commented that this was largely due to the irregular 
breathing pattern of the patients involved.  3/27 of these patients (11%) required a second fiducial 
placement procedure for fiducials that were not appropriate for tracking.  The authors did not discuss 
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any issues relating to fiducial tracking with fiducials sited <6cm from tumour, but this was not the focus 
of the article. 
The Synchrony system is designed to track the respiratory motion of tumour targets, to within an 
accuracy of 0.6-2.5mm (47, 55, 56).  Lu et al (57) noted a larger deformation due to breathing of liver 
tissue compared to lung tissue. 
However, the liver is known to be susceptible to deformation, and any non-respiratory motion will not 
be tracked by Synchrony.   
Von Siebenthal et al discovered that deformation was particularly common and problematic in the 
anterior/inferior part of the liver (Couinaud segments IVb and V) (58, 59).  The group used a gating 
technique to account for respiratory motion, but despite gating, systematic deviations from set-up 
position of >5mm due to deformation were noted for MR-defined liver sub-volumes in 58% of patients 
studied. 
Seppenwoolde et al (54) explored fiducial tracking in 20 patients with implanted fiducial markers and 
liver tumours.  All patients had abdominal compression immobilisation.  The patients had a Planning CT 
scan which was contrast-enhanced in exhale breath-hold.  The patients had repeat CT scans before each 
treatment fraction, which were co-registered with the Planning CT.  The group evaluated the inter-
fraction accuracy of liver tumour position prediction by fiducials as a function of fiducial-to-tumour 
distance.  Sophisticated statistical analysis revealed that fiducials were more reliable than anatomical 
surrogates (ribs/diaphragm).  The reliability of fiducials as a surrogate varied however, and was found to 
be related to fiducial-to-tumour distance.  A fiducial to tumour COM distance of 20mm was associated 
with an error (1SD) of 1.25mm.  If fiducial to tumour COM distance increased to 6cm, this error 
increased to 2mm.  The authors did not go on to give any guidelines on a threshold recommended 
distance of fiducial-to-tumour. 
Table 3.10 shows the results for 9 patients with liver tumours and multiple implanted fiducials (34 
fiducials).   
25/34 fiducials (74%) were sited outside of tumour, therefore they could potentially move non-
synchronously to tumour.  14/25 (56%) of these outside-of-tumour fiducials were rejected, although 2 of 
these rejected fiducials were only 1mm from the tumour edge.  The mean distance from rejected fiducial 
to closest tumour edge was 2.1cm (vs. 0.6cm for an accepted fiducial).  The two rejected fiducials which 
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lay only 1mm from tumour edge were implanted for peripheral metastases. Both were recommended 
for tracking by the Physicists (given they were positioned at the tumour edge), but were rejected at 
treatment delivery due to non-synchronous motion with other fiducials.  One fiducial (in patient 3) was 
sited close to the edge of liver, and adjacent to bowel, differential filling of this bowel between Planning 
CT and Day 1 CT was noted which shifted the Ant/Post fiducial position, and Sup/Inf fiducial position by 
2.4 and 3.1mm respectively.  The tumour was not located in the anterior/inferior portion of liver noted 
to be the most susceptible area to non-respiratory motion, however, previous hepatic resection had 
caused the bowel to shift superiorly to lie adjacent to tumour/liver, likely rendering the fiducial 
susceptible to instability, and rendering the tumour susceptible to deformation.  The other rejected 
fiducial (patient 7) which lay only 1mm from tumour showed a stable position when co-registering 
Planning CT and Day 1 CT (within 0.5mm), however it was rejected at treatment delivery due to 
inconsistent positioning relative to the other implanted fiducials.  Reviewing the CT placement of this 
rejected fiducial, this was a central metastasis, remote from bowel, and the reasons for the tracking 
difficulties cannot be easily explained, the necrotic nature of the tumour could possibly be implicated.  
The remaining 12/14 fiducials (80%) which were placed outside of tumour and were rejected were 
placed ≥1cm from tumour.  6/12 (50%) were rejected according to Physicist advice, to shift the fiducial 
COM to inside the PTV.  4/12 (33%) of the fiducials were rejected at treatment delivery due to non-
synchronous motion compared to the other implanted fiducials.  The reason for rejection for the 
remaining 2 fiducials was less clear from the records. 
In summary, multiple fiducials are recommended for tracking.  Four implanted fiducials are ideal as the 
challenging nature of fiducial placement means that often a fiducial needs to be rejected (44% rejection 
rate), and 3 remaining fiducials allows rotations to be tracked. The fiducial configuration should be such 
that the fiducial COM lies inside the tumour.  In practice, any fiducial placed ≥1cm from tumour edge 
was rejected.   14/17 fiducials (82%) placed <1cm from tumour edge were accepted in practice.  
Radiologists should aim to place fiducials within 1cm of tumour edge.  In addition, care should be taken 
with peripheral metastases to avoid placing fiducials at a liver edge adjacent to bowel/duodenum.  
 
 
 
136 
 
 
 
3.4.5C Fiducial location: Pancreas tumour site 
Kim et al (44) inserted fiducials via ultrasound guidance to mark pancreatic tumours in 39 patients.  They 
noted a failure to discriminate fiducials in 1 patient (3%).  The fiducials were either too close, or 
superimposed on the 450 oblique X-Rays.  The authors did not report any further issues with respect to 
fiducial tracking for pancreatic tumours. 
Table 3.15 shows the results for 9 patients with pancreatic tumours and multiple implanted fiducials.  27 
fiducials were sited in total, but 3 fiducials in one patient migrated, leaving 24 fiducials for analysis.  6/24 
fiducials (25%) were sited outside of tumour (3 in pancreas, 3 in mesenteric fat) therefore they could 
potentially move non-synchronously to tumour.  All fiducials sited outside tumour were rejected.  Mean 
distance of a rejected fiducial to closest tumour edge was 16mm (range 0-44mm).  In contrast, all 
accepted fiducials were placed in tumour. 
The 3 fiducials sited in pancreas (in 2 patients) were rejected at the time of treatment delivery for non-
synchronous motion compared to the other implanted fiducials.  The 2 rejected fiducials that were sited 
for patient 2 were located at the periphery of the pancreas, adjacent to stomach or duodenum.  While 
the rejected fiducials appeared stable on the co-registered CT scans, (sub-millimetre shift only), the 
stomach was noted to be fuller at Planning CT, and the non-synchronous motion of fiducials could be 
explained by deformation due to stomach/duodenum filling or motion. 
The 3 fiducials (in 3 patients) that were sited in mesenteric fat were rejected at the time of treatment 
delivery, due to non-synchronous motion with the remaining intra-tumour fiducials.  One of these 
fiducials had shifted by 4.8mm in the Left/Right, and 1.3mm in the Ant/Post direction compared to the 
Planning CT. 
In summary, I feel that pancreatic tumours present the greatest challenge for fiducial placement out of 
the 3 tumour locations studied here.  Four implanted fiducials are ideal as pancreatic tumours tend to be 
large and irregular, and the challenging nature of fiducial placement means that often a fiducial needs to 
be rejected (33% rejection rate), and 3 remaining fiducials allows rotations to be tracked. The fiducial 
configuration should be such that the fiducial COM lies inside the tumour.  In practice, all fiducials placed 
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outside of tumour were rejected.  Clinicians should therefore place at least one fiducial in tumour.  
Mesenteric fat should be avoided as a placement site due to the high risk (100%) of migration or non-
synchronous movement with intra-tumour fiducials.  It is recognised that fiducials are rejected when 
implanted at the edge of normal pancreas and adjacent duodenum/stomach.  However, the great 
majority of pancreatic tumours arise at the head of the pancreas and are therefore nestled in the C-
shape of the duodenum.  It is therefore unrealistic to request Radiology/EUS colleagues to avoid siting 
fiducials at the periphery of the pancreas (given the competing constraints e.g. needing to be >2cm 
apart, not superimposing on 45o views).  Rather, the emphasis should be on the CyberKnife team to 
ensure identical patient preparation with respect to eating/drinking for planning and treatment days. 
 
3.4.6 Organ At Risk Reproducibility and Dosimetry: 
As previously described, CyberKnife plans are chacterised by a sharp-dose gradient away from tumour, 
therefore any small geometric errors in fiducial tracking can lead to a large change in dose-delivery.  This 
is not only an important consideration with respect to tumour dose, it is equally important that doses 
delivered to Organs At Risk (OAR) are within safe limits. 
3.4.6A Thoracic OARs 
Thoracic OARs include Bronchus, Chest Wall, Great Vessels, Heart, Oesophagus, Spinal Cord, and Lung.  
The dose-limiting OARs in an individual patient plan will depend on the location and size of the tumour 
target. 
Zou et al (60) explored dose to OARs that may have been delivered (compared to planned doses) in 15 
patients that had undergone arc therapy to deliver SBRT.  The initial planning involved contouring of the 
GTV on different respiratory phases of the 4D CT to construct an Internal Target Volume (ITV), this was 
then expanded to a PTV.  The patients had restrospective analysis using computer simulation and 
deformable image registration modelling.  Mean differences in dosimetric parameters (between planned 
doses and simulated doses) were <1 Gy for OARs.  However, in patients where the target was adjacent 
to critical organs, doses to heart, great vessels and bronchus increased by 2Gy, 4.9Gy, and 6Gy 
respectively.  It is important to note that the patients were treated in free breathing (with an ITV 
technique to account for respiratory motion of the tumour as described), therefore the results may not 
be comparable to patients treated with tracking (e.g. Synchrony). 
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Section 3.3.4 describes an analysis of the reproducibility of Thoracic OAR position (relative to tumour 
target) on the Day 1 CT compared to the Planning CT.  This is therefore an assessment of the inter-
fractional variability of Thoracic OAR position. 
Table 3.6 displays data on the reproducibility of OAR position for 10 patients with lung tumours.  3/10 
(30%) of the patients studied had an inter-fractional change in OAR position which had the potential to 
increase OAR dose.  2 of these patients were suitable for assessment of the dosimetric impact of the 
OAR positional change (see Table 3.7). 
Chest wall was the OAR for patient 5.  It can be seen from Table 3.7 that planned doses to chest wall 
exceeded protocol doses for maximum point dose (MPD) and the 1cc/30cc threshold doses by 35%, 54% 
and 19% respectively.  As explained, this was accepted by the treating Consultant, because they did not 
wish for tumour dose to be compromised.   
It is interesting to note that the doses to Chest wall, based on the position of this organ at Day 1 CT, are 
actually marginally lower than planned doses, despite my judgement that the Chest Wall had moved 
towards tumour target (therefore closer to the high-dose region).  This can be explained by the fact that 
CyberKnife plans are heterogenous.  The prescription isodose line for Patient 5 was the 64% isodose line, 
with a PTV coverage of 98.97%.  This means that 98.97% of the PTV is being treated to 45Gy or more, the 
maximum dose inside the tumour is 70.3Gy, and large portions of the PTV are receiving doses much 
greater than 45Gy.  As a consequence, if the observed shift of OAR towards tumour occurred away from 
the highest dose volume, the OAR shift may not have a negative impact on OAR MPD/threshold doses. 
Patient 8 had planned doses to Bronchus within protocol limits, but a shift in Bronchus position observed 
on the Day 1 CT has caused a small increase in MPD to beyond protocol limits (breach of protocol limits 
by 2%). 
Both of these patients may be at risk of toxicity due to breach of OAR dose constraints. 
3.4.6B Abdominal OARs 
Velec et al (61) explored dose delivered to abdominal OARs for patients with liver tumours treated with 
hypofractionated radiotherapy delivered by a linac-based technique.  The patients were treated in free 
breathing, a majority were treated with abdominal compression.  Treatment planning was performed on 
an exhale breath-hold scan.  Simulations were performed based on the breathing motion observed by 
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4D CT, and a deformable image registration technique.  Results of change in doses to abdominal OARs 
were expressed as a percentage change of prescribed doses.  Mean changes are reported with range in 
brackets.  Results were as follows: Bowel -4% (-15 to 0), Duodenum -4% (-25 to +1), Oesophagus +2% (-1 
to +9), Stomach -2% (-13 to +4), Liver 0% (-3 to +4).  The mean dose to OAR only increased for 
Oesophagus, but it was noted that 2 patients had an increased dose (from the simulation), to 
oesophagus or stomach that would have exceeded dose constraints.  It is again important to note that 
the patient treatments/simulations did not incorporate tumour tracking. 
It is interesting that mean doses to OARs decreased in the simulations for 4/5 of the abdominal OARs 
studied.  The planning was performed in exhale breath-hold, and it is possible that the relative positions 
for OARs and tumour are more favourable on inspiration.  Loo et al conducted a planning study which 
considered likely oesophageal dose in patients being planned for lung SBRT with central tumours, 
according to respiratory phase.  The respiratory phase which gave the greatest separation of tumour and 
oesophagus was selected for planning.  This work was presented at ASTRO 2014, a number of patients 
showed favourable separation of oesophagus and lung tumour target. 
Sections 3.3.9 and 3.3.14 explore the reproducibility (inter-fractional variation) of abdominal OAR 
position for patients treated for liver and pancreatic tumours respectively. 
Table 3.11 displays data on the reproducibility of OAR position for 6 patients with liver tumours.  2/6 
(33%) of the patients studied (patients 4 and 5) had an inter-fractional change in OAR position which had 
the potential to increase OAR dose.  The possible dosimetric impact of the OAR positional change was 
explored in Table 3.12. 
Bowel was the OAR for patient 4.  It can be seen from Table 3.12 that planned doses to bowel exceeded 
protocol doses for both maximum point dose (MPD) and the 5cc threshold dose by 4%.  This was 
considered acceptable by the treating Consultant.  The coverage of the PTV by the prescription dose in 
this case was 93.9%, and reducing dose to bowel would only have been achieved by compromising PTV 
coverage further.  It is noted that doses to Bowel based on the Day 1 CT position of Bowel were higher 
than anticipated (18% increase in MPD over protocol doses, and 5% increase in 5cc threshold doses over 
protocol doses).  This could increase the risk of toxicity for the patient. 
Patient 5 had planned doses to Duodenum within protocol limits, but a shift in duodenal position 
observed on the Day 1 CT has caused an increase in MPD to beyond protocol limits (breach of protocol 
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limits by 15%).  Although the 5cc and 10cc threshold doses remained within protocol limits, this patient 
could be at increased risk of duodenal toxicity. 
Table 3.15 displays data on the reproducibility of OAR position for 1 patients with a pancreatic tumour.  
This patients studied had an inter-fractional change in OAR position which had the potential to increase 
OAR dose.  The possible dosimetric impact of the OAR positional change was explored in Table 3.18. 
Duodenum was the OAR for patient 1.  It can be seen from Table 3.18 that planned doses to bowel 
exceeded protocol doses for both maximum point dose (MPD) and the 5cc/10cc threshold dose by 25%, 
55% and 95% respectively.  This was considered acceptable by the treating Consultant in order to 
maintain an optimum coverage.  Unfortunately, the duodenal shift observed on the Day 1 CT increased 
the duodenal doses further such that doses to MPD and 5cc/10cc thresholds exceeded constraints by 
30%, 73%, and 107% respectively.  This patient may have therefore received double the recommended 
dose to 10cc of duodenum, they would therefore certainly be at risk of duodenal toxicity. 
A further pancreatic case (not reviewed here) showed an alarming change in duodenal position between 
Planning CT and Day 1 CT, such that Treatment was deferred.  The patient did not speak English and was 
diabetic.  Even though eating/drinking guidance was explained to her with the aid of an interpreter, the 
team had concerns about her understanding of these instructions.  Her diabetic control was also poor 
with labile sugar levels, and on the first day of treatment she had felt like she was having a 
hypoglycaemic episode and therefore ate.  The team decided to replan treatment using information 
from the Planning CT and “Day 1” Treatment CT scans, and a therapeutic, and safe, treatment plan was 
produced.  When the patient was scanned on the new Day 1 of treatment, interestingly the duodenal 
position was most analogous to the previous “Day 1” CT, justifying the re-plan. 
3.4.6C OAR summary 
There are some limitations to the methodology followed to explore OAR reproducibility and dosimetry. 
Firstly, assessments require delineation of OARs on the Day 1 CT.  Inter-observer variability has been 
discussed previously with respect to tumour volume assessment, and this is a potential source of error 
here.  However, it is considered likely that OAR delineation is more consistent than tumour volume 
delineation.  OARs are “standard structures”, so clinicians become experienced at outlining them, in 
contrast every tumour is individual in terms of size and shape.  The edges of OARs also tend to be better 
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defined on imaging than the edges of tumours.  Despite these caveats, inter-observer variability is a 
potential source of error. 
Secondly, the measurements made of the closest distance of OAR to tumour target were prone to error.  
An initial visual assessment of the CT was made to highlight the slice levels where OAR was closest to 
tumour target, and the shortest distance was measured on the candidate slices.  Whilst every effort was 
made to be as accurate as possible, this was accepted to be a fairly crude form of assessment, and it 
would have been possible for this methodology to miss some cases where there was OAR shift towards 
tumour.  Reassuringly however, Patient 6 from the liver group, who was judged to have a stable position 
of OAR on Day 1 CT and Planning CT, had a decrease in Day 1 CT doses to OAR. 
Thirdly, each CT reviewed is just a snap-shot of OAR position.  Even when an OAR appeared in a more 
concerning position on the Day 1 CT, the actual positions of the OAR on the remaining days of treatment 
could feasibly be more favourable to inter-fractional variation.  Equally, a patient with an OAR position 
which appeared more favourable on Day 1 CT, could have a less favourable OAR position on treatment 
days. 
It is noted that a number of the patient cases reviewed had planned doses to OAR which exceed “safe” 
dose constraints.  Doses delivered to tumour targets are largely limited by the dose constraints of 
adjacent OARs, so choosing an appropriately high dose to tumour, while also selecting a safe dose to 
adjacent OARs, is a constant challenge for Clinical Oncologists. It is known that uncontrolled tumour 
growth and organ invasion can be hazardous to the functioning of OARs e.g. rib fracture/pain due to 
tumour involvement, tumour invasion of the gastro-intestinal tract causing obstruction or fistulae.  
These risks of uncontrolled tumour growth therefore have to be borne in mind when considering 
whether to reduce prescribed doses in order to stay within safe OAR dose limits.  
It is worth noting here, that dose constraints in SBRT are guidelines only.  SBRT is a relatively new 
technique in radiotherapy, and compared to conventional fractionation there is a relative lack of long-
term data on OAR toxicity.  Therefore, staying within OAR dose constraints is far from a guarantee of 
delivering a safe treatment, and equally OAR dose constraints may possibly be overly conservative. 
When considering MPD, this means the hottest dose delivered to 0.035cc of OAR.  This is likely to be 
situated where a high-dose volume of the tumour target is adjacent to OAR, but the MPD based on Day 
1 CT data may be delivered to a different 0.035cc of OAR, which would be a protective factor for the 
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OAR being considered.  This same principle could apply to the threshold doses, but without real-time 
intra-fractional imaging of OARs, with subsequent dosimetric analysis, the actual position of MPDs 
cannot be assessed. 
A very recent area of development in radiotherapy technique is MR-guided radiotherapy delivery (62-
64).  Treatments can be gated according to tumour motion, or OAR motion.  This may offer the potential 
to assess doses actually delivered, and crucially to adaptively replan if necessary. 
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3.5 CONCLUSIONS 
The accuracy of fiducial-based tracking depends on the assumption that the inter-relationship between 
fiducials/tumour and Organs At Risk (OAR) is the same at the time of planning CT as at the time of 
treatment.  However, a number of factors which could invalidate this assumption have been assessed 
here: tumour volumetric change, tumour deformation, fiducial factors (migration/instability/optimum 
location) and OAR stability.  Discrepancies in fiducial/tumour/OAR position between planning and 
treatment due to the factors described above must be accounted for by planning margins.  In addition, 
for lung, liver, and pancreas tumour targets, a Synchrony tracking error of 2mm must be incorporated 
into the planning margins applied due to a correlation error (47). 
A summary of the assessment outcomes for the factors described, together with the solutions to 
overcome the issues encountered, appear below. 
Assessment Outcomes: 
1. Tumour volumetric change:   
Delineation issues were the biggest source of uncertainty here.  However, Volume Doubling Times are 
significantly longer than the short mean interval from planning to treatment, so this is not considered an 
important issue.   
2. Tumour deformation: 
This was noted to be a potential issue for 2 liver patients.  This was not an issue for lung and pancreatic 
tumours in the patients studied here. 
3. Fiducial issues:    
a) Migration: this was noted to be a particular concern when fiducials were inserted into fat. 
b) Instability: sub-millimetre instability was noted for lung/liver/pancreatic targets. 
c) Optimum location:  rejection rates for implanted fiducials due to sub-optimal location were high (lung 
rejection rate 22%, liver rejection rate 44%, and pancreas rejection rate 33%). 
   
4. Organs At Risk: Inter-fractional OAR shift was noted to be a significant issue for the pancreatic tumour 
site. 
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Solutions proposed: 
 
1. Tumour volumetric change:  
Improve delineation by careful consideration of the optimum imaging modality to best define a tumour 
target. It is also important to optimise the fusion of secondary scans e.g. PET-CT, MRI to the primary 
Planning CT scan. 
2.  Tumour deformation:  
Particular attention should be given to assessing this in liver tumours.  This can only be assessed 
adequately by CT, not by the Live X-Rays taken at treatment delivery.  This supports the strategy of 
performing a Day 1 CT scan.  Due to the difficulty in appreciating the contour of some liver tumours, a 
Day 1 CT with IV Contrast enhancement should be considered in selected patients, especially if a small 
planning margin has been applied. 
3. Fiducial issues: 
a) Migration: fiducials should not be implanted in fat 
b) Instability:  
Day 1 CT should be performed for all fiducial cases (not just Synchrony cases) as analysis has shown that 
instability of fiducial position is not just influenced by respiration, it is also influenced by organ filling and 
inter-fractional motion. 
c) Optimum location:  
Lung (large, irregular tumours): site 4 fiducials (due to risk of fiducial migration/rejection), and place 
fiducials within 1cm of tumour edge. 
Liver: site 4 fiducials (due to risk of fiducial migration/rejection), and place fiducials within 1cm of 
tumour edge.  In addition, try to avoid siting fiducials at the periphery of liver, adjacent to 
bowel/stomach/duodenum. 
Pancreas: site at least one fiducial in tumour.  Implant 4 fiducials, as many as possible within tumour, 
while following standard fiducial guidelines. 
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4. Organs At Risk:  
Consider daily treatment CT for pancreatic cases 
Optimise patient preparation: eating/drinking instructions and ensure patient compliance.   
For the future, consider adaptive SBRT techniques e.g. Viewray, where OAR can be imaged in real-time. 
Key Developments:  
1. Interaction with Radiologists to feedback on above fiducial insertion guidance 
2. Confirmation of importance of Day 1 CT for Synchrony cases: expand to perform a Day 1 CT for all 
fiducial cases 
3. Review of standard planning margins:    
Lung/Liver/Pancreas:   
Synchrony (2mm) + Delineation (1mm) + Fiducial instability (1mm) 
Therefore new minimum planning margin recommendation = 4mm 
 
Individualise margins:  
Delineation error likely to increase to minimum 2mm if e.g. a liver metastasis only shows well on an MRI 
scan, due to the Fusion error of minimum 1mm observed here. 
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Appendix 1: Lung tumour site: Multiple fiducials: Fiducial reproducibility: Patients 1-6 
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CHAPTER 4 
Optimising the Accuracy of Radiotherapy Treatment Delivery for Prostate 
Cancer: A focus on Bladder Filling 
 
4.1 AIMS  
1. Develop Bladder Filling Guidelines for Radiotherapy and CyberKnife patients, based on optimal 
dosimetry/reproducibility. 
 
2. Determine the relationship between the consistency of bladder filling (between planning and 
treatment), and the ability to track rotations of the tumour target for the CK treatment of Prostate 
cancer. 
 
4.2 INTRODUCTION 
In order for Radiotherapy to be delivered accurately, and for the tumour to be treated exactly as 
intended, it is critical that the set-up and conditions at the time of treatment delivery reproduce 
exactly the set-up/conditions of the Planning CT scan.  An accurate assessment of how closely the 
set-up/conditions/relative locations of tumour target and internal Organs At Risk (OAR) on treatment 
matches the set-up at planning, can only be achieved with imaging.  The ability to image at the time 
of treatment allows for Image-Guided Radiotherapy (IGRT) which is now considered a standard of 
care as set out in the National Radiotherapy Implementation Group (NRIG) report: “IGRT: Guidance 
for implementation and use” (1, 2). 
 
Reproducible set-up, and treatment delivery accuracy is dependent on a number of factors including:   
patient set-up errors, patient movements, delineation (contouring) errors, and organ motion (3-5).   
Organ motion is particularly relevant for the Radiotherapy treatment of prostate cancer, due to the 
anatomical location of the prostate gland.  It sits at the base of the bladder and lies directly anterior 
to the rectum (see Figure 4.1).  This means that the prostate tumour target will move due to bladder 
filling (or emptying), and due to passage of gas (flatus) through the rectum (6). 
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Fig 4.1  
Sagittal view of an MRI scan to illustrate the proximity of Organs At Risk (Bladder and Rectum) to the 
Prostate Gland 
 
 
 
 
 
 
 
4.2.1 Prostate motion and sources of error in accurate targeting of tumour 
The prostate gland is subject to Inter-fractional, as well as Intra-fractional, motion. 
Inter-fraction motion is the motion seen between images taken on different treatment fractions. This 
motion can create errors in the geometric accuracy of treatment delivery, the error has systematic 
and random components.   
Systematic inter-fraction error is the average variation in treatment position calculated from all 
treatment verification images/records across a course of radiation therapy for a given patient, 
compared with their CT planning scan (2).   
Random inter-fraction error is the variability seen in patient positioning observed between daily 
treatment verification/images, this varies each day in direction and magnitude (2, 7). 
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Systematic errors can arise at the treatment preparation stage. Once “locked in” to the process, 
systematic errors will occur in each treatment fraction.  Possible treatment preparation errors 
include: 
Target delineation error 
Target volumetric change (a change between Planning and Treatment due to tumour growth or 
regression) 
Target positional change/target deformation (due to bladder filling and/or rectal distension) 
Phantom transfer error (the error that accumulates when transferring image data from initial 
localisation at Planning CT, through the Treatment Planning System, and to the Linear Accelerator.  
This error is measured using a test phantom) 
Patient set-up error (e.g. due to a change in patient’s position, shape or size)  
 
Random errors occur at the treatment delivery stage.  Sources of error include: 
Patient set-up error (varying changes in a patient’s position between delivered fractions)  
Target position and shape (between fractions due to target motion/deformation) 
 
Intra-fraction motion is the variability seen in multiple images/assessments acquired in rapid 
succession during the delivery of a fraction of radiotherapy.  Intra-fraction error is considered to be 
random, as the causes of error tend to be related to patient movement and organ filling. 
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4.2.2 Influence of Rectal gas/filling on prostate motion, target and OAR dose, and toxicity 
As shown in Fig 4.1 the prostate gland lies anterior to the rectum.  Therefore, any change in rectal 
filling (due to gas or faeces), either inter-fractionally, or intra-fractionally, can cause prostate motion.  
The consequence of such prostate motion is uncertainty in dose delivery to the tumour target, and 
OARs, during radiotherapy. 
Ghilezan et al (4) used cine-MRI to quantify intra-fraction prostate motion, and concluded that the 
rectal filling status was the most important predictor of prostate motion.  Padhani et al (8) also 
assessed the effect of rectal distension/movement on prostate gland position using cine-MRI, and 
confirmed that rectal filling status had an important impact on prostate motion. 
A number of groups have attempted to reduce rectal distension, and optimise the reproducibility of 
rectal filling in order to minimise prostate motion.  Strategies have included dietary modification, 
rectal preparation (including laxatives and enemas), and use of endorectal balloons (9, 10). 
The possible consequence of rectal distension includes partial geometric miss of the prostate target, 
and therefore reduced tumour control, and this has been demonstrated in previous studies (11, 12).  
A limitation in these studies however, has been the lack of image-guidance during treatment (11).  A 
study by Kupelian et al has demonstrated similar disease control between patients with distended vs 
non-distended rectum at the time of planning CT when ultra-sound based prostate position was 
verified daily (13), this supports the need for Image-guided Radiotherapy (IGRT).   
A further refinement to radiotherapy dose delivery in recent years has been Volumetric Modulated 
Arc Therapy (VMAT).  The technique can achieve highly conformal dose distributions, with improved 
target volume coverage and sparing of normal tissues, compared with conventional radiotherapy 
techniques (14).  A group from Spain, Azcona et al (15), assessed the dosimetric impact of real-time 
prostate motion during VMAT on target dose.  Real-time target (prostate) motion was determined 
using electronic portal imaging (EPI) data of the prostate fiducials.  The team used an in-house 
simulation tool to calculate the dose received by the target (taking into account the observed 
prostate motion).  They found that whilst the minimum dose to the PTV was only slightly degraded 
due to motion, the proportion of the GTV receiving the prescribed dose could be significantly 
affected by motion, dropping below 60% (compared to a desired coverage of >95%) in one trajectory 
in one patient.  In contrast, the target dose delivered in those patients with minimal prostate motion, 
matched very well with the intended (planned) dose delivery.  This supports the need for rigorous 
attention to rectal preparation, and use of IGRT, to maintain tumour control rates. 
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The main dose-limiting OAR for radiotherapy to the prostate gland is the rectum.  It is important that 
planned dose-distributions to the rectum stay within “safe” dose limits.  It is equally important that 
the delivered dose to the rectum remains within safe limits, in spite of any unplanned rectal/prostate 
motion.  Thor et al applied motion models to two retrospective cohorts of prostate cancer patients 
that had had rigorous outcome data collection.    There were strong associations for the planned and 
motion-simulated dose distributions, with rectal morbidity (especially rectal bleeding), at high doses 
(>55Gy) (16). 
In summary, rectal preparation for the planning CT scan should result in a non-distended rectum.  For 
accurate and optimum treatment delivery, the rectum should be non-distended, as per the planning 
CT, for each treatment day.  IGRT should be employed in order that treatment can be delivered as 
intended, and prostate motion should be minimised.  This should result in excellent tumour control 
rates, with minimal morbidity. 
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4.1.3 Influence of Bladder filling on prostate motion, target and OAR dose, and toxicity 
 
In the past, patients receiving prostate radiotherapy were advised to empty their bladder before 
treatment.  This was advocated in order to minimise inter-fraction variability (17).  
However, dosimetric studies have shown that dose to OARs, including small bowel and bladder wall, 
are much higher when treating patients with an empty bladder (18-20). The clinical explanation for 
reduced high dose to the bladder wall with increased bladder filling, is that as bladder-filling 
increases, the bladder expands, partly within the high-dose region, but mainly outside this region.  
Simultaneously, the bladder wall stretches, with the overall result that the high-dose bladder wall 
volume decreases (18).  
Fig 4.2 
Lateral beam’s eye view of rectum, bladder and conformal field of a patient.  The view demonstrates 
the effect of bladder filling on the high-dose volume received by the bladder wall. 
Taken from Lebesque et al, “Variation in volumes, dose-volume histograms, and estimated normal 
tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate 
cancer” (12).  The red outline represents the conformal field and therefore the high-dose region. 
 
 
Bladder 
Rectum 
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A study by Pinkawa et al showed that the dose to small bowel reached 90% of prescription dose in 
37% of cases treated with an empty bladder, compared to only 3% of cases treated with a full 
bladder (p<0.01) (21).  Importantly, a number of studies have shown that the increased dose 
received by OARs when irradiating the prostate with an empty bladder, translates into increased 
toxicity to the patient.  Jain et al (22) performed a study on prostate cancer patients to evaluate 
whether using an IMRT technique to deliver elective pelvic nodal irradiation (vs. “4-field brick”) 
reduced acute treatment toxicity.  They found that bladder filling (full vs empty) had a greater 
influence on acute gastro-intestinal toxicity, particularly proctitis and flatulence (p<0.0001) ≥Grade 2 
(G2) than the treatment technique employed (p<0.0002).  In those patients treated with a 4-field 
brick technique, the rate of G2 toxicity was 14% for those treated with a full bladder, but as high as 
40% for those treated with an empty bladder. 
It is now widely accepted that patients receiving prostate radiotherapy should be treated with a 
“comfortably full” bladder.  This is specified in national and international trials of prostate 
radiotherapy (PACE and CHHiP) (23, 24).  However, achieving consistency of bladder filling on a daily 
basis for a course of conventionally fractionated External Beam Radiotherapy (which typically 
delivers 74Gy in 37 treatment fractions) is difficult to achieve.   Even with the use of bio-feedback 
wide variations in bladder filling are observed (25, 26). 
Ideal bladder preparation would have dosimetric advantages (bladder full enough to minimise dose 
to bowel and bladder wall), and would be consistent and reproducible on a daily basis (such that the 
treatment actually delivered to Prostate and OARs is exactly as intended). 
The 1st aim of this Chapter is therefore: 
To develop bladder filling guidelines for conventionally-fractionated Radiotherapy and CyberKnife 
patients, based on optimal dosimetry/reproducibility. 
 
4.1.4  Prostate radiotherapy delivered by CyberKnife: hypofractionation 
There is a good evidence base for the efficacy and tolerability of conventionally-fractionated external 
beam radiotherapy for the treatment of early stage, low to intermediate risk prostate cancer 
(prostate cancer which is confined to the prostate gland, with no capsular breach, Gleason≤4+3, 
PSA≤10-20) (27, 28).  A typical dose/fractionation regime employed in conventionally-fractionated 
external beam radiotherapy is 74Gy/37 fractions/7.5 weeks (29).  The BED for tumour control for this 
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regime (using alpha/beta for prostate cancer of 1.5Gy) = 173.  The BED for late effects to 
bladder/bowel (using alpha/beta of 3) = 123. 
The low α/β ratio (1.5Gy) of prostate cancer has stimulated interest in hypofractionated 
radiotherapy for prostate cancer.  Delivery of hypofractionated regimes should optimise prostate 
tumour control rates, without negative consequences on late toxicity (30).  Early results suggest that 
PSA relapse-free survival rates compare favourably with other definitive treatments for organ-
confined disease, although longer-term outcome data is awaited (31). 
The hypofractionated dose/fractionation regime for prostate cancer treated with CyberKnife at the 
author’s centre is 35Gy/5#/1 week (BED tumour control= 198, BED normal tissues= 116), therefore 
hypofractionation delivers a higher BED to tumour (compared to conventional fractionation), while 
limiting BED to normal tissues. 
 
4.1.5  Prostate radiotherapy delivered by CyberKnife: fiducial tracking 
The importance of image guidance to guide prostate radiotherapy delivery has been described (1, 2).  
Standardly, three fiducials are inserted into the prostate (32, 33) to guide prostate radiotherapy for 
CK patients.  In contrast to the patient groups described in Chapter 3 (lung, liver pancreatic tumours), 
prostate cancer patients do not undergo Day 1 Treatment CT at my Centre.  This is considered 
reasonable practice, as the risk of fiducial migration outside of the prostate gland once implanted is 
negligible, and fiducial instability in the prostate is recognised to be sub-millimetre, and therefore 
within the accuracy of CT measurement (33-35). 
At treatment, patients are positioned in immobilisation, exactly as at planning CT, and positional 
adjustments to the patient and couch are made according to information on fiducial position from 
the Live X-Rays.  Treatment is able to proceed when the following criteria are fulfilled: 
1. CyberKnife Radiographers are satisfied that the patient is well positioned 
2. The Rigid Body Error (RBE) of fiducial arrangement is within acceptable limits 
3. Suggested translations/rotations (to allow accurate treatment delivery) are sufficiently small that 
the CK robot can make the adaptations required 
Once treatment has commenced, intra-fractional prostate motion is analysed by review of Live X-
Rays, and evaluation of fiducial parameters (such as inter-marker distance and RBE). 
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Intra-rectal flatus can sometimes be appreciated on the Live X-Rays, but it is not possible to see 
bladder filling on the plain X-rays.  Bladder filling during a CK prostate treatment (typically 
>40minutes) has the potential to change the fiducial configuration from that at CK planning.  A 
change in fiducial configuration could potentially mean that rotational adjustments required are in 
excess of what the CK robot can adapt for.  If this is the case, rotations may need to be “switched off” 
such that treatment delivery can proceed, tracking translations only.  This is not ideal as tracking 
accuracy is improved by tracking both translations and rotations (36). 
The author was called to the CK bunker for consultation on a problematic treatment delivery, and 
observed changes in pitch that were beyond what the robot could adapt for towards the end of 
treatment.  The treatment had taken a long time to deliver and the patient commented post-CK that 
his bladder was very full. This prompted the author to consider the relationship between bladder 
filling and rotational tracking. 
The rotational changes that the CK robot can adapt for are:  Roll: 20, Yaw: 30, Pitch: 50. 
The 2nd aim of this Chapter is therefore: 
To determine the relationship between the consistency of bladder filling (between planning and 
treatment), and the ability to track rotations of the tumour target for the CK treatment of Prostate 
cancer. 
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4.3 MATERIALS AND METHODS 
4.3.1 CyberKnife (CK) patients: Planning 
A planning CT scan was performed 1 week after insertion of 3 gold fiducials into the prostate.  A 
planning MRI scan was always performed immediately after the planning CT scan.  This was a 
secondary scan to be fused with the planning CT to aid delineation of the target. 
Patients were asked to keep a record of the fluids consumed on the day of the planning CT scan, and 
the time of the last fluids consumed before scanning.   
Patients were catheterised prior to planning CT scan with an aseptic technique using a 12F rubber 
urinary catheter.  Catheterisation was standard procedure for all CK patients undergoing treatment 
for primary prostate cancer.  The aim of catheterisation was that the intra-prostatic urethra could be 
more easily visualised/delineated on CT.  The dose to the intra-prostatic urethra could then be 
limited to safe dose constraints at the treatment planning stage.   
All patients emptied their bladder before catheterisation (and recorded the time of voiding as 
requested), so in order to fill the bladder appropriately for the planning CT scan, sterile water was 
instilled into the bladder via the catheter.  A bladder volume of approximately 180mls was 
considered optimum (full enough to improve bladder dosimetry, but empty enough for patient 
comfort during CK treatment).  However, after each 60mls was instilled the patient was consulted as 
to their level of comfort.  A minimum of 100mls was instilled.  Once the bladder was filled as 
considered appropriate, the catheter was clamped, and the volume of fluid instilled into the bladder 
was recorded.  This was standard pre-treatment planning procedure. 
The department had recently purchased a BVI9400 bladder scanner (Verathon Medical UK, Sandford, 
UK).  This is a portable 3D Ultrasound device that is designed to measure urinary bladder volumes.  
This Ultrasound device measures specifically the volume of urine (fluid), not “whole bladder” (i.e. the 
volume does not include bladder wall).  The department was keen to use the bladder scanner to its 
full potential to help develop bladder filling guidelines. 
Once the bladder had been filled as described, 3 ultrasound measurements of the urinary volume 
were taken in quick succession, and recorded.  Patients were scanned by placing the ultra-sound 
transducer at the midline, 2cm above the pubic symphysis, and angled towards the bladder.  The 
time of scanning was recorded. 
The patient then proceeded to planning CT scan as standard (in immobilisation, 1.25mm slices). 
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Initially, the methodology was that the patients had 3 x bladder ultrasounds pre-CT, and then 3 x 
bladder ultrasounds immediately post-MRI.  As an additional assessment as to the accuracy of the 
bladder ultrasound, the catheter was unclamped and the urine allowed to drain into the catheter 
bag.  The volume of urine drained was recorded. 
However, there were difficulties encountered with the above approach.  
The patients often felt very full after MRI and wanted the catheter out immediately.  It was not 
possible to perform ultrasound bladder scanning in the MRI room due to the incompatibility of the 
metal-containing ultrasound machine, and the magnet of the MRI scanner.  It was often difficult to 
find a suitable room to perform ultrasound bladder scanning post-MRI in a timely way.   
In addition, there were issues with measuring the volume of urine drained from the bladder post-MRI 
in the way described.  One patient was so full that some urine bypassed the catheter.  In others, 
urine did not completely drain via the catheter, some was retained.   
For these reasons, the author felt it more constructive to abandon post-MRI measurements.   
Following this change to the methodology, a further 3 bladder ultrasound measurements were 
recorded post-CT scan. 
Urine volumes were subsequently estimated from the Planning CT scan as explained below. 
“Bladder” was outlined on the planning CT in MultiPlan by the physics team. “Bladder wall” was 
created using the Boolean operator tool of MultiPlan, applying a 4mm internal margin on “Bladder” 
(37).  Bladder volume minus Bladder Wall volume provided an estimate of urine volume at the time 
of planning CT. 
 
4.3.2 CyberKnife (CK) patients: Dosimetry 
Treatment planning was performed by the CK physicists as per standard protocol.  Bladder wall 
dosimetry was recorded for analysis.  Maximum Point Dose (MPD), dose to ≤ 5cc of bladder wall and 
≤ 15cc of bladder wall (standard constraints) were recorded.  PTV coverage and PTV volume were 
also recorded. 
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4.3.3 CyberKnife (CK) patients: Treatment  
Patients were treated in 5 treatment sessions on consecutive days. 
Patients were asked to record the quantity of fluids consumed prior to each CK treatment. They were 
advised to stop drinking 2 hours prior to each treatment. 
For Day 1 of treatment, following standard protocol, patients were asked to void (just prior to 
treatment), and then drink 2 plastic cups of water (200mls).  The cups were filled by a staff member.  
An Ultrasound bladder scan was performed prior to treatment (x 3 consecutive readings). The times 
of voiding, drinking and scanning were recorded. 
The CK Radiographers then positioned the patient for treatment.  The set-up time and start time was 
recorded.   
Prior to treatment start, the inter-fiducial marker distances were recorded. 
Each treatment session was observed and the following was recorded from the CK console data:  
translational and rotational robot corrections, Rigid Body Error (RBE).  If rotational corrections 
needed to be disabled, or if couch corrections needed to be applied then this was also recorded. 
Just before the end of treatment the CK Radiographers performed a “soft stop” of treatment 
delivery, and inter-fiducial marker distance was again recorded. 
Immediately after each treatment session, the bladder was scanned (again, 3 x consecutive 
measurements).  The time of scanning was recorded. 
The average urine volume during treatment was calculated (end of treatment volume plus pre-
treatment volume divided by 2).  The average urine volume was compared to the planning CT urine 
volume in order to inform drinking instructions for the next day’s treatment.  The “baseline” pre-
treatment water volume of 200mls was increased or decreased as considered appropriate.   
 
4.3.4 Radiotherapy (RT) patients: Planning: Early patient group: pilot study 
A planning CT scan was performed on each patient.  The patients were not catheterised for scanning. 
The initial protocol for these patients (in the pre-bladder scanner era) was to attend clinic 40 minutes 
prior to CT scan.  The patients were asked to void, then drink 400-500mls within 5 minutes.    The aim 
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was that when the patients were ready for CT scanning 40 minutes later, the bladder would be 
“appropriately full”.  
Once the bladder scanner was purchased, the CT simulator staff scanned the patients with the 
ultrasound bladder scanner (3 consecutive measurements) prior to proceeding to planning CT scan.  
Some patients were advised that more time/water was required to fill the bladder (times and 
volumes were recorded).  A “threshold” bladder volume was not well defined in protocol at this point 
in time, however.   
A bladder filling working party was established to analyse the early results from these pilot patients, 
and to refine the bladder filling guidelines in light of the results.  The results will be reported in 
Section 4.4. 
Urine volumes were subsequently estimated from the Planning CT scan as previously explained, with 
a few key differences.  The RT patients were planned on Eclipse terminals.  For these patients a 2mm 
thickness of bladder wall was assumed (38, 39).   
The reasons for the different thickness of bladder wall assumed for the 2 groups of patients will be 
discussed and critiqued in Section 4.5. 
 
4.3.5 Radiotherapy (RT) patients: Treatment  
The pilot group of patients, were given identical drinking instructions for treatment fractions to their 
pre-CT instructions. 
Three ultrasound bladder scan readings were taken prior to RT treatment.  Given the much shorter 
treatment times in RT treatments (compared to CK), a post-treatment bladder scan was considered 
less informative and was therefore not undertaken. 
 
4.3.6 Radiotherapy (RT) patients: Dosimetry analysis  
As previously described, RT patients undergoing conventionally-fractionated for prostate cancer 
receive 33-37 treatment fractions.  It is important for the accuracy of treatment delivery that there is 
image-guidance (1, 2).  Standard protocol for these patients is to undergo Cone beam CT scan on the 
treatment couch just prior to radiotherapy delivery on Days 1-3 of treatment, then weekly Cone 
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beam CT scans thereafter.  Any positioning errors noted on Cone beam CT are corrected before 
treatment delivery (40).   
The Cone beam CT scans provide a helpful dataset for analysis of the impact of differential bladder 
filling on bladder and bowel dosimetry. 
The bladder contour was outlined on the Cone beam CT scans for a sample of 3 patients.  “Bladder 
wall” was created as before using an internal margin of 2mm on the bladder.  The Cone beam CT 
scans were then blended with the original treatment plan for analysis of bladder/bowel doses 
received, which could be compared with planned doses.   
 
4.3.7 Radiotherapy (RT) patients: Data collection 
The author collected the bladder filling and dosimetry data for CK patients. 
The bladder filling data for RT patients was collected by the treatment radiographers.  The author 
analysed the results of the pilot group of RT patients and presented the outcomes in the RT 
department medical journal club, with suggestions for refinements to bladder filling guidelines.  A 
“bladder filling working party” was subsequently established, which the author was an integral part 
of, and new guidelines were agreed. 
The author designed the technique for assessing bladder dosimetry by use of the Cone beam CT 
scans in collaboration with the Physics department, and performed the dosimetric analysis on an 
example patient.  The technique, and the DVH parameters of interest, were disseminated to a 
dosimetrist from the “bladder filling working party” for further analysis of a sample group of patients. 
164 
 
4.4 RESULTS 
4.4.1 CK patients: Planning 
The bladder filling results for 9 CK patients undergoing Planning CT scan are shown in Table 4.1 
below. 
Table 4.1: CK patients: Pre-treatment bladder filling 
U/S = Ultrasound. m = Readings taken post-MRI rather than post-CT.  * = see text below. 
SD = Standard Deviation. 
Patient 
Fluid 
instilled 
into 
Bladder 
(mls) 
U/S Bladder scan fluid volume 
pre-CT (mls) 
Plan CT 
Urine 
Volume 
(cc) 
% change  
Bladder 
scan pre-
CT volume 
to Plan CT 
volume 
U/S Bladder scan urine volume 
post-CT (mls) 
1 2 3 
Mean 
(SD) 
1 2 3 
Mean 
 (SD) 
1 180 207 249 247 
234 
 (19) 
176 -25 250
m
 228
m
 235
m
 
234
m  
(9) 
2 180 218 221 235 
225  
(7) 
333 +48 417
m
 450
m
 258
m
 
375
m 
(84) 
3 180 332 318 342 
331  
(10) 
325 -2 127* 122* 125* 
125* 
(2) 
4 180 308 314 296 
306  
(7) 
211 -31 268
m
 246
m
 247
m
 
254
m 
(10) 
5 180 250 266 262 
259  
(7) 
242 -7 234 252 245 
244  
(7) 
6 180 200 179 178 
186  
(10) 
173 -7 182 183 195 
187  
(6) 
7 150 106 127 127 
120  
(10) 
144 +20 141 140 142 
141  
(1) 
8 180 171 180 194 
182  
(9) 
204 +12 274 290 267 
277  
(10) 
9 180 249 250 248 
249  
(1) 
186 -25 227 234 223 
228  
(5) 
Mean 177    232 222 +4    
230 
(71) 
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8/9 patients (89%) could tolerate 180mls of water instilled into their bladder.  The remaining patient 
(patient 7) felt reasonably full after 150mls of water was instilled. 
On analysis of the Ultrasound bladder volume taken prior to CT, the mean volumes measured by 
bladder scanner were greater than the volume instilled for all patients except for patient 7.  It would 
be expected that the volume of intra-bladder fluid recorded by bladder scanner would be >180mls 
because the bladder would have filled with urine to some extent in the interval between the patient 
voiding and the bladder scanner reading being taken.  Mean interval between voiding and first 
bladder scanner reading was 23mins.   
The likely explanation for the results for patient 7 is inaccuracies of the bladder scanner readings.  
There was no observation of fluid bypassing the catheter for this patient. 
Mean pre-CT bladder scanner urine volume for the group as a whole was 232mls. For the 8 patients 
that had 180mls of water instilled into bladder, the mean bladder scanner urine volume pre-CT was 
247mls.  The range of mean urine volumes pre-CT for those with 180mls instilled into bladder was 
wide: 182-331mls. This is likely to reflect a significant individual variation in rate of bladder filling, 
which is dependent on multiple factors.  These will be discussed further in the Discussion, section 
4.5. Of note, the time interval between instilling water into the bladder and taking bladder scanner 
readings was minimal, and it was consistent across all patients studied, range was 2-3 minutes. 
Examining the consistency of pre-CT bladder scan readings for each patient, these are largely 
consistent.  The mean Standard Deviation for the group as a whole was 8mls (range 1-19).  
Interestingly, the largest Standard Deviation occurred in the first patient, so this may have 
represented a learning curve on taking the scan measurements.Nera 
The mean Planning CT urine volume was 222cc, which was remarkably consistent with the mean 
Ultrasound bladder scan volume pre-CT (232mls), a change of 4%.  Note 1 ml= 1cc.  However, there 
were wide individual variations in the consistency between bladder scan measurements, and the 
measurements calculated by CT.  It would be expected that the urine volumes measured at CT would 
be larger, because the CT scans were taken at a later time point (5-10 minutes later) and therefore 
the bladder would have continued to fill. In fact, only 3 patients (patients 2, 7 and 8) showed an 
increase in urine volume at CT.  The range of percentage variation between bladder scanner urine 
volumes, and planning CT urine volumes is -31% to +48%.  Possible explanations for these 
observations will be discussed in Section 4.5. 
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Reviewing the results for post-CT bladder scanner readings, patients 1-4 had readings taken following 
MRI scan.  The post-MRI readings were taken on average 1.5 hours after the pre-CT bladder scan 
readings, therefore, the readings might have been expected to be considerably more than the pre-CT 
readings.  This was the case for patient 2, but not the other patients.  The results for patient 3 cannot 
be interpreted sensibly because this patient had a significant amount of urine bypass the catheter 
post-MRI.  For patients 1 and 4, the results may potentially be explained by a combination of 
inaccuracies in bladder scanner readings, and it was also possible that bladder filling rate may have 
slowed significantly due to the MRI scan taking place a long time after drinking.  Patient 1 had last 
consumed fluids 4 hours 20 minutes prior to the post-MRI bladder scans.  Patient 4 had not recorded 
their fluid intake. 
Patients 5-9 had repeat bladder scanner readings taken immediately after planning CT scan.  4/5 
patients (80%) showed an increase in bladder scan volumes, patient 7 had a slight decrease in 
volume recorded (-2%).  Average change in volume between planning CT and post-CT bladder scan 
volume was +12% (-2 to +35%).   
Post-CT bladder scanner readings were largely consistent, except for patient 2, who had a SD of 
84mls.  Of note, this patient had the largest urinary volumes recorded, so this could potentially 
suggest something about the accuracy of the bladder scanner at larger volumes. 
Patients 1 and 3 had the catheter unclamped after the post-MRI bladder scanner readings, and the 
urine was allowed to empty into the catheter bag.  This was subsequently measured in a measuring 
cylinder.  The measured urine volume for patient 1 was 290mls, and for patient 3 was 120mls.  The 
recorded volume for patient 3 was very similar to the bladder scanner readings (125mls).  The 
volumes for patient 1 were less similar.  
In summary, mean pre-CT bladder scanner urine volume measurements are consistent with mean 
planning CT urine volume measurements (only 4% difference), however, there are large individual 
patient variations.  There are early suggestions that inaccuracies with bladder scanner measurements 
may be more significant at larger bladder volumes. 
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4.4.2 CyberKnife (CK) patients: Dosimetry 
Table 4.2 shows bladder wall dosimetry for 9 patients undergoing CK treatment for primary prostate 
cancer. 
MPD = Maximum Point Dose 
Table 4.2: CK patients: Bladder wall dosimetry 
Patient MPD (Gy) 
≤ 5cc threshold 
(Gy) 
≤ 15cc threshold 
(Gy) 
PTV coverage 
(%) 
PTV volume 
(cc) 
Protocol 38 35 18.3 >95  
1 37.3 32.6 14.9 98.8 49.7 
2 37.9 33.6 17.1 99 70.8 
3 37.8 34 18 96 42.6 
4 37.4 34.1 17.5 97 99.8 
5 37.4 33.6 14.9 98.6 40.9 
6 37.3 30.1 14.4 99 54.5 
7 37.8 34.9 16.5 98.1 80.3 
8 37.2 33.3 18.4 89.4 121 
9 37.5 34.3 17.8 95.7 47.7 
 
Table 4.2 shows that for all 9 patients (the same patients as in Table 4.1) the bladder wall maximum 
point dose, and the 5cc threshold, were within protocol constraints.  Patient 8 had up to 18.4 Gy 
delivered to ≤15cc of bladder wall, which is just outside of protocol.  All other patients achieved 
protocol constraints.   
Table 4.1 shows that patient 8 had a planning CT urine volume of 204 cc, which is just less than the 
mean volume for the group (222 cc).  There were 4 patients (44%) with bladders which were less 
filled (≤186 mls), that would therefore potentially have had less favourable bladder filling to achieve 
bladder wall dosimetry within constraints.  All of these achieved bladder wall constraints however, 
without compromising on PTV coverage. 
Patient 8 had the largest PTV volume (121 cc) and PTV coverage was compromised (to 89.4%) in 
order to stay within bladder wall constraints as much as possible.  It is likely that PTV volume (rather 
than bladder filling) was the dominant factor which caused a breach of bladder wall constraints, and 
also compromise of PTV coverage. 
168 
 
For all patients studied with a PTV volume of ≤100 cc, treatment plans were produced which were 
within safe constraints to bladder wall and other OARs, without dropping PTV coverage below the 
recommended lower limit of 95%.  This supports planning CT urine volume of between 144mls and 
333mls (and pre-CT bladder scanner volumes of 120-331mls) as an “optimum bladder volume” from 
a dosimetric perspective.   
Reproducibility of bladder volumes on treatment is an important consideration and this is reported in 
the following section. 
 
4.4.3  CyberKnife (CK) patients: Treatment bladder filling 
Table 4.3 shows the results of bladder filling pre- and post-treatment for a patient undergoing CK 
treatment for primary prostate cancer. 
BS = Bladder scan.  BSV = Bladder scan volume.   
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Table 4.3: CK patient: Pre- and post-treatment bladder filling 
Fraction 
Fluids 
given 
(mls) 
Time 
Void to 
Pre-CK 
BS 
(mins) 
Time 
Void to 
Post-CK 
BS 
(mins) 
Planning 
CT 
Bladder 
urine 
volume 
(cc) 
Mean 
Pre-CK 
BSV 
(mls) 
Mean 
Post-CK 
BSV 
(mls) 
Average 
CK BSV 
(mls) 
% change 
Plan CT 
Bladder 
urine volume 
to Mid-CK  
BSV 
1 200 5 60 238 20 250 135 -43 
2 250 3 54 238 0 306 152 -36 
3 300 3 56 238 7 340 174 -27 
4 350 5 55 238 0 327 163 -32 
5 400 5 54 238 4 399 202 -15 
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The patient whose results are displayed in Table 4.3, was advised to drink an increased volume of 
fluids before CK treatment each day, as the average CK bladder scan volume was less than the 
volume recorded at planning CT for each fraction of treatment.  The aim of the focus on bladder 
filling, and the individualised advice to patients, was to match the planning CT urine volume, and the 
average CK bladder scan volume (i.e. the likely bladder urine volume mid-way through a fraction of 
CK).   
The advice given improved the consistency of bladder filling on treatment days.  The application of 
“standard advice” on fraction 1 resulted in under-filling of the bladder on treatment by 43%.  By 
fraction 5, refined bladder filling guidance which had been individualised to this patient, meant that 
the bladder was under-filled by 15% only.  It is important to note that treatment times were 
remarkably consistent in this patient (as evidenced by the consistency of times between voiding and 
first post-CK bladder scan reading). 
 
Table 4.4 shows the pooled results of bladder filling pre- and post-treatment for 6 patients 
undergoing CK treatment for primary prostate cancer. 
BS = Bladder scan.  BSV = Bladder scan volume.   
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Table 4.4: CK patients: Pre- and post-treatment bladder filling: summary results 
 
Patient Fraction 
Fluids 
given 
(mls) 
Time 
void to 
post-CK 
BS (mins) 
Plan CT 
bladder 
urine 
volume 
(cc) 
Mean 
Pre-CK 
BSV 
(mls) 
Mean 
Post-CK 
BSV 
(mls) 
Average 
CK BSV 
(mls) 
% change Plan CT 
Bladder urine 
volume to Mid-CK 
Rx BSV 
1 
1 200 60 
238 
20 250 135 -43 
5 400 54 4 399 202 -15 
Mean 
(Range) 
300 
(200-400) 
56 
(54-60) 
6 
(0-20) 
324 
(250-399) 
165 
(135-202) 
-31 
(-43 to -15) 
2 
1 300 63 
80 
0 121 61 -24 
5 350 72 29 328 179 +123 
Mean 
(Range) 
340 
(300-350) 
74 
(63-81) 
7 
(0-29) 
224 
(121-462) 
164 
(61-231) 
+105 
(-24 to +189) 
3 
1 200 71 
211 
81 469 275 +30 
5 200 98 0 293 147 -30 
Mean 
(Range) 
200 
(200-200) 
88 
(63-107) 
106 
(0-174) 
423 
(256-704) 
265 
(147-433) 
+26 
(-30 to +105) 
4 
1 200 61 
325 
134 X X X 
4 200 61 9 336 173 -47 
Mean 
(Range) 
200 
(200-200) 
58 
(48-63) 
77 
(9-134) 
304 
(227-350) 
181 
(145-226) 
-44 
(-55 to -30) 
5 
1 200 100 
144 
27 337 181 +26 
5 250 72 5 158 82 -43 
Mean 
(Range) 
230 
(200-250) 
84 
(72-100) 
17 
(4-29) 
234 
(158-337) 
125 
(82-181) 
-13 
(-43 to +26) 
6 
1 200 68 
204 
0 230 115 -44 
5 250 85 63 411 237 +16 
Mean 
(Range) 
250 
(200-300) 
86 
(68-115) 
32 
(0-63) 
308 
(182-411) 
138 
(115-237) 
-33 
 
Patient 1 in Table 4.4 above is the same patient from Table 4.3 so the results will not be discussed 
further here.   
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Patients 3 and 4 were not advised to drink different amount of fluids than the standard 200mls.  Both 
were patients that complied with voiding instructions with difficulty.  This was the reason for the high 
pre-CK BSV’s for these patients, even though the patients were asked to void immediately before 
arrival on the CK unit. Both patients were better at following this instruction towards the final 
fraction of CK.  The author found it difficult to suggest a change to fluid consumption on the 
information gathered. 
Patient 2 had a small bladder volume at CT.  This was by design.  The patient had attended for CK 
planning initially a number of months before.  However, due to a combination of a large prostate 
gland, and the configuration of the bladder against the prostate, it was not possible to produce an 
acceptable treatment plan.  The patient therefore underwent hormonal cytoreduction of the 
prostate gland.  At repeat planning the aim was to scan the patient with a bladder volume of 
approximately 100mls rather than 180mls (as advised by the Physics team).  This patient could not be 
catheterised therefore his bladder was filled by drinking at planning CT.  Mean BSV prior to planning 
CT was 110mls.  The patient was noted to have slow bladder filling at planning CT, which is the 
reason he was commenced on 300mls.  This was not sufficient to adequately fill the bladder at 
fraction 1, but the adjustment strategy led to over-filling of the bladder on subsequent fractions, 
which was disappointing. 
Patient 4 was so full at the end of his first fraction of CK, that he had to go immediately to the toilet 
without pausing for a post-CK BSV assessment.  The fluids were not adjusted because he had such a 
high BSV before CK (134 mls), the author thought that the post CK BSVs may be acceptable for 
subsequent fractions if he voided just before CK. 
As previously described, the aim of taking bladder filling measurements and individualising drinking 
instructions for patients, is to match average CK bladder volume to planning CT bladder volume.  This 
aim was not achieved for patients 2 or 5, but was achieved for patients 1 and 6.  Patient 3 had stable 
bladder volumes, and drinking instructions were not adjusted.  Patient 4 could not be assessed fully 
due to the issues in measuring the post-CK readings for fraction 1. 
It was previously highlighted that patient 1 had very consistent treatment times (and therefore 
consistent readings for Void to Post-CK BSV interval). The other 5 patients had wide variations in 
treatment times on a day-to-day basis, and this exacerbated the difficulty of deciding on an ideal 
volume of fluids for the patients to drink prior to CK. 
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An interesting and unexpected observation of daily assessment of post-voiding pre-CK bladder 
volumes, was an early indication of flow issues in some patients.  Patients 1, 3, and 4, did not have 
any symptoms of poor urinary stream, or incomplete emptying, and the post-voiding volumes were 
reasonable.  Patient 2 was asymptomatic until Day 5, and then complained of obstructive symptoms. 
An alpha-blocker was recommended given the post-voiding residual volume of 29mls and the 
symptoms.  Patient 5 had a mean post-voiding volume of 8mls on Day 3, but on direct questioning he 
had obstructive symptoms therefore he was started on alpha blockade.  The symptoms did not 
progress, and in fact the post-voiding volume improved marginally to 5mls on Day 5. 
Patient 6 had a mean post-voiding volume of 63mls on Day 3, and was symptomatic.  Alpha blockade 
was prescribed, but he did not wish to take medication and therefore was not compliant.  Post-
voiding residual volumes were stable for the remaining days of treatment. 
In summary, individualising drinking instructions in order to optimise bladder filling is challenging. 
Individualised instructions led to optimised bladder filling in 2/6 patients (33%), but there was still 
room for improvement.  A further patient had stable bladder volumes (comparing fractions 1 and 5), 
and drinking instructions were unchanged during treatment.  One patient was difficult to assess, and 
2 patients did not benefit from individualised instructions. 
Half the group had obstructive symptoms accompanied by an increase in post-voiding residual 
volumes (arising on Days 3-5 of treatment), and were prescribed Tamsulosin. 
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4.4.4 CyberKnife (CK) patients: Treatment and Rotational tracking 
Treatment delivery was observed for 7 patients undergoing CK treatment of primary prostate cancer.  
The frequency of rotational tracking, and couch adjustments made for rotations were recorded, 
results are displayed in Table 4.5. 
The aim of the analysis was to determine the relationship between the consistency of bladder filling 
(between planning and treatment), and the ability to track rotations of the tumour target for the CK 
treatment of Prostate cancer.   
Table 4.5: CK patients: Rotational tracking vs Consistency of bladder filling 
RT = Rotational tracking.  CA = Couch Adjustments. Rx = Treatment. # = Fraction 
Patient 
Percentage 
(%)  of 
fractions 
with full RT 
Percentage 
(%) of 
fractions 
requiring CA 
Total CA 
made over 
Rx course 
Problematic 
rotation 
Most 
problematic 
fraction 
Problematic 
quartile of Rx 
fraction 
1 100 20 1 Roll #4 First 
2 100 100 29 
Roll for 4#s 
Pitch for 2#s 
Roll: #5 
Pitch: #2 
Roll: All 
Pitch: Final 
3 100 60 5 
Roll: for 2#s 
Pitch: for 1# 
Roll: #2 & 4 
Pitch: #1 
Roll: Final 
Pitch: First 
4 40 40 7 Pitch: all #s #s 3-5 All quartiles 
5 100 50 3 
Pitch: for 2#s 
Yaw: for 1# 
Pitch #1 &3 
Yaw: #3 
Pitch: First & Final 
Yaw: First 
6 100 60 8 
Roll: #1 & 5 
Pitch: #2 & 5 
Roll & 
Pitch: #5 
#1 & 2:Final 
#5: First 
7 100 60 8 
Pitch: #2 & 4 
Yaw: #2 & 3 
Pitch: #2 
Yaw: #2/3 
Final 
 
The relationship between consistent bladder filling, and the ability to track target rotations, was 
investigated due to an observation of significant pitch rotation (therefore rotations needed to be 
“switched off” for treatment to proceed) of a prostate target towards the end of a treatment 
fraction, in a patient who had a full bladder at the end of treatment.  
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Table 4.5 shows that only a single patient, Patient 4, (1/7, 14%) had to have rotational tracking 
disabled due to rotations being larger than what CK can adapt for.  Pitch was the problematic 
rotation, which might be expected to be related to bladder filling (bladder filling would be less likely 
to cause a roll or yaw rotation).  Of interest, the rotational tracking needed to be disabled with equal 
frequency in all quartiles of treatment fractions.  Patient 4 had a planning CT urine volume of 211mls, 
and the patient exceeded a fill volume of 211mls in each fraction where rotational tracking was 
disabled (fractions 3-5).  It might have been expected that rotational adjustments would be at a 
minimum where the bladder volume on treatment matched the planning CT, but this did not seem to 
be the case in this patient.  As previously described, the rotational changes that the CK robot can 
adapt for are:  Roll: 20, Yaw: 30, Pitch: 50 (for prostate treatments).  However, there was an error 
made in the physics planning of this patient and the patient was set-up as a “Body” as opposed to a 
“Prostate” treatment.  This meant that the rotations that could be adjusted for were: Roll 1.50, Pitch 
1.50, and Yaw 30.  Reviewing the pitch rotations observed for fractions 3-5, all were within 50, 
meaning that if the patient was set-up as a “prostate” patient, rotational tracking would have been 
employed in all treatment fractions (and therefore in all patients). 
Patient 1 above is the patient that had consistent treatment delivery times, and no treatment 
delivery took >1 hour (see Table 4.2).  As a guide, physicists aim to keep treatment delivery times to 
<1 hour for CK patients, for patient comfort, and in the knowledge that patients are more likely to 
move the longer a treatment takes to deliver.  For this patient, only a single couch adjustment 
needed to be made in the entire course of treatment (for Roll in the first quartile of fraction 4), this 
adjustment brought the adjustment that the robot needed to make to within range, and treatment 
delivery proceeded without event. 
Patient 2 above needed the largest amount of couch adjustments of all patients studied for delivery 
to proceed with rotational tracking enabled (29 for the entire treatment course).  Roll was the most 
problematic rotation, and was responsible for 26/29 rotations (90%), the adjustments needed to be 
made equally in all quartiles of treatment delivery.  Interestingly, this patient had a Left Total Hip 
Replacement. In order to maximise access for beam delivery (as beams would not be able to enter 
through the left metal hip), the patient was positioned in a roll in his immobilisation at planning CT, 
with his left hip down and the right hip up.  This position was reproduced at treatment, but the 
position is likely to have been less stable than a patient lying supine on the couch (with no roll 
applied).  The 3 couch adjustments made for pitch were made in the final quartile of treatment 
delivery in fractions 2 and 4.  These were the treatment fractions associated with the largest post-CK 
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bladder volumes (373mls and 462mls respectively), therefore bladder filling could have been 
responsible for the need to make these couch adjustments. 
Patient 3 only required 5 couch adjustments throughout the whole course of treatment.  The only 
adjustments for Pitch were in the first 2 minutes of fraction 1 (when the patient had an empty 
bladder), and otherwise no adjustments were required.  These pitch adjustments are likely to be 
related to set-up issues rather than bladder filling issues.  The other adjustments were made for Roll 
in the final quartile of treatment delivery, at >60 minutes treatment delivery (for fractions 2 and 4).  
It may be that these minor couch adjustments needed to be made for patient movement. 
Patient 5 only required 3 couch adjustments throughout the whole course of treatment, 2 for pitch 
(of note no data was recorded for fraction 5).  The adjustment required for pitch on fraction 1 
occurred at the end of treatment when the patient had a full bladder (so much so that he declined 
post-CK bladder scanning so that he could get promptly to the toilet).  This adjustment may have 
been required therefore due to bladder filling (or patient discomfort).  The other adjustments 
required were made early in fraction 3 and are likely to be related to set-up issues. 
Patients 6 and 7 both required 8 couch adjustments total throughout the whole course of treatment, 
for 3 of the delivered fractions.   
For patient 6, 3 of the adjustments were made in the final quartile of treatment delivery (for 
fractions 1 and 2), and the remainder were made early in fraction 5.  This patient had long treatment 
delivery times (always > 60 minutes) due to interruption by passing flatus.  Only 1 of the couch 
adjustments made in the final quartile was made for pitch.  Fraction 4 was a particularly problematic 
treatment to deliver, lasting 115 minutes in total (including set-up time and interruptions).  Set-up 
took a long time, and flatus was an issue during treatment delivery.  The patient also needed to void 
twice during treatment, once 65 minutes following the pre-CK void, and then again 36 minutes later.  
Despite the issues with bladder filling for this fraction, no couch adjustments were required. 
For patient 7, 6/8 of the couch adjustments required were for pitch, these adjustments needed to be 
made in the final quartile of treatment delivery (in fractions 2 and 4).  These treatment fractions 
were not associated with the fullest bladders. 
In summary, rotational tracking was employed for all fractions in 86% of the patients studied.  The 
one patient where rotational tracking had to be disabled for 3 of the treatment fractions, would have 
had rotations compatible with rotational tracking if standard “prostate” adjustments were applied.  
Couch adjustments most frequently needed to be made in the final quartile (in 6/7, 86% patients), 
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but there was no clear relationship with bladder filling.  In general, required couch adjustments did 
not impact on treatment delivery times, other issues were more problematic (flatus, patient 
positioning). 
 
4.4.5 Radiotherapy (RT) patients: Planning: pilot study 
The bladder filling results for 10 patients undergoing a planning CT scan for the conventionally-
fractionated radiotherapy treatment of prostate cancer are displayed in Table 4.6.  These patients 
were given bladder filling instructions as described in Section 4.3.4, and CT staff scanned patients 
according to their best judgement, before guidelines had been refined. 
Analysis of this early group of patients was to help inform new guidelines. 
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 Table 4.6: RT patients: Planning: Early patient group: pilot study:  
BS = Bladder scan.  BSV = Bladder Scan Volume 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fluids consumed by patients was largely within protocol (400-500mls), except for 1 patient that 
drank 600mls.  Bladder urine volume at scanning as a percentage of fluids consumed in the 
department was noted to be highly variable.  This is likely to be related to a number of factors such 
as: time interval to scanning, pre-hydration levels, cardiac output, renal function, and more. 
The data completed in red font represents those patients and bladder scan volumes that were 
considered unsuitable for proceeding to immediate planning CT.  The probability of having a BSV that 
was compatible with proceeding directly to planning CT was only 44% if the patients had a BS taken 
<40 minutes post-voiding (4 instances out of 9).  In contrast, the probability of having a BSV 
compatible with proceeding directly to CT was 86% if a BS was performed at ≥ 40 minutes post-
Patient 
Fluids 
consumed 
(mls) 
Interval void to 
BS (mins) 
Mean BSV (mls) 
(SD) 
Bladder urine 
volume (as % of 
fluids consumed) 
Bladder volume 
judged suitable 
for CT scan 
1 400 15 207 (21) 52 No 
  40 334 (12) 84 Yes 
2 400 25 312 (10) 78 No 
  50 539 (11) 135 Yes 
3 500 25 19 (1) 4  No 
  50 159 (3) 32 No 
  68 237 (27) 47 Yes 
4 400 30 177 (6) 93 Yes 
5 600 30 493 (48) 82 Yes 
6 400 30 103 (5) 26  No 
  43 294 (11) 74 Yes 
7 400 30 228 (11) 57 Yes 
8 500 35 307 (21) 77 No 
  40 514 (49) 103 Yes 
9 500 35 681 (29) 136 Yes 
10 400 45 189 (21) 47 Yes 
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voiding.  The conclusion was therefore to wait a minimum of 40 minutes post-drinking before 
checking bladder volume with the bladder scanner. 
The above data was evaluated to decide upon an appropriate bladder threshold at ultrasound 
scanning, to proceed to planning CT.  The mean BSV of those that proceeded directly to CT was 369 
mls.  In contrast, the mean BSV of those that required extra time and/or water before proceeding to 
CT was 185mls, although a BSV of 177 was considered reasonable to proceed to CT in patient 4.  A 
minimum of 160mls appeared to be required to proceed to CT.  
In determining “bladder threshold” guidance, the pragmatic data observed above is not the only 
consideration.  Reproducibility is also important, i.e. will the patient be able to maintain the optimum 
(planning CT) bladder volumes at treatment.  Bladder dosimetry is also important. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
180 
 
4.4.6 Radiotherapy (RT) patients: Treatment: Pilot group 
Considering the above group of 10 patients it seemed that 250mls was generally considered 
sufficient for proceeding to scanning, only twice was a bladder volume >250mls rejected for 
proceeding directly to planning CT.   
The author wished to consider the reproducibility of volumes <250mls and >250mls. 
Graph 4.1: Reproducibility of planning CT urine volumes of <250mls 
BSV = Bladder Scan Volume 
 
Graph 4.1 displays the on-treatment data for 3 prostate cancer patients with a planning CT volume 
<250mls which were treated before definitive bladder filling guidelines were refined.  0% difference 
between CT and Treatment BSV represents a perfect match between CT and on-treatment bladder 
filling.  A recognised side-effect of radiotherapy to the prostate is urinary frequency, patients feel the 
need to empty their bladder more frequently, typically after 2 weeks of treatment.  Therefore it 
might be expected that patients would find it harder to tolerate/achieve a fuller bladder towards the 
end of treatment. 
Patient 2 however, achieved bladder volumes at treatment which were at least as full as at planning 
CT (237mls) throughout the whole course of treatment.   
Patient 1, whose “baseline” planning CT urine volume was 223mls, achieved a bladder volume at 
least as full as at planning CT for 10 fractions in the first half of the treatment course, and for 7 
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fractions in the final half of their treatment course.  So there may be a slight suggestion of bladder 
irritability in the final half of the treatment course.  Overall the patient shows less variability from 
planning CT in the final half of treatment however, which may suggest that the patient has learned 
how to match his bladder volume to the planning CT volume. 
Patient 3 had a “baseline” bladder volume at planning CT of 192mls.  They were able to achieve at 
least this volume in 6 fractions of radiotherapy in the first half of treatment, and in 7 fractions in the 
second half of treatment.  This suggests that bladder irritability as a side-effect of treatment is not 
having a significant impact on the consistency of bladder filling on-treatment in this patient. 
Graph 4.2 shows the reproducibility of a comparator group of 5 patients with prostate cancer with a 
planning CT bladder volume of >250mls. 
Graph 4.2: Reproducibility of planning CT urine volumes of >250mls 
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As can be seen from Graph 4.2, 4/5 patients studied (80%) achieved a bladder volume of baseline 
(i.e. planning CT volume) or greater in <20% of fractions.  This group of patients therefore find it hard 
to achieve or tolerate bladder volumes of 250mls at treatment. 
  
4.4.7 Radiotherapy (RT) patients: Treatment: Pilot group: Dosimetry analysis 
A small sub-set of 3 patients was analysed to assess bladder dosimetry according to on-treatment 
Cone-Beam CT analysis (CBCT), as compared to planned dosimetry.  This was related to degree of 
bladder filling. 
Table 4.7 shows the planned dosimetry and CBCT-based dosimetry for the bladder in 3 patients 
receiving 74Gy/37 fractions to the prostate.  Data for Patient 1 is shown in full, summary data is 
shown for patients 2 and 3. 
CBCT = Cone-Beam CT, the number refers to the fraction of treatment, i.e. CBCT13 was performed 
prior to the 13th treatment fraction.  
HSC = Harley Street Clinic 
QUANTEC = Quantitative Analyses of Normal Tissue Effects in the Clinic (41) 
Rx = Treatment 
V50 = % of Bladder receiving ≥ 50Gy  
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Table 4.7: Bladder dosimetry for patients receiving radical radiotherapy for prostate cancer 
Scan 
PTV 
Volume 
(cc) 
Bladder  
CT Vol (cc) 
V50 (%) 
HSC protocol 
V60 (%) 
HSC protocol 
V65 (%) 
QUANTEC 
V70 (%) 
QUANTEC 
Target  150-250 <50% <25% <50% <35% 
Pt 1 Plan 151 203 25.5 18.1 15.1 11.9 
Pt 1 CBCT1  182 27.8 20.6 17.9 15.2 
Pt 1 CBCT2  215 30.1 23.2 20.3 17.2 
Pt 1 CBCT3  473 16.5 12.8 11.3 9.7 
Pt 1 CBCT8  215 13.6 8.8 7.2 5.6 
Pt 1 CBCT13  137 21.3 12.5 9.3 6.4 
Pt 1 CBCT17  216 20.1 13.7 11.3 9
Pt 1 CBCT22  298 28.3 22.8 20.6 18.1 
Pt 1 CBCT27  244 27.5 21.9 19.6 17.2 
Pt 1 CBCT32  249 26.6 20.9 18.6 16.1 
Pt 1 Mean On Rx  243.2 23.7 17.5 15.1 12.6 
Pt 1 SD  86.5 5.3 4.9 4.7 4.5 
Pt 2 Plan 94 172 16 11.9 9.8 7.5 
Pt 2 Mean On Rx 
(Range) 
 
239.7 
(167-347) 
11.7 
(10.2-16.8) 
7.7 
(8-14) 
5.9 
(6.5-12.6) 
4.1 
(4.7-10.7) 
Pt 2 SD  58.2 2.5 1.9 1.7 1.4 
Pt 3 Plan 111 177 13.5 9 7 4.7 
Pt 3 Mean On Rx 
(Range) 
 
184 
(130-279) 
11.7 
(5.6-13.9) 
7.7 
(3.6-10.4) 
5.9 
(2.7-8.7) 
4.1 
(1.7-6.9) 
Pt 3 SD  48 2.5 1.9 1.7 1.4 
 
The doses delivered to the bladder for the 3 patients displayed above are all within protocol limits.  
Exceeding the QUANTEC report limits would be associated with a risk of Grade 3+ urinary toxicity 
(CTCAE: Common Terminology Criteria Adverse Events v4.0).  A grade 3 toxicity for urinary 
obstruction would mean that an elective operation is required (the need for catheterisation is a 
grade 2 toxicity).  
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Considering patient 1 that has full data displayed.  This patient had the largest PTV of the patients in 
Table 4.7 (potentially making it harder for bladder dosimetry to be within standard dose constraints).  
The bladder volume at planning CT was 203cc, the range for bladder volume at CBCT on treatment 
was 137-473cc.  In fact, the bladder was only under-filled at CBCT, as compared to planning CT, for 
fractions 1 and 13 (137cc and 182cc).  An under-filled bladder on treatment could lead to the bladder 
doses being higher than planned, and indeed this was the case for the 1st fraction.  However, this was 
not the case for fraction 13, all dose levels assessed were more favourable on treatment than on the 
planning CT for fraction 13.   
The bladder was more generously filled at treatment than planning CT for 7/9 fractions (78%) for 
patient 1.  This might have been expected to be associated with more favourable dosimetry.  In fact, 
doses at treatment were higher than planning for 5/9 fractions (56%).   
Patient 1 had an identical CBCT bladder volume on fractions 2 and 8 (215cc).  Therefore, the 
dosimetry may have been expected to be very similar for these fractions.  However, Table 4.7 shows 
that the dosimetry is markedly different. 
The mean dosimetric parameters from the treatment CBCTs for patient 1 were more favourable than 
on the planning CT for all parameters except V70 (which was only marginally increased on 
treatment).  This was a reassuring outcome. 
Patient 2 had a smaller PTV (94cc), and a mean bladder volume on treatment (239.7cc) which was 
greater than at planning CT (172cc).  In fact only one CBCT had a bladder volume less than the 
planning CT volume.  In keeping with this, the mean treatment bladder dosimetry was more 
favourable than the planned dosimetry. 
Patient 3 had a PTV of 111cc, and a mean bladder volume on treatment (184cc) which was greater 
than at planning CT (177cc).  In keeping with this, the mean treatment bladder dosimetry was more 
favourable than the planned dosimetry. 
Although the full data is not displayed in Table 4.7, both patients 2 and 3 had all dosimetric 
parameters lying well within protocol constraints for each CBCT assessed. 
Comparing the 3 patients, patient 1 had the most generously filled bladder at planning, therefore 
potentially this would be associated with the lowest bladder doses. In fact, this patient had the 
highest doses delivered to bladder, which is likely to be due to the dominant factor that patient 1 had 
the largest PTV (151cc vs 94/111cc). 
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In summary, these 3 patients had bladder volumes at planning CT of <250cc.  Each of the 3 patients 
studied had a mean bladder volume on treatment which was greater than the planning CT volume.  
The mean bladder dosimetry was improved on treatment compared to the planned bladder 
dosimetry for all patients and dosimetric parameters, except for V70 for patient 1.  Although, this 
suggests the expected relationship between bladder filling and dosimetry (greater bladder filling 
leads to more favourable bladder dosimetry), this relationship is not clear cut.  The wide variation in 
dosimetry noted for patient 1 on two CBCTs with identically filled bladders (fill volume 215cc), shows 
that other factors could be at play.  This will be discussed further in Section 4.5.7. 
In these patients with bladder volumes at planning of <250mls, all planned and treatment bladder 
dosimetry was well within treatment protocol. This supports an optimum bladder CT threshold of 
<250mls. 
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4.5 DISCUSSION 
The prostate gland is susceptible to inter- and intra-fractional motion as described due to its 
anatomical location at the base of the bladder, and anterior to the rectum (6).  Bladder filling is, 
therefore, a critical factor for radiotherapy teams to consider when treating all patients with prostate 
cancer, to ensure no target miss. 
Equally, bladder filling can affect bladder dosimetry.  The bladder is a hollow organ and can vary in 
both volume and position according to differences in filling, this presents a special problem with 
regards to relying on DVH data.  However, the influence of irradiated bladder volume on acute and 
late urinary toxicity is well recognised (18). 
Given the universal importance of optimum bladder filling on the delivery of safe and therapeutic 
external beam radiotherapy for prostate cancer, it is surprising that there is very little published 
literature on optimum bladder filling (25, 42).  It is a topic that would value from further research. 
 
4.5.1 CK Planning 
 
Bladder filling instructions for prostate cancer patients undergoing CK treatment varies widely.  Some 
centres advocate planning and treatment with an empty bladder for patient comfort and 
reproducibility (43).  Other centres and trial protocols recommend voiding 30 minutes-1 hour prior to 
planning/treatment and drinking 200-250mls of fluid (23, 44).  The optimum bladder volume in 
centres that advocate treating with a “partially full” bladder are not specified.  Optimum bladder 
volume, together with strategies to achieve the optimum bladder volume consistently, were 
assessed here. 
Table 4.1 shows that nearly all patients could tolerate a bladder volume of 180mls.  The only patient 
that felt full at a lower bladder volume tolerated 150mls.  It is worth noting that this was a subjective 
assessment, and it is also possible that filling a bladder per catheter, and with a bolus amount of 150-
180mls, is more likely to make a patient feel uncomfortable than a gradual filling to the same level 
due to drinking. 
As the simulation technique employed here introduced a known quantity of fluid into the bladder, it 
provides a useful guide as to the likely accuracy of the ultrasound bladder scanner.  Comparing the 
volumes of fluid instilled, to the mean measured bladder scanner readings, the bladder scan volumes 
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were greater than the instilled volume (as would be expected due to bladder filling in the interval 
since patient voiding) for 89% of patients.   
The reduced scanner reading in the remaining patient is likely to be due to the margin of error in 
bladder scanner readings.  The manufacturer of the bladder scanner reports that the machine can 
measure bladder volume to within 15-20% accuracy (45).  Patient 7 in Table 1 had 150mls instilled to 
the bladder, with a mean ultrasound reading of 120mls, which was 20% less than the volume 
instilled.  This is therefore within the quoted range of error of the manufacturers. 
Considering the 8 patients that had 180mls of water instilled into their bladder, the mean bladder 
scanner urine volume (prior to CT scanning) was 247mls.  The range of urine volumes was wide (182-
331mls), despite the fairly consistent time interval between void and first bladder scan reading of 
23mins (range 21-31).  Hynds et al (46) measured pre-treatment bladder inflow rate in patients 
undergoing simulation for prostate cancer radiotherapy.  They calculated the rate to be 4.6mls/min 
(+/- 2.9mls/min).  If the 8 patients studied here filled at the same rate for the average interval of 
23mins between void and ultrasound scan, there would be an expected volume in the bladder of 
286mls (180mls instilled + 106mls of filling), which is well within the range of measured urine 
volumes reported.  Of note, the patients in the Hynds study were drinking a specified volume of 
fluids (500mls) prior to simulation, whereas the 8 patients studied by the author drank variable 
volumes of fluids on the day of CT (200-950mls) at varying intervals before bladder scanning. 
Intra-patient bladder scanner readings taken prior to CT scanning were largely consistent (SD = 1-
19mls) which gives some confidence to the accuracy of bladder scanner readings.  Review of the 
methodology of other groups reporting on use of the bladder scanner suggests that single readings 
only were taken (46) .  This may therefore be the first study to report on the reliability of the bladder 
scanner readings (although the other groups did compare bladder ultrasound volumes with CT 
volumes it is known that volumes assessed by differing imaging modalities can vary) (47). 
The mean Planning CT urine volume for the 9 patients studied (222cc) was consistent with mean 
bladder scanner volume prior to CT scan (232mls), a variation of only 4%.  However, there was wide 
variability noted in CT vs bladder scanner volumes for certain individual patients (-31 to +48%).  
Although 4 patients (44%) had measured bladder volumes which were more consistent and varied by 
<15% between the 2 modalities.  The greatest disparity between volumes (48% difference) measured 
by different imaging modalities occurred in patient 2, who had the largest bladder volume assessed 
by CT. The bladder scanner may have underestimated urinary volume (equally CT may have over-
estimated urinary volume).  This greater variability observed at larger volumes confirms findings by 
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Hynds et al, who noted a statistically significant larger variability at larger bladder volumes (when 
assessing data by means of Spearman’s correlation coefficient) (46).  However, Hynds et al reported 
good correlation between CT scan bladder volumes, and bladder scanner readings for the 30 patients 
studied overall (Pearson correlation coefficient = 0.91, a value of 1 would indicate perfect 
correlation). 
Reviewing the methodology of the Hynds et al paper for assessing CT-measured bladder volumes, it 
is not clear that any adjustment in volume was made for the likely thickness of bladder wall.  In 
contrast, as described in Section 4.3.1, the CT-measured urinary volume was assessed in this study by 
assuming a bladder wall thickness (BWT) of 4mm, and subtracting “bladder wall” from “whole 
bladder” to derive urine volume.  A mean BWT of 3.67mm was found in men with obstructive urinary 
symptoms and benign prostatic hypertrophy by Hakenberg et al (37).  When it comes to assessing 
DVH data, it is more conservative (safer) to assume a thicker bladder wall hence selecting a BWT of 
4mm for calculations in this study.  However, this may over-estimate bladder thickness, as other 
studies report BWT of closer to 2mm, although this thickness was in healthy Korean adults (38). It is 
also important to note that bladder filling in itself can affect BWT, therefore BWT could be variable 
within the same patient.  Morgan considers a BWT of <5mm normal if the bladder is empty, and 
states <3mm would be a “normal” bladder wall thickness if the bladder was distended (39). The 
patients studied here would be expected to have bladder outlet obstruction due to prostate cancer, 
often co-existing with Benign Prostatic Hypertrophy (BPH).   
Calculating CT-assessed urine volume applying BWT of 4mm vs ~2mm has a significant effect on the 
volume calculations.  Taking patient 4 as an example, the plan CT urine volume based on BWT of 
4mm was 211cc vs urine volume of 242cc for BWT 2.6mm.  Whole bladder for patient 4 was 293cc, 
which is similar to the mean bladder scanner reading of 306mls. 
Considering post-CT bladder scanner volumes and the consistency with CT-assessed volumes, the 
average change in volume between planning CT and post-CT bladder scan volume was +12% (range -
2 to +35%).  This compared to the average change between pre-CT bladder scan volume and planning 
CT of -4% (range -31 to +48%).  The moderate increase in mean difference between CT volume and 
the post-CT bladder scanner readings (as compared to pre-CT bladder scanner readings) may be due 
to the mean interval between CT and post-CT bladder scanner readings of 10 minutes (compared to 
an interval of 3 minutes between pre-CT bladder scanning and CT). 
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Intra-patient post-CT bladder scanner readings were largely consistent, except for patient 2 who had 
a SD of 84mls.  This patient had the largest urinary volumes recorded, and may again be a suggestion 
that bladder scanner readings might be less reliable at larger volumes. 
In summary, this appears to be the first study of the role of ultrasound volumetric imaging of the 
bladder in assessing bladder filling at simulation for hypofractionated SBRT of primary prostate 
cancer.  It will be important to analyse dosimetric as well as on-treatment data for these patients, 
but the data reviewed above demonstrates that all patients could tolerate a minimum of 150mls at 
simulation.  The bladder scanner was found to be reliable (intra-patient SD<19mls) at smaller bladder 
volumes (mean volumes <331mls), but may be less reliable at larger volumes (mean volume of 
375mls, SD=84mls).  This is the first radiotherapy study to assess the reliability of the bladder scanner 
by taking 3 consecutive bladder scanner readings, therefore these results are important.  Despite the 
short interval between voiding and pre-CT bladder scanning (mean interval 23 mins), and the short 
interval between voiding and CT scan (27-35mins), there can be significant extra filling of the bladder, 
which supports not instilling more water than 180mls.  
 
4.5.2 CK Dosimetry 
 
Table 4.2 shows that in 8/9 of patients studied (89%) bladder wall dosimetry was within protocol 
constraints, and there was no compromise of PTV coverage.  In the remaining patient the 15cc 
threshold dose was exceeded (marginally), and there was compromise of PTV coverage.  Bladder wall 
was the dose-limiting OAR for this patient, rectal doses were well within constraint.  As described in 
section 4.4.2, the breach of bladder wall dosimetry, and the compromise on PTV coverage, was most 
likely related to the large PTV size in this patient (121cc), rather than sub-optimal bladder filling. 
There are no reports in the literature relating bladder wall dosimetry to bladder filling at planning CT 
for hypofractionated prostate treatments. 
However, the literature does report on prostate volume limits for SBRT to the prostate.  The PACE 
study is an International study of the efficacy of SBRT for prostate cancer, compared to surgery and 
conventionally-fractionated radiotherapy (23).  The eligibility criteria requires a patient to have a 
prostate volume (not PTV) of ≤ 90 cc.  Patient 8 had a prostate volume that would have been eligible 
(71cc) but the PTV coverage of 89.4% was not ideal and would have represented a protocol 
deviation.   
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Janowski et al reported on outcomes for patients treated with SBRT with prostate volumes ≥ 50 cc 
(48).  Median prostate size was 62.9 cc (range 50 -138.7 cc).  They reported a clinically acceptable 
Grade 3 + urinary toxicity rate of 3.5%, although nearly half of patients experienced Grade 2 urinary 
toxicity.  The toxicity peaked at 1 month and 9 months post-treatment.  The authors aimed for PTV 
coverage of 95%, but they did not comment on the frequency of exceeding bladder constraints, or 
compromising on PTV coverage. 
It was noted in the patients studied here, that all with a PTV of ≤ 100 cc had target and bladder wall 
dosimetry within constraints.  Patient 4 had a PTV of just under 100 cc, and had a prostate volume of 
58 cc.  Therefore a patient accepted for CK treatment with a prostate volume of ≤ 58 cc, and bladder 
filling on planning CT of minimum 144 mls (or pre-CT bladder scan volume of minimum 120mls) is 
likely to achieve a therapeutic (good PTV coverage) and safe (with respect to bladder wall dose) CK 
treatment plan. 
 
4.5.3 CK Treatment: Bladder filling 
 
There are no reports in the literature relating bladder wall dosimetry to bladder filling at planning CT 
for SBRT prostate treatments. 
Section 4.4.3 describes the bladder filling achieved on-treatment in 6 patients undergoing CK for 
primary prostate cancer.  The aim was to match the mid-CK urine volume with the planning CT urine 
volume.  Standard bladder filling instructions were given to patients for their 1st day of treatment, 
thereafter the bladder filling instructions were individualised where possible to improve 
reproducibility of bladder volume (between planning and treatment). 
In practice, whilst this was a small sample of patients, and therefore the author was still gaining in 
experience in individualising drinking instructions, it proved challenging to improve bladder filling 
reproducibility.  Individualised instructions led to optimised bladder filling in patients 1 and 6 (33% of 
the group).  However, others did not benefit from individualising instructions, or could not be fully 
assessed. 
One factor that led to the difficulty in suggesting an ideal quantity of fluids for the patients to drink 
pre-CK was the widely variable time for treatment delivery.  Treatment delivery times were the most 
consistent for patient 1, variation of only 10% of treatment time.  In the remaining patients 
treatment delivery times varied by between 29% and 70% of the minimum treatment time.  The 
reasons for prolongation in treatment delivery time were variable, and challenging to manage.  Some 
191 
 
of the reasons were: varying lengths of time to achieve ideal patient set-up, flatus (causing the 
prostate to move out of position temporarily), and rotational changes in either prostate or patient 
position which required couch adjustments.   
It is also possible that more consideration should have been given to a patient’s general hydration 
level.  It may have been sensible to suggest that a patient drinks a given (fixed) quantity of fluids for 
each treatment day. 
Finally, patient compliance with voiding instructions could have been improved. 
A consequence of bladder scanning pre- and post- each fraction of CK was that obstructive symptoms 
and signs were addressed at an early stage.  Half the group had obstructive symptoms accompanied 
by an increase in post-voiding residual volumes (arising on Days 3-5 of treatment), and were 
prescribed alpha-blockade.  Longer term follow-up of these patients is not yet available.  In the 
publication by Janowski et al on prostate cancer patients receiving SBRT, 37% of patients were on 
alpha-blockade at the start of treatment, rising to 67% at 1 month post the start of treatment (48).  
The article does not report the time-point at which additional alpha-blockade was started.  
In summary, optimising the reproducibility of bladder filling by individualising drinking instructions 
was challenging and unsuccessful in the majority of cases.  The reasons for the difficulty include 
variable set-up/treatment delivery times, and patient compliance.  Both of these factors are difficult 
to correct.  A further factor could be a variation in general hydration levels each day of CK treatment, 
and this could potentially be addressed by additional drinking instructions.   
Alpha-blockade was prescribed in 50% of patients, based on reported patient symptoms, and 
increases in post-voiding residual volumes. 
 
4.5.4 CK Treatment: Rotational tracking  
 
The author wished to consider the relationship between optimum bladder filling and the ability to 
track rotations of the tumour target for the CK treatment of prostate cancer following a chance 
observation. Attendance at the CK control room during a prostate treatment was required for a 
separate reason.  It was noted that rotations needed to be switched off for the final part of the 
treatment fraction due to a pitch rotation greater than what could be adapted for.  The same patient 
was extremely full at the end of treatment. 
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As explained, tracking accuracy is improved by tracking rotations (36), therefore if optimising bladder 
filling resulted in increased ability to track rotations, this could potentially improve the outcome of 
CK treatment for primary prostate cancer. 
There are no reports in the literature relating bladder filling reproducibility to ability to track 
rotations for the CK treatment of prostate cancer. 
Section 4.4.4 reports the results of 7 patients studied to assess the relationship between bladder 
filling and rotational tracking.  86% of patients (6/7) received CK treatment with rotational tracking 
employed for all treatment fractions.  The remaining patient would have had rotational tracking 
employed for all treatment fractions if treatment had been planned with a prostate (rather than 
“body”) treatment path/rotational adjustment capability. 
Couch adjustments most frequently needed to be made to adjust for rotations in the final quartile of 
treatment fractions (for 86% of fractions), but there was no clear association with bladder filling as 
described.  Patient movement could also be expected to be more likely (due to discomfort) in the 
final quartile of a treatment fraction.  Couch adjustments were not the most important factor in 
prolonging treatment times.  Patient set-up times, flatus, and other issues e.g. need to void, were 
more significant. 
In conclusion, there was no relationship between the consistency of bladder filling (between planning 
and treatment), and the ability to track rotations of the tumour target for the CK treatment of 
primary prostate cancer. 
4.5.5 Radiotherapy (RT) patients: Planning: pilot group 
 
It is widely accepted that conventionally-fractionated radiotherapy for prostate cancer should be 
delivered with a “comfortably full” bladder.  The aim of bladder filling is to minimise dose to bowel 
and bladder wall.  Ideally bladder filling would be consistent between planning CT and each 
treatment fraction. 
Bladder filling guidelines vary widely however.  Centres/Trials advise patients to void 30-60 minutes 
prior to planning CT and then drink 300-500 mls of fluids (23, 46).  These publications do not state an 
optimum bladder volume however.  It is also unclear if the quantity of fluids/time interval between 
voiding and CT recommended, is evidence-based.   
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Haworth et al reported on the use of an ultrasound bladder scanner to aim to improve radiotherapy 
treatment delivery for patients receiving treatment to the prostate bed (49).  The authors accepted a 
minimum pre-CT bladder scanner volume of 80 mls and a maximum volume of 350 mls. 
Optimum bladder volume and drinking instructions were investigated further here.  A pilot group of 
10 patients undergoing conventionally-fractionated radiotherapy for prostate cancer were assessed.  
The results of the assessments were shown in Table 4.6. 
Patients drank between 400 and 600 mls of fluids, a majority consumed 400 – 500 mls.   
The patients had ultrasound bladder scanner volumes measured (to assess if bladder volume was 
appropriate for CT) between 15 and 68 minutes post-voiding.  5/10 patients (50%) needed to have 
their bladders scanned with the ultrasound device 2-3 times before proceeding to CT due to under-
filling of the bladder.  A clear threshold for bladder filling had not been set at this time point. 
The probability of having a Bladder Scanner Volume (BSV) compatible with proceeding to immediate 
CT was only 44% if the BSV was taken <40 minutes post-voiding.  In contrast, 86% of patients could 
proceed to immediate CT if the BSV was assessed at ≥ 40 minutes post-voiding. 
This result conformed to the “bladder filling working party” that a BSV should be assessed 40 minutes 
post-voiding, and prior to Planning CT. 
A minimum of 160 mls appeared to be required to proceed to CT.  No patient was asked to void and 
recommence drinking instructions due to an over-filled bladder.   
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4.5.6 Radiotherapy (RT) patients: Treatment: pilot group 
 
When considering optimum bladder filling instructions/bladder volume for prostate radiotherapy, 
the pragmatic data discussed in Section 4.5.5 is not the only consideration.  Reproducibility, for each 
fraction of a patient’s treatment, and dosimetry, are also important. 
It has been described previously that for dosimetric reasons it is advantageous to fill the bladder (to 
move bowels and bladder away from the high-dose region), see Figure 4.2 in the Introduction.  
However, there is a risk that if a patient has a bladder which is “too full” at planning CT, the level of 
filling is difficult to reproduce consistently on treatment.  This can be particularly challenging towards 
the end of a course of radiotherapy (due to bladder irritability) (18, 25). 
There is little guidance on an “ideal” standard for bladder filling in the literature however.  Haworth 
et al state that from previous unpublished work they found that >350mls is not reproducible on 
treatment (49). For practical reasons (to make bladder filling achievable) they recommended a 
tolerance range of 150mls in total, therefore, e.g. if planning CT for a patient had a bladder volume of 
300mls, the tolerance range for them on treatment would be 200mls – 350mls. 
Consistent bladder filling is challenging as previously described.  Hynds et al, who assessed patients 
undergoing prostate radiotherapy with an ultrasound bladder scanner, concluded “in this cohort, 
bladder-filling instructions failed to provide a consistent and reproducible bladder filling from CT 
planning to treatment”.  The ideal bladder volume at planning CT was not stated, but the average 
volume at planning CT was 291mls (range 87-579mls).  The average bladder volume fell during 
treatment, with a mean of all treatments of 189mls, and a mean bladder volume on the final day of 
treatment of 165mls.  This suggests that the issue for poor reproducibility is under-filling of the 
bladder on treatment compared to planning CT volumes. 
The author wished to consider reproducibility of bladder volumes comparing <250mls and >250mls.  
This was a somewhat arbitrary cut-point, although it was shaped by the experience of Haworth and 
Hynds et al (46, 49).  350mls or greater (from planning CT) was too large a volume to be reproduced 
according to the work by Haworth et al.  Given the difficulties with reproducibility experienced by 
Hynds et al with a mean planning CT bladder volume of 291mls, a volume just less than this was 
selected. 
The on-treatment bladder volumes for 3 patients with a planning CT volume of <250mls were 
displayed in Graph 4.1.  The graph shows that under-filling of the bladder on-treatment was never an 
issue for patient 2.  Patient 1 had greater reproducibility of CT bladder volume in the second half of 
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his treatment course, and patient 3 was able to achieve the planning CT volume or greater at least as 
often in the second half of his treatment course (compared to the first half of treatment).  In this 
small sub-set of patients therefore, under-filling of the bladder on-treatment is not a significant issue. 
The on-treatment bladder volumes for 5 patients with a planning CT volume of >250mls were 
displayed in Graph 4.2.  4/5 patients studied (80%) achieved a bladder volume of baseline (i.e. 
planning CT volume) or greater in <20% of fractions.  This group of patients therefore find it hard to 
achieve or tolerate bladder volumes of 250mls at treatment, and under-filling of the bladder on 
treatment is a significant issue. 
Concerns over reproducibility led the “bladder filling working party” to set 250mls as the upper 
threshold limit for optimum planning CT bladder volume.  150mls was set as a minimum theshold 
volume in order that bladder filling in the desired range was achievable.  It was hoped that a bladder 
volume of 150mls would be sufficient to provide dosimetric sparing of the bladder and bowels.   
 
4.5.6 Radiotherapy (RT) patients: Dosimetry 
 
The results for planned and delivered dosimetry for 3 patients that completed a course of radical 
radiotherapy to the prostate were displayed in Table 4.7, Section 4.4.7. 
Akin et al assessed bladder dosimetry in a group of 20 patients receiving radical radiotherapy in the 
post-prostatectomy setting (50).  Bladder was re-outlined on Cone-Beam CT (CBCT) scans and the 
doses recalculated analogous to the Methodology described in Section 4.3.6.  The group noted that 
most DVH parameters for bladder (V50, V60 and V65) were increased on treatment as compared to 
planning.  This was statistically significant.  The group applied tighter dose constraints than described 
in the QUANTEC report, but they were concerned to note that the V65 bladder limit was breached in 
10%, and the V40 bladder limit was breached in 20% of the patients studied.  The group concluded 
that the potential variability for bladder doses received on treatment supported an image guidance 
approach to treatment delivery. 
Haworth et al used an ultrasound bladder scanner to try to improve radiotherapy treatment delivery 
in the post-prostatectomy setting.  They assessed the relationship between change in bladder 
volume (between planning and treatment) and potential compromise of target coverage.  Their 
analysis showed that there was no statistically significant relationship between bladder volume 
change and target coverage (49). 
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Image guidance is certainly important in ensuring accurate treatment delivery, but consistent patient 
preparation is also important, as bladder filling can affect the relative geometry of 
prostate/bladder/rectum, which can in turn affect dosimetry.  Patient 1 in table 4.7 had variable 
bladder filling on treatment.  If the planning CT bladder volume is taken as the reference volume 
(203cc), the bladder volume on treatment varied by -33% to +133%. 
Despite this wide variation, bladder dosimetry was well within constraint limits on treatment which is 
reassuring.  Bladder dosimetry was also consistently within constraint limits for patients 2 and 3, 
despite variable bladder filling on treatment. 
As discussed in Section 4.4.7, patient 1 had an identical bladder volume at fraction 2 and 8.  
Intuitively, this might be expected to give near-identical dosimetry to the bladder, but in reality the 
dosimetry was very different.  The possible causes for the disparity in bladder dosimetry observed 
include changes in rectal filling, and random inter-fractional changes in the relative positions of 
prostate/bladder/rectum.  Haworth et al hypothesised that a possible reason for why they failed to 
demonstrate a relationship between change in bladder filling and target coverage, was the co-
dependence on rectal filling.  
Encouragingly, the 3 patients studied in Table 4.7 had more favourable bladder dosimetry on-
treatment (except for a marginal increase in the V70 for patient 1), than at planning.  However, there 
are some caveats to this observation.   
The 3 patients studied all had mean bladder volumes which were greater on-treatment than at 
planning.  This would be likely to make the bladder dosimetry more favourable.  It would, therefore, 
be interesting and informative to perform dosimetric analysis on patients whose mean bladder 
volumes are reduced on treatment compared to planning.   
It is also important, given the inter-relationship of prostate/bladder/rectum that bladder dosimetry is 
not considered in isolation.  It is important to assess target coverage and rectal dosimetry for the 
above patients.  It is important that the observed improvement in bladder dosimetry on-treatment is 
not at the expense of target coverage. 
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4.6 CONCLUSIONS 
In order for Radiotherapy to be delivered accurately, and for the tumour to be treated exactly as 
intended, it is critical that the set-up and conditions at the time of treatment delivery reproduce 
exactly the set-up/conditions of the Planning CT scan. 
Prostate is a difficult target for radiotherapy as it is susceptible to motion due to organ filling 
(bladder and bowel).   
The research undertaken in this Chapter was designed to develop bladder filling guidelines for 
Radiotherapy and CyberKnife patients based on optimal dosimetry and reproducibility.  In addition, 
the author wished to investigate the relationship between the consistency of bladder filling, and the 
ability to track rotations of the prostate for CyberKnife cases. 
Assessment Outcomes: 
1. Ultrasound bladder scanner reliability: 
This is believed to be the first radiotherapy study to assess the intra-patient reliability of the scanner 
by taking 3 consecutive readings. 
Bladder volumes <331mls: bladder scanner likely to be reliable (intra-patient SD = 1-19mls) 
Bladder volumes ≥375mls: bladder scanner may be less reliable (intra-patient SD = 84mls) 
 
2. CyberKnife: 
a) Planning:  
All patients could tolerate a minimum bladder volume of 150mls at planning CT. 
Despite the short interval between patient voiding and CT scan, there can be significant extra filling 
of the bladder, which supports not instilling more water into the bladder than 180mls. 
b) Dosimetry: 
All patients with PTV of ≤100cc (equating to prostate volume of ≤58cc) had bladder wall dosimetry 
within constraints, with therapeutic coverage of the PTV.  A “safe to bladder”, and therapeutic plan 
to a 100cc prostate PTV was produced for a patient with a bladder volume at CT of 144mls, therefore 
this would be a reasonable minimum volume at CT. 
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c) Treatment: Bladder filling: 
Optimising the reproducibility of bladder filling by individualising drinking instructions was 
challenging and unsuccessful in the majority of cases studied. 
Variable set-up/treatment delivery times contributed to the challenge. 
Where treatment times were extended beyond what was expected, patients experienced full 
bladders, and voiding mid-treatment was sometimes required. 
Pre-hydration could have been considered/addressed. 
Alpha-blockade was prescribed in 50% of patients, based on symptoms and increases in post-voiding 
residual volumes, frequently for fraction 4. 
d) Treatment: Rotational tracking: 
86% of patients received CK treatment with rotational tracking employed for all treatment fractions.  
The remaining patient would have had rotational tracking employed for all fractions if a prostate 
path/rotational adaptation capability had been selected. 
There was no relationship between the consistency of bladder filling, and the ability to track 
rotations of the prostate. 
e)   Protocol discussions: 
A consequence of focussing on the bladder filling aspects of the CK Prostate protocol through this 
research, was that wider discussions were had within the CK team, and with Clinical Oncologists.  The 
outcome of the discussions was that the team/Clinical Oncologists wished to move to a non-catheter 
planning technique for prostate targets.  
3. Radiotherapy: 
a) Planning: 
The probability of having a bladder scan volume compatible with proceeding immediately to planning 
CT was 86% if there was an interval since voiding of at least 40 minutes, but only 44% if the interval 
was <40 minutes.  40 minutes was therefore set as the recommended interval between voiding and 
CT scanning. 
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The volume of fluids drunk by patients in the pilot study was 400-500mls.  If a patient required extra 
time, due to under-filling of bladder, this had an impact on workflow in the radiotherapy 
department.  To minimise the risk of under-filling, 500mls was selected as the recommended volume 
of fluids to drink pre-CT. 
b) Treatment: 
Reproducibility of bladder volumes was improved on treatment for a subset of patients with planning 
CT bladder volumes of <250mls vs a comparator group with planning CT bladder volumes of >250mls. 
250mls was therefore set as the upper threshold limit for optimum planning CT bladder volume.  
In order that obtaining a bladder volume in the desired range was achievable, a lower threshold limit 
of 150mls was proposed.   
c) Dosimetry: 
Bladder wall dosimetry was well within constraints for all patients studied.   
These patients had bladder volumes at planning CT of 172-203mls, therefore well within the 
proposed ideal range for bladder volume at planning CT. 
 
Evidence-based bladder filling guidelines: 
A. CyberKnife: 
1. Pre-hydrate by drinking minimum of 1.5litres of water per day in the 2 days leading up to planning 
scan/treatment.  Continue to drink this volume whilst on treatment. 
2. Attend clinic 1 hour prior to planning CT/treatment for bowel preparation. 
3. Void, then drink 250mls of water, 40 minutes prior to CT scan. 
4. Ultrasound bladder scan x 3 prior to CT planning scan.  Aim is for bladder volume of 140-250mls.  
140mls-200mls is likely to be ideal to avoid over-full bladder on treatment. 
5. On Treatment: 
Pre-hydration/bowel prep as described above. 
Void immediately before CK treatment, then drink 250mls of water. 
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Ultrasound bladder scan x 3 pre- and post-treatment to individualise bladder filling instructions 
where appropriate. 
 
B. Radiotherapy: 
1. Pre-hydrate by drinking minimum of 1.5litres of water per day in the 2 days leading up to planning 
scan/treatment.  Continue to drink this volume whilst on treatment. 
2. Attend clinic 1 hour prior to planning CT/treatment for bowel preparation. 
3. Void, then drink 500mls of water, 40 minutes prior to CT scan. 
4. Ultrasound bladder scan x 3 prior to CT planning scan.  Aim is for bladder volume of 150-250mls at 
planning CT. 
5. On Treatment: 
Pre-hydration/bowel prep as described above. 
Void, then drink 500mls of water, 40 minutes prior to treatment. 
Ultrasound bladder scan x 3 pre-treatment. 
Individualise bladder filling instructions where appropriate. 
 
Further work: 
1. CyberKnife: 
Audit the feasibility/implementation of the new bladder filling guidelines, and the planned 
dosimetry. 
Adapt the drinking volume if necessary. 
A non-catheter approach means that the prostatic urethra cannot be easily visualised, record likely 
maximum doses to prostatic urethra (by considering homogeneity index), and compare to catheter-
based treatment plans. 
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2. Radiotherapy: 
Audit the feasibility/implementation of the new bladder filling guidelines, and the planned 
dosimetry. 
Analyse the dosimetry (through CBCT assessment) for a sub-set of patients whose mean bladder on-
treatment was under-filled compared to planning CT. 
Analyse the on-treatment dosimetry for prostate, rectum and bowel. 
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CHAPTER 5 
 
Planning margins for Prostate Cancer patients: an analysis 
 
5.1 INTRODUCTION 
The importance of “planning margins” has been explained in previous Chapters.  Planning margins 
need to take account of all uncertainties and errors during treatment planning and delivery (1).  The 
Planning Target Volume (PTV) is treated to a high dose to ensure that the CTV receives a therapeutic 
dose despite small geometric errors in treatment planning/delivery (2).   
“Systematic error” describes a deviation which occurs in the same direction and of a similar 
magnitude for each fraction through the treatment course.  “Random errors” occur at the treatment 
delivery stage, and are varying (both intra- and inter-fraction) and unpredictable. 
Sources of potential error between planned and executed radiotherapy delivery are discussed here.  
 
5.1.1 Planning: Delineation error: 
There are 3 components to delineation error.   
The first is that all imaging modalities have limited spatial resolution.  The magnitude of the 
resolution error is modality dependent, and varies according to the plane being considered (3, 4).  
Secondly, there can be intra-observer variation in outlining, as discussed in Chapter 3, where 
repeated delineations by the same observer yield different outlines (5, 6). Finally, inter-observer 
variability can be a factor which contributes to delineation uncertainty (5, 6). 
Delineation error is a purely systematic error, it influences all treatment fractions in an identical way 
throughout the treatment planning process. 
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5.1.2 Planning & Treatment Delivery errors: 
A) Organ motion: 
At the planning CT scan, the target organ position is captured at a snap-shot position.  All beams will 
subsequently be targeted at this arbitrary tumour position at planning CT.  If the target position at 
planning CT is not representative of the position across all treatment fractions, this introduces a 
systematic error. 
Organ motion also occurs within a treatment fraction (intra-fractional variation of target position).  
For the prostate, this occurs due to bladder filling and rectal motion due to flatus as discussed in 
Chapter 4 (7).  In general, errors introduced once during treatment preparation (i.e. at planning CT, a 
systematic error), are more significant than day-to-day variation during treatment delivery (random 
error) (2). 
B) Phantom transfer error: 
 
This is the error that accumulates when transferring image data from initial localisation through the 
treatment planning system to the CyberKnife treatment delivery system (8).   In order to regularly 
assess the magnitude of this error, an essential part of monthly quality assurance (QA) for CyberKnife 
is the film targeting test, or the “end-to-end” test.  The test involves planning treatment delivery to a 
target in a phantom, and evaluating the doses delivered (by reference to film within the phantom).  
This test assesses treatment planning, robot motion, image processing, and Linac delivery (9).  
 
Departmental QA shows the end-to-end error to be 0.42 mm (Range 0.26-0.66mm).  The phantom 
testing described in Chapter 2 incorporated testing of errors in image processing and robot 
movements, but not dose delivery.  The error from the testing described in Chapter 2 was 0.24mm. 
 
The phantom transfer error is a systematic error because it occurs in the same direction, with similar 
magnitude, for each fraction of the treatment course (8). 
 
C) Patient set-up error: 
This describes all causes of treatment set-up error (meaning a discrepancy between intended and 
actual treatment position) not accounted for by phantom transfer error.  The error comprises 
systematic and random components.  Possible causes include changes in a patient’s position, shape 
or size (8). 
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D) Fiducial tracking error: 
 
When a patient is to undergo CyberKnife treatment that will be tracked via fiducials, they are set up 
according to fiducial position.  
 
Initially, the patient lies down on the treatment couch, aided by the immobilisation specified by CT 
simulation.  The CK Radiographers then align the patient approximately, with the help of in-room 
lasers, to bring the fiducials close to the imaging centre of the room.  The first pair of live images is 
then taken, and adjustments to patient and couch position are applied until the fiducials are well 
visualised on the Live images, and the inter-fiducial distances are as established at planning CT (or 
very similar). 
Errors in fiducial position, such as those described in Chapter 3, can therefore contribute to patient 
set-up errors. 
 
Fiducials for prostate treatments are implanted directly into the prostate gland in all patients treated 
by CyberKnife.  If there were a shift in the position of any fiducial compared to its corresponding 
position at planning CT this would be a source of error. 
 
This error would be a systematic error if there were a change in position of a given fiducial between 
planning CT and the start of treatment, which was consistent for every treatment fraction.  Equally, 
the error could be random if the positional change of the fiducial varied from day-to-day and during a 
treatment fraction. 
 
5.2 AIMS 
1. To quantify errors and uncertainties in CK treatment planning and delivery for prostate patients. 
2. To calculate ideal planning margins for CK prostate patients. 
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5.3 MATERIALS AND METHODS 
5.3.1 Treatment planning and delivery: 
Comparison of inter-fiducial pair distances both inter-fractionally and intra-fractionally provided an 
assessment of fiducial instability as a potential source of error. 
Inter-fiducial pair distances were calculated manually from the fiducial positions on the Planning CT 
scan (as described in Chapter 2) for 8 patients undergoing CK treatment for organ-confined prostate 
cancer.  
CK Treatment delivery was observed in full for all 8 patients.  Patients were treated in 5 treatment 
fractions on consecutive days. 
Bladder preparation for the patients was described in Section 4.3.3. 
The CK Radiographers positioned each patient for treatment according to standard procedures. 
Immediately prior to delivery of the first treatment beam, the inter-fiducial marker distances (based 
on Live X-ray positions) were recorded. 
Just before the end of each treatment fraction, the CK Radiographers performed a “soft stop” of 
treatment delivery, and inter-fiducial marker distance was again recorded. 
During treatment delivery, translational and rotational corrections were recorded after each pair of 
live X-Rays were captured.  Rigid Body Error was also recorded at intervals. 
 
5.3.2 Statistical Analysis: 
A) Inter-fiducial distance: 
Planning CT, Pre-treatment and Post-treatment inter-fiducial distances were compared for each 
patient as a measure of the variability of fiducial position.  
Inter-fiducial distances were also compared according to treatment fraction (e.g. fraction 1 vs 
fraction 5).  The aim was to evaluate whether a change in target size/formation due to treatment 
effect has any impact on inter-fiducial distances.  
Changes in inter-fiducial distances were compared to recorded Rigid Body Error (RBE). 
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B) Translational corrections: 
For each patient, and each fraction, the mean translational corrections in Left/Right (lateral), 
Superior/Inferior (longitudinal), and Anterior/Posterior (vertical) directions were calculated. 
Individual patient errors: 
A Mean shift for lateral/longitudinal/vertical directions (considering all 5 treatment fractions) was 
recorded for each individual patient (mindiv) along with the respective Standard Deviations (σindiv). 
mindiv = The individual mean set-up error for each lateral/vertical/longitudinal directions.  
𝒎𝒊𝒏𝒅𝒊𝒗 =  
 𝑀𝑒𝑎𝑛 𝑆ℎ𝑖𝑓𝑡#1 + 𝑀𝑒𝑎𝑛 𝑠ℎ𝑖𝑓𝑡#2 + ⋯ . . + 𝑀𝑒𝑎𝑛 𝑠ℎ𝑖𝑓𝑡#𝑛
𝑛
 
Where # = treatment fraction, and n = number of treatment fractions. 
For this sample of patients, n=5. 
 
This is a systematic set-up error. 
σindiv = The inter-fractional daily set-up error (in each direction) . 
𝞼𝒊𝒏𝒅𝒊𝒗 = √
(𝑀𝑒𝑎𝑛 𝑆ℎ𝑖𝑓𝑡#1 − 𝒎𝐢𝐧𝐝𝐢𝐯)2 + … … . (𝑀𝑒𝑎𝑛 𝑠ℎ𝑖𝑓𝑡#𝑛 − 𝒎𝐢𝐧𝐝𝐢𝐯)2
n − 1
 
This is a random error.  
The denominator when calculating Standard Deviation above = number of fractions - 1. 
Population errors: 
This data was used to calculate Systematic and Random set-up errors for the population of prostate 
patients, which contribute to recommended planning margins.  Calculations were performed 
according to guidance in the Royal College of Radiologists “On Target” document (8). 
The overall population mean set-up error (Mpop) for the sample of 8 patients studied here, which 
should ideally be 0, is given by the following formula: 
𝑴𝒑𝒐𝒑 =  
 𝑚𝑖𝑛𝑑𝑖𝑣1 + 𝑚𝑖𝑛𝑑𝑖𝑣2 + 𝑚𝑖𝑛𝑑𝑖𝑣3 + 𝑚𝑖𝑛𝑑𝑖𝑣4 + 𝑚𝑖𝑛𝑑𝑖𝑣5 + 𝑚𝑖𝑛𝑑𝑖𝑣6 + 𝑚𝑖𝑛𝑑𝑖𝑣7 + 𝑚𝑖𝑛𝑑𝑖𝑣8
𝑛
 
 
Where n= number of patients. n = 8 for this sample of patients. 
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Mpop (population mean set-up error) is calculated for each lateral/ longitudinal/vertical directions. 
The systematic error for the population, ∑set up, is defined as the Standard Deviation of the individual 
mean set-up errors around the overall population mean, Mpop. This is calculated according to the 
following formula: 
∑𝒔𝒆𝒕 𝒖𝒑 = √
(𝑚𝑖𝑛𝑑𝑖𝑣1 − 𝐌𝐩𝐨𝐩)2 + (𝑚𝑖𝑛𝑑𝑖𝑣2 − 𝐌𝐩𝐨𝐩)2 + ⋯ (𝑚𝑖𝑛𝑑𝑖𝑣8 − 𝐌𝐩𝐨𝐩)2
n − 1
 
Where n= number of patients. n = 8 for this sample of patients. 
The population random error, 𝞼set up , is the mean of all the individual random errors (σ1 , σ2 , ….σ8 ) . 
𝞼𝒔𝒆𝒕 𝒖𝒑 =  
  σ1 + σ2 + σ3 … . . + σn
𝑛
 
C) Margin Calculations: 
As described previously, the Planning Target Volume (PTV) is treated to a high dose to ensure that 
the CTV receives a therapeutic dose despite small geometric errors in treatment planning/delivery 
(2).   
The population systematic error, ∑set up , was combined in quadrature with the other systematic 
errors previously described, to generate an overall systematic error, ∑. 
 
∑ = √(∑𝑑𝑒𝑙𝑖𝑛𝑒𝑎𝑡𝑖𝑜𝑛2 +  ∑𝑚𝑜𝑡𝑖𝑜𝑛2 + ∑𝑝ℎ𝑎𝑛𝑡𝑜𝑚 𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑟2 +  ∑𝑠𝑒𝑡 𝑢𝑝2) 
 
Planning margins also need to take account of random error. 𝞼𝒔𝒆𝒕 𝒖𝒑 , calculated as described 
above, was incorporated into the margin recipe. 
Several margin recipes have been published in the literature (10, 11), but the Van Herk formula was 
used here, as it is perhaps the most widely accepted (12) : 
Planning Margin (mm) = 2.5∑ + 0.7𝞼 
 
D) Inter-fiducial marker analysis 
Melanie Green, medical statistician performed statistical tests for trend. 
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5.4 RESULTS 
 
5.4.1 Inter-fiducial pair distance: Planning vs Treatment 
The results for inter-fiducial distances at planning (calculated from the fiducial positions on the 
planning CT scan), are displayed in Appendix 5.1.  
The results for inter-fiducial distance measurements pre- and post- each CK treatment fraction are 
shown in Appendix 5.2.   
Accuray recommend that fiducials are located >2cm apart, to ensure that the fiducial tracking system 
can appreciate fiducials as separate entities (13).  Mean inter-fiducial distance for the 7 patients 
displayed in Appendix 5.1 is 23.6mm, which is within guidance.  However, range = 16.3mm – 30mm.  
Only 3/21 fiducial pairs sited (14%) were spaced by <2cm (Patient 3: fid 1/2; Patient 5: fid 1/2, and 
Patient 6: fid 1/3). 
The exact arrangement and positions of the 3 intra-prostatic fiducials implanted for each patient can 
change due to inter-fractional motion.  Comparing the inter-fiducial pair distances at planning CT 
(from Appendix 5.1), with the pre-CK inter-fiducial pair distances at fraction 1, (from Appendix 5.2) 
there is reasonable stability.  All pre-CK fraction 1 inter-fiducial pair distances were within 3mm of 
the corresponding planning CT inter-fiducial pair distances.  The majority (76%) of pair distances 
were within 1mm of the corresponding planning CT inter-fiducial pair distances. 
 
5.4.2 Inter-fiducial pair distance: First fraction to Final fraction: Treatment analysis 
Appendix 5.3 shows the change in inter-fiducial pair distance between the first and final recorded 
fraction for each patient.  The table compares pre-CK inter-fiducial pair distances.  This is a further 
assessment of inter-fractional fiducial motion. 
The mean change in inter-fiducial pair distance (in mm) between the first and final fraction recorded 
was + 0.8mm (SD = 0.7). 5/7 patients studied (71%) and 17/21 inter-fiducial pair distance changes 
(81%) had increased spacing of fiducials in the final fraction, as compared to the first fraction.   
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Linear regression was used to explore any trend in inter-fiducial distance over the treatment period 
(fraction 1 to fraction 5) for the patient group. The dependent variable was fraction number, and the 
independent variable was the mean of pre- and post-treatment fiducial movement for D1, D2 or D2 
(where D1 = Fid1-Fid2 distance, D2=Fid1-Fid3 distance, and D3=Fid 2-Fid 3 distance). There was no 
evidence of any trend (see Table 5.1 below). 
 
Table 5.1: Test for trend: inter-fractional prostate fiducial motion: #1 vs #5 
Fiducials Coefficient (95% CI) p-value 
D1 0.019 (-0.126, 0.165) 0.788 
D2 0.006 (-0.125, 0.136) 0.928 
D3 0.034 (-0.148, 0.215) 0.708 
 
Although a group trend in inter-fraction motion was not found, there was evidence of some 
substantial inter-fraction motion during treatment for some patients. Inter-fiducial distance (D1 [F1-
F2], D2 [F1-F3] and D3 [F2 – F3]) was plotted for each patient (P1 = patient 1, P2= patient 2 etc) at 
planning (P) and for fractions #1 - #5 (Figure 5.1). Enlarged symbols signify a change in inter-fiducial 
distance from planning >1.5mm (patients 4, 5 and 7), indicating a clinically relevant inter-fraction 
displacement of fiducial COM of >2mm (14). 
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Figure 5.1: Inter-fractional change in marker pair distance: Planning vs #1 vs #5 
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5.4.3 Inter-fiducial pair distance: Pre-CK vs Post-CK: Treatment analysis 
A further assessment of any instability of fiducial arrangement for these prostate cases (and 
therefore a potential source of error) can be made by comparing inter-fiducial pair distances pre- and 
post- each CK treatment fraction using pair distances captured on the Live X-rays.  This is a measure 
of intra-fractional motion, although based on only 2 “snap-shots” of fiducial position per fraction 
(just prior to commencing a treatment fraction, and immediately prior to completing a treatment 
fraction). 
Appendix 5.3 shows the change in inter-fiducial pair distance (in mm) pre- and post- a CK fraction.  A 
negative distance signifies that the fiducials have been imaged closer together on the post-CK 
images, compared to the pre-CK images.  A positive distance change signifies that the fiducials have 
been imaged further apart.  The mean change in pre- to post-CK inter-fiducial pair distance was 
+0.3mm, indicating that there is relative intra-fraction stability of pair distances.  The range of 
measured changes in pair distances was -2.2mm to +3mm, however 81% of changes were sub-
millimetre. Differences between the means of each inter-fiducial distance (D1 [F1-F2], D2 [F1-F3] and 
D3 [F2 – F3]) pre- and post-treatment were tested using the paired t-test; results are shown in table 
5.2. No significant differences were observed in pre- and post-treatment D1 and D2, but there was 
borderline difference in D3 (p=0.059).  
 
Table 5.2: Test for trend: intra-fractional prostate fiducial motion 
Fiducials Mean (pre-treatment) Mean (post-treatment) Difference p-value 
D1 22.74 22.87 -0.12 0.441 
D2 23.69 23.78 -0.10 0.529 
D3 23.80 24.13 -0.33 0.059 
 
Where there was a large change in inter-fiducial distance observed (e.g. patient 3, #4/5 and patient 
4, #5, highlighted in Appendix 5.3) it would be expected that this would be reflected in the Rigid Body 
Error (RBE).  This is considered below. 
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5.4.4 Rigid Body Error (RBE): Treatment analysis 
Appendix 5.5 displays the Rigid Body Error (RBE) readings for the patients studied. 
As discussed in Chapter 2, the RBE refers to the discrepancy (in mm) in fiducial positions (relative to 
each other) between the CT planning scan and the time of treatment.  The method of manually 
calculating RBE from inter-fiducial distance changes is demonstrated in Chapter 2 Section 2.4.3. 
For tracking with multiple fiducials, the upper limit of RBE is often set at 2mm.  It is possible to 
increase the acceptable RBE to allow treatment delivery if the RBE>2, but increasing the RBE 
threshold is considered carefully by CK radiographers, and Physics will be consulted.  The greater the 
RBE, the greater the discrepancy between planning CT positions of fiducials and those at treatment, 
and in turn, the greater the risk of inaccuracies with treatment delivery.  
Appendix 5.5 shows that only 2 fractions out of the 27 fractions reported (7%) were associated with a 
Mean RBE>2mm threshold (Patient 4: #5 and Patient 7: #4).  However, Maximum RBE was >2mm 
threshold in 6/27 fractions (22%), always occurring in the 3rd to 5th fraction of treatment. 
The highlighted data in Appendix 5.5, refers to those patients and fractions in Appendix 5.3 where 
there was a change of >2mm in on-treatment inter-fiducial pair distance.  Each patient/fraction 
highlighted had a maximum RBE>2mm.  For patient 4/#5, where 2 of the 3 inter-fiducial on-
treatment pair distances changed by >2mm, the Mean RBE of 2.5mm was the largest for all patients 
and fractions studied.  Patient 7/#4 in Appendix 5.5 had the 2nd largest Mean RBE (2.2mm), with only 
tiny changes in inter-fiducial pair distances shown in Appendix 5.3 (0-0.1mm).  However, the inter-
fiducial pair distance changes in Appendix 5.3 are based only on 2 snap-shots of fiducial positions 
(pre-CK and post-CK).   
 
5.4.5 Translational corrections analysis: 
Individual patient errors: 
mindiv = The individual mean set-up error for each lateral/ longitudinal/vertical directions, along with 
the respective Standard Deviations (σindiv), were calculated as per description in Section 5.3.2B. 
These values, for 8 CK prostate patients, are displayed in Table 5.1. 
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Table 5.1: Individual patient errors for CK prostate patients 
Patient 
Number of 
fractions 
(n) 
Lateral  
(Left/Right) (mm) 
Longitudinal  
(Sup/Inf) (mm) 
Vertical  
(Ant/Post) (mm) 
mindiv σindiv mindiv σindiv mindiv σindiv 
1 5 -0.2 0.5 -1.9 1 1.8 0.7 
2 5 -0.1 0.6 -0.1 0.6 1 0.8 
3 5 0.6 0.6 0 0.3 1.2 0.4 
4 4 0.2 0.9 -1.7 1.3 2.2 1.1 
5 4 0.9 2.3 -1 2.2 1.7 1.2 
6 5 0.4 1.1 -1 1.4 1.9 0.8 
7 4 -1.3 3.8 -0.8 2 1.6 1.6 
8 4 0.8 1 -0.7 1.4 1 1.6 
Mean 5 0.2 1.4 -0.9 1.3 1.6 1 
 
mindiv = the systematic individual patient error, the range of mindiv  for the Lateral direction is   -1.3mm 
to +0.9mm, for the Longitudinal direction: -1.9mm to 0mm, and for the Vertical direction: +1 to 
+2.2mm. 
σindiv is the random individual patient error.  The ranges of σindiv for Lateral direction is: +0.5-3.8mm, for 
Longitudinal direction: +0.3-2.2mm, and for the Vertical direction: +0.4-1.6mm. 
Population patient errors: 
The overall population mean set-up error (Mpop) for the sample of 8 patients studied here, is the 
average of mindiv values displayed in Table 5.1.   
Mpop (population mean set-up error) for Lateral direction is +0.2mm, for Longitudinal direction -
0.9mm, and for the Vertical direction +1.6mm. 
The systematic error for the population, ∑set up, is defined as the Standard Deviation of the individual 
mean set-up errors around the overall population mean, Mpop. This was calculated according to the 
formula described in Section 5.3.2B. 
∑set up for the population is 0.7mm, 0.7mm and 0.4mm in Lateral, Longitudinal, and Vertical directions 
respectively. 
The population random error, 𝞼set up , is the mean of all the individual random errors.  Table 5.1 shows 
that 𝞼set up is 1.4mm, 1.3mm and 1mm in Lateral, Longitudinal, and Vertical directions respectively. 
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5.4.6 Margins calculations: 
The population systematic error, ∑set up , was combined in quadrature with the other systematic 
errors previously described, to generate an overall systematic error, ∑. 
∑ = √∑𝑠𝑒𝑡 𝑢𝑝2 + ∑𝑚𝑜𝑡𝑖𝑜𝑛2 +  ∑𝑑𝑒𝑙𝑖𝑛𝑒𝑎𝑡𝑖𝑜𝑛2 +  ∑𝑒𝑛𝑑 − 𝑡𝑜 − 𝑒𝑛𝑑2  
 ∑set up for the population, as calculated above according to the “On Target” (8) document, was 
0.7mm, 0.7mm and 0.4mm in Lateral, Longitudinal, and Vertical directions respectively.  However, at 
the start of a CK treatment fraction the CK radiographers will set the patient up carefully as described 
in Section 5.3.1.  They acquire a pair of Live images just before delivering the first beam, and the 
robot will adjust to correct for the translational and rotational changes (between DRR and Live 
images, based on fiducial position), before delivering the beam.  This is an example of on-line 
correction.  If the Live X-Rays acquired are an exact representation of fiducial position at the time of 
beam delivery, then the systematic set-up error is effectively 0mm (due to the on-line correction 
applied).  
For this population ∑set up = 0mm, justification as above. 
∑motion describes the motion error for the population of prostate patients studied.  The imaging 
frequency during a CK treatment fraction can be set by the CK radiographers, but for prostate 
patients the imaging frequency is often every 30 seconds at the start of treatment, moving to every 
60 seconds once the radiographers are reassured that the translational and rotational adjustments 
are fairly stable.  There is therefore the potential for residual motion of the prostate between a pair 
of acquired images and delivery of a treatment beam.  This is a potential source of error.  The 
calculations for “∑set up” described in Section 5.3.3 were based on translational adjustments applied by 
the CK robot in response to changes in fiducial position (on Live X-Rays compared to DRR) due to 
motion or deformation of the prostate.  The values calculated are therefore appropriate for ∑motion. 
For this population ∑motion = 0.7mm (lateral), 0.7mm (longitudinal) and 0.4mm (vertical). 
∑delineation would ideally have been evaluated on the sample of 8 patients reviewed here by assessing 
intra-observer and inter-observer variation in outlining.  However, a 2mm error is assumed as quoted 
in Nyholm et al (15).  ∑delineation = 2mm. 
∑end-to-end = 0.42 mm as assessed by the Departmental QA (“end-to-end testing”).  
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Therefore applying the above formula, ∑, the overall systematic error, is as follows: 
∑lateral = 2.2mm 
∑longitudinal = 2.2mm 
∑vertical = 2.1mm 
 
Planning margins also need to take account of random error.  
𝞼set up , calculated as described above, was incorporated into the margin recipe.  𝞼set up was 1.4mm, 
1.3mm and 1mm in Lateral, Longitudinal, and Vertical directions respectively. 
 
Van Herk Planning Margin (mm) = 2.5∑ + 0.7𝞼 
Margins for each direction are as follows: 
Lateral = 6.5mm 
Longitudinal = 6.4mm 
Vertical = 6mm  
219 
 
5.5 DISCUSSION 
Planning margins need to take account of all uncertainties and errors during treatment planning and 
delivery, in order to ensure that a therapeutic dose is delivered to the tumour target.  Potential 
sources of error have been described in Section 5.1.  The author has undertaken work to quantify 
errors and uncertainties in treatment planning and delivery for CK prostate patients. 
Once quantified, the errors and uncertainties have been incorporated into a margin recipe to 
generate “ideal” planning margins for CK prostate patients. 
As described in Chapter 3, stability and reproducibility of implanted fiducials is critical for accurate 
treatment delivery in any CK treatment tracked using fiducials.  Any discrepancy between fiducial 
location on the planning CT (an arbitrary snapshot of target/fiducial position) and treatment has the 
potential to lead to targeting error. 
 
5.5.1 Inter-fiducial pair distance: Planning vs Treatment : Inter-fractional variation 
Chapter 3 examined fiducial stability and reproducibility by comparing CT planning scan fiducial 
locations, to “first day of treatment” CT fiducial locations. 
A “first day CT” is not performed for CK Prostate patients.  This is considered acceptable as there 
have been no recorded cases of migration of fiducials outside of the prostate at this centre.  
However, as Chapter 3 illustrated, gross migration is not the only consideration.  Fiducial migration 
within the prostate, where the fiducial has migrated a few millimetres from the site of implantation, 
can also have a deleterious effect on tumour targeting.  
Inter-fiducial distance information is available from the CK console at the time of treatment.   This 
has been recorded and analysed by the author to assess the reproducibility of fiducial location in 
prostate patients.  
When comparing inter-fiducial distance at planning (from planning CT data) vs. inter-fiducial distance 
at treatment (from CK console data) as a measure of inter-fractional variation, the comparison was 
made with the first fraction of treatment, to eliminate treatment effect as a potential confounding 
factor.  The only exception to this was patient 7, where inter-fiducial distances were not available on 
fraction 1, inter-fiducial distances were taken from fraction 2 instead. 
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Van der Horst et al (16) analysed marker pair distance changes between planning CT scan and first 
day of treatment CT in pancreatic tumours.  The group found that 81% of marker pair distance 
changes were sub-millimetre.  
Inter-fractional changes in marker pair distance for the prostate patients studied here were within 
3mm for all patients, and 76% of inter-fractional marker pair distance changes were within 1mm. This 
is comparable to the results of the Van der Horst group.  
The lung, liver and pancreas patients that were studied for fiducial reproducibility in Chapter 3 were 
assessed by co-registering planning and Day 1 treatment CT scans by means of the implanted 
fiducials.  The CT scans were translated and rotated until an optimum match was achieved.  This was 
the technique used by the Van der Horst group.  This process might be expected to achieve a better 
match of fiducial position than the scenario faced by the CK radiographers at treatment, where a 
fiducial match can only be achieved by adjusting patient and couch position. 
Despite the caveat about the different methodology, it is interesting to compare the fiducial 
reproducibility results from the lung, liver and pancreas patients with the prostate group. 
Chapter 3 reported mean Centre of Mass (COM) of fiducials shift (between planning CT and Day 1 
Treatment CT) as a measure of fiducial reproducibility.  Taking COM as the measure of fiducial 
reproducibility (vs individual marker position) tends to minimise the magnitude of shift, due to the 
effect of individual marker shifts being averaged out (14, 16).  Considering cases of multiple 
implanted fiducials, Mean COM shift for lung was sub-millimetre (0.6mm, 0.9mm and 0.7mm in x/y/z 
axes respectively), Mean COM shift for liver was 0.6mm, 0.4mm and 1.2mm in x/y/z axes 
respectively, and Mean COM shift for pancreas was 1mm, 0.8mm and 0.4mm in x/y/z axes 
respectively. 
Therefore, despite the more challenging process required to achieve a fiducial match at treatment, it 
is encouraging that 76% of inter-fiducial marker pair distance changes (between planning and 
treatment) were within 1mm for prostate patients.  The prostate inter-fiducial pair distance stability 
results compare favourably with the COM shifts observed (between planning and treatment) for 
lung, liver and pancreas patients previously studied by the author. 
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5.5.2 Inter-fiducial pair distance: First vs Final treatment fraction: Inter-fractional variation 
Comparison of inter-fiducial pair distances between the first and final fraction recorded for each 
patient is a further measure of inter-fractional variation of fiducial position.  However, this time there 
is the potential for the analysis to incorporate the effect of treatment. 
Van der Horst et al (16) found that there was a mean change in pair distance of -0.03mm/day in 
pancreatic cancer patients tracked with implanted fiducials.  This amounted to a mean change of 
1.1mm over the course of treatment, with the markers moving closer together.  The authors 
concluded that this was due to tumour shrinkage.  This was however a different tumour type, and 
the patients were treated with conventional fractionation for 25 fractions. 
Prostate brachytherapy is an example of extreme hypofractionation (single fraction treatment).  A 
study of such patients by Cury et al (17) showed that 7 days after implantation, 68% of patients had 
an increase in volume of the prostate, associated with increased dimensions of the gland by 0.6mm, 
0.5mm and 0.2mm in Ant/Post, Lateral and Sup/Inf dimensions respectively. 
This is the first study to analyse change in inter-prostatic marker pair distance on treatment, treated 
with hypofractionated radiotherapy (35Gy/5#).  The mean change in inter-fiducial pair distance 
between the first and final recorded fraction was +0.8mm (SD=0.7mm).  71% of patients studied had 
increased spacing of fiducials in the final fraction, as compared to the first fraction.  The percentage 
of patients showing increased spacing of fiducials (which could be due to swelling of the prostate 
gland, or fiducial migration), is very similar to the results of Cury et al. 
It may be intuitive that those patients whose fiducials became more spaced (due to possible prostate 
swelling), might also develop early obstructive symptoms (poor stream, residual urine volume).  In 
fact, there was no correlation between increased fiducial spacing and obstructive symptoms.  It may 
be that prostatic urethra dose is more closely correlated with early urinary symptoms. 
 
5.5.3 Inter-fiducial pair distance: Pre- vs Post-CK Treatment: Intra-fractional variation 
The Calypso system lends itself to measurement of intra-fractional assessment of fiducial marker 
stability in the prostate.  Electro-magnetic transponders are implanted into the prostate to allow 
intra-fractional tracking of prostate motion.  Transponder position is continuously monitored by a 
magnetic array which is positioned over the patient’s pelvis. Tanyi et al (18) and Kupelian et al (19) 
assessed inter- and intra-fraction motion of the prostate assessed with Calypso.  However, the 
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Calypso system reports COM of transponder position (or transponder “centroid”), rather than inter-
fiducial pair distance. 
Inter-fiducial distance information is available from the CK console at the time of treatment as 
previously described.   This data was recorded immediately prior to delivery of the first treatment 
beam, and also just before completing treatment.  This is a measure of intra-fractional motion, 
although based on only 2 images per treatment fraction which is a limitation. 
The mean change in inter-fiducial pair distance was +0.3mm, and mean SD of pair distance was 
0.5mm, signifying relative intra-fraction stability of pair distances. 
In summary, analysis of inter- and intra- fractional variation of fiducial stability has shown that mean 
positional changes of fiducials are <1mm. 
 
5.5.4 Rigid Body Error (RBE): Treatment analysis 
The RBE refers to the discrepancy (in mm) in fiducial positions (relative to each other) between the 
CT planning scan and the time of treatment.  The larger the RBE, the greater the risk of inaccuracy in 
treatment delivery. 
As a Quality Assurance check, the CyberKnife tumour tracking system generates a warning if the 
distance between fiducial markers (reported as RBE) has deviated by >1.5mm from the reference 
configuration on the planning CT scan (9).  This also gives the opportunity to the CK radiographers to 
“switch off” a fiducial which has clearly migrated and is no longer a good surrogate for tumour 
position. 
Tumour localisation at treatment delivery of a CyberKnife plan is based on the COM of fiducials.  
Therefore, Van der Voort van Zyp et al (14) evaluated whether a clinically relevant displacement of > 
2mm in the fiducial COM was accompanied by a change in the distance between markers of >1.5mm 
(reported as RBE).  The group assessed 42 patients treated by CyberKnife for lung cancer.  Planning 
CT scans and On-treatment CT scans were co-registered by means of soft tissue matching on the lung 
tumour.  Fiducial stability (between planning and treatment) was analysed by displacement of 
fiducials, and displacement of fiducial COM. 
The group found that median individual fiducial displacement was 1.3mm, and median displacement 
in fiducial COM = 1mm.  Displacements in the fiducial COM of >2mm were detected by changes in 
inter-fiducial distance of >1.5mm (reported as RBE) in 96% of treatment fractions. 
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In comparison, considering the 7 prostate patients treated by CK, mean RBE was 1.1mm (see 
Appendix 5.5).  Maximum RBE was >1.5mm in 13/27 observed treatment fractions (48%).  Applying 
the findings of Van der Voort van Zyp, almost half of treatment fractions observed could have had a 
fiducial COM displacement of >2mm, for at least a portion of the delivered treatment fraction, this 
could be potentially significant. 
As described, implantation of 3 intra-prostatic fiducials is the current standard at the author’s centre.  
Implantation of a 4th fiducial per-patient would allow the possibility to “switch off” a fiducial at 
treatment delivery, if there had been apparent migration (compared to planning CT position), whilst 
still retaining the ability to track prostate rotations. 
It is important to note that there were some limitations to the RBE results recorded by the author.  
As described, the CK radiographers can decide the frequency of imaging during delivery of a CK 
fraction (usually every 30 – 60 seconds).  Therefore, the number of image pairs captured varied 
between fractions, and between patients.  It was sometimes challenging for the author to record (by 
hand and in real-time) full translational, rotational and RBE data in between image pairs.  Therefore, 
more RBE readings were available for some patients than others.  The mean number of RBE records 
per treatment fraction was 18 (range 5-29). 
Appendix 5.5 shows that 6/27 treatment fractions (22%) studied were associated with a Maximum 
RBE > 2mm. These large RBE values always occurred in the 3rd to 5th fraction of treatment.  The 
above-threshold RBE values in these instances reflect a moderate change in fiducial position between 
planning CT scan positions, and the positions on treatment.   
The observation that the larger RBE values tended to occur towards the end of a course of treatment 
fraction is interesting.  If the reason for this was inflammation, it might be expected that the starting 
RBE would increase with each fraction, but this was not borne out in the results.  It could be 
hypothesised that the effect of treatment on the prostate, makes the fiducials more prone to 
displacement (e.g. due to bladder/rectal filling) in the later, rather than the early, treatment 
fractions. 
Whilst the RBE is a QA check that can flag up potential issues with targeting, the critical factor in 
accurate treatment delivery is stability of the fiducial COM.  It would be possible for the 3 fiducials to 
migrate apart from each other (e.g. due to inflammation) whilst keeping an identical COM, this would 
increase RBE (flagging up a warning), but accuracy of treatment delivery would potentiallynot be 
affected (due to the identical COM), as long as the planning margins were sufficient. 
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5.5.5 Margins calculations: 
Assessment of inter-fiducial distance and RBE as described above has provided critical information on 
fiducial reproducibility for CK prostate cases.  However, other factors are of considerable importance 
when calculating optimum planning margins for the population of prostate patients treated by CK. 
It is important that each source of potential error is minimised where possible.  Equally, adequate 
planning margins must be applied which will allow for these errors, whilst ensuring that the target 
receives a therapeutic dose. 
5.5.5A: Phantom transfer error: 
Departmental QA has assessed this to be 0.42mm.  The error is related to the technical accuracy of 
the CyberKnife system.  The QA to monitor this source of error is undertaken monthly.  Whilst it is 
likely for there to be minor random variation in this source of error (borne out in the monthly 
readings), the magnitude of any variation is likely to be small.  It would be unlikely for there to be a 
significant improvement in this source of error, unless there is an upgrade to CK software/hardware 
at the author’s centre. 
5.5.5B: Set-up error: 
As described in section 5.4.6, once a patient has been optimally set-up, a pair of live images is 
acquired just before delivering the 1st treatment beam.  The robot will adjust for any translational or 
rotational changes (between planning CT and treatment) before delivering a beam.  This error is 
therefore reduced to 0mm by online correction.  However, this is an assumption.  If there is a change 
in inter-fiducial positions, in between live imaging assessment and treatment delivery, there is a 
potential for error.  This is considered to be a low risk given the time delay between imaging and 
delivery.  
5.5.5C: Motion: 
Fiducials implanted into the prostate act as surrogates for target motion.  The prostate is subject to 
inter and intra-fractional motion, for example due to bladder and rectal filling.  
Tanyi et al (18) assessed inter- and intrafraction of the prostate to inform PTV margin expansions in 
14 patients undergoing 39 fractions of intensity-modulated radiotherapy (IMRT) for prostate cancer.  
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The group assessed motion by means of implanted transponders and the Calypso system.  The 
observed intra-fraction movement was as much as 4.8mm, 8.6mm and 9.1mm in the lateral, 
longitudinal and vertical directions respectively. 
In comparison, the maximum motion of prostate observed by fiducial tracking in the patients studied 
here was 7.2mm, 6.7mm and 7.5mm in lateral, longitudinal and vertical directions respectively.   
Maximum motion in the vertical (Anterior/Posterior) direction was greatest in both studies.  
In order to minimise errors in targeting due to prostate motion, strategies to reproduce bladder 
filling and rectal filling can be employed.  Bladder filling is discussed in detail in Chapter 4.  Bowel 
preparation for the patients studied here involve an enema 1 hour pre-planning CT and pre- each CK 
treatment fraction.  In addition, Buscopan is administered 30 minutes before planning CT/treatment 
fractions. 
However, other groups have gone further with bowel preparation, advocating a low-fibre diet from 5 
days prior to planning scans until the end of treatment (20), and fasting from 4 hours prior to 
planning CT/treatment (21). 
Section 5.4.5 displays the individual mean set-up errors in each direction.  These were used to 
calculate population systematic errors for set-up/motion as described. 
For this population ∑motion = 0.7mm (lateral), 0.7mm (longitudinal) and 0.4mm (vertical).  These 
compare to errors determined with the Calypso system of 0.33mm (lateral), 0.7mm (longitudinal) 
and 0.52mm (vertical) in the Tanyi et al paper (18). 
𝞼set up , population random error for the 7 prostate patients studied here was 1.4mm, 1.3mm and 
1mm in lateral, longitudinal and vertical directions.  Population random error for the 14 prostate 
patients tracked with Calypso transponders in the Tanyi et al study (18) was 0.76mm, 1.29mm, and 
1.38mm in lateral, longitudinal and vertical directions. 
The longitudinal direction systematic and random errors were therefore remarkably consistent 
between the study groups.  Whilst there was variation in lateral/vertical systematic and random 
errors this was sub-millimetre. 
5.5.5D: Delineation: 
There can be errors in delineation due to limited spatial resolution of the imaging modality used, as 
well as intra-and inter-observer variability (3-6).  At the author’s centre, the prostate is delineated 
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largely on MRI, which is co-registered to the planning CT scan.  Chapter 3 discussed some of the 
issues around fusion uncertainties when outlining on a secondary scan (rather than the planning CT 
scan). 
Nyholm et al (15) assessed inter-physician variability of prostate contouring on MRI and found that 
this was 0.7-1.7mm.  The error for the patients studied here could be exaggerated if there was any 
error in CT-MRI fusion. 
∑delineation = 2mm was selected for calculation of PTV margins.  Tanyi et al (18) did not incorporate a 
delineation error into their margin calculation. 
 
5.5.5E: Marcel van Herk margin calculation: 
The systematic error (∑) for the CK prostate population studied here having combined phantom 
transfer, set-up, motion and delineation errors in quadrature as described is 2.2mm in lateral and 
longitudinal directions, and 2.1mm in the vertical direction. 
Applying the Marcel van Herk equation of Planning Margin (mm) = 2.5∑ + 0.7𝞼 yields planning 
margins of 6.5mm in the lateral direction, 6.4mm in the longitudinal direction, and 6mm in the 
vertical direction.  These would be the margins needed to deliver 95% of the prescription dose to 
95% of the clinical target volume for 90% of the patients. 
Tanyi et al calculated planning margins according to the same equation for their prostate patients 
tracked with Calypso guidance.  Their margins were much smaller (1.4mm, 2.6mm and 2.3mm in 
lateral, longitudinal, and vertical directions respectively).  But their margins did not incorporate 
delineation error, or phantom transfer error. 
The systematic error, ∑,  is given the largest weighting in the Marcel van Herk formula quoted above 
(2).  In addition, given the way that ∑ is calculated in quadrature, the delineation error of 2mm, is the 
dominant factor in the planning margin calculation.  To illustrate this, if the margins are recalculated, 
using a delineation error of 2mm, but setting all other systematic errors, and the random error as 
0mm, the required margins are 5mm. 
This underlines the importance of optimum imaging and fusion protocols. 
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5.5.5F: Limitations  
Tanyi et al (18) demonstrated that margin requirements are less with Calypso set-up/tracking 
compared to other techniques (skin-mark alignment, bony anatomy alignment, image-guided marker 
alignment).  However, the planning margins that the group calculated did not take into account 
delineation (as previously discussed), or rotational and deformation errors. 
The CyberKnife can adapt for rotational changes in fiducial position, as long as these are within 
threshold.  Rotational changes were tracked throughout for all patients studied here, except for 
patient 4, and as explained in Chapter 4, this was due to an exceptional circumstance in this patient. 
Deformation of the prostate gland may be a more significant issue than rotation in CK prostate 
patients.  Nichol et al (22) assessed prostate deformation in 25 patients with implanted fiducial 
markers that were treated to 78.9Gy in 42 fractions.  The patients had 2 MRIs for assessment, one on 
the day of the Planning CT, and the second on a randomly allocated treatment day assigned by the 
study statistician.  The scans were fused in a treatment-planning system by means of the fiducials, 
and the residual errors due to mismatch of the prostate surfaces due to prostate deformation were 
assessed.  The maximum prostate deformations were as large as 6mm, 13mm and 7mm in the 
lateral, longitudinal, and vertical directions respectively, so deformation is not a trivial issue.  An 
interesting observation was that the superior aspect of the prostate patients who had undergone a 
TURP procedure (Trans-Urethral Resection of Prostate) appeared to splay open on sagittal imaging 
when the bladder volume increased from smaller to larger. 
Finally, the Marcel van Herk formula does not account for penumbral uncertainties at the collimator 
edge. 
5.5.6 Current planning margins vs Calculated Marcel van Herk margins 
The standard planning margins applied at the author’s centre are: 5mm in all directions except 
posteriorly, where a 3mm margin is applied.  The reason for the smaller margin in the posterior 
direction is not due to reduced motion in the posterior direction (indeed Tanyi et al (18) showed 
increased motion in this direction), but in order to protect the anterior rectal wall from toxicity.  
The standard margins applied are clearly less than the calculated Marcel van Herk margins of 6.5mm, 
6.4mm and 6mm.  This is clearly concerning at first glance. 
However, the standard planning margins of 5mm/3mm are widely employed internationally and 
there is outcomes evidence that the margins are sufficient.  Chris King reported the pooled analysis 
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clinical outcomes of 1100 prostate cancer patients treated with CyberKnife to a median dose of 
36.25Gy in 4-5 fractions with planning margins of 5mm/3mm (23).  At 36 months follow up the 5 year 
biochemical Progression-Free Survival (bPFS) was 93%.  A cohort of 135 patients with a minimum 5 
years follow up have a 5-year bPFS of 99% and 93% for low and intermediate-risk prostate cancer 
respectively.  These results compare favourably with the results of the RT01 study, (24) although 
comparison of outcomes is best assessed in a randomised trial, such as the PACE study (25).  Another 
note of caution is that long-term data (i.e. 10 years plus data) for those treated with 
hypofractionation and small planning margins is still awaited. 
So why might we get away with it? 
Imaging:  
It may be that the spatial resolution of MRI is such that observers are outlining the prostate 
generously, and in reality the actual outline of the prostate (the clinical target volume) lies within the 
MRI-visualised outline.  If this were the case there may be no need to apply a “delineation” error 
when calculating PTV margins. 
Anatomy:  
Targeted transperineal biopsies of the prostate via multi-parametric MRI (mpMRI) and template 
guidance have become more common-place in recent years.  The technique is being compared to 
trans-rectal ultrasound (TRUS) biopsy technique in the PROMIS study (26).  For clinical oncologists, 
the additional spatial information provided by the mpMRI technique is of great importance in 
identifying where prostate cancer nodules lie.  For peripherally located tumour nodules this is helpful 
in highlighting which margins may be at risk. 
Equally, if a tumour nodule lies more centrally in the prostate, the CTV may already be generous. 
Biology: 
The dose-escalated arm of the RT01 study delivered 74Gy in 37 treatment fractions (24).   There is 
now good evidence that the α/β ratio for prostate cancer is 1.5 (27), the calculated BED of the 
74Gy/37# regime for tumour control is 173 (using α/β of 1.5 for tumour control).  In comparison, the 
BED for 35Gy in 5 fractions, using the same α/β ratio is 198.  Therefore, despite the sharp dose fall-
off outside the prescription isodose line observed with CK treatments, it may be that the CTV is being 
treated to a biologically therapeutic dose. 
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Treatment planning and delivery: 
There has been great progress in refinement of radiotherapy technique to treat prostate cancer in 
recent years.  Image-guided radiotherapy is an especially important improvement to the technique 
(28).  It is likely that despite the addition of smaller planning margins, we are more reliably delivering 
a therapeutic dose to the prostate target than ever before. 
These are hypotheses only and the testing of these hypotheses is beyond the scope of this thesis. 
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5.6 CONCLUSIONS 
The Aims of this Chapter were: 
1. To quantify errors and uncertainties in treatment planning and delivery for CK prostate patients. 
2.  To calculate ideal planning margins for CK prostate patients. 
 
Errors and Uncertainties taken from published data: 
Systematic error:  
Delineation ∑delineation = 2mm (15). 
 
Errors and Uncertainties evaluated in this work: 
Population Systematic errors: 
Set-up error: ∑set up = 0mm  
Motion error: ∑motion = 0.7mm (lateral), 0.7mm (longitudinal) and 0.4mm (vertical) 
End-to-End error: ∑end-to-end = 0.42mm 
 
Population Random errors: 
𝞼set up = 1.4mm (lateral), 1.3mm (longitudinal) and 1mm (vertical)  
 
“Ideal” planning margins for CK prostate patients: 
Applying the above sources of errors and uncertainties into the Marcel van Herk equation yields the 
following margins: 
6.5mm, 6.4mm and 6mm in lateral, longitudinal and vertical directions respectively. 
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These would be the margins required to deliver 95% of the prescription dose to 95% of the CTV for 
90% of the patients.  The above margins do not incorporate rotational/deformation errors, or 
penumbral uncertainties. 
The Van Herk margins calculated here are more generous than the “standard planning margins” 
applied (of 5mm in all directions except posteriorly = 3mm), which is potentially concerning.  
However, there is good clinical outcome data at 5yrs following the application of standard planning 
margins (23).  Some potential reasons for this have been hypothesised. 
Recommendations: 
1. Do not reduce planning margins below “standard margins” of 5mm/3mm. 
2. Patient selection: care with post-TURP patients, they may be more prone to prostate deformation. 
3. Fiducial placement: Place 4 fiducials per patient.  This will allow the CK Radographers the flexibility 
to “switch off” a fiducial, but still track rotations, if a fiducial has migrated, or the prostate has 
deformed (reflected in a high RBE). 
4. Delineation: 
Assess inter-observer and intra-observer error/uncertainty as this is potentially the biggest source of 
error. 
Close liaison with radiology to optimise MRI sequences for target delineation and to aid CT-MRI 
fusion. 
5. Motion: 
Low-fibre diet to minimise rectal filling motion (20) 
Follow bladder filling guidelines recommended in Chapter 4. 
6. Outcome data: 
Analyse clinical outcomes for disease control (measured by bPFS) as well as toxicity in-house. 
Review published 10-year outcome data when it becomes available. 
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Appendices: 
Appendix 5.1: Inter-fiducial distances for CyberKnife prostate cancer patients (Planning) 
Patient Fid 1 to 2 distance(mm) Fid 1 to 3 distance(mm) Fid 2 to 3 distance(mm) 
1 23.2 26.9 23.4 
2 27.6 21 27.8 
3 17.9 24.1 20.4 
4 27.6 24.9 29.5 
5 18.3 21.1 21.4 
6 20.8 16.3 20.3 
7 25.1 30 28.1 
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Appendix 5.2: Inter-fiducial distances for CyberKnife prostate cancer patients (Treatment) 
# = fraction.  SD = Standard Deviation.  Fid 1/2 = Distance between fiducial 1 and fiducial 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient # 
Pre-CK inter-fiducial 
distance (mm) 
Post-CK inter-fiducial 
distance (mm) 
Mean 
(mm) 
SD 
(mm) 
Fid 1/2 Fid 1/3  Fid 2/3 Fid 1/2 Fid 1/3  Fid 2/3 
1 
1 22 26.1 22.6 23.2 26.8 23.4 24 1.8 
2 22.6 26.4 22.6 24 27.6 24.2 24.6 1.9 
3 23.4 27.7 23.9 24.1 27.8 24.2 25.2 1.8 
4 23.9 27.9 24 24.6 28.4 24.4 25.5 1.9 
5 24.2 28.2 24 24.4 28.5 23.9 25.5 2 
2 
1 26.6 21.2 26.6 27.1 21.1 26.4 24.8 2.6 
2 27.2 21.5 27.2 27.7 21.5 26.2 25.2 2.7 
3 27.5 21.8 27.4 28.3 21.9 27.7 25.8 2.8 
4 27.4 21.7 27.5 28.1 21.6 27.5 25.6 2.8 
5 27.7 21 27.1 27.9 20.8 26.9 25.2 3.1 
3 
1 19 24.6 20.3 19.2 24.6 21 21.5 2.3 
2 19 25.1 21.1 19 25.7 21.7 21.9 2.7 
3 18 24.8 20.8 17.8 24.6 21 21.2 2.8 
4 17.4 24.3 21.4 19.8 26.3 22.5 22 2.9 
5 17.2 23.2 20.7 17.4 24.8 23.1 21.1 2.9 
4 
1 27.1 25.4 26.8 26.8 26.2 28.4 26.8 0.9 
3 28.4 26.2 29.3 27.8 24.7 29 27.6 1.6 
5 29.6 30.3 27.6 27.4 30.1 30.6 29.3 1.3 
5 
1 18.5 21.7 21.6 18.1 21.2 21.7 20.5 1.6 
2 18.1 23.3 21.5 18.3 21.6 20.9 20.6 1.9 
3 18.7 22 22.5 18.9 21.6 22 21 1.5 
4 18.2 21.4 21.4 18.1 20.2 20.7 20 1.4 
5 18.6 20.9 21.7 18.4 21.5 21.9 20.5 1.5 
6 
1 21.1 16.1 20.2 20.9 16.6 19.7 19.1 2 
3 21.6 16.8 20.9 21.8 16.6 20.8 19.8 2.2 
4 21.7 16.8 20.9 20.2 16.5 20.9 19.5 2.1 
5 22.2 16.6 20.9 22 16 20.7 19.7 2.5 
7 
2 25.6 31.6 28.7 25.7 32.5 29.4 28.9 2.6 
4 27.1 32.4 29 27.2 32.4 29 29.5 2.2 
Mean 22.7 23.7 23.8 22.9 23.8 24.1 23.5 2.2 
SD 3.9 4.2 3 3.8 4.5 3.2 3.1 0.6 
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Appendix 5.3: Change in inter-fiducial distance: 1st fraction to final fraction 
Patient 
Inter-fiducial pair distance change (mm) 
Mean SD 
Fiducial 1/2 Fiducial 1/3 Fiducial 2/3 
1 2.2 2.1 1.4 1.9 0.4 
2 1.1 -0.2 0.5 0.5 0.5 
3 -1.8 -1.4 0.4 -0.9 1 
4 2.5 4.9 0.8 2.7 1.7 
5 0.1 -0.8 0.1 -0.2 0.4 
6 1.1 0.5 0.7 0.8 0.2 
7 1.5 0.8 0.3 0.9 0.5 
Mean  0.8 0.7 
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Appendix 5.4: Change in inter-fiducial pair distance at Treatment (pre- to post-CK) 
Patient # 
Fid 1 to 2 Change  
Pre- to Post-CK 
(mm) 
Fid 1 to 3 Change  
Pre- to Post-CK 
(mm) 
Fid 2 to 3 Change  
Pre- to Post-CK 
(mm) 
Mean 
(mm) 
SD 
(mm) 
1 
1 1.2 0.7 0.8 0.9 0.2 
2 1.4 1.2 1.6 1.4 0.2 
3 0.7 0.1 0.3 0.4 0.3 
4 0.7 0.5 0.4 0.5 0.1 
5 0.2 0.3 -0.1 0.1 0.2 
2 
1 0.5 -0.1 -0.2 0.1 0.3 
2 0.5 0 -1 -0.2 0.6 
3 0.8 0.1 0.3 0.4 0.3 
4 0.7 -0.1 0 0.2 0.4 
5 0.2 -0.2 -0.2 -0.1 0.2 
3 
1 0.2 0 0.7 0.3 0.3 
2 0 0.6 0.6 0.4 0.3 
3 -0.2 -0.2 0.2 -0.1 0.2 
4 2.4 2 1.1 1.8 0.5 
5 0.2 1.6 2.4 1.4 0.9 
4 
1 -0.3 0.8 1.6 0.7 0.8 
3 -0.6 -1.5 -0.3 -0.8 0.5 
5 -2.2 -0.2 3 0.2 2.1 
5 
1 -0.4 -0.5 0.1 -0.3 0.3 
2 0.2 -1.7 -0.6 -0.7 0.8 
3 0.2 -0.4 -0.5 -0.2 0.3 
4 -0.1 -1.2 -0.7 -0.7 0.5 
5 -0.2 0.6 0.2 0.2 0.3 
6 
1 -0.2 0.5 -0.5 -0.1 0.4 
3 0.2 -0.2 -0.1 0 0.2 
4 -1.5 -0.3 0 -0.6 0.7 
5 -0.2 -0.6 -0.2 -0.3 0.2 
7 
2 0.1 0.9 0.7 0.6 0.3 
4 0.1 0 0 0 0.1 
Mean 0.3 0.5 
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Appendix 5.5: Rigid Body Error (RBE) for CK prostate patients 
Patient # Mean RBE Min RBE Max RBE 
1 
1 0.5 0.2 1.3 
2 0.6 0.4 0.8 
3 0.8 0.2 1 
4 1.2 0.6 1.6 
5 1.5 0.5 2.3 
2 
1 1.3 1.2 1.5 
2 0.6 0.4 0.9 
3 1 0.7 1.9 
4 0.7 0.6 0.8 
5 0.7 0.5 0.8 
3 
1 0.9 0.3 1.6 
2 1.4 0.5 1.7 
4 1.6 0.8 2.2 
5 1.9 0.8 2.6 
4 
1 1.1 0.6 1.5 
3 1.3 0.4 2.3 
5 2.5 1.8 2.8 
5 
1 0.6 0.3 0.8 
2 0.5 0.1 0.7 
3 0.8 0.4 1.1 
4 0.4 0.2 0.7 
5 0.5 0.1 0.8 
6 
1 0.4 0.2 0.8 
4 1.1 0.9 1.4 
5 1.3 1 1.5 
 7 
2 1.5 0.7 2 
4 2.2 1.4 2.5 
Mean 1.1 0.6 1.5 
SD 0.5 0.4 0.6 
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CHAPTER 6 
Optimising dose-fractionation in Stereotactic Body RadioTherapy (SBRT) 
 
6.1 INTRODUCTION 
Patients referred for SBRT have either primary tumours for treatment, recurrence within a previously 
treated area, or oligometastatic disease.  Prescription dose and number of fractions are selected 
according to the radiosensitivity of the primary tumour, as well as the radiation sensitivity of the 
surrounding normal tissues.  Other factors such as previous radiotherapy are also considered. 
Chapter 1, Section 1.3.5 describes an introduction to dose-fractionation issues in SBRT, but these are 
discussed further here. 
 
6.1.1 The concept of Oligometastasis 
Localised primary cancer is usually treated with curative intent with local treatments such as surgery 
and/or radiotherapy often in combination with a systemic therapy component for the elimination of 
micrometastatic disease.  In contrast, patients with distant metastasis are usually treated with 
palliative intent with systemic therapy such as chemotherapy or hormone treatment. 
More recently, however, the existence of a status intermedius between widespread metastatic 
disease and local, organ-confined disease has been hypothesised, this state has been coined as 
“oligometastatic disease” (1). Local therapies have been trialled in this group of patients in recent 
years, in the hope that the oligometastases seen on scans (usually defined as <5 in number) are the 
only sites of disease.  This would make the local treatment potentially curative, although long-term 
local control is a more realistic aim.   
Alternatively, the Norton-Simon hypothesis suggests that reducing tumour burden by local treatment 
may increase the efficacy of subsequent systemic therapy (2). 
Approximately 20% of patients with oligometastic disease treated with SBRT are progression-free at 
2-3 years after SBRT (3). 
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6.1.2 The importance of Biologically Effective Dose (BED) 
The radiation schedules used in SBRT cannot be directly compared with those used in conventional 
radiotherapy, as explained in Chapter 1, because the dose per fraction is different.   
 
To compare the regimes, therefore, Biologically Effective Dose (BED) must be calculated according to 
the following formula, where D = Total Dose (Gy), d = dose per fraction (Gy), and 𝛼/𝛽 is a useful 
measure of how a tumour/tissue will respond to different doses/fraction (4). 
A majority of tumours are assumed to have an 𝛼/𝛽 ratio of 10 (5). 
𝐵𝐸𝐷 =  𝐷 𝑥 (1 + 
𝑑
𝛼/𝛽
) 
There is a large evidence base on the importance of BED for Stage 1 Non-Small cell lung cancer 
(NSCLC).  Zhang et al (6) performed a meta-analysis on 2587 patients across 34 studies to evaluate 
the optimal BED for SBRT for Stage I NSCLC.  The delivered BED was divided into quartiles 
(83.2Gy10=Low, 83.2-106Gy10=Medium, 106-146Gy10=Medium-to-High, and >146Gy10=High).  There 
was a statistically significant Overall Survival benefit at 2 years for those receiving Medium to 
Medium-to-High BED regimes. 
There is also limited evidence on the importance of BED in controlling oligometastatic disease.  
Stinauer et al analysed the importance of BED in controlling 30 patients with 53 metastases.  The 
primary pathology was renal cell cancer and melanoma, metastatic sites included lung, liver and 
bone.  BED was a significant predictor of in-field control, with BED>100Gy10 having a greater control 
rate.  Modelling studies predicted that at least 48Gy in 3 fractions (BED 125Gy10) would be needed to 
achieve >90% 2-year control (7).  
 
6.1.3 Dose-fractionation in SBRT for primary pancreatic cancer 
Approximately 40% of patients present with locally advanced, inoperable disease without clinically 
detectable metastases.  The treatment strategy for these patients often involves systemic 
chemotherapy at the outset, as pancreatic cancer tends to metastasise early in the course of its 
disease, and the patient may have occult metastases (8).   
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Conformal radiotherapy may also be delivered to the primary disease for symptom palliation, and to 
prevent local disease progression from causing morbidity or death.  Radiotherapy is often given 
concurrently with 5-fu or Capecitabine systemic therapy.  However, disease control rates can be low 
(50% disease progression at 6 months) (9).  An additional drawback is the number of daily 
treatments, typically 28 fractions over 5.5 weeks , in a disease where the median prognosis is 8 
months.  A typical regime of 50.4Gy in 28# over 5.5 weeks (1.8Gy/fraction) is associated with a BED 
of 59.5Gy10, assuming an 𝛼/𝛽 ratio of 10 for tumour control. 
SBRT technique has a number of potential technical advantages over conformal radiotherapy which 
have been discussed in this thesis.  The short duration of treatment (typically 3-5 fractions) is also an 
attractive feature for these patients who either ultimately have a limited prognosis, or who benefit 
from a shorter period of interruption of chemotherapy to control micro-metastatic disease.   
Chang et al (10) delivered a single fraction of 25Gy for patients with unresectable pancreatic cancer.  
The BED of this regime = 87.5Gy10.  Freedom from local progression (FFLP) rate at 1 year was 84%, 
but Overall Survival at 1 year was only 21%, and a quarter of patients had Grade ≥ 2 toxicity at 1 year. 
Mahadevan et al delivered induction Gemcitabine and selected out those patients with no 
metastases after 2 cycles to receive SBRT.  Dose delivered was 24-36Gy in 3 fractions (BED = 43.2-
79.2Gy10).  Local control rate was 85% at median follow-up of 21 months, Median Progression-Free 
Survival (PFS) was 15 months, and median Overall Survival (OS) was 20 months in those receiving 
SBRT.  Late Grade 3 toxicity was observed in 9% (11).  The authors concluded that the extreme 
hypofractionation of the above SBRT regime allowed minimal interruption to systemic therapy, which 
improved the overall survival of patients. 
Overall, there is scope for refinement of dose-fractionation in order to improve local control rates, 
while limiting toxicity, and improving overall survival. 
6.1.4 Dose-fractionation in SBRT for Lymph Node oligometastases 
Patients treated with SBRT for lymph node oligometastases are a heterogenous group.  They 
comprise a range of primary cancers, and a range of metastatic sites (e.g. cervical, abdominal, pelvic, 
supraclavicular).  Disease-Free Interval, number of lymph node metastases, and metastasis size, (all 
factors which are known to affect local control rates and prognosis) often vary, which makes it hard 
to draw conclusions on optimum dose fractionation (3). 
Literature reported on SBRT case series comprising various primary cancers (Prostate, Cervix, Gastric, 
Breast, Colorectal, Renal cell) treating various lymph node sites (abdominal, para-aortic, pelvic, 
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mediastinal) to a variety of BEDs (60Gy10 – 125Gy10) show Local Control rates of 67.4%-100% at a 
follow-up of 2-4 years.  Toxicity is also important: Grade 3+ toxicity rates were 0-20% (12-15). 
As before, there is scope for refinement of dose-fractionation in order to improve local control rates, 
while limiting the toxicity of SBRT. 
 
6.1.5 Dose-fractionation for Oligometastatic breast cancer 
Milano et al analysed the results from a large series of patients (n=121) with oligometastases (16).  
Those patients with breast cancer histology (n=39) were evaluated separately, as this histology 
confers a better prognosis than other primary tumours.  For breast cancer patients the 6-year local 
control rate was 87%.  Freedom from Distant Metastasis rate was 36% at 6-years, indicating that 
some treated patients truly had oligometastatic disease (rather than radiologically-occult widespread 
metastases).  BED was not specifically evaluated in this study, but 72% of non-brain metastases were 
treated with 50Gy in 10#, a BED of 75Gy10. 
 
6.2 AIMS 
To assess the effects of SBRT on tumour control and normal tissue toxicity, by comparing 
radiobiological calculations and RBE with clinical outcome.  Three clinical models were chosen: 
1.  A radiobiological comparison between SBRT regimes delivered for the treatment of primary 
pancreatic cancer, and conventional radiotherapy schedules was performed. 
2. The outcomes of SBRT treatment to lymph node oligometastases according to delivered BED were 
evaluated. 
3. The outcomes of SBRT to oligometastatic breast cancer according to delivered BED were 
evaluated. 
 
  
243 
 
6.3 MATERIALS AND METHODS 
6.3.1 SBRT vs Conventionally-fractionated radiotherapy for primary pancreatic cancer  
42 patients with localised but inoperable pancreatic cancer were treated with 3-fraction SBRT on the 
CyberKnife platform at the author’s centre.  To give context to the radiobiological comparison (Aim 1) 
it is important to also evaluate outcome data (toxicity and disease control). 
6.3.1A: Treatment planning and delivery: SBRT pancreatic cancer 
The pancreas moves with respiration and bowel filling, as described in Chapter 3, therefore SBRT 
treatment to the pancreas is best tracked with implanted fiducials and the Synchrony system.  
Approximately 1 week after fiducial placement, patients underwent a Planning CT scan. Patients 
were scanned supine in a patient-specific Vac-Bag immobilisation device for supporting the arms and 
upper torso, with knee and ankle supports as needed.  Patients were advised to drink 300mls of cold 
water 30 minutes before the scan for duodenal filling.  A non-contrast CT scan was performed, a 
Contrast CT scan was also performed to aid target definition in all patients.  A PET scan was 
performed if it would aid localisation. 
Gross disease (GTV) was outlined and expanded to PTV by adding a margin of 2-3 mm.  Treatment 
was planned on the non-Contrast CT scan.  Treatment was prescribed to 18-36Gy in 3#.  Dose-
fractionation was decided according to Clinician preference, and according to the proximity of dose-
limiting Organs At Risk, and any prior Radiotherapy.  The prescription isodose line was chosen to 
provide optimum coverage of the PTV.  Treatment was delivered on consecutive days. 
The patients drank 300mls of water prior to treatment to re-create the conditions on the Day of the 
Planning CT scans.  Patients had a CT scan performed on Treatment Day 1 to check for fiducial 
stability prior to treatment, as described in Chapter 3.  This scan was a non-contrast scan with the 
patient in the treatment position, taken in mid-breath hold.   
Patients were given prophylactic anti-sickness medication (Ondansetron 4mg bd and Maxalon 10mg 
tds prn) unless contra-indicated. 
Treatment planning and delivery parameters were recorded for all patients.  This included 
prescription dose, number of fractions, prescription isodose, minimum and maximum dose to PTV, 
coverage and PTV size. 
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6.3.1B: Outcome data: SBRT pancreatic cancer 
Toxicity and outcome data were prospectively collected.  Patients were clinically reviewed 3 months 
after treatment, then at 3 or 6 monthly intervals thereafter, when post-treatment CT scans were 
acquired.  Toxicity was assessed using CTCAEv4 criteria, and local failure was determined by the 
reporting radiologist and treating physician. 
6.3.1C: Radiobiology: SBRT pancreatic cancer 
Radiobiology calculations were performed for the 42 patients treated by SBRT.  These were 
compared to calculations performed on a comparator external beam radiotherapy regime 
(50.4Gy/28#/5.5 weeks). 
Radiobiology calculations were performed under the supervision and guidance of Roger Dale.  The 
methodology for the calculations is explained here. 
Pancreatic tumours are fast-growing.  Volume Doubling Time (VDT) of pancreatic cancer has been 
shown to be 6 weeks.  This is faster than the VDT of head and neck tumours (VDT = 8 weeks) (17). 
Tumour cell repopulation is known to occur during a course of radiotherapy, and this is a factor that 
limits tumour control.  It is therefore important to consider this factor when calculating the potency 
of a given radiotherapy regime. 
The maximum repopulation correction factor (k value) was assumed to be 0.5Gy/day.  This is the 
biological dose per day required to compensate for ongoing tumour cell repopulation. This was 
incorporated into BED calculations using the formula proposed by Dale et al (18) with the following 
justification by Roger Dale.  
“It is assumed that the k value for pancreatic cancer is the same as that for Head and Neck tumours, 
i.e. k = 0.9Gy/day. In Squamous Cell Cancers of the Head and Neck the delay time before significant 
repopulation begins is ~28 days, but there is very little documentation about delay times for other 
tumour types. I have therefore assumed that the repopulation factor for the fastest-growing 
pancreatic cancers is an average of 0.5Gy/day over the entire duration of treatment.” 
Formula for BED, taking into account tumour repopulation: 
𝐵𝐸𝐷 = 𝑇𝑜𝑡𝑎𝑙 𝑑𝑜𝑠𝑒 × [1 +
𝑑
𝛼/𝛽 
] − (𝑘 × 𝑇) 
Where T = overall treatment time in days. 
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This formula was used to calculate BED for the conventionally fractionated comparator, as well as the 
SBRT regimes delivered by CyberKnife at the author’s centre.  To allow fair comparison the formula 
above was also used to calculate the BED of alternative SBRT regimes described in the Discussion. 
 
6.3.2 SBRT Dose-Fractionation for Lymph Node oligometastases 
38 patients with unresectable lymph node metastases were studied.  The patients were treated at 
the author’s centre between 2009 and 2012. 
6.3.2A: Treatment planning and delivery: Lymph Node oligometastases 
Treatment technique varied according to the site of the lymph node target to be treated.  Thoracic 
and upper abdominal lymph nodes move with respiration, and therefore these were tracked with 
implanted fiducials and the Synchrony system.  Other nodes were tracked with X-Sight spine tracking, 
or fixed fiducial tracking. 
For those patients with implanted fiducials, a planning CT scan was performed 1 week after fiducial 
placement. Patients were scanned supine in a patient-specific Vac-Bag immobilisation device.  A non-
contrast CT scan was performed.  Contrast CT, PET and MRI scans was also performed if this would 
aid target definition, or definition of adjacent Organs At Risk.  X-Sight Spine patients were planned on 
a non-contrast CT scan acquired in immobilisation with secondary scans performed as appropriate. 
The target node(s) was outlined as Clinical Target Volume (CTV) and expanded to PTV by adding a 
margin of 0-5 mm.  Treatment was planned on the non-Contrast CT scan.  Treatment was prescribed 
to 18Gy in 1#, 24-36Gy in 3#, or 35-47Gy in 5#.  Dose-fractionation was decided according to Clinician 
preference, and according to the proximity of dose-limiting Organs At Risk, and any prior 
Radiotherapy.  The prescription isodose line was chosen to provide optimum coverage of the PTV.  
Treatment was delivered on consecutive days. 
Patients that were to be tracked with fiducials/Synchrony had a CT scan performed on Treatment 
Day 1 to check for fiducial stability prior to treatment, as described in Chapter 3.  This scan was a 
non-contrast scan with the patient in the treatment position, taken in mid-breath hold.   
Supportive medication was prescribed to patients as appropriate. 
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Patient demographics, histopathology, prior treatment details and target details were recorded.  
Treatment planning and delivery parameters were also recorded.  These included prescription dose, 
number of fractions, prescription isodose, PTV size, CTV-to-PTV margin, conformality and coverage. 
BED was calculated according to the more commonly used equation (4): 
𝐵𝐸𝐷 =  𝐷 𝑥 (1 + 
𝑑
𝛼/𝛽
) 
6.3.2B: Outcome data: Lymph Node oligometastases 
Toxicity and disease control data were prospectively collected.  Patients were clinically reviewed 3 
months after treatment, then at 3 or 6 monthly intervals thereafter, when post-treatment CT scans 
were acquired.  Toxicity was assessed using CTCAEv4 criteria, and local failure was determined by the 
reporting radiologist and treating physician. 
6.3.2C: Statistical analysis: Lymph Node oligometastases 
Local control was analysed according to BED as per Aim 2.  A Weibull test with Gamma fragility was 
performed to analyse Progression Free Survival (PFS) by Histopathology, adjusted for BED.  This test 
was performed with SPSS statistical software by Paul Seed, medical statistician, St. Thomas’ hospital, 
London. 
 
6.3.3 Dose-Fractionation for Oligometastatic breast cancer 
57 patients with unresectable oligometastatic breast cancer were studied. 
6.3.3A: Treatment planning and delivery: Oligometastatic breast cancer 
Treatment technique varied according to the site of the oligometastasis to be treated.  Targets that 
move with respiration were tracked with implanted fiducials and the Synchrony system.  Other 
targets were tracked with X-Sight spine tracking, fixed fiducial tracking, or 6D Skull tracking as 
appropriate. 
For those patients with implanted fiducials, a planning CT scan was performed 1 week after fiducial 
placement. Patients were scanned supine in a patient-specific Vac-Bag immobilisation device.  A non-
contrast CT scan was performed.  Contrast CT, PET and MRI scans were also performed if they would 
aid target definition, or definition of adjacent Organs At Risk.  X-Sight Spine and 6D Skull patients 
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were planned on a non-contrast CT scan acquired in immobilisation with secondary scans performed 
as appropriate. 
The target(s) was outlined as GTV or CTV, and expanded to PTV by adding a margin of 0-5.1 mm.  
Treatment was planned on the non-Contrast CT scan.  Treatment was prescribed to 12-48Gy in 1-5 
fractions.  Dose-fractionation was decided according to Clinician preference, and according to the 
proximity of dose-limiting Organs At Risk, and any prior Radiotherapy.  The prescription isodose line 
was chosen to provide optimum coverage of the PTV.  Treatment was delivered on consecutive days. 
Patients that were to be tracked with fiducials/Synchrony had a CT scan performed on Treatment 
Day 1 to check for fiducial stability prior to treatment, as described in Chapter 3.  This scan was a 
non-contrast scan with the patient in the treatment position, taken in mid-breath hold.   
Supportive medication was prescribed to patients as appropriate. 
Patient demographics, prior treatment details and target details were recorded.  Treatment planning 
and delivery parameters were also recorded.  These included prescription dose, number of fractions, 
prescription isodose, PTV volume, and GTV-to-PTV margin. 
BED was calculated according to the formula below (4): 
𝐵𝐸𝐷 =  𝐷 𝑥 (1 + 
𝑑
𝛼/𝛽
) 
6.3.3B: Outcome data: Oligometastatic breast cancer 
Toxicity and disease control data were prospectively collected.  Patients were clinically reviewed 3 
months after treatment, then at 3 or 6 monthly intervals thereafter, when post-treatment CT scans 
were acquired.  Toxicity was assessed using CTCAEv4 criteria, and local failure was determined by the 
reporting radiologist and treating physician. 
 
6.3.3C: Statistical analysis: Oligometastatic breast cancer 
Local control was analysed according to BED as per the Aim.  Local Progression-free survival Kaplan-
Meier curves were constructed in SPSS by Mel Green, medical statistician. 
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6.4 RESULTS 
6.4.1 SBRT vs Conventionally-fractionated radiotherapy for primary pancreatic cancer  
6.4.1A: Treatment planning and delivery: SBRT primary pancreatic cancer 
The majority of pancreatic tumours in the 42 patients treated were locally advanced (90%) with 
T3/T4 staging.  A majority of tumours (90%) were located at the pancreatic head.  The patients were 
largely pre-treated, some patients had received multiple-modality treatment prior to CK.  77% had 
received prior chemotherapy, 23% prior radiotherapy and 21% prior surgery.  All patients had an 
imaging-defined macroscopic target (i.e. none were treated adjuvantly). 
Treatment planning and delivery variables are displayed in Table 6.1. 
Table 6.1: Dosimetric variables for patients with primary pancreatic cancer treated by SBRT 
Factor   
Number of fiducials 1 N = 8 (19%) 
 2 N = 6 (14%) 
 ≥ 3 N = 28 (67%) 
PTV (cc) Median (range) 69.2cc (15.8-193.6) 
 Mean (SD) 75.1cc (41.7) 
Prescription dose (Gy) Median (range) 27Gy (18-36) 
 Mean (SD) 27Gy (29) 
Number of fractions 3# N=42 (100%) 
BED Median 49.5Gy10 (27.3-77.7) 
 Mean 48.6Gy10  
Prescription isodose (%) Median (range) 67% (53-82) 
 Mean (SD) 67% (7) 
Coverage (%) Median (range) 97.6% (80-99.5) 
 Mean (SD) 96.6% (3.5) 
 
The PTV volumes varied widely (15.8cc-193.6cc) which would be likely to have a bearing on both 
toxicity and local control. The patients studied were all treated with a 3-fraction regime, to a range of 
prescription doses, which will be discussed further in the section on Radiobiology (Section 6.4.1D). 
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6.4.1B: Outcome data: Toxicity: SBRT primary pancreatic cancer 
Outcomes for Acute and Late toxicity are displayed in Table 6.2. Data is available for 40 and 32 
patients respectively.  Some data is missing due to incomplete follow-up information from 
treating/referring Physician.  Mel Green (medical statistician) performed full statistical analysis to see 
if any Patient/Treatment/Delivery factors were related to Toxicity on Univariate or Multivariate 
analysis but there was no factor that reached statistical significance (p values 0.084-0.875 for acute 
toxicity and p values 0.212-0.991 for late toxicity) . 
Table 6.2: Acute/Late toxicity data: primary pancreatic cancer treated by SBRT 
Acute Toxicity (≤ 3months post-treatment) 
 
None N=10 (25%) 
 
 Grade 1-2 Grade 3  Grade 4 
Diarrhoea N=6 (15%) 0 0 
Nausea N=8 (20%) 0 0 
Vomiting N=2 (5%) 0 0 
Dyspepsia N=2 (5%) 0 0 
Anorexia N=2 (5%) 0 0 
Pain N=7 (18%) N=1 (2.5%) 0 
Fatigue N=10 (25%) 0 0 
Jaundice N=1 (2.5%) N=1 (2.5%) 0 
    
Late Toxicity (> 3months post-treatment) 
 
None N=27 (84%) 
 
 Grade 1-2 Grade 3 Grade 4 
Pain N=1 (3%) 0 0 
Nausea N=1 (3%) 0 0 
Bleeding N=1 (3%) 0 0 
Duodenal 0 0 N=2 (6%) 
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Note: sometimes a patient will experience more than one toxicity symptom so the percentages of 
acute/late toxicity do not add up to 100%. 
In terms of acute toxicity, the most common all grade toxicities were fatigue (25%), nausea (20%) and 
abdominal pain (18%).  The most severe toxicity experienced was G3 abdominal pain, experienced by 
one patient and managed with analgesia.  A further patient developed G3 jaundice but went on to 
die of metastatic pancreatic cancer 4 months after development of this symptom, therefore the 
cause of jaundice may have been disease progression. 
In terms of late toxicity, one patient had grade 2 nausea and pain 1-year post-CK.  It was notable that 
the patient was of poor performance status pre-treatment (she was considered too frail for 
chemotherapy).  A further patient who was taking Diclofenac had a duodenal haemorrhage 4 months 
after CK.  The patient was transfused, the Diclofenac was stopped and he was started on a proton-
pump inhibitor. 
A further 2 patients had G4 duodenal strictures as late toxicity. The dosimetry vs late toxicity of the 
patients described will be discussed in the Discussion. 
6.4.1C: Outcome data: Disease control: SBRT primary pancreatic cancer  
Graph 6.1 shows Kaplan-Meier and log-rank survival analysis with respect to Freedom-from-local 
progression (FFLP) for 42 patients treated with SBRT for primary pancreatic cancer.  The actuarial 
FFLP rate at 1-year was 44%. 
Graph 6.1:  
Freedom-from-local-progression for patients treated with SBRT for pancreatic cancer 
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As discussed in the Introduction, pancreatic cancer is a disease which metastasises frequently, and 
early in the course of disease (8).  It is therefore important to consider progression-free survival 
(PFS), which incorporates distant progression as well as local progression.   
The Kaplan-Meier curve for progression-free survival (PFS) is shown in Graph 6.2. 
The actuarial PFS at 1 year is 23%. 
Comparing the FFLP curve (Graph 6.1) with the PFS curve (Graph 6.2) shows that more patients 
progressed with metastatic disease earlier than those that progressed with local disease. 
Graph 6.2:  
Progression-free survival (PFS) for patients treated with SBRT for pancreatic cancer 
 
Finally it is important to consider Overall Survival. 
Graph 6.3 shows the Overall Survival curve for the 42 patients treated with SBRT to primary 
pancreatic cancer.  Overall survival at 1-year was 40%, with a Median Survival of 8.4 months. 
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Graph 6.3:  
Overall Survival (OS) for patients treated with SBRT for pancreatic cancer 
 
 
The above Outcome data will be fully discussed in the Discussion. 
 
6.4.1D: Radiobiology: primary pancreatic cancer 
Aim 1 was to perform a radiobiological comparison between SBRT regimes delivered for the 
treatment of primary pancreatic cancer, and conventional radiotherapy schedules.  Radiobiological 
comparison needs to consider both tumour control and normal tissue toxicity. 
Tumour control calculations: 
Tumour α/β values tend to be related to growth rate, i.e. faster-growing tumours have high α/β 
ratios.  As pancreatic cancer is fast-growing (17) a generic α/β value of 10Gy is assumed in these 
calculations. 
Taking a Conventionally-fractionated external beam radiotherapy regime of 50.4Gy/28#/5.5weeks 
(9).  For the purpose of this discussion this is considered the “Reference” radiotherapy schedule. 
Formula for BED calculation, taking into account tumour repopulation: 
𝐵𝐸𝐷 = (𝑇𝑜𝑡𝑎𝑙 𝑑𝑜𝑠𝑒 × [1 +
𝑑
𝛼/𝛽 
]) − (𝑘 × 𝑇) 
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Where k= maximum repopulation correction factor (units=Gy/day), d= dose per fraction (units = Gy) 
and T = overall treatment time (units = days).   
k = 0.5Gy/day (justification as per Section 6.3.1C).  T = 38 days. 
BED = 40.5Gy10 (Reference: Tumour control) 
Assuming that the Linear Quadratic model is valid for all potential fraction sizes, and back-converting 
from BED = 40.5Gy10, the 3-fraction CyberKnife tumour equivalents to the reference schedule is: 
3 fractions of 7.85Gy = Total dose = 23.55Gy (CK: Tumour control) 
(A fixed repopulation of 3 x 0.5Gy =1.5Gy was assumed in calculating the equivalent CK schedule). 
 
Assuming that Conventionally-fractionated external beam radiotherapy treatments are planned 
according to ICRU guidelines (19), then all doses within the PTV should be in the range of 95-107% of 
prescribed dose. The minimum tumour dose is known to be the most significant determinant of local 
control, therefore re-calculating the Reference schedule taking into account the minimum dose to 
PTV: 47.88Gy/28#/5.5weeks: 
Minimum BED = 37.1Gy10 (Reference) 
Back-converting from BED as before, and assuming a 1.5Gy allowance for repopulation as before, the 
equivalent CK 3-fraction minimum dose equivalents is: 
3 fractions of 7.4Gy = Total dose = 22.2Gy (CK minimum dose equivalent: Tumour control) 
The CK planning system, MultiPlan, reports minimum total dose to the PTV.  The range of minimum 
total dose to the PTV for the 42 CK patients studied here = 11.1Gy-34.5Gy.  Among these 42 patients, 
22 patients (52%) received minimum PTV total doses which were equal to, or greater than, 22.2Gy 
(i.e. the CK minimum dose equivalent to the Reference schedule).  The other 20 patients (48%) 
received minimum PTV total doses which were, in radiobiological terms, less potent than those 
delivered by the Reference schedule (this suggests there would be scope to dose escalate if Normal 
tissue doses allow). 
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Normal tissue calculations: 
When calculating BEDs to normal tissue in the upper gastro-intestinal tract, an α/β ratio of 3Gy is 
generally used. (Duodenum, Stomach and Small Bowel are the dose-limiting OARs when delivering 
radiotherapy to pancreatic tumours).  In contrast to the considerations for tumour control, it is not 
the minimum dose that is relevant, but the higher delivered doses. 
Calculations assume that some normal tissue volumes receive 100% of prescription dose.  This is a 
reasonable assumption as tumours in the pancreatic head lie adjacent to the Duodenum, and once 
the tumour volume is expanded by a planning margin the PTV invariably overlaps Duodenum.  
Doses>100% of prescribed dose are not considered as treatment planning should not produce plans 
with a hot spot in normal tissue.  BED is calculated according to the formula below, k value is not 
relevant in this situation, as the calculation is considering normal tissue (not tumour) response to 
radiotherapy.  D =Total dose (Gy). D= Dose per fraction (Gy). 
𝐵𝐸𝐷 =  𝐷 𝑥 (1 + 
𝑑
𝛼/𝛽
) 
Reference schedule (50.4Gy/28#/5.5w): = BED 80.6Gy3  (Reference:  Normal tissues) 
Taking the minimum dose equivalent CK regime for tumour control calculated above (of 3 x 7.4Gy = 
Total dose 22.2Gy): 
BED = 77Gy3   (CyberKnife : Normal tissues) 
Overall, this suggests that there is scope to dose escalate. 
The calculations are summarised in Table 6.3. 
The implications of the above calculations, and the recommendations for treatment planning for 
primary pancreatic cases treated by CyberKnife are discussed in the Discussion. 
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Table 6.3: BED summary for Reference Schedule vs SBRT (CK) for pancreatic cancer 
Schedule 
Total Dose 
(D) (Gy) 
Fraction 
dose (d) 
(Gy) 
Fraction 
number (n) 
Treatment 
time (T) 
(days) 
BEDGy10 
(Tumour 
Control) 
BEDGy3 
(Normal 
tissues) 
Reference 
(prescribed) 
50.4 1.8 28 38 40.5 80.6 
CK  
(equivalent to Ref for 
Tumour Control) 
23.55 7.85 3 3 40.5 N/A 
Reference 
(minimum PTV dose 
:Tumour control) 
47.88 1.71 28 38 37.1 N/A 
CK  
(equivalent to 
minimum of Ref 
:Tumour Control) 
 
22.2 7.4 3 3 37.1 77 
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6.4.2 SBRT Dose-Fractionation for Lymph Node oligometastases  
6.4.2A: Treatment planning and delivery: SBRT lymph node oligometastases 
The 38 patients studied were largely pre-treated: 30 patients (78%) had previously received 
chemotherapy as treatment for their oligometastatic disease, and 14 patients (38%) had received 
prior radiotherapy to the target nodal sites.  The patients had a median disease-free interval of 19 
months (Range 5-106 months). 
41 lymph node sites were treated (Range = 1-3 sites per patient).  The anatomical distribution of the 
sites were as follows: 
Neck 3 (7%), Thorax 14 (34.5%), Abdomen 14 (34.5%) and Pelvis 10 (24%). 
The histopathology of the primary is shown in Table 6.4. 
Table 6.4: Histopathology of primary tumour: Lymph node oligometastases 
Histopathology Number of patients (n) Percentage (%) 
Colorectal 12 31.5 
Breast 8 21 
Urological 6 16 
Lung 4 10.5 
Gynae 4 10.5 
Other/Unknown 1
0
 4 10.5 
Total 38 100 
 
Radiotherapy technique was described in Section 6.3.2.  Treatment and delivery parameters are 
displayed in Table 6.5.  BED was calculated according to the formula below: 
𝐵𝐸𝐷 =  𝐷 𝑥 (1 + 
𝑑
𝛼/𝛽
) 
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Table 6.5 Treatment and delivery parameters: Lymph node oligometastases 
Parameter   
PTV volume (cc) Median = 65cc Range: 1.2 – 126.1cc 
CTV-PTV margin (mm) Median = 2mm Range: 0 – 5mm 
Dose-Fractionation 
18Gy/1# BED = 50.4Gy10 
24-36Gy/3# BED = 43 - 79Gy10 
35-47Gy/5# BED = 60 - 91Gy10 
BED Median 59.5Gy10 Range:  
43Gy10 – 91Gy10  Mean 57Gy10 
Prescription isodose line (%) Median = 66% Range: 48 – 78% 
Conformality index (nCI) Median = 1.2 Range: 1.06 – 1.65 
Coverage (%) Median 98.1% Range: 96.7 - 99.9% 
 
There was a wide range of PTV volumes treated, which would be expected to be reflected in toxicity 
and local control outcomes. 
The BED of the SBRT regimes delivered ranged from 43 – 91Gy10. The most commonly prescribed 
regimes were 24Gy/3# (BED = 43.2Gy10) (13 patients, 34%) and 30Gy/3# (BED = 60Gy10) (10 patients, 
26%).  The planned SBRT treatments had a high degree of conformality, and there was excellent 
coverage of the PTV with the prescribed dose. 
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6.4.2B: Outcome data: SBRT lymph node oligometastases 
Outcome data was assessed at a Median follow-up of 15 months. 
Acute Toxicity 
The majority of patients (23 patients, 61%) had no acute side-effects following SBRT.  13 patients 
(34%) had Grade 1-2 acute reactions, largely grade 1 fatigue.  A single patient had a Grade 3 acute 
toxicity reaction: this was pain escalation in a patient that was a disease progressor.  The patient was 
managed with analgesia. 
Late Toxicity 
There were 2 cases of Grade 3 late toxicity (5%).  Both patients had received prior radiotherapy to 
the target nodal site.   
One patient experienced Grade 3 pneumonitis following SBRT to a large Internal Mammary Chain 
nodal mass (PTV = 126 cc).  The pneumonitis resolved with steroid therapy. 
A further patient experienced Grade 3 oedema (lower limb oedema) following SBRT to left inguinal 
lymph nodes.  The patient had pre-existing oedema, and notably she was a disease progressor. 
Local Control (LC): 
The local control rate was 88%.  There was in-field disease progression in 5 irradiated sites (5/41 
nodal sites, 12%). 
Progression-Free Survival (PFS): 
Median PFS = 11 months, PFS at 1 year = 48%.  Therefore, as for outcomes in primary pancreatic 
cancer, distant progression occurred earlier than local progression. 
Overall Survival (OS): 
Overall Survival at 1 year = 91%. 
Aim 2 was to evaluate outcomes of SBRT to lymph node oligometastases according to delivered BED. 
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6.4.2C: Statistical analysis: SBRT lymph node oligometastases 
BED vs Local Control: 
The calculated BED (y axis) was compared to Local Control (x axis) in the dot-plot below.  Each dot 
represents a patient.  BED was calculated as described above assuming an α/β ratio of 10 for tumour 
control. 
Dot Plot 1: BED vs Local progression status for SBRT to Lymph node oligometastasis 
 
The dot-plot illustrates that the regime with the lowest BED (24Gy/3#, BED=43.2Gy10) was associated 
with the highest risk of local progression. 
Importantly, it can be seen that when patients were treated to a threshold BED of ≥ 72Gy10 , the local 
control rate was 100%.  This equates to a prescribed dose of ≥ 36Gy/3# or ≥ 40Gy in 5#. 
 
Histopathology vs PFS: 
The radiation response of a tumour is known to vary according to its histopathology.  Each primary 
tumour has an intrinsic Radiosensitivity (20).  In addition, the biology of a tumour (e.g. the propensity 
to metastasis) varies according to the histopathology.  Given the wide range of Histopathology in the 
sample of patients studied here, it was interesting to compare PFS by Histopathology.  The 
importance of BED has been illustrated above, so the patients were stratified according to BED.  
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Graph 6.4 shows PFS for 5 histopathological categories of tumours, adjusted for BED. 
Graph 6.4: PFS by Histopathology, adjusted for BED: lymph node oligometastases  
 
Graph 6.4 shows that in the sample of patients studied, the colorectal cancer patients had the most 
favourable PFS, the Median PFS for the Colorectal cancer histopathology group was 22 months. 
The lung cancer group had the least favourable PFS, with a median PFS of just over 3 months. 
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6.4.3 Dose-Fractionation for Oligometastatic breast cancer  
6.4.3A: Treatment planning and delivery: Oligometastatic breast cancer 
57 patients received radiotherapy delivered with stereotactic technique to 84 unresectable 
oligometastases at the author’s centre between May 2009 and March 2014. 42 patients (74%) had a 
solitary site of oligometastatic disease. 
Chart 6.1 shows the distribution of oligometastases by anatomical site. 
The most commonly treated anatomical site of metastasis was the brain, accounting for 41% of 
metastases. Spinal, lymph node, and non-spinal bone metastases made up a further 56% of the 
metastases. 
Chart 6.1: Distribution of metastases by anatomical site: Oligometastatic breast cancer 
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Table 6.6: Treatment and delivery parameters: Oligometastatic breast cancer 
Parameter   
PTV volume (cc) 
Median 
(range) 
11.4 
(0.2-126.1) 
GTV-PTV margin (mm) 
Median  
(range) 
2 
(0-5.1) 
Prescription dose (Gy) 
Median  
(range) 
26 
(12-48) 
Fraction number (n) 
Median  
(range) 
3 
(1-5) 
Dose per fraction (Gy) 
Median  
(range) 
9 
(4-20) 
Prescription isodose line (%) 
Median  
(range) 
61 
(48-80) 
BED (Gy10) 
Median  
(range) 
51.3 
(16.8-124.8) 
 
There was a wide range of PTV volumes treated, which would be expected to be reflected in toxicity 
and local control outcomes. 
The BED of the regimes delivered ranged from 16.8 – 124.8Gy10. The most commonly prescribed 
regimes were 30Gy/3# (BED = 60Gy10) (16 metastases, 19%) and 24Gy/3# (BED = 43.2Gy10) and 
27Gy/3# (BED = 51.3Gy10) both 14 metastases (17%).   
  
263 
 
 
6.4.3B: Outcome data: oligometastatic breast cancer 
Outcome data was assessed at a Median follow-up of 13 months.  Toxicity and local control was 
analysed per oligometastatic lesion.  Overall survival was analysed per patient. 
Acute Toxicity 
Outcomes are shown in Table 6.7. 
Table 6.7: Acute toxicity following stereotactic radiotherapy: Oligometastatic breast cancer 
Toxicity grade 
(CTCAE v4.0) 
None Grade 1-2 Grade 3 No data 
Toxicity incidence 
(%) 
71.5 19 1.2 8.3 
 
The vast majority of oligometastatic sites (71.5%) were treated without any acute toxicity.  There 
were no cases of Grade 4 toxicity.  The single case of Grade 3 toxicity was an incidence of skin 
ulceration following a high skin dose in a superficial bony target treated to BED112.5Gy10. 
Late Toxicity 
Outcomes are shown in Table 6.8. 
Table 6.8: Late toxicity following stereotactic radiotherapy: Oligometastatic breast cancer 
Toxicity grade 
(CTCAE v4.0) 
None Grade 1-2 Grade 3 No data 
Toxicity incidence 
(%) 
83.3 2.4 4.8 9.5 
 
The vast majority of oligometastatic sites (83.3%) were treated without any late toxicity.   
There were no cases of Grade 4 toxicity.  The Grade 3 acute skin reaction persisted after 3 months so 
was also counted as a late reaction.  It subsequently healed.  There were 2 cases of Grade 3 pain, and 
a single case of radionecrosis in an intra-cranial target. 
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Local Progression-Free Survival (Local PFS): 
This is displayed in the Kaplan-Meier survival curve below. 
It was noted on reviewing the outcomes that there was an increased incidence of local recurrence in 
the patients receiving stereotactic radiotherapy to intracranial metastases, therefore the Intracranial 
vs Body survival curves were compared. 
Graph 6.5: Local PFS: Intracranial vs Body site: Oligometastatic breast cancer 
 
 
 
 
 
 
 
 
The local PFS for Body sites was promising at 92% at 2 years, the local PFS for intra-cranial sites was 
74% at 2 years.  This was a statistically significant difference.  Intracranial oligometastases do 
significantly worse than body metastases (log-rank p=0.015). 
Distant Progression: 
Median freedom from distant disease progression, considering all 57 patients = 6 months. 
Therefore, as for outcomes in primary pancreatic cancer, and lymph node oligometastases, distant 
progression occurred earlier than local progression. 
Overall Survival (OS): 
Overall Survival considering all 57 patients was 75% at 2 years. 
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6.4.3C: Statistical analysis: Oligometastatic breast cancer 
Aim 3 was to evaluate outcomes of oligometastatic breast cancer according to delivered BED. 
For the purposes of this analysis the author decided to focus on stereotactic radiotherapy delivered 
to body metastases. 
BED vs Local Control: 
The calculated BED (y axis) was compared to Local Control (x axis) in the dot-plot below.  Each dot 
represents a “Body” oligometastasis.  BED was calculated as described above assuming an α/β ratio 
of 10 for tumour control. 
Dot plot 2: BED vs Local progression status:  
Body metastases from oligometastatic breast cancer treated with SBRT 
 
The dot-plot clearly shows that there was only a single case of local progression.  
The solitary case of Body metastasis Local Progression was treated to BED 48Gy10 (30Gy/5#).  Time to 
Local Progression was 20 months.  Treating to ≥ 50Gy BEDGy10 (i.e. ≥27Gy/3# or ≥31Gy/5#) in this 
cohort gives 100% Local Control at Median follow-up 13 months. 
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6.5 DISCUSSION 
Tumour control can be maximised, and normal tissue toxicity can be minimised, by optimising the 
accuracy of dose delivery.  These aspects have been discussed in Chapters 3-5 (tumour delineation, 
optimum fiducial location, reproducible bladder filling, appropriate planning margin). 
It is also important for the dose/fractionation regime selected to be optimum for tumour control, 
while being protective to Organs At Risk. 
As explained in Chapter 1, the clinical evidence for the efficacy and safety of Conventionally-
fractionated radiotherapy has been gathered over decades.  In contrast, there is more limited long-
term data for SBRT regimes, because the treatment approach is newer.  Dose-fractionation regimes 
for Lung SBRT have been piloted in dose-escalation Phase 1 clinical trials (21).  There is now good 
clinical data for optimum BED for Stage 1 lung cancer following a meta-analysis (BED>100Gy10 is 
associated with improved tumour control), but the evidence for other indications is less clear (22). 
The BED formula can be used to compare the biological potency of a given SBRT regime with a 
conventionally-fractionated regime (which might be more familiar to an Oncologist).  However, there 
are some caveats to this approach, the BED model tends to over-estimate the radiation effects of 
larger fraction sizes (23).  
It is therefore extremely important that outcome data (toxicity and disease control data), is collected 
and critically analysed, in order to inform optimum dose/fractionation in SBRT. 
6.5.1 SBRT vs Conventionally-fractionated radiotherapy for primary pancreatic cancer  
The majority of pancreatic tumours lie in the head of the pancreas (24) where the tumour lies 
adjacent to duodenum, and in close proximity to small bowel and stomach.  It is therefore critical to 
evaluate the toxicity of delivered SBRT regimes. 
6.5.1A: Outcome data: Toxicity: SBRT primary pancreatic cancer 
A number of studies have assessed the toxicity of SBRT regimes to treat localised pancreatic cancer. 
Acute Toxicity 
Certain studies report Grade 2+ Acute toxicity rates of 5-8% (10, 24).  However, a further study 
(Hoyer et al, (25)) reported pronounced acute toxicity, with deteriorating performance status at 14 
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days, and progression to Grade 2+ toxicity in 79% of patients.  Notably the Hoyer et al study did not 
employ real-time tumour-tracking (Synchrony), median PTV volume was large (136cc), and the 
prescribed dose was high (45Gy/3#, BED = 111Gy10). 
In contrast, the 42 patients whose treatment was described in Section 6.3.1 had Grade 3 acute 
toxicity rates of 5%, and there was no recorded Grade 4 acute toxicity.  These rates are therefore 
comparable to the acute toxicity reported by Mahadevan et al, and Chang et al (10, 24).   
The median PTV in the author’s series (69.2cc) was notably smaller than the median PTV of the Hoyer 
et al series (136cc).  In addition, the mean prescribed dose (27Gy/3#, BED = 48.6 Gy10), was 
biologically much less potent than the regime delivered by Hoyer et al (BED = 111Gy10).  These 
differences may partially explain the differences in observed acute toxicity. 
Outside of a randomised controlled trial, toxicity rates of different radiotherapy regimes should be 
compared with caution.  That said, Grade 3 upper gastrointestinal acute toxicity was 7.3% in patients 
treated at 1.8-2Gy/fraction (conventionally-fractionated) to a median prescribed dose to the PTV of 
54Gy in a study by Fuss et al (26). 
In conclusion, the observed Grade 3 acute toxicity rate of 5% in the author’s series is considered 
acceptable, and compares well with SBRT and conventionally-fractionated radiotherapy regimes 
reported in the literature. 
Late Toxicity 
Locally advanced pancreatic cancer has a poor prognosis, and this limited the reporting of late 
toxicity in studies.  Hoyer et al had a 5% overall survival rate at 1 year (25).  Chang et al (10) reported 
the late Grade 3+ toxicity rate “in the absence of progressive disease” as 9%.  Mahadevan et al (24) 
selected chemo-responders to receive SBRT and had a Grade 3+ late toxicity rate of 6%. 
In the current study, 2 patients (6%) experienced late Grade3+ duodenal toxicity (Grade 4 duodenal 
stricture).  Both patients were treated in an early cohort at the author’s centre and had a Maximum 
point dose (MPD) to the Duodenum which exceeded the current dose constraint of 24Gy to 0.035cc 
of Duodenum.   
The first patient received a treatment dose of 25.5Gy/3# to the 58% isodose (BED= 45.7Gy10) to an 
above average PTV of 79cc (compared to Median PTV of 69cc).  MPD to Duodenum was 29.4Gy, 
(therefore exceeding the current MPD dose constraint of 24Gy). 
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A further patient experienced a duodenal stricture 14 months after SBRT and sadly died from 
perforation due to duodenal obstruction.  The patient was treated to a median BED (49.5Gy10, 
27Gy/3# to 70% isodose).  Of note the PTV was large at 104cc (compared to Median PTV of 69cc).  
The patient also had a MPD to the Duodenum which exceeded the current dose constraint of 24Gy to 
0.035cc. Duodenal MPD was 31.6Gy. 
The reported Grade 4 toxicity rate of 6% is therefore comparable to the reported literature, and 
notably occurred only in those patients whose Duodenal MPD exceeded 24Gy (current constraint). 
Statistical analysis: 
Chi-squared test and ANOVA were used to test for association between treatment factors and 
toxicity.  The treatment factors evaluated were: Number of fiducials, PTV (cc), PTV (min/mean/max 
dose), Prescribed dose, Prescription isodose, Coverage (%), and BED. 
There was no statistically significant association (p values 0.084-0.991). 
Summary: 
The observed acute and late Grade 3+ toxicity rates (5% and 6% respectively) following SBRT to 
localised pancreatic cancer, compare favourably with toxicity rates reported in the literature. 
There was no statistically significant association between treatment delivery factors and toxicity. 
Late Grade 4 duodenal toxicity occurred only in those patients where Duodenal MPD constraint was 
exceeded. 
Disease outcome data and radiobiological calculations will be discussed in the subsequent sections, 
but these results suggest there may be scope for cautious dose escalation, although Duodenal MPD 
constraint should be respected. 
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6.5.1B: Outcome data: Disease control: SBRT primary pancreatic cancer  
The poor prognosis of pancreatic cancer patients is largely related to the propensity for early 
metastatic progression.  Median time to disease progression is often 6 months, predominantly due to 
distant progression (27).  However, achieving local control is important to prevent symptoms of local 
disease (such as abdominal pain, and jaundice).  It is also important to secure local control because a 
certain percentage of patients progress locally only (10). 
Wong et al reported disease control outcomes for patients receiving 50.4Gy/28 fractions over 5.5 
weeks (at 1.8Gy/fraction).  The patients received concurrent 5fu chemotherapy by protracted venous 
infusion.  Median Local progression-free survival, and Median Distant progression-free survival was 6 
months.  Median overall survival was 9 months (27). 
There would be a number of potential advantages of an SBRT strategy for the treatment of localised 
pancreatic cancer.  There is a potential to deliver an increased BED to the tumour, the shorter 
fractionation allows for greater patient convenience, and the shorter fractionation allows minimal 
interference with chemotherapy delivery. 
Outcomes for SBRT for the treatment of primary pancreatic cancer have been reported by Chang, 
Hoyer, and Mahadevan et al (10, 24, 25). 
Chang et al delivered 25Gy/1# to pancreatic tumours using the CyberKnife treatment platform (10).  
Their radiobiological calculations determined that this dose was equivalent to 74Gy to tumour if 
delivering 1.8Gy/fraction.  A majority of the patients had localised disease.  The authors concluded 
that while the local control rates were promising, they would move to fractionated SBRT schedules to 
aim to reduce morbidity. 
Hoyer et al delivered 45Gy/3# with a Linac-based SBRT technique (25).  The regime was toxic as 
described in Section 6.5.1A.   
Mahadevan et al selected chemo-responders with locally advanced pancreatic cancer to receive SBRT 
delivered by CyberKnife (24-36Gy/3#, based on duodenal tolerance) (24).  The patients were then 
offered Gemcitabine for 6 months, or until tolerance or disease progression.  The outcomes from this 
study are more encouraging.  The authors felt that the promising outcomes were largely due to 
minimal interruption of systemic chemotherapy. 
The disease control outcomes of these studies will be compared with those at the author’s centre, 
and hypotheses for the different outcomes will be put forward. 
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Patients studied at the author’s centre were a heterogenous group.  23% had not received 
chemotherapy prior to SBRT, because they were judged too frail. 23% had received prior 
radiotherapy, thereby limiting the SBRT dose that could be safely delivered.  Treatment doses were 
18-36Gy/3#, dose was largely adapted according to duodenal tolerance as per Mahadevan et al.   
Local control analysis: 
Actuarial Freedom From Local progression (FFLP) was 85% at 6 months, and 44% at 1 year at the 
author’s centre.  This compared favourably to the patients in the Hoyer (25) et al study (FFLP at 6 
months = 57%), which is encouraging given that the toxicity outcomes of the author’s SBRT regime 
were also more favourable. 
The FFLP rate also compared favourably to the outcome of 50.4Gy/28#/5.5 weeks (BED 40.5Gy10) 
with 5fu delivered by Wong et al (50% FFLP at 6 months)(9).  The improvement may have been 
related to the higher BED delivered by the SBRT regime (Mean BED 48.6Gy10), but may also be 
related to refinements in treatment delivery with SBRT e.g. tracking of respiratory movement. 
However, FFLP at 1 year (44%) was poorer at the author’s centre than the SBRT studies of 
Mahadevan et al and Chang et al (78-84%) (10, 24).  Chang et al delivered a regime much more 
potent (BED = 87Gy10) than the author’s regime (Mean BED = 48.6Gy10) which may partially explain 
the difference in control.  Mean BED of Mahadevan et al (56.4Gy10) was also more potent than the 
author’s regime, but the potency of the regimes is more similar.  On review of the treatment 
planning and delivery technique, the approach is very similar between the authors, the most notable 
difference was in the number of fiducials implanted.  Chang and Mahadevan et al both followed a 
strategy of implanting 3-5 fiducials for all patients, whereas only 67% of the author’s patients were 
tracked with 3+ fiducials.  If there were inaccuracies in treatment delivery due to sub-optimal 
number of fiducials implanted it would be expected that FFLP rates may decrease, and Toxicity rates 
may increase.  Statistical analysis was performed to evaluate if the number of fiducials implanted (≤2 
vs ≥3) was associated with toxicity, but this was not found to be the case (p value 0.084 for acute 
toxicity and p value 0.718 for late toxicity).  A formal statistical test for association between number 
of fiducials implanted and FFLP has not yet been undertaken, but it would be interesting to do this. 
Progression-free survival (PFS) analysis: 
PFS at the author’s centre was 49% at 6months, and 23% at 1 year. 
This compares favourably with the PFS of Hoyer et al SBRT regime (PFS at 1 year = 9%)(25), and was 
similar to the PFS of Wong et al (50.4Gy/28#, 50% PFS at 6 months)(9). 
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The PFS of the SBRT regime at the author’s centre compared favourably to Chang et al (PFS 26% at 6 
months, and 9% at 1 year) (10), although it is noted that 19% of the Chang et al cohort had 
established metastatic disease at the time of SBRT, whereas all patients treated at the author’s 
centre had localised disease only. 
However, Mahadevan et al (24) had superior PFS results, Median PFS = 9.6 months.  All patients 
treated by Mahadevan et al were chemo-responders, which would naturally select a better prognosis 
cohort of patients.  In contrast, 23% of the author’s cohort had not received prior chemotherapy 
because the patients were considered too frail.  In addition, the patients in Mahadevan et al’s study 
were treated with adjuvant Gemcitabine chemotherapy, which was re-commenced soon after SBRT.  
Data on subsequent treatments has not been formally analysed at the author’s centre, but this would 
be interesting.  It may also be informative to statistically compare the PFS outcomes of 
chemotherapy-naïve patients with those pre-treated with chemotherapy. 
Overall Survival (OS) analysis: 
Median Overall Survival at the author’s centre was 8.4 months.  Overall survival was 40% at 1 year. 
This was similar to the Median Overall Survival of the 50.4Gy/28# chemoradiotherapy regime 
delivered by Wong et al (Median Overall Survival 9 months) (26).  
However, the SBRT regime delivered by Hoyer et al was associated with poorer survival (Median 
survival 5.4 months, survival 5% at 1 year).  This may have been related to the toxicity of the regime 
(25). 
Overall survival of the Chang et al SBRT regime was 21% at 1 year, therefore poorer than the 
outcomes at the author’s centre, though again it is noted that 19% of the Chang et al cohort had 
established metastatic disease at the time of SBRT (10). 
The most encouraging Overall Survival was observed by Mahadevan et al, median overall survival 
was 14.3 months (24). 
Summary: 
The SBRT regime delivered at the author’s centre (Mean BED 48.6Gy10) was associated with the 
following outcomes at 1 year: FFLP 44%, PFS 23%, and OS 40%. 
FFLP was improved compared to the biologically less potent regime delivering 50.4Gy/28# (BED 
40.5Gy10) (27), perhaps due to refinements in treatment delivery with SBRT technique (e.g. tracking 
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of respiratory motion), as well as the increased biological potency of the SBRT regime. FFLP was also 
improved compared to the potent SBRT regime delivering 45Gy/3# (BED 111Gy10)(25), underlining 
the importance of accurate treatment delivery.   
FFLP at the author’s centre compared less favourably, however, with SBRT regimes tracked with 
Synchrony, which were biologically more potent (Mean BED 56.4-87Gy10) (10, 24). 
The poor outcomes for PFS and OS across all studies indicates that improvements in systemic therapy 
will be crucial in improving the prognosis of pancreatic cancer.  However, the improved local control 
that can be achieved with SBRT (vs. 50.4Gy/28#/5.5 weeks), as well as the shorter fractionation 
(beneficial for patient convenience and minimal interruption of systemic treatment) supports the 
SBRT technique for the treatment of localised pancreatic cancer in well-selected patients.  However, 
the FFLP rates show that there is clearly scope for improvement of SBRT technique/Dose-
fractionation selection. 
 
6.5.1C: Radiobiology: primary pancreatic cancer  
Aim 1 was to perform a radiobiological comparison between SBRT regimes delivered for the 
treatment of primary pancreatic cancer, and conventional radiotherapy schedules.  The results of the 
calculations are reported in Section 6.4.1D. 
The analysis above has shown that SBRT regimes delivered at the author’s centre had improved FFLP 
rates compared to conventional (“reference”) radiotherapy schedules (50.4Gy/28#, BED 40.5Gy10).  
There is scope for improvement in FFLP rates, however, to improve the FFLP rates to those of the 
more potent SBRT regimes delivered by Chang and Mahadevan et al (10, 24).  Improved FFLP should 
not be at the expense of worsened toxicity. 
When considering FFLP rates with the reference schedule of 50.4Gy/28#, it is worth noting that this is 
associated with a low tumour BED (40.5Gy10).  This figure will be even lower in patients exhibiting the 
fastest repopulation.  The reference BED of 40.5Gy10 , even when applied to a reasonably 
radiosensitive tumour (α = 0.35Gy-1) is unlikely to control tumours containing more than about 1 
million clonogenic cells (20). 
In the worst cases, the reference schedule dose losses to tumour repopulation may be 30% or more, 
and any form of radiotherapy which involves an accelerated schedule, e.g. SBRT, will reduce such 
losses. 
273 
 
The analysis performed in Section 6.4.1D shows that SBRT regimes can emulate the potency of the 
reference schedule, and half of the treatments at the author’s centre delivered dose schedules which 
would be expected to produce disease control outcomes comparable with those from the reference 
schedule (based on minimum doses delivered to the PTV).  Given the low overall toxicity (discussed in 
Section 6.5.1A), there could be scope for dose escalation based on gradual increase in minimum PTV 
dose, while respecting the Duodenal MPD dose constraint.  This suggestion would be supported by 
the fact that when considering the CK regime that will deliver the minimum dose equivalent of the 
reference schedule (22.2Gy/3#), the BEDGy3 for Normal tissues (77Gy3) of this regime is less than the 
BEDGy3 of the reference schedule (80.6Gy3), see Table 6.3.  Minimum dose to PTV is currently not the 
most considered parameter in CK treatment planning.  A “good” CK treatment plan will have 95% of 
the PTV treated by the prescription isodose, but due to the sharp dose fall-off of CK plans, plans with 
>95% coverage could still have low minimum doses to the PTV.  This analysis has highlighted that 
Minimum dose to the PTV in CK plans should be >22.2Gy (in a 3 fraction plan). 
The 3-fraction regimes delivered at the author’s centre are less likely (than single fraction regimes) to 
involve fraction sizes beyond the normally accepted reliability of the LQ model (10Gy fractions), and 
therefore the regimes would be a reasonable candidate for carefully-monitored dose escalation (23) 
as described above.  
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6.5.2 SBRT Dose-Fractionation for Lymph node oligometastases 
Aim 2 was to evaluate the outcomes of SBRT to lymph node oligometastases according to delivered 
BED.   
In contrast to the treatment of localised primary pancreatic cancer, conventionally-fractionated 
radiotherapy would not usually be employed to treat a solitary lymph node metastasis.  Systemic 
therapy would be the standard of care, but this approach is rarely ablative.  Systemic therapy is 
therefore the Control arm in the CORE study, a randomised trial which will shortly be opened in the 
UK, comparing systemic therapy vs systemic therapy + SBRT to oligometastases (≤ 3 metastases) (28). 
This discussion will therefore focus on the outcomes of SBRT to treat lymph node oligometastases.  
Review of the literature reveals that studies reporting SBRT outcomes for lymph node 
oligometastases are a heterogenous group.  They comprise a range of metastatic sites, prognostic 
factors (disease-free interval, number of sites, tumour volume) as well as varying tumour pathology, 
making it difficult to draw conclusions on optimum dose-fractionation (3). 
Local control analysis: 
The primary pathology of lymph node oligometastases treated by SBRT studies in the literature 
include: Prostate, Cervix, Gastric, Breast, Colorectal and Renal cell.  The BED of the regimes delivered 
varied widely (60Gy10 – 125Gy10), as did the outcomes: Local Control 67.4-100% at a follow-up of 2-4 
years (12-15). 
Considering the 2 studies that showed the most encouraging Local control rate, the first study was a 
small study (n=7) by Kim et al delivering SBRT to para-aortic lymph nodes from recurrent gastric 
cancer. Local control rate was 100% at a median follow-up of 26 months.  Interestingly, the highest 
BED of the above studies (125Gy10, 48Gy/3# to 80% isodose) was delivered, and importantly toxicity 
was acceptable (no Grade 3+ toxicity recorded).  Patients were treated with a CyberKnife technique 
with 6 implanted fiducials per patient (15). 
The next most promising study of SBRT for lymph node oligometastases (for local control) was 
performed by Casamassima et al (13).  This was a study of 25 patients with lymph node 
oligometastases from prostate cancer.  The lowest BED of the above studies was delivered (BED 
60Gy10, 30Gy/3#), but an encouraging local control rate of 90% at 3 years was achieved with no 
Grade 2+ toxicity.  SBRT was delivered using a Linac-based technique. 
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The observation that the 2 most encouraging SBRT lymph node oligometastasis studies (in terms of 
local control) employed the lowest and highest BED regimes, suggests that histopathology of the 
primary may be an important consideration in dose selection.  
Local control rate at the author’s centre was 88% at a median follow-up of 15 months (n=38, Median 
BED 59.5Gy10, majority 24Gy/3#), with Local-PFS at 1 year 80%.  Toxicity was acceptable (Acute 
toxicity Grade 3+: 3%, Late Toxicity Grade 3+: 5%).  The cohort at the author’s centre had mixed 
histology of the primary site, similar to the study by Bignardi et al (n=19, Median BED = 79Gy10, 
majority 45Gy/6#) which had comparable outcomes (Local control = 77.8% at 2 years, Grade 3+ 
Toxicity: 5%).  Interestingly, the Bignardi et al study treated to a higher median BED, but of note no 
patients studied had received prior radiotherapy to the target site (compared to 38% of those 
studied at the author’s centre had received prior radiotherapy, which limited the re-treatment dose). 
Progression-Free survival (PFS) and Overall Survival (OS) analysis: 
The SBRT studies reported in the literature have a wide range of PFS and OS outcomes, as would be 
expected given the wide range of histopathologies included, together with variable prognostic 
factors such as disease-free interval and tumour volume.  PFS at 1 year was 29.5-80%, OS rates at 1 
year were 76-100% (12-15). 
At the author’s centre, PFS at 1 year was 48%, and OS at 1 year was 91%, therefore the outcomes 
were in keeping with those in the literature.  The heterogeneity of the patients included in the 
studies prevent further comparison.  The outcome of randomised trials, such as the CORE trial, will 
allow comparison of outcomes stratified by prognostic and treatment factors. 
BED vs Local Control: 
The studies reported in the literature discussed above did not formally study local control with 
respect to delivered BED.  This analysis was not possible in some studies due to small numbers of 
patients, and in other studies due to more standardised dose-prescription. 
A range of BEDs were delivered at the author’s centre (Range: 43Gy10 – 79Gy10, 9 x BED levels 
delivered).  This is well illustrated in the dot-plot in Section 6.4.2C, where BED is plotted against Local 
Control.  The dot-plot clearly shows that the regime with the lowest BED (24Gy/3#, BED = 43.2Gy10) is 
associated with the highest risk of local progression.  The dose-prescription was limited in these 
cases by a combination of prior radiotherapy and normal tissue dose constraints.  It is therefore 
possible that radio-resistance of these tumour targets was partially responsible for the poorer local 
control rates.  This outcome for the 24Gy/3# dose level fits with a dose-escalation trial by Salama et 
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al (29), a study evaluating SBRT to a variety of metastases (lung/liver/bone/lymph node/brain).  
Those who received 24Gy/3# (the lowest BED regime tested) had poor local control (45.7%). 
Importantly, the dot-plot also shows that when patients were treated to a threshold BED of ≥ 72Gy10, 
the local control rate was 100% at a median follow-up of 15 months (equating to a prescribed dose of 
≥ 36Gy/3# or ≥ 40Gy in 5#).  There was no Grade 3+ toxicity in patients treated to this dose level.  The 
Kim et al study that achieved 100% local control at 26 months follow-up treated to a BED above the 
72Gy10 threshold so these results are in keeping.  In addition, the Salama et al dose-escalation trial 
showed that for the 4 patients prescribed 48Gy/3# (BED 125Gy10) a local control rate of 100% was 
achieved (29).  However, the Bignardi et al cohort were treated to BED 79Gy10, and there were local 
recurrences noted in 2 patients, both recurred within 1 year, the paper did not comment further on 
characteristics of the 2 patients that recurred locally (e.g. PTV volume, tumour pathology, 
coverage)(12). 
Histopathology vs PFS: 
The biology of a tumour (e.g. the propensity to metastasis) varies according to the histopathology.  
As well as the wide range of delivered BEDs, there was a wide range of histopathologies treated in 
the author’s cohort which warranted analysis.  Given the importance of BED, the analysis by 
Histopathology was stratified according to BED.   
Graph 6.4 shows PFS by Histopathology, adjusted for BED.  The Colorectal cancer patients had the 
most favourable PFS: Median PFS for the Colorectal cancer histopathology group was 22 months, 
which is encouraging in a cohort of patients that was heavily pre-treated (78% prior chemotherapy).  
It is interesting that the Colorectal group had the superior PFS, as Takeda et al reported that lung 
metastases from Colorectal cancer had substantially worse local control rates than metastases from 
other primaries (including lung cancer primaries)(30).  However, a study by Milano et al showed no 
significant differences in outcomes between colorectal cancer and other (non-breast) primaries (16). 
In contrast, the lung cancer group had the least favourable PFS, with a median PFS of just over 3 
months (the time point that the first post-SBRT imaging would be performed).  All cases of 
progression in the lung group were distant progression, therefore, patient selection factors (such as 
disease-free interval, number of metastases) are likely to be implicated. 
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Summary 
The SBRT regime delivered at the author’s centre (Median BED 59.5Gy10) was associated with the 
following outcomes at 1 year: Local-PFS 80%, PFS 48%, and OS 91%.  Toxicity was acceptable (Grade 
3+ toxicity: ≤ 5%). 
PFS and OS rates are comparable with other series quoted in the literature. 
Analysis of outcomes according to BED has shown that tumour targets treated to a threshold BED of 
72Gy10 (equating to 36Gy/3# or 40Gy/5#) have a local control rate of 100% at a median follow-up of 
15months.  There was no G3+ toxicity in patients treated to this dose level.  It will be important to 
confirm whether the observed local control rate is maintained with longer follow-up. 
The PFS of patients was analysed by histopathology of the primary, adjusted by BED.  Colorectal 
cancer histology was associated with the most favourable PFS (Median PFS =22 months).  There were 
relatively small numbers in each histopathology group, larger numbers will allow analysis of the 
reasons for the differences observed, specifically looking at prognostic factors such as disease-free 
interval, tumour volume, and number of metastases. 
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6.5.3 SBRT Dose-Fractionation for Oligometastatic breast cancer 
Aim 3 was to evaluate the outcomes of SBRT for oligometastatic breast cancer according to delivered 
BED.   
As for the treatment of lymph node oligometastases, systemic therapy would be the standard of care 
for oligometastatic breast cancer.  Breast cancer is one of 3 histopathologies being evaluated in the 
CORE trial (the other histopathologies are prostate and lung)(28). 
The literature regarding SBRT for oligometastatic breast cancer comprises a range of metastatic sites, 
therefore a variety of organs are the Organs At Risk, which in turn affects the doses which can safely 
be delivered to the oligometastases. The largest study on SBRT for oligometastatic breast cancer was 
conducted by Milano et al (16). 
Local control analysis: 
At the author’s centre Local Progression-Free Survival (Local PFS) was 92% at 2 years for Body sites 
(extra-cranial). 
Local PFS for intra-cranial sites (i.e. Brain metastases) was 74% at 2 years (see Graph 6.5). 
There was a statistically significant difference between the outcomes of intracranial vs extracranial 
metastases, intracranial oligometastases do significantly worse (log-rank p=0.015).   
Grade 3+ toxicity rate was 5%. 
Milano et al analysed a subgroup of 39 patients with oligometastatic breast cancer treated with a 
Linac-based SBRT technique (16).  The most commonly treated metastases were located in Liver, 
Bone and Lung.  A single patient was treated for a brain metastasis.  Local control rate at 2 years was 
87%.  The local control rate at 4 and 6 years was also 87% suggesting that local recurrences will occur 
within 2 years.  Performing univariate and multivariate analysis, the authors found that local control 
was favourable for bone metastases (0/17 bony metastases recurred locally) vs. non-bone 
metastases (10/68 non-bone metastases progressed locally). 
The Local PFS rates at the author’s centre for extracranial breast cancer metastases (92% at 2 years) 
compared favourably with the Local control rate of Milano et al (87% at 2 years).  A single patient 
(3%) of the Milano et al cohort had intracranial metastasis, shown in Section 6.4.3B to have poorer 
local control, which would slightly negatively bias the Milano et al cohort.  Taking this into 
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consideration, the Local PFS (92%) at the author’s centre still compares favourably to the Milano et al 
cohort. 
Freedom from Distant Metastasis (FFDM) and Overall Survival (OS) analysis: 
Median FFDM at the author’s centre, considering all 57 patients, was 6 months.  Therefore, as for 
outcomes in primary pancreatic cancer, and lymph node oligometastases, distant progression 
occurred earlier than local progression.  In contrast, Milano et al reported a FFDM of 52% at 2 years, 
which would be a far more encouraging outcome.  However, the author’s centre would count any 
new distant metastasis.  In contrast, the definition of FFDM applied by Milano et al was “widespread 
distant progression, not amenable to resection or locally ablative therapy”.  This difference in 
endpoints would therefore negatively bias against the author’s centre.   
Overall survival at the author’s centre was 75% at 2 years (considering all 57 patients).  The 2 year 
overall survival for the Milano et al cohort was 74% at 2 years, which is remarkably similar.  It is 
encouraging that overall survival is similar across the 2 cohorts of patients given the proportion of 
patients with intracranial disease in the author’s cohort (41%) vs Milano et al cohort (3%).  
Intracranial metastases are associated with a worse prognosis than extracranial metastases. 
BED vs Local Control (Body sites): 
This Thesis/Chapter is exploring aspects of SBRT, so the author has decided to focus on extra-cranial 
(body) metastases for this analysis. 
Section 6.4.3C displayed a dot-plot for Local progression (x axis) vs delivered BED (Gy10).  Each dot 
represents a treated “Body” oligometastasis.  It can be clearly seen that there was only a single case 
of local progression.  This solitary case was treated to a BED of 48Gy10 (30Gy/5#).  Treating to BED ≥ 
50Gy10 (equating to ≥ 27Gy/3# or ≥31Gy/5#) in this cohort gives 100% local control at a Median 
follow-up of 13 months. 
Interestingly, the solitary case of local progression was a patient with sternal metastasis (PTV=20cc), 
whilst the Milano et al paper showed that bony metastases had the best local control rates.  There 
could be a few potential reasons for the disease progression (which was an edge-of-target 
progression).  The patient had been treated with 2 lines of chemotherapy previously.  The patient 
had had a good response to treatment but there was a PET-positive focus of residual disease post-
chemotherapy.  This was accepted for SBRT treatment.  The GTV was grown by a small planning 
margin (1.25mm) to create the PTV.  The patient may have recurred due to a) micrometastatic 
deposits being present in the sternum adjacent to the GTV post-chemotherapy, this could have been 
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incorporated into a CTV expansion, or b) planning margin inadequate (given Synchrony case, target 
best seen on a PET which needed fusing to primary CT), or c) aggressive tumour biology, the patient 
recurred simultaneously at other distant sites (mediastinal lymph nodes), or a combination of these 
possibilities. 
It will be interesting to see if the encouraging Local control outcomes for extra-cranial sites will 
persist at longer follow-up (beyond 2 years). 
Summary: 
At the author’s centre, Local PFS for SBRT to extra-cranial oligometastatic breast cancer was 92% at 2 
years.  Toxicity was acceptable (Grade 3+ toxicity = 5%). 
Considering the entire cohort of 57 patients (41% brain metastases, 59% extra-cranial metastases), 
those with extracranial disease had significantly improved Local PFS (vs. intracranial metastases), p = 
0.015. 
Overall survival (considering all 57 patients) was 75% at 2 years, which compares well with Overall 
Survival outcomes reported in the literature. 
At an early median follow-up of 13 months, SBRT delivery to a threshold BED of ≥ 50Gy10 (equivalent 
to ≥ 27Gy/3# or ≥ 31Gy/5#) to extra-cranial metastases gives 100% local control. 
This is the first work evaluating local control according to BED for breast oligometastasis treated by 
SBRT.  It will be important to see if the Local control outcomes are borne out on longer follow-up 
beyond 2 years. 
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6.6 CONCLUSIONS 
It is important that the dose/fractionation regime that is selected in SBRT should be optimum for 
tumour control, while also being protective to Organs At Risk.  Selection of dose/fractionation 
regimes based on extrapolation from conventionally-fractionated data may not be sound due to the 
limitations of the Linear Quadratic formula at the high doses per fraction delivered in SBRT.  It is 
therefore important that outcome data is critically analysed, in order to inform optimum 
dose/fractionation in SBRT. 
The Aims of this Chapter were: 
1. To perform a radiobiological comparison between SBRT regimes delivered for the treatment of 
primary pancreatic cancer, and conventional radiotherapy schedules. 
2. To evaluate the outcomes of SBRT to lymph node oligometastases according to delivered BED. 
3. To evaluate the outcomes of SBRT to oligometastatic breast cancer according to delivered BED. 
 
Primary pancreatic cancer: 
The SBRT regimes delivered at the author’s centre (Mean BED 48.6Gy10) were associated with the 
following outcomes at 1 year: FFLP 44%, PFS 23%, and OS 40%. 
This FFLP rate (following SBRT) is improved compared to a standard reference conventional 
radiotherapy schedule of 50.4Gy/28#/5.5 weeks (BED 40.5Gy10). 
There is, however, scope for improvement in the FFLP rates to those achieved by other more potent 
SBRT regimes reported in the literature (FFLP at 1 year 78-84% following BED 56.4Gy10 -87Gy10), 
although it would be important that improved FFLP should not be at the expense of worsened 
toxicity. 
The radiobiological comparison performed between the reference schedule (50.4Gy/28#/5.5weeks, 
BED 40.5Gy10) and the SBRT regimes delivered at the author’s centre, as per Aim 1, has shown that 
half the SBRT treatments delivered would be expected to produce FFLP outcomes comparable with 
those of the reference schedule (based on minimum doses delivered to the PTV).  Given the low 
overall toxicity experienced by patients treated with SBRT at the author’s centre, there would be 
scope for dose escalation based on increase in minimum PTV dose, while respecting the Duodenal 
MPD constraint.  The radiobiological comparison which has been performed supports that this 
should be possible, potentially without an increase in toxicity. 
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Minimum dose to the PTV is currently not the most considered parameter in CyberKnife treatment 
planning.  This novel radiobiological analysis has highlighted that Minimum dose to the PTV in 3-
fraction CyberKnife treatment plans should be >22.2Gy.  This sets out new planning guidance in SBRT 
for localised pancreatic cancer.  
 
Lymph node Oligometastases: 
The SBRT regimes delivered at the author’s centre (Median BED 59.5Gy10) achieved the following 
outcomes at 1 year: Local PFS 80%, PFS 48%, and OS 91%.  Toxicity was acceptable (Grade 3+ toxicity 
≤ 5%).  PFS and OS rates are comparable with other series quoted in the literature. 
Analysis of outcomes according to BED, as per Aim 2, has shown that tumour targets treated to a 
threshold BED of 72Gy10 (equivalent to 36Gy/3#, or 40Gy/5#) have a local control rate of 100% at a 
median follow-up of 15 months.  There was no Grade 3+ toxicity in patients treated to this dose level.  
If these results are confirmed on longer follow-up, this is important data.  Previous studies have 
shown 100% local control rate with BED125Gy10, and equally, poor local control at BED 43.2Gy10 
(confirmed also in this work), but if BED 72Gy10 is shown to secure 100% local control long-term, then 
it will be a more favourable regime than BED 125Gy10 as it would be associated with a safer toxicity 
profile.  The recommendation is that 36Gy/3#, or 40Gy/5# should be the preferred dose prescription 
for lymph node oligometastasis. 
Comparing the histopathology of primary tumours, adjusted by BED, Colorectal cancer histology was 
associated with the most favourable PFS (Median PFS = 22 months). 
 
Oligometastatic breast cancer: 
The SBRT regimes delivered at the author’s centre (Median BED 51.3 Gy10) achieved Local PFS of 92% 
at 2 years for extra-cranial metastases.  Toxicity was acceptable (Grade 3+ toxicity = 5%).  The 
patients with extra-cranial metastases (59% of the cohort) had statistically significantly improved 
Local PFS compared to patients with intracranial metastases receiving hypofractionated radiotherapy 
with a stereotactic technique (p = 0.015). 
Analysis of Local control according to BED, as per Aim 3, for SBRT to extra-cranial metastases showed 
that delivery of a threshold BED of ≥ 50Gy10 (equivalent to ≥ 27Gy/3# or to ≥ 31Gy/5#) gives 100% 
local control at a median follow-up of 13 months. 
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This is the first work evaluating local control according to BED for breast oligometastasis treated by 
SBRT.  It will be important to see if the Local control outcomes are borne out on longer follow-up 
beyond 2 years. 
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